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Abstract 
Background   
Gout is a common inflammatory arthritis affecting an estimated 2.5% of the UK population.  
The hallmark of gout is sudden onset, extremely painful acute inflammatory flares, which are 
strongly associated with impaired health-related quality of life (HRQOL) in cross-sectional 
studies.  Little is known about change in gout flares and HRQOL over time, and the factors 
associated with worse outcomes. 
Methods  
In a three-year prospective cohort study in primary care, people registered with gout reported 
gout flares and completed the Gout Impact Scale (GIS) subscales, 36-Item Short-Form Health 
Survey  Physical Function subscale (SF-36 PF10) and Health Assessment Questionnaire 
Disability Index (HAQ-DI) at baseline, 6, 12, 24 and 36 months.  Responders to the follow-up 
surveys and non-participants were compared to investigate attrition bias.  Latent class growth 
analysis (LCGA) was used to identify and describe distinct gout flare trajectory classes.  Linear 
mixed models were used to describe the factors associated with change in GIS subscales 
(disease-specific HRQOL), SF-36 PF10 and HAQ-DI (generic HRQOL). 
Results 
Responders had slightly less frequent gout flares and better HRQOL at baseline compared with 
non-participants.  Six distinct gout flare trajectory classes were identified.  The infrequent flare 
class had the lowest mean serum urate level and the highest proportion of participants taking 
allopurinol, whilst frequent flare classes had more participants who were socioeconomically 
deprived, obese, and had chronic kidney disease and oligo/polyarticular flares.  Factors 
associated with deterioration in both disease-specific and generic HRQOL included more 
frequent gout flares, oligo/polyarticular flares, using allopurinol, body pain, worse pain 
severity, and worse depression score. 
iv 
 
Conclusion  
Gout flare trajectory classes with distinct characteristics and the factors associated with 
change in HRQOL were identified in people living with gout in primary care, highlighting people 
at risk of worse outcomes over three years and at greatest need of targeted interventions. 
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Glossary of terms 
 
 
Gout flare A clinically evident episode of acute inflammation induced by 
monosodium urate crystals (Bursill et al 2019), characterised by 
joint pain, tenderness, swelling, erythema and heat (Roddy, 
Mallen & Doherty, 2013; Taylor et al 2015; Teng, Nair & Saag, 
2006). 
 
Health-related quality 
of life (HRQOL) 
A multi-dimensional concept, the dimensions of which can 
include physical functioning, social networks or support, 
psychological or emotional wellbeing, role functioning or 
performance, and general health (Bowling, 2005; Fitzpatrick et al 
1992; Hennessy et al 1994; Testa & Simonson, 1996; Wilson & 
Cleary, 1995).     
 
Disease-specific HRQOL 
measure 
A HRQOL measure which assesses domains deemed more 
relevant to a disease of interest (Hickey et al 2005; Testa & 
Simonson, 1996).  For example, the Gout Impact Scale (GIS) as a 
HRQOL measure of gout-specific HRQOL. 
 
Generic HRQOL 
measure 
A HRQOL measure which assesses domains applicable to a variety 
of health states (Hickey et al 2005; Testa & Simonson, 1996). For 
example, 36-Item Short-Form Health Survey (SF-36), Health 
Assessment Questionnaire Disability Index (HAQ-DI). 
  
Minimal clinically 
important difference 
(MCID) 
The smallest difference in a score on a domain of interest (e.g.  
quality of life) which patients perceive as beneficial (Jaeschke, 
Singer & Guyatt, 1989). 
 
 
Trajectory The within-person pattern of a longitudinal outcome over time 
(Curran, Obeidat & Losardo, 2010; Nagin & Odgers, 2010). 
 
Urate-lowering therapy 
(ULT) 
Medication used in the management of gout to lower serum 
urate levels e.g. Allopurinol, Febuxostat. 
 
Read code Alphanumeric medical codes which allow primary care health 
care workers to code clinical consultations in the UK (Chisolm, 
1990; Porcheret et al 2004). 
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1 Chapter One Introduction and background 
1.1 Overview of chapter and aim 
The aim of this chapter is to introduce the topic of this thesis and to provide relevant 
background to the topic.  This thesis relates to the analysis of outcomes reported by people 
living with gout in a prospective three-year cohort study in primary care.  Thus, background 
relating to gout, gout flares, and health-related quality of life is presented.  
1.2 Gout in history and society 
Evidence of gout dates back to 7000 BC with pathological findings identified in Egyptian 
remains (MacKenzie, 2015). Early clinical descriptions of gout are attributed to Hippocrates 
(MacKenzie, 2015; Nuki & Simkin, 2006), and the writings of the Greek Physician Aretaeus 
referred to the classical presentation of gout in the first metatarsophalangeal joint (MTPJ) as 
‘podagra’ (‘foot trap’) (Porter & Rousseau, 1998).  The term gout is thought to derive from 
‘gutta’, the Latin word for drop, referring to the historical belief that ‘humours’ of the body 
had dropped into a joint (Nuki & Simkin 2006; Porter & Rousseau, 1998).  Thomas Sydenham 
described the clinical presentation of both acute and chronic gout, and how gout differs from 
other forms of arthritis, in as early as the 17th century (MacKenzie, 2015; Porter & Rousseau, 
1998).  Through history, gout has frequently been referred to as the ‘disease of kings’, due to 
historical associations with royalty and affluence (Nuki & Smikin, 2006) and those afflicted 
with gout have frequently endured caricature and a satirical portrayal (Porter & Rousseau, 
1998).   A recent content analysis of US & UK popular newspaper articles by Duyck, Petrie & 
Dalbeth (2016) revealed that gout still remains a source of humour and is frequently portrayed 
as a self-inflicted condition caused by overindulgence.  Societal misconceptions regarding the 
cause and management of gout, which are also prevalent in healthcare professionals (Spencer, 
Carr & Doherty, 2012), can lead to stigma for people living with gout (Chandratre et al 2016; 
Lindsay et al 2011). 
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1.3 Pathophysiology, clinical manifestation and diagnosis of gout 
Hyperuricaemia  
Uric acid is a weak acid, which exists predominantly in its ionic form urate at physiological pH 
(Choi, Mount & Reginato, 2005; Mandal & Mount, 2015), and is the final breakdown product 
of purine metabolism in humans, produced through the action of xanthine oxidase on 
xanthine (Hediger et al 2005; Roch-Ramel & Guisan, 1999; Teng, Nair & Saag, 2006).  
Underexcretion (inadequate removal) of urate from the body accounts for around 90% of 
hyperuricaemia (Choi, Mount & Reginato, 2005; Teng, Nair & Saag, 2006). Renal 
underexcretion is the predominant cause of hyperuricaemia (Dalbeth, Merriman & Stamp, 
2016) as two-thirds of daily urate excretion is via the kidneys and one-third is excreted via the 
gut (Hediger et al 2005; Roch-Ramel & Guisan, 1999).  After glomerular filtration of urate, 
renal transporters and exchanger molecules located in the proximal renal tubule play a key 
role in regulating serum urate levels; by the reuptake of urate (via SLC2A9, URAT1, OAT4 & 
OAT10) and urate secretion (via ABCG2, NPT1, OAT1-3, MRP4) (Dalbeth, Merriman & Stamp, 
2016; Enomoto et al 2002; Hediger et al 2005; Mandal & Mount, 2015; Roch-Ramel & Guisan, 
1999; Teng, Nair & Saag, 2006) see Figure 1.1.  A range of factors, associated with reduced 
excretion of urate, predispose to hyperuricaemia and gout including chronic kidney disease, 
hypertension, loop or thiazide diuretics, obesity and genetic factors (Hyndman, Liu & Miner, 
2016; Merriman, Choi & Dalbeth, 2014; Roddy, Mallen & Doherty, 2013) (see section 1.5). 
In contrast to decreased excretion, an increase in endogenous (due to de novo synthesis or 
increased cell turnover) and exogenous sources of purines (due to dietary intake) accounts for 
a smaller proportion of elevated urate levels (Choi, Mount & Reginato, 2005; Dalbeth, 
Merriman & Stamp, 2016;  Teng, Nair & Saag, 2006). 
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Figure 1.1 Mechanism of hyperuricaemia by Dalbeth, Merriman & Stamp (2016)   
(included with permission from Elsevier Ltd)
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Crystal formation 
Elevation of serum urate (above 380 μmol/L [6·8 mg/dL]) leads to precipitation, nucleation 
and deposition of needle-shaped monosodium urate (MSU) crystals (Dalbeth, Merriman & 
Stamp, 2016; Roddy, Mallen & Doherty, 2013).  Factors asserted to be associated with uric 
acid crystallisation and deposition include temperature, trauma, cartilage damage and pre-
existing osteoarthritis (Choi, Mount & Reginato, 2005; Roddy, Zhang & Doherty, 2007a; Roddy, 
2011). 
Gout flares 
When MSU crystals shed from their location in cartilage into the joint space, this can initiate 
the inflammatory process observed in a gout flare (Roddy, Mallen & Doherty, 2013). This 
inflammatory process involves the phagocytosis of MSU crystals by macrophages, which leads 
to the engagement of the inflammasome NALP3 (Martinon et al 2006; Petrilli & Martinon, 
2007).  The enzyme Capase-1 is activated by the engagement of NALP3 which leads to the 
production of biologically active pro-inflammatory cytokine interleukin-1β (IL-1β), expediting 
the arrival of neutrophils and other inflammatory cells (Dalbeth, Merriman & Stamp, 2016; 
Martinon et al 2006; Petrilli & Matrinon, 2007).   The influx of inflammatory cells such as 
neutrophils, and the subsequent inflammatory response, results in synovitis and the clinical 
manifestations observed in a gout flare (Choi, Mount & Reginato, 2005; Martinon et al 2006; 
Petrilli & Matrinon, 2007).  These symptomatic manifestations of flares involve excruciating 
joint pain and tenderness with associated swelling, erythema and heat (Roddy, Mallen & 
Doherty, 2013; Taylor et al 2015; Teng, Nair & Saag, 2006). The rapid onset of such symptoms 
is distinctive of a gout flare, with symptoms typically reaching peak intensity within the first 
24 hours and resolving in around one to two weeks (Roddy, Mallen & Doherty, 2013; Taylor 
et al 2015). The first MTPJ is the most commonly affected joint (Roddy, 2011; Stewart et al  
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2016), followed by the midfoot, ankle, knee and fingers (Roddy, Zhang & Doherty, 2007a; 
Roddy, Mallen & Doherty, 2013; Taylor et al 2015).  Monoarthritis is most commonly observed 
during a gout flare, however oligo- or polyarthritis (involvement of two to five joints or more 
than five joints respectively) may occur particularly as the disease process progresses 
(Dalbeth, Merriman & Stamp, 2016; Prowse et al 2013). Whilst the terms gout flare and gout 
attack have been used interchangeably, a recent consensus statement has endorsed the term 
gout flare to describe a clinically evident episode of acute inflammation induced by 
monosodium urate crystals (Bursill et al 2019). 
Intercritical period 
The natural history of gout includes periods of time without any overt symptoms of a flare; 
these periods are of a variable length of time and are referred to as the intercritical period 
(Dalbeth, Merriman & Stamp, 2016; Roddy, 2011; Roddy, Mallen & Doherty, 2013; Teng, Nair 
& Saag, 2006). Ultrasound studies have revealed that subclinical synovitis can persist in the 
intercritical period despite a lack of symptoms (Roddy et al 2013). 
Tophi and chronic gout 
The indicative characteristic of chronic gout, tophaecous deposits, are typically generated 
over many years via a chronic inflammatory pathway (Dalbeth et al 2010; Dalbeth, Merriman 
& Stamp, 2016) and are composed of an MSU crystalline core surrounded by zones of both 
pro-inflammatory and anti-inflammatory factors (Chhana & Dalbeth, 2015).  Tophi present as 
nodular deposits of MSU crystals in subcutaneous tissue, which mainly occur in the toes, 
fingers, olecranon bursae, Achilles tendon, knees and the helix of the ear (Chhanna & Dalbeth, 
2015; Roddy, Mallen & Doherty, 2013). Whilst tophi may initially be asymptomatic, advanced 
chronic tophaecous and arthritic gout can lead to chronic joint pain, structural damage, 
stiffness and limited activity (Dalbeth, Merriman & Stamp, 2016; Roddy, 2011).   
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Diagnosis 
The gold standard for diagnosis of gout is the identification of MSU crystals in synovial fluid or 
tissue samples using polarising light microscopy (Dalbeth, Merriman & Stamp, 2016; Hui et al 
2017; Richette et al 2020).  Imaging, such as ultrasound, plain radiographs and dual-energy 
computed tomography (DECT), may also be used to aid the diagnosis of gout (Dalbeth, 
Merriman & Stamp, 2016; Hui et al 2017).  However, synovial fluid microscopy or imaging are 
not routinely used to diagnose gout in primary care and a clinical diagnosis of gout can be 
made based on classic clinical manifestations of flares when synovial fluid analysis is not 
feasible (Richette et al 2020). 
1.4 Epidemiology of gout 
1.4.1 Prevalence 
Gout is a common inflammatory arthritis with a reported prevalence in the UK of 2.5% based 
on a Read coded (codes for clinical consultations) diagnosis in the Clinical Practice Research 
Datalink (CPRD) (Kuo et al 2015a).  Prevalence is higher in males (3.97%), compared with 
females (1.05%) (Kuo et al 2015a).  Whilst Kuo et al (2015a) reported that gout was uncommon 
in individuals younger than 20 years (5.11 cases per 100 000 individuals), the prevalence 
increased with age for both males and females until the age of 80 years.   A lower prevalence 
of gout of 1.4% was reported previously in CPRD records in the UK between 1990 and 1999 
(Mikuls et al 2005) and in a GP database in the UK between 2000 and 2005 (Annemans et al 
2008).  Kuo et al (2015a) confirmed that the prevalence of gout in the UK had increased by 
63.9% between 1997 and 2012.    
Differences in study populations and methodologies between studies mean that the 
comparison of prevalence between countries is difficult (Kuo et al 2015b).  Globally a higher 
prevalence of gout is observed in more developed countries and also in Pacific countries (Kuo 
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et al 2015b).  A prevalence of gout of 3.8% in the US, based on a self-reported history of a gout 
diagnosis in participants in the National Health and Nutrition Examination Survey (NHANES) in 
2007-2008, has been reported by Juraschek, Miller & Gelber (2013).  Similar prevalences were 
identified more recently in NHANES 2015-2016 (Singh, Lingala & Mithal, 2019) and using 
medical record diagnoses in British Colombia, Canada (Rai et al 2017a).     The prevalence of 
gout in Australia, based on general practice electronic records between 2008 and 2013, was 
reported to be 1.5% (Robinson, Taylor & Dalbeth, 2015).  However, this is likely to be an 
underestimate as data for territories with more Australian Aborigines were not available 
(Robinson, Taylor & Dalbeth, 2015).  Winnard et al (2012) reported a higher prevalence of 
gout in New Zealand of 2.7% in the Aotearoa New Zealand Health Tracker (ANZHT) dataset, 
with a higher prevalence of gout amongst Maori and Pacific populations.  A higher prevalence 
of gout of 6.2%, based on health insurance database records, has been reported in Taiwan 
and gout was more prevalent in areas of Taiwan with greater aboriginal populations (Kuo et 
al 2015c).     
1.4.2 Incidence 
The incidence of gout reported by Kuo et al (2015a) in the UK in CPRD was 1.77 per 1000 
person-years in all ages, with a higher incidence in men (2.58 per 1000 person-years) in 
comparison with females (0.99 per 1000 person-years).  The incidence of gout had increased 
by 29.6% between 1997 and 2012 (Kuo et al 2015a).  Incidences of gout in the UK were 
reported of 1.31 per 1000 person-years in CPRD between 1990 and 1999 (Mikuls et al 2005) 
and 2.68 per 1000 person-years in The Health Improvement Network (THIN) primary care 
database between 2000 and 2007 (Cea Soriano et al 2011).  Whilst an incidence of 2.9 per 
1000 person-years in Canada (Rai et al 2017a) and 2.74 per 1000 person-years in Taiwan have 
been reported (Kuo et al 2015c), a lower incidence of 0.95 per 1000 person-years was reported 
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in Italy (Trifiro et al 2013). The incidence of gout has been shown to increase with age; with a 
peak in incidence observed at 80-84 years (Kuo et al 2015a).   
1.5 Factors associated with gout 
1.5.1 Serum urate 
Hyperuricaemia is a well-established risk factor for gout (Roddy & Choi, 2014).  In population-
based studies, higher levels of serum urate have been associated with a greater prevalence of 
gout (Campion, Glynn & Delabry, 1987; Lin, Lin & Chou, 2000).  A recent study, using data from 
four cohorts, highlighted serum urate as a strong concentration-dependent predictor of 
incident gout with a 15-year cumulative incidence of 49% in people with serum urate 
≥10 mg/dL (Dalbeth et al 2018).  Hazard ratios (HRs) of 2.7 and 6.4 for incident gout in men 
with serum urate levels between 361 to 405 μmol/L and >405 μmol/L respectively, compared 
to those with a serum urate less than 361 μmol/L, were reported in data from a Swedish 
screening program  (Kapetanovic et al 2018).  
However, the presence of hyperuricaemia does not guarantee that an individual will acquire 
gout, and many individuals in population studies with elevated urate levels did not go on to 
develop gout (Brauer & Prior, 1978; Campion, Glynn & Delabry, 1987; Dalbeth et al 2018; Lin, 
Lin & Chou, 2000). 
1.5.2 Chronic kidney disease & nephrolithiasis  
The association between gout and chronic kidney disease (CKD) is bidirectional, as CKD is a 
risk factor for gout but gout is also a risk factor for CKD (Choi & Roddy, 2014; Roughley et al 
2018).    In a case-control study using CPRD the odds of incident gout were 5.96 times higher 
in people with renal disease compared with those without renal disease and also patients with 
gout were three times more likely to develop renal disease compared with those without gout 
(Kuo et al 2016).  The increased odds of CKD in people with gout (OR 2.41) was also reported 
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in a systematic review and meta-analysis (Roughley et al 2015).   The increased risk of CKD in 
people living with gout may be attributable to a number of potential mechanisms including 
hyperuricaemia, chronic inflammation, or medications such as non-steroidal anti-
inflammatory drugs (NSAIDs) (Roughley et al 2018).   
A systematic review and meta-analysis also reported that gout was associated with self-
reported lifetime nephrolithiasis (OR 1.77) (Roughley et al 2015). 
1.5.3 Metabolic syndrome  
Metabolic syndrome is a common comorbidity in people living with gout with a prevalence of 
62.8% amongst people with gout in the third NHANES (Choi et al 2007).  Several of the clinical 
conditions, such as obesity, diabetes, hyperlipidaemia and hypertension, which are 
considered to be entities of metabolic syndrome are associated with gout (Roddy & Choi, 
2014).  
Obesity has been highlighted in a recent systematic review and meta-analysis as a major risk 
factor for incident gout, with individuals with a BMI > 30 kg/m2 being over two times more 
likely to develop gout (relative risk (RR) of 2.24) compared with non-obese individuals (Evans 
et al 2018).   It is thought that obesity promotes insulin resistance which can reduce renal 
urate excretion (Ter Maaten et al 1997).   
In the THIN dataset, the incidence of gout was lower in people with diabetes (RR 0.67) 
compared with individuals without diabetes (Rodriguez, Cea Soriabo & Choi, 2010).  Diabetes 
was also not identified as a risk factor for incident gout in a more recent CPRD study (Kuo et 
al 2016).  The lack of a positive association between diabetes and gout may be attributable to 
the uricosuric effect of glycosuria or an impaired inflammatory response in diabetes 
(Rodriguez, Cea Soriabo & Choi, 2010; Roddy & Choi, 2014).  
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A recent systematic review and meta-analysis identified that individuals with hypertension 
were 2.11 (RR) times more likely to develop gout than those without hypertension (Evans et 
al 2018). 
1.5.4 Cardiovascular diseases  
A higher risk of incident cardiovascular diseases such as cerebral vascular disease (CVD) (HR 
1.29), myocardial infarction (MI) (HR 1.16) and congestive heart failure (CHF) (HR 1.81) has 
been observed in people with a diagnosis of gout, compared with people without gout (Kuo 
et al 2016).  In a retrospective cohort study using CPRD Clarson et al (2014) reported that 
whilst both men and women with gout were at an increased risk of any vascular event, any 
coronary heart disease (CHD), and peripheral vascular disease (PVD) compared with those 
without gout, a greater risk was observed in women with HRs of 1.25 for any vascular event, 
1.25 for any CHD, and 1.89 for PVD in women with gout compared with women without gout.  
The association between cardiovascular diseases and gout may be mediated by endothelial 
dysfunction caused by elevated uric acid or inflammation (Kuo et al 2016).   In a retrospective 
cohort study using Medicare data from the US a diagnosis of gout was associated with a higher 
risk of incident atrial fibrillation (AF) (HR 1.71) (Singh & Cleveland, 2018a). 
1.5.5 Other medical conditions 
A higher odds of incident gout in people diagnosed with hypothyroidism compared with those 
without hypothyroidism was reported by Kuo et al (2016) (OR 1.50), and also a later case-
control study by Bruderer et al (2017) (OR 1.12).  The associations observed between 
hypothyroidism and gout could be attributable to the effect of thyroid hormones on 
glomerular filtration rate (GFR) affecting serum urate levels (Bruderer et al 2017).   
Osteoarthritis (OA) was associated with an increased odds of incident gout (OR 1.27), and an 
increased risk of OA has been reported following a diagnosis of gout (HR 1.45) (Kuo et al 2016).   
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The deposition of monosodium urate (MSU) crystals in osteoarthritic cartilage is thought to 
play a part in the link between the two conditions (Roddy, 2011).  
An increased risk of gout has been identified in patients with obstructive sleep apnoea (OSA) 
compared to those without OSA, in retrospective cohort studies using data from CPRD 
(Blagojevic-Bucknall et al 2019) and THIN database (Zhang et al 2015).  It is thought that 
hypoxia-induced nucleotide turnover leads to hyperuricaemia (Zhang et al 2015).  
An increased risk of erectile dysfunction in people with gout, in comparison with controls, was 
identified in a CPRD cohort (Sultan et al 2017).   A recent observational cohort study using 
medicate claims data in the US reported a higher risk of age-related macular degeneration 
(AMD) in older adults with gout in comparison to those without gout (Singh & Cleveland, 
2018b).  These findings may be attributable to the effects of hyperuricaemia on vascular 
structure and oxidative stress (Singh & Cleveland, 2018b; Sultan et al 2017). 
1.5.6 Medications 
In a retrospective case–control analysis using the General Practice Research Database in the 
UK, an increase in the odds of incident gout was observed in patients currently using loop 
diuretics, thiazide diuretics, and thiazide-like diuretics (ORs 2.64, 1.70, and 2.30 respectively) 
(Bruderer et al 2014). 
An increased risk of gout in people with hypertension currently using specific antihypertension 
medications was detected in the THIN database; with RRs of 1.48 for β blockers, 1.24 for 
angiotensin converting enzyme inhibitors, and 1.29 for non-losartan angiotensin II receptor 
blockers (Choi et al 2012).  
1.5.7 Alcohol 
In a Health Professionals Follow Up Study (HPFS) prospective cohort study, Choi et al 
(2004a)reported a RR of 2.53 for incident gout in males consuming more than 50g of alcohol 
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per day, compared with consuming no alcohol. A dose-response between the amount of 
alcohol consumed and the risk of incident gout was observed (Choi et al 2004a).  The 
association between alcohol and increased risk of gout may be attributable to increased 
purine intake and nucleotide turnover (beer is particularly high in the purine, guanosine), 
along with reduced renal excretion due to lactic acidosis (Roddy & Choi, 2014).  
1.5.8 Diet    
In the HPFS, a higher risk of gout also was reported in participants with higher intakes of meat 
and seafood (Choi et al 2004b),  sugar sweetened soft drinks (Choi et al 2008), free fructose 
(Choi et al 2008) and also participants with higher ‘western diet’ pattern scores (characterised 
by red or processed meats, sugar sweetened drinks, sweets, desserts, and refined grains) (Rai 
et 2017b).  Conversely, a higher consumption of dairy foods (Choi et al 2004b), vitamin C (Choi, 
Gao & Curhan, 2009),  coffee (Choi, Willet & Curhan, 2007), decaffeinated coffee (Choi, Willet 
& Curhan, 2007) and higher ‘DASH’ (Dietary Approaches to Hypertension) dietary pattern 
scores  (Rai et 2017b) were associated with a reduced risk of gout. 
1.5.9 Genetics, serum urate and gout 
Twin studies have revealed that an estimated 45-75% of serum urate levels can be explained 
by inherited genetic variants (Dalbeth, Stamp & Merriman, 2017; Major et al 2018).  
Observational genome-wide association studies (GWAS) have identified a range of genes 
coding for individual urate transporters and proteins associated with metabolic pathways 
(Dalbeth, Stamp & Merriman, 2017; Major et al 2018), with genes coding for the transporter 
SLC2A9 thought to explain 2 to 3 % of the variation in urate in European populations (Dalbeth, 
Stamp & Merriman, 2017; Major et al 2018).  
In contrast to our knowledge of the genetic influence on urate, less is known about the role 
of genetics in the development of gout (Major et al 2018).  Genes associated with gout which 
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encode proteins involved in the pathogenesis of gout flares, TLR4 gene and NLRP3 
inflammasome gene, have been identified in candidate gene studies (Dalbeth, Stamp & 
Merriman, 2017; Major et al 2018).  GWAS have indicated that variants of ABCG2 and SLC2A 
genes were associated with gout in European participants (Major et al 2018).  
1.6 Management of gout flares 
Colchicine or non-steroidal anti-inflammatory drugs (NSAIDs) are advocated as first line 
management of gout flares in the management guidelines from the British Society of 
Rheumatology (BSR) (Hui et al 2017) (see Figure 1.2), European League Against Rheumatism 
(EULAR) (Richette et al 2017), and American College of Rheumatology (ACR) (Khanna et al 
2012a).  Which medication is selected to manage acute gout flares will be influenced by 
patient choice, renal function, and existing comorbidities (Hui et al 2017; Khanna et al 2012a; 
Richette et al 2017).    
1.6.1 Colchicine 
Colchicine is a naturally occurring alkaloid which modulates both pro- and anti-inflammatory 
pathways involved in the pathogenesis of gout (Dalbeth, Lauterio & Wolfe, 2014; Roddy, 
Mallen & Doherty, 2013).  Systematic reviews (Khanna et al 2014; Van Echteld et al 2014) 
report an improvement in pain following the use of colchicine during gout flares, but 
colchicine use was associated with gastrointestinal symptoms and other adverse events.     
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Figure 1.2 Algorithm for the management of gout by  Hui et al (2017) 
 (included with permission from Oxford University Press) 
Coxib, cyclooxygenase-2 inhibitor; PPI, proton pump inhibitor; sUA, serum uric acid 
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1.6.2 Non-steroidal anti-inflammatory drugs 
Non-steroidal anti-inflammatory (NSAID) medication at full dose, with the co-prescription of 
a gastro-protective agent, has been advocated as first line acute management of gout flares 
in the BSR (see Figure 1.2), EULAR and ACR gout management guidelines (Hui et al 2017; 
Khanna et al 2012a; Richette et al 2017) as an alternative to colchicine. NSAIDs are more 
commonly prescribed than colchicine and prednisolone for gout flares in the UK (Mikuls et al 
2005; Roddy et al 2010). 
A systematic review of treatment strategies for acute gout by Khanna et al (2014) revealed 23 
RCTs reporting the efficacy of NSAIDs (e.g. indomethacin, naproxen) in the management of 
flares.   No difference in pain intensity was observed by Roddy et al (2019) in people 
randomised to either colchicine or naproxen treatment, but naproxen was associated with 
fewer side-effects. 
NSAIDs are contraindicated in patients with impaired renal function or a history of 
gastrointestinal ulceration or perforation (Hui et al 2017).  
1.6.3 Corticosteroids 
Corticosteroids, oral or intra-articular injection, have been advocated as alternative treatment 
for gout flares by BSR (see Figure 1.2) and EULAR gout management guidelines for individuals 
who are unable to tolerate colchicine or NSAIDS (Hui et al 2017; Richette et al 2017).   Oral 
prednisolone has been shown to be an equivalent treatment to NSAIDs (Janssens et al 2008; 
Man et al 2007).  Whilst a systematic review by Wechalekar et al (2013) failed to identify any 
RCTs investigating the efficacy and safety of intra-articular glucocorticoids for gout flares, their 
use has been advocated for acute management, particularly monoarticular flares (Hui et al 
2017). 
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1.6.4 Non- pharmacological management 
 Guidance to rest, elevate and ice a joint affected by a gout flare is based on expert opinion 
(Hui et al 2017).  A Cochrane review of lifestyle interventions for acute gout by Moi et al (2013) 
found low quality evidence from a single study that the addition of topical ice therapy to oral 
prednisolone and colchicine for people experiencing an acute flare led to a greater pain 
reduction at one week. 
1.7 Urate-lowering therapy and gout management 
1.7.1 Allopurinol    
Allopurinol is recommended as first line therapy in the management of gout (Hui et al 2017; 
Khanna et al 2012b; Richette et al 2017; Seth et al 2014) (Figure 1.2).   Allopurinol is a purine 
non-specific xanthine oxidase inhibitor which inhibits the synthesis of uric acid (Abhishek, 
Roddy & Doherty, 2017; Roddy, Mallen & Doherty, 2013) and is later metabolised to 
oxypurinol which is renally excreted (Abhishek, Roddy & Doherty, 2017).  A Cochrane review 
of 11 trials (RCTs and quasi RCTs) by Seth et al (2014) investigated the efficacy and safety of 
allopurinol in comparison to either placebos or active comparators (alternative medication or 
alternative different dose of allopurinol) concluding that, based on low to moderate quality 
evidence, allopurinol was more successful than placebo in achieving target serum urate levels 
and there were similar withdrawals compared to placebo and active comparators. A starting 
dose of 50-100 mg of Allopurinol has been advocated by practice guidelines, followed by up-
titration of Allopurinol to achieve target serum urate levels (Hui et al 2017; Khanna et al 2012b; 
Richette et al 2017). A serum urate level below 360 µmol/L was achieved by 95% of 
participants receiving up titration of their allopurinol dose in a recent nurse-led treat to target 
(T2T) RCT by Doherty et al (2018). 
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The BSR gout management guidelines (Hui et al 2017) advocated that the option of ULT should 
be discussed with all patients with a diagnosis of gout, but ULT should be particularly advised 
if patients experience ≥2 gout flares in the previous 12 months, tophi, chronic gouty arthritis, 
joint damage, renal impairment, renal stones, a prescription for diuretics or a diagnosis of gout 
at a young age.    
Allopurinol is usually well tolerated although around 2% of users may develop a rash and 5% 
may stop allopurinol due to an adverse event (Stamp et al 2012).  BSR gout management 
guidelines recommend adjustment of the starting dose of Allopurinol depending on a patient’s 
eGFR (Hui et al 2017).  
Despite the availability of allopurinol gout is frequently sub-optimally managed and only a 
third of people with gout consulting a GP in the UK in 2012 received urate-lowering therapy 
(ULT) (Kuo et al 2015a). When ULT is prescribed, in the majority of patients the dose is not 
adjusted to optimise urate levels (Cottrell et al 2013), and over two thirds of patients 
prescribed ULT are non-adherent to ULT (Scheepers et al 2018).     
1.7.2 Febuxostat 
Febuxostat has been recommended by the National Institute for Health and Care Excellence 
(NICE) for ULT in situations where allopurinol is not tolerated or contraindicated, including 
where renal impairment precludes an increase in allopurinol dose to achieve target serum 
urate levels (Hui et al 2017;  National Institute for Health and Care Excellence, 2008) (Figure 
1.2).  Febuxostat is a non-purine xanthine oxidase inhibitor which unlike allopurinol inhibits 
both the oxidised and reduced form of xanthine oxidase and is metabolised in the liver (Liu et 
al 2018; Roddy, Mallen & Doherty, 2018; Ye et al 2013).     
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1.7.3 Uricosuric agents  
Uricosuric medication reduces serum urate levels by increasing the amount of uric acid which 
is secreted by the kidneys (Kydd et al 2014).  Uricosuric medications such as sulfinpyrazone, 
probenecid and benzbromarone may be used as ULT where individuals are intolerant, 
resistant or have contraindications to xanthine oxidase inhibitors (Hui et al 2017; Richette et 
al 2017).  Losartan and fenofibrate have mild uricosuric effect but should not be used as the 
sole ULT. They can be considered as adjunctive ULT where medication for hypertension or 
lipid lowering respectively is required (Hui et al 2017).  
Allopurinol is the most commonly used ULT in UK general practice, with 38% of patients with 
gout prescribed allopurinol and less than 1% of patients prescribed febuxostat (0.2%) or 
uricosuric agents (0.1%) as a first line ULT between 1987 to 2014 (Scheepners et al 2018). 
1.7.4 Diuretics and lifestyle factors 
A review of diuretics prescribed to individuals with a diagnosis of gout is recommended and 
where possible alternatives to thiazide and loop diuretics can be prescribed (Hui et al 2017; 
Richette et al 2017).   
 Guidelines for the management of gout recommend that, where relevant, dietary 
modification, reduction in alcohol intake, weight optimisation/loss, and modification of 
cardiovascular risk factors should be promoted (Hui et al 2017; Khanna et al 2012b). 
1.8 Gout flares  
Rapid onset acute inflammatory gout flares, characterised by excruciating joint pain, 
tenderness, swelling, erythema and heat, are the clinical hallmark feature of gout (Roddy, 
Mallen & Doherty, 2013; Taylor et al 2015; Teng, Nair & Saag, 2006). More frequent flares are 
associated with poorer HRQOL (Hirsch et al 2008; Khanna et al 2012c; Scire et al 2013), 
functional disability (Lee et al 2009; Scire et al 2013), higher use of healthcare resources 
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(Jackson et al 2015; Khanna et al 2012c; Saseen et al 2012), and lower work productivity 
(Khanna et al 2012c).  
Gout flares have been identified as a key patient-reported outcome measure in the 
management of chronic gout by both people living with gout and clinicians (Schumacher et al 
2009).  However, until recently there has been no widely agreed definition of gout flare used 
in the research literature and no consensus on how gout flares should be measured as an 
outcome (Gaffo et al 2012; de Latour, Dalbeth & Taylor, 2015; Taylor et al 2009). 
Consequently, a standardised definition of a gout flare outcome measure has yet to be 
endorsed as a clinical outcome measure by Outcome Measures in Rheumatology Clinical Trials 
(OMERACT) (de Latour, Dalbeth & Taylor, 2015).   A recent definition of gout flares has been 
validated for use in clinical research (Gaffo et al 2018).  This definition of gout flares requires 
fulfilment of three or more of the following criteria: a patient-defined gout flare, pain score of 
three or more out of ten, the presence of at least one swollen joint, or the presence of at least 
one warm joint (Gaffo et al 2018).  However, the authors have acknowledged the potential 
limitations regarding the generalisability of the validation process for this definition to primary 
care (Gaffo et al 2018). 
Where the frequency of flares has been investigated previously, flares have been recorded by 
various different methods and over different reference time-periods.  For example, studies 
have reported either the mean, median or number (proportion) of gout flares in three months 
(Dalbeth et al 2011; Dalbeth et al 2013; Wallace et al 2016; Wu et al 2009), six months (Wu et 
al 2009), 12 months (Becker et al 2009; Khanna et al 2012c; ten Klooster et al 2014; Lee et al 
2009; Rashid et al 2015; Saseen et al 2012; Scire et al 2013; Spaetgens et al 2015; Strand et al 
2012; Wu et al 2009), or another length of time (Annemans et al 2008; Halpern et al 2009; 
Rothenbacher et al 2011; Sarawate et al 2006).  Whilst some studies use self-reported gout 
flares (Dalbeth et al 2013; Khanna et al 2012c; Khanna et al 2015; ten Klooster et al 2014), 
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many studies use gout consultations or prescriptions recorded in health insurance, clinical 
consultation or prescription databases, assuming these were for gout flares (Annemans et al 
2008; Halpern et al 2009; Jackson et al 2015; Rashid et al 2015; Rothenbacher et al 2011; 
Sarawate et al 2006; Saseen et al 2012; Wu et al 2009).   
Observational studies which report the number of gout flares over a 12-month period, have 
reported a mean of 3.1-3.9 (ten Klooster et al 2014; Spaetgens et al 2015) and median of 1 
(Scire et al 2013).  However, these included patients recruited from secondary care 
Rheumatology clinics only.  Of the participants in the US and EU Health and Wellbeing survey, 
a quarter reported experiencing no flares in the previous 12 months, whilst over a third 
reported three or more flares during the same period (Khanna et al 2012c).  Conversely in a 
population-based survey by Proudman et al (2019) using data from the South Australian 
Health Omnibus Survey, most participants (58%) reported no flares in the last 12 months, but 
25% of participants reported two or more flares in this time period.    
1.8.1 Trajectories of clinical outcomes 
Whilst existing studies have reported the number of flares experienced by people living with 
gout over different time-periods, little is actually known about the pattern or ‘trajectory’ of 
flares over time.  Over the last decade, there has been increased interest in utilising latent 
class growth analysis (LCGA) to investigate trajectories in longitudinal cohorts (Jung & 
Wickrama, 2008; Kongsted et al 2016).  LCGA has been used to identify trajectories of pain, 
activity limitation, psychological factors, and comorbidities in a range of musculoskeletal and 
rheumatological conditions (Holla et al 2014; Nicholls et al 2014; Rzewuska et al 2015; Strauss 
et al 2014; Verkleji et al 2012).  Trajectories of other clinical parameters such as disease activity 
and pain have also been identified using other methods such as growth mixture modelling 
(GMM) (Ogollah et al 2018; Siemons et al 2014).  However, methods such as LCGA or GMM 
have yet to be utilised to investigate latent trajectories of gout flares. 
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1.8.2 Factors associated with gout flares 
Gout characteristics 
Several studies have investigated the relationship between serum urate levels and risk of gout 
flares.  In a retrospective review of medical claims data, Halpern et al (2009) showed that the 
odds of gout flare in a two-year period were 1.3 times higher in patients with a serum urate 
level over 6 mg/dL in comparison with patients with a serum urate below 6 mg/dL (OR 1.3).   
Further retrospective reviews of medical claims data reported that a serum urate level over 6 
mg/dL or initiation of ULT was associated with a greater frequency of gout flares in 12 months 
(Jackson et al 2015; Sarawate et al 2006) and higher average number of gout flares was seen 
at higher serum urate levels (Wu et al 2009).   
In a case-control study by Abhishek et al (2016), a serum urate greater than 541 µmoles/litre, 
and disease duration of 13.4 years or more was associated with an increased odds of more 
than 2 gout flares in a 12 month period (OR of 1.96 and 1.97 compared with a serum urate ≤ 
480 µmoles/litre and disease duration ≤ 5.1 years respectively).  Whilst in a retrospective 
cohort study of patients newly initiated on ULT, Rashid et al (2015) identified that the odds of 
gout flares in a 12 month period were higher in participants with a serum urate level greater 
than 6.0 mg/dl (OR 1.64 one to two flares, OR 3.61 three or more flares), compared with those 
with a serum urate ≤ 6.0 mg/dl. 
 Medications  
The use of certain medications has been associated with an increased risk of gout flares.  In 
an internet-based case-crossover study there was an increased odds of a recurrent flare (a 
flare within a 12-month period in people with existing gout) in participants who self-reported 
using aspirin  (OR 1.81) (Zhang et al 2014) or diuretics (OR 3.6) (Hunter et al 2006)  in the 
previous 48 hours, compared with those who did not.  Participants in a retrospective cohort 
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with a prescription for a diuretic or anti-inflammatory medication in their medical record were 
more likely to have had gout flares in a 12-month period (OR of 1.23 for ≥3 flares with diuretic 
prescription, OR of 3.10 for ≥3 flares with anti-inflammatory medication prescription), 
compared with those without prescriptions for diuretic or anti-inflammatory medication 
(Rashid et al 2015). However, no difference was identified in the number of flares experienced 
in the previous 12 months in participants taking diuretics, compared with those not taking 
diuretics, in a case-control study by Mitnala et al (2016).  
Comorbidities 
Renal disease, hypertension and ischaemic heart disease were identified as risk factors for first 
post-diagnosis gout flare in the UK THIN database (Rothenbacher et al 2011) (HR of 1.33, 1.15, 
1.12 respectively).    The number of comorbidities was a risk factor for gout flares in a 
retrospective cohort study of patients newly initiated on ULT, and participants who had three 
or more comorbidities had an increased odds of 1-2 flares or ≥3 flares during  a 12-month 
period (OR 1.34, 1.93 respectively) (Rashid et al 2015).    
BMI, alcohol consumption and dietary factors 
Obesity (BMI ≥30 kg/m2) was identified as an independent risk factor for first post-diagnosis 
gout flare in the UK THIN database (Rothenbacher et al 2011) (HR 1.22).  Proudman et al (2019) 
reported that a higher BMI was associated with a greater probability of flares in the South 
Australian Health Omnibus Survey, and in participants who reported flares there was a greater 
probability of two or more flares.  Baseline BMI was not associated with recurrent gout flares 
in an analysis of observational data from the Multiple Risk Factor Intervention Trial (MRFIT) 
database, however more than a 5% increase or decrease in BMI was associated with an 
increase and decrease respectively in recurrent gout flares (OR 1.60, 0.61 respectively) 
compared with no change in BMI (Nguyen et al 2017).  A systematic review of longitudinal 
23 
 
studies reporting weight loss in people with gout reported that six out of eight studies 
reported an improvement in gout flares (Nielsen et al 2017). 
An internet-based case-crossover study by Zhang et al (2006) identified that, compared to no 
alcohol consumption, consuming alcohol was associated with an increased odds of recurrent 
gout flares (OR 2.5 for ≥7 drinks in the last 48 hours) and the relationship was present for all 
types of alcohol reported. A dose-response relationship between the amount of alcohol 
consumed in the previous 24 hours and the odds of a recurrent flare was also observed (Zhang 
et al 2006).  Later internet-based case-crossover studies found that the highest quintile of 
purine intake (Zhang et al 2012a) and cherry consumption (Zhang et al 2012b) over a two-day 
period was associated with an increased and reduced odds of recurrent gout flares 
respectively (OR 4.76 compared with lowest quintile of purine intake, OR 0.65 compared with 
no cherry consumption). A randomised double-blind controlled trial by Dalbeth et al (2012) 
demonstrated a reduction in gout flares over a three-month period in participants receiving 
enriched skimmed milk powder. 
Socio-demographic 
Non-attendance at further education and living in a socioeconomically deprived area were 
associated with having two or more gout flares over a 12-month period in a cross-sectional 
analysis in primary care (Bowden-Davies et al 2018). Younger age but not socio-economic 
status (SES) was associated with flare frequency in the preceding year in a population-based 
study using data from the South Australian Health Omnibus Survey (Proudman et al 2019).  
This is in contrast to the study by Rashid et al (2015) which reported that patients over the 
age of 65 years were more likely to experience three or more flares (OR 1.81) compared with 
individuals aged ≤65 years.    
In summary, serum urate, disease duration, medications, number or type of comorbidities, 
obesity, alcohol consumption, diet, educational attainment, socio-economic status  and  age 
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have been associated with recurrent flares or flare frequency.  Although some previous 
studies have reported the risk of gout flares in a follow-up time period, there has been no 
studies using data from multiple follow-up time-points to identify and describe people 
experiencing different patterns or trajectories of gout flares over time.    
1.9 Health-related quality of life (HRQOL) 
Interest in health research relating to quality of life has increased significantly over the last 30 
to 40 years (Hickey et al 2005; Fayers & Machin, 2016). Despite interest in health-related 
quality of life (HRQOL), there remains a lack of consensus regarding a precise definition of 
HRQOL and the terms ‘quality of life’, ‘health-related quality of life’, ‘wellbeing’ ‘health status’, 
‘functional status’ and ‘satisfaction’ are often used interchangeably (Bakas et al 2012; Dijkers, 
2007; Moons, 2004; Taillefer et al 2003). HRQOL is multidimensional and conceptualisations 
of HRQOL often include the dimensions of physical functioning, social networks or support, 
psychological or emotional wellbeing, role functioning or performance, and general health 
(Bowling, 2005; Fitzpatrick et al 1992; Hennessy et al 1994; Testa & Simonson, 1996; Wilson 
& Cleary, 1995).    The various published definitions of HRQOL, displayed in Table 1.1, concur 
with the view that HRQOL is a multifaceted concept. The assessment of HRQOL can involve 
the use of generic HRQOL instruments; to assess a variety of domains applicable to a variety 
of health states, and disease specific instruments; to assess domains deemed more relevant 
to a disease of interest (Hickey et al 2005; Testa & Simonson, 1996).  An individual’s subjective 
assessment of their HRQOL may be influenced by their perception or satisfaction of their 
situation, in contrast to their expectations or aspirations (Bowling, 2003; Felce & Perry, 1995; 
Moons, Budts & De Geest, 2006).  
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Table 1.1 Published definitions of health-related quality of life 
 
Authors Definition of health-related quality of life 
Bowling, 2005 
p.7 
 
“Quality of life, then, is about the goodness of life, and in relation 
to health it is about the goodness of those aspects of life affected 
by health”. 
 
Carr, Gibson & 
Robinson, 2003 
p.10 
“Health-related quality of life is a broader concept concerned with 
whether disease or impairment limits one’s ability to fulfil a 
normal role”. 
 
Cieza & Stucki, 2008 
p.311 
"Health-Related Quality of Life can be defined as an individual’s 
perceptions of health and health related domains of well-being". 
 
Hays & Reeve, 2008 
p.241 
“Health-related quality of life (HRQOL) refers to how well a 
person functions in their life and his or her perceived wellbeing 
in physical, mental, and social domains of health”. 
 
Hennessy et al 1994 
p.665 
 
“Health-related quality of life is multidimensional and is composed 
of, at minimum, physical functioning, psychological well-being, 
social and role functioning, and health perceptions”. 
 
Kempen, Jelicic & 
Ormel, 1997 
p. 539 
“Health-related quality of life (HRQL) is a broad, multidimensional 
concept covering significant domains of daily functioning and 
subjective experience, such as physical functioning, role and 
social functioning, somatic sensation, perceived health, and 
subjective well-being.” 
 
Moons, Budts & de 
Geest, 2006 
p.896 
“Health-related quality of life has been developed to describe 
aspects of an individual’s subjective experience that relate both 
directly and indirectly to health, disease, disability and 
impairment…..and the effectiveness of treatment”. 
 
Muldoon et al 1998 
p.542 
“..study of the patient's personal morbidity- that is the various 
effects that illness and treatments have on daily life and life 
satisfaction”. 
 
Skevington,  
Lofty & 
OConnell, 2004 
p.299   
“An individual’s perception of their position in life in the context 
of the culture and value systems in which they live, and in relation 
to their goals, expectations, standards and concerns”. 
Testa & Simonson, 
1996 
p. 835 
“health-related quality of life refer to the physical, psychological, 
and social domains of health, seen as distinct areas that are 
influenced by a person’s experiences, beliefs, expectations, and 
perceptions”. 
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1.9.1 The importance of HRQOL measurement 
Patient-completed HRQOL measures can provide information on the wider impact of a disease 
on the individual involved (Haywood et al 2015; Calvert & Freemantle, 2003; Moons, 2004). 
This information can include details relating to the prevalence of any dysfunction or disability, 
in addition to psychosocial or emotional problems (Calvert & Freemantle, 2003; Detmar et al 
2002; Higginson & Carr, 2001).  Self-completion of HRQOL measures by patients is important 
as healthcare professionals and patients judge quality of life from very different perspectives 
(Fayers & Machin, 2016; Fitzpatrick et al 1992).    The use of HRQOL measures over a period 
of time can also help to detect the dynamic impact of a disease, due to psychosocial 
adaptation or changes in the course of the disease (Fayers & Machin, 2016; Hahn et al 2007).  
Data obtained through HRQOL measurement have the potential to facilitate decision-making 
concerning clinical management, service development and health policy (Green, Brazier & 
Deverill, 2000; Hahn et al 2007; Hennessy et al 1994; Fayers & Machin, 2016), through an 
understanding of the wider impact of disease on patients and identifying patients at risk of 
poorer outcomes (Calvert & Freemantle, 2003; Fitzpatrick et al 1992). 
1.9.2 HRQOL in people living with gout 
The various instruments which have been used to assess HRQOL in people with gout were 
described, and their clinimetrics evaluated in a systematic review by Chandratre et al (2013).  
The instruments most commonly used to measure generic HRQOL were found to be the 36-
Item Short-Form Health Survey (SF-36) (Ware & Sherbourne, 1992) and Health Assessment 
Questionnaire Disability Index (HAQ-DI) (Bruce & Fries, 2003), which have been endorsed by  
the OMERACT group as  patient reported outcome measures in chronic gout (Singh et al 
2011a). The newer disease-specific measure, the Gout Impact Scale (GIS) (Hirsch et al 2008), 
was used by a smaller number of studies (Chandratre et al 2013).  More information relating 
to the interpretation of these instruments along with the validity, reliability and 
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responsiveness of these instruments can be found in chapter three.  Other instruments which 
have been used to measure HRQOL in people with gout included AIMS, EQ-5D, HAQ-II, MOS 
20, SF-12, WHO-QOL BREF (Chandratre et al 2013).    
Studies which have investigated HRQOL in people living with gout which were reported in the 
systematic review by Chandratre et al (2013) and identified in a subsequent review of the 
literature for this thesis are listed in appendix 1.   
Lower scores on the physical component of the SF-36, indicating worse generic HRQOL, have 
been reported in people living with gout in comparison with population normative values 
(Becker et al 2009; Khanna et al 2011a; Lee et al 2009; Strand et al 2012), and individuals 
matched on age and gender (Fu et al 2017; Scire et al 2013).  Worse quality of life overall and 
on the physical domain, measured using the WHO-QOL BREF, was reported by Roddy, Zhang 
& Doherty (2007c) in people with gout registered with two general practices in the UK, in 
comparison with controls.  More recently, worse physical component scores (PCS) on the SF-
12 were reported in people who reported a diagnosis of gout in the population-based survey 
by Proudman et al (2019), in contrast with those without gout.   
Conversely no difference between quality of life in the mental or psychological domains in 
people living with gout, in comparison with either controls or population normative values, 
has been reported by several studies (Becker et al 2009; Roddy, Zhang & Doherty, 2007c; Scire 
et al 2013; Singh & Strand, 2008).  In fact some studies suggest that quality of life on the 
mental domain may in fact be slightly better for people living with gout; Lee et al (2009) 
reported that people living with gout over the age of 75 had a higher SF-36 mental component 
score (MCS) than the general population, whilst Khanna et al (2011a) reported that the SF-36 
MCS for participants with gout were 0.2 SD above the US population norm.   
The level of activity limitation and disability, measured via HAQ-DI, in people living with gout 
reported in observational studies at a group level is mild (mild functional disability HAQ-DI 
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score less than 1.0) (Khanna & Khanna, 2012), with the majority of observational studies 
reporting mean HAQ-DI scores of 1.0 or below (Alvarez-Hernandez et al 2008; Alvarez-
Hernandez et al 2009; Becker et al 2009; Chandratre et al 2018; Fu et al 2017; Lopez Lopez et 
al 2017; Spaetgens et al 2015; Scire et al 2013; ten Klooster et al 2011; ten Klooster et al 2014; 
van Groen et al 2010; Wallace et al 2016).  In addition, lower levels of disability were reported 
in people with gout in comparison with other diseases such as rheumatoid arthritis (Van Groen 
et al 2010).  
The disease-specific GIS places a stronger emphasis on emotional consequences of gout, in 
comparison to SF-36 and HAQ-DI (Spaetgens et al 2014). Patient-rated gout severity has been 
shown to correlate with GIS scores in both cross-sectional and prospective studies (Hirsch et 
al 2008; Khanna et al 2011b), with participants with more severe gout having higher GIS scores 
indicating a greater impact of gout on HRQOL and worse disease-specific HRQOL.   The five 
subscales of the gout impact scale cover different domains of disease-specific HRQOL; gout 
concern overall (CO), medication side effects (MSE), unmet treatment need (UTN), wellbeing 
during an attack (WBDA), and concern during an attack (CDA).   
1.9.3 Change in HRQOL in people living with gout over time 
The majority of studies investigating HRQOL in people living with gout are cross-sectional (see 
appendix 1), thus fail to capture the dynamic nature of HRQOL.  Of the prospective studies 
which report HRQOL in people with gout, only a small number explicitly describe the change 
in HRQOL measures over time by describing mean change, effect sizes, and standardised 
response means (SRM).    
Gout impact scale (GIS) 
Mean change (SD) ranging from -2.0 (22.6) to -9.1 (21.2) were observed in different GIS 
subscales between baseline and one year, indicating an improvement in HRQOL, in an 
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American observational cohort study (Wallace et al 2016).    Standardised response means 
(SRM) ranging from 0.09 to 0.43 for the different GIS subscales, and effect sizes ranging from 
0.07 to 0.34 for different GIS subscales were observed for the same cohort (Wallace et al 
2016).    
Mean change (SD) in different GIS subscales ranging from -5.24 (14.26) to -7.61(18.76) were 
observed between week four and week eight in a subgroup of RCT participants deemed to 
have ‘minimally improved’ gout based on specific anchor questions (Khanna et al 2011b).  
Effect sizes for different GIS subscales ranging from 0.22 to 0.38 were observed for the same 
group of participants (Khanna et al 2011b). 
More recently higher standardised response means (SRM) for GIS subscales over two years, 
ranging from 0.18 to 1.08, were reported by Chinchilla, Doherty & Abhishek (2019) for 
participants whose gout status was classified as ‘better’ after two years in an RCT.  This group 
of participants were recruited from GP practices in the UK and included both participants 
receiving the nurse-led urate-lowering intervention and those receiving usual care.  
SF-36 PF10 
An effect size of 0.48 was observed in SF-36 Physical function (PF10) scores from baseline to 
one year, displaying an improvement in HRQOL, in a Spanish prospective cohort with 
participants who attended specialist gout clinics (Khanna et al 2011a).  Improvement in HRQOL 
was also reported between baseline and 25 weeks in an RCT by Strand et al (2012), with mean 
change (SD) in SF-36 Physical function (PF10) scores of 0.25 (18.97) and 11.8 (24.1) in the 
placebo and intervention group respectively.  
HAQ-DI 
Change in HAQ-DI scores over six months was reported in a Mexican prospective study of 
participants from rheumatology departments by Alvarez-Hernandez et al (2008).   No change 
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in HAQ-DI score was seen in 28.7% of participants, 38.3% experienced an improvement, and 
32.9% experienced a deterioration.  An effect size of 0.62 was reported for HAQ-DI scores 
from baseline to six months in this cohort. 
The studies which have investigated HRQOL prospectively predominantly include participants 
from secondary care and often involve a clinical intervention.  Studies in primary care often 
combined participants with those from rheumatology clinics, thus not permitting separate 
interpretation of HRQOL in people in primary care (Dalbeth et al 2013; Singh et al 2016; 
Stewart et al 2018; Wallace et al 2016). Hence results may not be generalizable to primary 
care populations where most patients with gout are managed.  The majority of studies 
prospectively investigating HRQOL follow people with gout for one year or less, thus only 
permitting a short period of time to capture any change in HRQOL.  
Thus, there is a paucity of observational studies prospectively investigating change in both 
disease-specific and generic HRQOL in people with gout, specifically in primary care and over 
periods longer than one year.   
1.9.4 Factors associated with HRQOL in people living with gout 
A range of gout-specific, comorbid, socio-demographic and other factors have been reported 
to be associated with HRQOL in people living with gout.  A summary of different factors 
identified as associated with either generic or gout-specific HRQOL can be found in appendix 
2. The key findings of these cross-sectional and prospective studies, relating to the factors 
associated with HRQOL, are described here. 
Gout characteristics 
Flare frequency 
Gout flares have been highlighted as the major factor associated with HRQOL in people with 
gout (Chandratre et al 2013) with flare frequency associated with worse disease-specific 
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HRQOL on some of the GIS subscales (Chandratre et al 2018; Hirsch et al 2008), worse generic 
HRQOL in the physical domain (Becker et al 2009; Khanna et al 2011a; Khanna et al 2012c; 
Proudman et al 2019; Scire et al 2013) and greater activity limitation measured via HAQ-DI 
scores (Scire et al 2013).  In prospective studies flare frequency has been associated with 
change in both SF-36 PF10 scores (Khanna et al (2011a) and HAQ-II scores (Stewart et al 2018) 
with more frequent flares associated with worse scores.  
Current/recent flare 
Experiencing a current or recent flare has been associated with worse GIS subscale scores 
(Chandratre et al 2018; Khanna et al 2015; Lee et al 2019), worse generic HRQOL measured 
via SF-12 PCS and SF-36 (Khanna et al 2015; Scire et al 2013) and worse HAQ-DI scores 
(Chandratre et al 2018; Scire et al 2013).   In addition, a flare within the previous three months 
was associated with a worsening total GIS score (summary of all GIS subscales) over one year 
in a prospective study by Wallace et al (2016).    
Number of joints affected 
Several studies have reported worse gout-specific HRQOL (Chandratre et al 2018; Hirch et al 
2010; Wallace et al 2016), generic HRQOL on the physical or mental domain (Becker et al 2009; 
Khanna et al 2011a; Lee et al 2009; Scire et al 2013; Wallace et al 2016) or activity limitation 
(Alvarez-Hernadez et al 2008; Becker et al 2009; Chandratre et al 2018; Scire et al 2013) where 
more joints are affected by gout.  Tender joint count was associated with change in activity 
limitation, displayed by worse HAQ-II scores, at one year in a prospective analysis by Stewart 
et al (2018).  
Gout severity/activity 
Patient or physician rated ‘gout severity’ or ‘gout activity’ have correlated with worse HRQOL 
measured via the GIS subscales (Chincilla, Doherty & Abhishek, 2019; Hirsch et al 2008; Hirsch 
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et al 2010; La-Crette et al 2018;  Sarkin et al 2010) or measured via HAQ-DI (Wallace et al 
2016).  Wallace et al (2016) also reported that a worsening physician severity score was 
associated with worse prospective total GIS scores.   
Disease duration, serum urate levels and medications to treat gout 
Studies investigating the relationship between HRQOL and other gout-specific factors such as 
disease duration, tophi, serum urate levels, and medication to treat gout, have revealed 
conflicting findings.  Living with gout for longer has been associated with better disease-
specific HRQOL measured via GIS unmet treatment need (UTN) subscale (Chandratre et al 
2018) but worse generic HRQOL measured via HAQ-DI and SF-36 MCS (Scire et al 2013).  
However other studies have reported no association between disease duration and SF-36 or 
HAQ-DI scores (Becker et al 2009; Chandratre et al 2018).   In addition, Wallace et al (2016) 
eliminated disease duration, along with tophi, and serum urate level, as covariates from 
multivariable analysis as they were not associated with change in total GIS score. 
The presence of tophi has been associated with worse scores for GIS concern overall (CO) 
(Hirsch et al 2010), SF-36 PCS (Becker et al 2009; Scire et al 2013), SF-36 PF10 (Becker et al 
2009; Edwards et al 2019), SF-12v2 (Khanna et al 2012), and HAQ-DI (Alvarez-Hernadez et al 
2008; Edwards et al 2019; Scire et al 2013).  However, no association between a history of 
tophi and any of the GIS subscales (Chandratre et al 2018; Lee et al 2019) or HAQ-DI scores 
(Becker et al 2009) has been reported.   
Elevated serum urate levels have been associated with worse disease-specific HRQOL 
measured via GIS concern overall (CO) and GIS unmet treatment need (UTN) (Hirsch et al 
2008; Lee et al 2019), generic HRQOL on the physical domain measured via SF-36 PCS (Khanna 
et al 2011a) and HAQ-II scores (Stewart et al 2018). However, only a minimal correlation 
between the latest serum urate level and GIS concern overall was observed by Hirsch et al  
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(2010), and no correlation between serum urate and HAQ-DI or any of the SF-36 subscales 
was observed by Becker et al (2009). In addition, no difference in generic HRQOL, measured 
via WHO-QOL BREF, was observed in participants dichotomized by serum urate levels (Roddy, 
Zhang & Doherty, 2007c).  Serum urate was not associated with change in HAQ-II scores over 
time (Stewart et al (2018). 
Several observational studies have reported no association between allopurinol use and 
generic HRQOL measured by SF-36, HAQ-DI (Chandratre et al 2018; Scire et al 2013), SF-12 
(Proudman et al 2019) or WHO-QOL BREF (Roddy, Zhang & Doherty, 2007c).  However, 
Chandratre et al (2018) reported that using allopurinol was associated with better disease-
specific HRQOL measured via GIS unmet treatment need (UTN) and with worse disease-
specific HRQOL measured via GIS wellbeing during an attack (WBDA). Worse SF-36 PCS and 
HAQ-DI scores have been associated with colchicine (Fu et al 2017; Scire et al 2013) and NSAID 
use (Scire et al 2013) in other observational studies, whereas Alvarez-Nemegyei et al (2005) 
described how NSAID requirement was not associated with disability, indicated by a HAQ-DI 
score greater than 0.5.  However, caution is required when interpreting the findings of 
observational studies and associations between use of medication such as ULT and outcomes 
should not be interpreted as causal effects. 
Comorbid characteristics 
Number and type of comorbidities 
A number of studies have reported associations between generic HRQOL and comorbidities.  
Worse SF-36 PCS and HAQ-DI scores have been associated with experiencing one or more 
comorbidities (Becker et al 2009), the total number of comorbidities (Scire et al 2013; 
Spaetgens et al 2015), and the Charlson Comorbidity Index (Spaetgens et al 2015).  Medical 
and musculoskeletal comorbidities were associated with reduced generic HRQOL overall, 
measured via WHO-QOL BREF, across all domains except the social domain (Roddy, Zhang & 
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Doherty, 2007c).  Alvarez-Nemegyei et al (2005) reported that hyperlipidaemia and ischaemic 
heart disease (IHD) were associated with disability measured via the HAQ-DI.  A range of  
comorbidities including renal disease, diabetes, and hypertension were correlated with both 
worse SF-36 PCS and MCS, indicating worse generic HRQOL in the study by Lee et al (2009). 
Whilst various comorbidities including renal disease, diabetes, angina, and stroke, were 
associated with worse generic HRQOL, measured via both SF-36 PF10 and HAQ-DI (Chandratre 
et al 2018).   Type II diabetes was associated with a worse HAQ-II score after one year but only 
for participants who experienced no activity limitation (had a HAQ-II of 0) at baseline (Stewart 
et al 2018).   
However, studies investigating the relationship between comorbidities and disease-specific 
HRQOL have yielded less consistent findings.  Lee et al (2019) found that participants with 
more comorbidities had better disease-specific HRQOL measured via the GIS concern overall 
(CO) and GIS medication side effects (MSE), compared to those participants with less 
comorbidities.  Apart from an association with worse GIS concern overall score and 
hypertension, no associations between individual self-reported comorbidities and any of the 
GIS subscales was reported by Chandratre et al (2018).  No association between either GIS 
subscales or total GIS score and individual comorbidities (Wallace et al 2016), the number of 
comorbidities (Spaetgens et al 2015), or the Charlson Comorbidity Index (Spaetgens et al 2015; 
Wallace et al 2016) have been observed. 
Anxiety and depression 
Both worse disease-specific and generic HRQOL has been observed in participants reporting 
anxiety or depression.  Participants who indicated some or severe problems on the anxiety 
and depression items of the EQ-5D-3L questionnaire  in a study  by Lee et al (2019) had higher 
scores on all of the GIS subscales, compared with those who did not report problems relating 
to anxiety and depression.  Worse disease-specific HRQOL, indicated by higher scores on all of 
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the GIS subscales, and worse generic HRQOL, indicated by SF-36 PF10 and HAQ-DI scores, has 
been associated with both depression and anxiety (Chandratre et al 2018).  Conversely Fu et 
al (2017) reported that whilst depression was associated with both worse generic HRQOL in 
the physical domain, measured via SF-36 PCS and HAQ-DI, anxiety was only associated with 
worse generic HRQOL on the mental domain, measured using SF-36 MCS.   
Pain 
The relationship between pain and HRQOL in people living with gout has been investigated by 
a range of studies.  Worse GIS subscale scores have been associated with more time between 
gout flares with gout-related pain (Hirsch et al 2010), typical gout pain measured via an 11-
point visual analogue scale (VAS) (Hirsh et al 2010) and the presence of body pain (Chandratre 
et al 2018).  Worse SF-36 PCS, SF-36 PF10, SF-36 MCS, HAQ-DI or HAQ-II scores have been 
associated with the presence of body pain (Chandratre et al 2018), worse gout-related pain 
(Becker et al 2009), more time between flares with pain (Lee et al 2009), and greater pain 
severity on a Likert scale or visual analogue scale (VAS) (Fu et al 2017; Lee et al 2009; Lopez 
Lopez et al 2017; Stewart et al 2018). VAS score was also associated with change in HAQ-II 
scores at one year, but this was only in participants who had a HAQ-II score of 0 at baseline 
(Stewart et al 2018).   
Socio-demographic characteristics 
Age 
Studies investigating the relationship between age and HRQOL in people living with gout have 
indicated that older age is associated with worse generic HRQOL on the physical domain but 
better disease-specific HRQOL and generic HRQOL in the mental domain.   Older age has been 
associated with increased HRQOL on all the WHO-QOL domains, except for HRQOL on the 
physical domain where older age was associated with worse HRQOL (Roddy, Zhang & Doherty 
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2007c).  Older age was also associated with better scores for SF-36 MCS (Lee et al 2009; 
Wallace et al 2016) but worse SF-36 PCS scores (Lee et al 2009; Khanna et al 2011), SF-36 PF10, 
HAQ-DI  (Chandratre et al 2018) and HAQ-II scores (Stewart et al 2018).   Older age was 
associated with worse HAQ-II scores at one year in a prospective study by Dalbeth et al (2011). 
Wallace et al (2016) found that older age was associated with an improved disease specific 
HRQOL, measured by total GIS score, in people living with gout over one year.   Better disease-
specific HRQOL with older age was also reported on all the GIS subscales, except GIS unmet 
treatment need (UTN), by Chandratre et al (2018).  
Sex 
Few studies have identified associations between sex and HRQOL in people living with gout.  
Roddy, Zhang & Doherty (2007c) reported that being male was associated with a better 
HRQOL on the psychological domain (measured via WHO-QOL BREF), but a reduced HRQOL in 
the social domain in people living with gout.  In contrast Chandratre et al (2018) reported that 
being female was associated with worse generic HRQOL measured by both SF-36 PF10 and 
HAQ-DI. 
Ethnicity 
Chandratre et al (2018) observed an association between being Caucasian and better GIS 
concern during an attack (CDA) and medication side effects (MSE) scores but no association 
with SF-36 PF10 or HAQ-DI scores.  Whilst Singh et al (2016) described worse disease-specific 
HRQOL, demonstrated by higher GIS unmet treatment need (UTN), wellbeing during an attack 
(WBDA), and concern during an attack (CDA), in African American participants with gout in 
comparison with Caucasian participants.  African American participants also had worse 
generic HRQOL on the mental domain, indicated by lower SF-36 MCS score, however there 
was no difference in HAQ-DI scores between the two groups (Singh et al 2016).  In another 
prospective study of people living with gout Dalbeth et al (2013) identified worse HAQ-II and 
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SF-36 PF10 scores, in Maori and Pacific participants in comparison with non-Maori or non- 
Pacific participants. 
Education 
Attendance at further education was associated with better generic HRQOL, measured via SF-
36 PF10 in the study by Chandratre et al (2018), however no relationship between attendance 
at further education and either HAQ-DI scores or GIS scores was reported in this cohort.  
Educational attainment was not associated with higher HAQ-DI scores in a multi variable 
analysis by Alvarez-Nemegyei et al (2005).  Conversely, educational attainment to upper 
secondary level or beyond has been associated with better generic HRQOL and activity 
limitation, measured via SF-36 PCS and HAQ-DI respectively (Scire et al 2013).   
Other socio-demographic factors 
Chandratre et al (2018) also investigated the relationship between other socio-demographic 
factors and HRQOL in people living with gout.  Being classified as most deprived based on 
indices of multiple deprivation (IMD) was associated with worse SF-36 PF10 scores, but not 
worse GIS scores. Whilst not being married or cohabiting was associated with worse SF-36 
PF10 scores, it was not associated with either worse HAQ-DI scores or GIS scores.  
BMI and alcohol frequency 
BMI 
Greater BMI was associated with a lower HRQOL on all domains except the social domain in 
the multivariable analysis by Roddy, Zhang & Doherty (2007c).  Obesity or a BMI ≥35 kg/m2 
has been associated with worse  SF-36 PCS (Scire et al 2013), SF-36 PF10 (Chandratre et al 
2018)  and HAQ-DI scores (Chandratre et al 2018; Scire et al 2013), but not GIS subscales scores 
(Chandratre et al 2018).  Stewart et al (2018) identified an association between a higher BMI 
and worse HAQ-II at baseline, but not change in HAQ-II at one year.  
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Alcohol frequency 
Compared to consuming alcohol daily, consuming alcohol only on special occasions or never 
consuming alcohol was associated with worse SF-36 PF10 and HAQ-DI scores, and consuming 
alcohol only on special occasions was associated with worse GIS unmet treatment need (UTN) 
scores.   
In summary, disease-specific and generic HRQOL in people living with gout has been 
associated with several gout-specific, comorbid, socio-demographic and other factors in 
previous studies.  Such factors include gout flares, experiencing a current or recent flare, the 
number of joints affected by gout, disease duration, serum urate level, medication used to 
treat gout, number or type of comorbidities, anxiety, depression, pain, age, sex, ethnicity, BMI, 
educational attainment and other  factors.  Of all of the factors identified gout flares are the 
major factor associated with impaired disease-specific and generic HRQOL in people living 
with gout.  However, there is a paucity of studies which have investigated the factors 
associated with HRQOL, whilst adjusting for a range of gout-specific, comorbid,  socio-
demographic and other factors.   The majority of studies which investigated factors associated 
with HRQOL in people living with gout only report associations observed in cross-sectional 
analyses, with a paucity of studies investigating factors associated with change in HRQOL 
particularly in primary care.  The studies which have investigated factors associated with 
change in HRQOL in people with gout have done so over periods no longer than 12 months. 
This paucity in the literature justifies the investigation undertaken within the following 
chapters. 
1.10 Conclusion  
In conclusion, this chapter provides background and context to the topics which are covered 
in this thesis.  This chapter highlights the paucity of research relating to gout flare trajectories, 
change in HRQOL over time, and factors associated with change in HRQOL in people living with 
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gout in primary care.  In the following chapter the structure of this thesis, the overall aim of 
each chapter and the key objectives of the thesis are outlined. 
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2 Chapter Two Overview of thesis  
2.1 Overview of chapter and aim 
The previous chapter provided relevant background to gout, gout flares, and health-related 
quality of life.  The aim of the following chapter is to outline the structure of the thesis, the 
overall aim of each chapter and the key objectives of the thesis.   
2.2 Thesis statement 
Gout is a common inflammatory arthritis which, despite the availability of effective treatment, 
is often sub-optimally managed in primary care (Kuo et al 2015a). The clinical hallmark of gout 
is rapid onset extremely painful acute inflammatory flares, characterised by swelling, 
erythema, heat and joint tenderness (Roddy, Mallen & Doherty, 2013; Taylor et al 2015; Teng, 
Nair & Saag, 2006).  Gout is associated with impaired HRQOL, and the impact on HRQOL is 
greater in the physical domain (Chandratre et al 2013).  Gout flares are the major factor 
associated with impaired HRQOL in people living with gout but further factors associated with 
poor HRQOL include other gout-specific, comorbid,  socio-demographic and other factors 
(Chandratre et al 2013).  
Little is known about change in gout flares or HRQOL over time in people living with gout in 
primary care.   
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2.3 Structure of thesis chapters and aim of each chapter 
 
 
 
 
Chapter One Introduction and background 
Aim To introduce the thesis and provide relevant background to the topic. 
  
Chapter Two Overview of thesis 
Aim 
To outline the structure of this thesis, the overall aim of each chapter 
and the key objectives of the thesis. 
  
Chapter Three Prospective cohort study 
Aim To describe the prospective cohort study in which this thesis is nested. 
  
Chapter Four Description of cohort and assessment of bias 
Aim 
To describe the flow of participants through this cohort study and 
investigate attrition bias and missing data. 
  
Chapter Five Frequency and pattern of gout flares 
Aim 
To describe the frequency and pattern of self-reported gout flares in a 
prospective cohort of people living with gout in primary care.  
  
Chapter Six Gout flare trajectory classes 
Aim 
To identify and describe latent classes of distinct gout flare trajectories 
in a prospective cohort of people living with gout in primary care. 
  
Chapter Seven Change in health-related quality of life  
Aim 
To describe how gout-specific and generic HRQOL in people living with 
gout changes over a three-year period 
  
Chapter Eight Factors associated with change in health-related quality of life 
Aim 
To describe the factors associated with change in gout-specific and 
generic HRQOL in people living with gout in primary care over a three-
year period. 
  
Chapter Nine Discussion and conclusion 
Aim 
To discuss the key findings of the thesis, considering the strengths, 
limitations, implications for clinical practice, implications for future 
research, and to draw conclusions. 
Figure 2.1 Title and overall aim of each thesis chapter 
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2.4 Key thesis objectives 
Chapter 4 objectives 
1. Describe the response and the flow of participants through this cohort study. 
2. Compare characteristics of responders and non-participants at the five questionnaire 
mail-out time points (i.e. Baseline, 6, 12, 24, 34 months). 
3. Compare characteristics of participants who responded on a different number of 
occasions (i.e. only baseline, baseline plus one other time-point, baseline plus two 
other time-points, baseline plus three other time-points, all time-points).  
4. Determine the number and percentage of missing item responses of key variables 
within the questionnaire and medical record review data; indicating the type and 
volume of missing item response data. 
Chapter 5 Objectives 
1. Use descriptive statistics and spaghetti plots to describe the frequency and pattern of 
self-reported gout flares.  
2. Use latent growth curve modelling (LGCM) to determine the shape of the growth curve 
which best describes the longitudinal gout flare data. 
Chapter 6 Objectives 
1. Use latent class growth analysis (LCGA) and growth mixture modelling (GMM) to 
identify distinct latent classes of gout flare trajectories in people living with gout in 
primary care. 
2. Describe the characteristics of members of each gout flare trajectory class. 
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Chapter 7 Objectives 
1. Describe change in GIS subscales (CO, MSE, UTN, WBDA, CDA), SF-36 PF10 and HAQ-
DI scores over a three-year period.  
2. Describe the correlation, and distribution of the GIS subscales (CO, MSE, UTN, WBDA, 
CDA), SF-36 PF10 and HAQ-DI scores over a three-year period. 
3. Describe the GIS subscales, SF-36 PF10 and HAQ-DI scores over three years for 
participants in each distinct latent gout flare trajectory class identified in chapter 6. 
Chapter 8 Objective 
1. Use linear mixed modelling to describe the variables associated with change in GIS 
subscales (CO, MSE, UTN, WBDA, CDA), SF-36 PF10, and HAQ-DI scores over a three-
year period. 
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3 Chapter Three Prospective Cohort Study 
3.1 Overview of chapter and aim 
The previous chapter outlined the structure of the whole thesis and described the aims and 
key objectives of this thesis.  The aim of the following chapter is to describe the prospective 
cohort study in which this thesis is nested.  The aim of the study was to investigate health-
related quality of life (HRQOL) in a large cohort of people living with gout in primary care 
(Chandratre et al 2012). 
3.2 Study design 
The study was a prospective cohort study utilising a postal questionnaire survey of people 
with gout based in primary care. Figure 3.1 displays the seven phases of the cohort study 
which include the five time-points where participants were mailed a postal questionnaire.  The 
cohort study was established as part of a previous PhD studentship and the study protocol has 
been described and published previously (Chandratre et al 2012).  In addition to a postal 
questionnaire, the study included an electronic review of medical records and qualitative 
focus group interviews. The baseline findings from this prospective cohort study (Chandratre 
et al 2018) and nested qualitative study (Chandratre et al 2016) have been published 
previously.  This thesis used data derived from baseline and the postal follow-up of the cohort 
over a three-year period and medical record review. The thesis used data from the entire 
cohort but only a selected number of outcomes from the study questionnaire were analysed 
as part of this thesis.   The author’s role in relation to the cohort study included writing data 
analysis plans, preparing data for analysis (e.g. building databases, cleaning data, recoding and 
categorising variables), running PPIE group meetings, undertaking statistical analysis, and 
reporting and communicating findings.   
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Figure 3.1 Phases of prospective cohort study 
 
3.3 Participants and setting 
Study population  
All adults (over the age of 18 years) registered with 20 general practices within the West 
Midlands who had either: 
 Consulted primary care in the preceding two years for gout or, 
 Received a prescription for either colchicine or allopurinol in the last two years 
Inclusion criteria 
 Registration with a participating general practice during the course of the study 
 Read code consultation for gout or prescription of colchicine or allopurinol during the 
preceding two years 
 Provided written informed consent to participate in the study 
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Exclusion criteria 
 Under the age of 18 years of age 
 Vulnerable groups e.g. significant dementia, severe enduring mental illness, active 
cancer or other terminal illness. 
Identification of participants  
Eligible participants for the study were identified via general practice Read codes assigned to 
consultations or prescriptions relating to gout.  Read codes are alphanumeric medical codes 
which allow primary care health care workers to code clinical consultations (Chisolm, 1990; 
Porcheret et al 2004) and have been shown to be a valid indicator of the true presence of 
disease; with Read codes for gout displaying a sensitivity of 93.7% and positive predictive 
value (PPV) of 97.6% (Hassey, Gerret & Wilson, 2001). Whilst a diagnosis of gout in CPRD has 
been validated with a PPV of 90% reported (Meier & Jick, 1997).  Table 3.1 details the Read 
codes used by the Primary Care Centre Versus Arthritis (PCCVA) at Keele University for 
participant identification. Clinical staff in the local area have received training on the use of 
Read codes and data entry as part of a programme of assessment, feedback and training 
(Porcheret et al 2004).   
Table 3.1 Read codes used by the Primary Care Centre Versus Arthritis 
Code Term 
C34 Gout 
N023 Gouty Arthritis 
EGTON 227 Gout NOS 
OX2740G Gout Acute/ ox 
1443 H/O: gout 
EMISR4QG01 Gouty tophi + Gout NOS 
2D52 O/E-auricle of ear-tophi 
669 Gout Monitoring 
 
The GP practices have a formal agreement with the West Midlands Clinical Research Network  
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(CRN) and staff contracted to work for the practice undertake various functions including the 
identification of patients for the participation in research.  Staff from the West Midlands CRN 
health informatics team ran a one-off electronic search of primary care records from 
participating practices in order to identify patients who in the preceding two years had had a 
consultation for gout or a prescription for colchicine or allopurinol. The lead general 
practitioner at each general practice was requested to identify vulnerable patients from the 
list obtained who would be excluded from the study. To ensure patients were not contacted 
inappropriately, the CRN team screened the mailing list prior to the first and subsequent 
mailing to identify patient deaths or departures from the practice. 
Contacting participants  
All eligible patients were mailed a study pack from their GP which was presented on the GP 
practice headed notepaper. The baseline mail-out took place in October & November 2012. 
The study pack included: 
 A cover letter inviting patients to take part in the study (see appendix 3) 
 A participant information sheet (PIS) (see appendix 4) 
 A pre-paid envelope for the return of the questionnaire and consent form  
 Baseline questionnaire and attached consent form (see appendix 5) 
Reminder postcards (see appendix 6) were sent out if there was no response after two weeks 
and a repeat questionnaire with PIS and covering letter (see appendix 7) was mailed if there 
was no response after four weeks. 
Follow-up out to participants 
For each follow-up mail-out at 6, 12, 24 and 36 months the following process was followed; 
removal of deaths and departures from the mailing database, mail-out of questionnaire with 
covering letter, reminder postcard sent if no response in two weeks and repeat questionnaire 
was mailed if there was no response in four weeks. 
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Medical note review 
Individuals who consented to medical record review had their computerised medical records 
tagged by a member of the CRN. A medical record review included a review of records over 
the two years prior to recruitment and the three year follow-up period to collect anonymised 
consultation data relating to diagnosis, investigations, treatment and comorbidities. Specialist 
health informatics staff linked to GP practices undertook the medical record review.  
Patient Public Involvement and Engagement 
Patient public involvement and engagement (PPIE) was incorporated in the design and 
management stages of the study. Advertisements, via posters and flyers, were used to find 
patients with a diagnosis of gout to take part in the PPIE for this study.  Lay members of the 
PPIE group provided feedback on conceptual and design aspects of the questionnaire survey.  
Patient engagement has been proposed to improve participant enrolment and decrease 
attrition (Domecq et al 2014; Shippee et al 2013). PPIE members were involved in 
interpretation of findings and planning dissemination of results. 
3.4 Ethics 
Approval 
Ethics approval for the study was granted by National Research Ethics Service (NRES) 
committee North West Liverpool East Research and Ethics Committee (REC) reference number 
12/NW/0297.  A copy of the ethical approval letter can be found in appendix 8. 
Consent 
The consent form was included in the study pack attached to the baseline questionnaire.  
Participants were asked to consent separately to medical record review and future postal 
contact.   
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Confidentiality 
Each participant was allocated a unique study identification number. Research data obtained 
from responses to the study questionnaire were recorded on a confidential and anonymised 
study data entry database which is separate from personal mailing data, so that research data 
is not linked to personal data.  
3.5 Data management 
Data input  
For quality assurance, one in ten questionnaires were checked for accuracy of coding by a 
member of the study team, corrections were made to the data entry database as necessary.  
Comments and queries which arose whilst returned questionnaires were inputted to the data 
entry database were recorded on a comments and queries spreadsheet along with any actions 
taken or lessons learnt which could be applied to any future queries with data entry.  
Data cleaning  
The data were checked using descriptive statistics to detect and then correct any potential 
errors (Pallant, 2016; Van de Broeck et al 2005; Osborne, 2013). Data cleaning is advocated to 
promote data standardisation and data quality (Van de Broeck et al 2005).   This inspection 
and correction of error within data sets can help to prevent later difficulties with the analysis 
and interpretation of data (Pallant, 2016; Osborne, 2013). 
Sample size 
A sample size calculation was undertaken at the inception of this study. Over 1,800 people 
were contacted at baseline (Chandratre et al 2012).   The sample size calculation was based 
on the assumption of a 70% response rate at baseline and a 30% drop out over the three years, 
and indicated that in order to use the information recorded at all five time-points a sample of 
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 882 would allow a smallest meaningful difference in HRQOL of 0.2 standard deviation units 
to be detected between two groups (441 participants per group) defined in terms of frequency 
of gout attacks (<2 attacks, ≥2 attacks per year) using a linear mixed model (significance 0.05, 
power 90%, autocorrelation 0.8) (Chandratre et al 2012). 
3.6 Questionnaire content 
A summary of the content of the questionnaire mailed to participants can be found in Table 
3.2.  The baseline questionnaire contained seven sections (see appendix 5 for a copy of 
baseline questionnaire and appendix 9 for tables of the content of each questionnaire 
section). Sections 3.6.1 to 3.6.5  on the following pages describe the questionnaire content 
used in the analysis in this thesis.   
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Table 3.2 Summary of questionnaire content at five mail out time-points 
Questionnaire content Baseline 6 months 12 months 24 months 36 months 
Gout  
Frequency of gout flares      
Age at gout diagnosis      
Occurrence of current gout 
flare 
     
History of oligo-/ polyarticular 
gout 
     
Use of allopurinol      
How gout affects life 
GIS      
IPQ-R      
General health 
SF-36 PF 10      
HAQ-DI      
Pain NRS      
Global assessment of health      
Comorbidities      
How participants feel 
PHQ-9      
GAD-7      
Foot & other joint problems 
Hallux Valgus      
Foot pain, aching & stiffness      
Foot pain location      
Foot function      
Health care consultations 
regarding feet 
     
Body pain      
How gout affects work 
Current employment status      
Taken time off work due to 
gout in last 6 months 
     
Ability to undertake usual 
employment 
     
Inability to undertake normal 
employment attributed to 
joint problems 
     
Demographics & socioeconomics 
Date of birth      
Sex      
Relationship status      
Education      
Ethnic origin      
Height, weight & alcohol       
Height      
Weight      
Alcohol consumption      
GIS, Gout Impact Scale; IPQ-R, Revised Illness Perception Questionnaire; SF-36 PF 10, 36-Item 
Short-Form Health Survey 10-item Physical Function subscale; HAQ-DI,  Health Assessment 
Questionnaire Disability Index;  NRS, numerical rating scale; GAD-7, Generalised Anxiety Disorder-
7;  PHQ-9, Patient Health Questionnaire-9. 
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3.6.1 Questions about gout 
Participants were asked to report how many flares of gout they had experienced in the last 12 
months, or in the last six months at the six and 12-month time-point, using six response 
options (0, 1, 2, 3, 4, ≥5).  Self-reported gout flares have been compared to the criterion of an 
assessment by a rheumatologist and shown to have a sensitivity of 91% and negative 
predictive value of 96% (Gaffo et al 2012).  Respondents were asked whether they were 
experiencing a flare of gout at the point of completion of the questionnaire and if they had 
ever had gout affecting more than one joint (a history of oligo-/polyarticular flares).  
Participants were asked their age at diagnosis of gout. Gout disease duration was calculated 
by subtracting a participant’s age at gout diagnosis from their current age at baseline.  
Respondents were asked to state whether they were currently taking allopurinol. If allopurinol 
was taken, participants were asked to either select the dose taken (50 mg, 100 mg, 200 mg, 
300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg or ‘don’t know’) or state, via free 
text, an alternative dose to the categories stated.  Self-reporting of current medication use, 
collected via mail in a large cohort, has displayed acceptable agreement with pharmacy 
records (Drieling et al 2016).  
3.6.2 Questions about how gout affects life 
Gout Impact Scale (GIS) 
The self-reported impact of gout on study participants was assessed using the disease-specific 
HRQOL measure, the Gout Impact Scale (GIS) (Hirsch et al 2008).  The GIS originally formed 
the Gout Impact section of the Gout Assessment Questionnaire (GAQ) 2.0 (Hirsch et al 2008) 
and was developed from the earlier Gout Assessment Questionnaire (GAQ 1.0) (Colwell et al 
2006). The GIS consists of 5 subscales; gout concern overall (GIS CO) (first four items), gout 
medication side effects (GIS MSE) (two items), gout unmet treatment need (GIS UTN) (three 
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 items), wellbeing during an attack (GIS WBDA) (11 items) and gout concern during an attack 
(GIS CDA) (four items) (Hirsch et al 2008). This totals 24 items each with response options 
provided on a five-point ordinal scale (Hirsch et al 2008).  Each scale is scored from 0-100 with 
a higher score indicating worse HRQOL (Khanna et al 2011b).  Changes in the GIS subscales of 
5 to 8 points have been estimated as minimal clinically important differences (MCID) in 
patients with gout, however MCID results were not reported for the GIS MSE subscale (Khanna 
et al 2011b). See Table 3.3 for details relating to recall period, calculation and interpretation 
of scores.  
Content validity has been demonstrated for the GIS and GAQ 1.0 by the involvement of 
rheumatologists and patient groups in the development of the scale (Colwell et al 2006; Hirch 
et al 2008). Patient-rated gout severity has been shown to correlate with all GIS subscale 
scores demonstrating construct validity (Hirsch et al 2008).  Further construct validity has been 
displayed by the correlation of total GIS scores with HAQ-DI and SF-36 scores, and higher GIS 
scores in groups of patients who had experienced recent gout attacks (Wallace et al 2016).   In 
a longitudinal study of gout patients, the GIS has been shown to be responsive to change with 
effect sizes of 0.07 to 0.34 and standardised mean response (SMR) of 0.09 to 0.45 (Wallace et 
al 2016).  
The GIS subscales have been shown to have good test-retest reliability (Hirsch et al 2008) and 
adequate internal consistency (Hirsch et al 2008; Khanna et al 2011b). However, lower 
Cronbach alpha scores have been reported for the two-item GIS MSE and the three-item GIS 
UTN (Wallace et al 2016). Readability scores for the GIS suggest that a reading age of 12 years 
or older is required (Janssen et al 2019). 
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Table 3.3 Recall period, calculation of score and interpretation of score for measures about how gout affects life, general health and how participants feel 
 
 
 
 
 
 
 
 
 
 
 
Section of 
questionnaire 
Measure Recall 
period 
Calculation of score Interpretation of score 
How gout 
affects your 
life 
GIS 
subscales 
 
Not 
specified 
Item response rescaled and reversed as necessary 
to score from 0-100.  Score is the mean of the 
responses for each subscale. 
Each GIS subscale scored from 0-100. Higher scores on each scale 
indicating a greater impact of gout/ worse HRQOL.  
 
About general 
health 
SF-36  
PF 10 
Current 
situation 
"health 
now" 
Scores for all items are coded, summed and then 
transformed on to a scale of 0 to 100  
SF-36 PF10 scored from 0-100. Lower scores indicate worse 
HRQOL. 
 
Low= Limited a lot in performing all physical activities including 
bathing or dressing.  High= Performs all types of physical activities 
including the most vigorous without limitations due to health. 
HAQ-DI Past week Highest component score in each category 
determines score for category. Dependence on 
device, aid or help increases a lower score to 2. 
The 8 category scores are averaged in to an overall 
HAQ-DI score.  
Overall HAQ-DI scored from 0 to 3. Higher scores indicate worse 
activity limitation. 
 
0 = No disability 
3 = Complete disability 
NRS Pain Past one 
week 
Score from 0 to 10  0 = No pain 
10 = Pain as bad as it can be 
NRS 
Patient 
Global 
Current 
situation 
Score from 0 to 10 0 = Very well 
10 = Very poor health 
How 
participants 
feel 
PHQ-9 Last two 
weeks 
Addition of scores 0 = Minimal depression                            Minimal 0-4 
27 = Severe depression                            Mild 5-9 
                                                                      Moderate 10-14 
                                                                      Moderately Severe 15-19 
                                                                      Severe 20-27 
GAD-7 Last two 
weeks 
Addition of scores 0 = Minimal anxiety                                  Minimal 0-4 
21 = Severe anxiety                                  Mild 5-9 
                                                                     Moderate 10-14 
                                                                     Severe 15-21 
GIS, Gout Impact Scale; SF-36 PF10, 36-Item Short-Form Health Survey 10-item Physical Function subscale; HAQ-DI, Health Assessment Questionnaire Disability Index; 
NRS, numerical rating scale; GAD-7, Generalised Anxiety Disorder-7; PHQ-9, Patient Health Questionnaire-9. 
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3.6.3 Questions about general health   
SF-36 PF10 
Self-reported physical function was assessed in this study using the 10-item physical function 
(PF10) subscale of the medical outcomes study 36-Item Short-Form Health Survey (SF-36) 
(Ware & Sherbourne, 1992).  The SF-36 is a generic measure of generic HRQOL and the SF-36 
PF-10 consists of 10 questions relating to the ability to undertake different activities during a 
typical day, and responses are obtained via a three-point ordinal scale (Ware & Sherbourne, 
1992).   SF-36 PF10 is scored from 0-100 with a lower scale score suggesting worse HRQOL 
(Brazier et al 1992).  A low score is interpreted as suggesting that an individual is limited a lot 
in performing all physical activities including bathing or dressing (Ware & Sherbourne, 1992; 
Ware et al 1995). A high score is interpreted as indicating that an individual is able to perform 
all types of physical activities including the most vigorous, without limitations due to health 
(Ware & Sherbourne, 1992; Ware et al 1995). A MCID in SF-36 PF10 scores in people with gout 
of 5 has been cited by Khanna et al (2011a).  See Table 3.3 for details relating to the recall 
period, calculation and interpretation of scores.  
A range of studies have demonstrated the construct validity of the SF-36 when used with 
patients with gout. Lower SF-36 scores were associated with the presence of tophi, co-
morbidities and polyarticular disease in a prospective study by Khanna et al (2011a). SF-36 
scores were correlated with HAQ-DI scores in both prospective (Becker et al 2009) and cross-
sectional studies (ten klooster et al 2011).  SF-36 PF10 scores have also been able to 
discriminate between different levels of general health (ten Klooster et al 2011). The SF-36 
has been shown to be responsive to change in a longitudinal cohort of gout patients, with SF-
36 PF10 demonstrating an effect size of 0.48 (Khanna et al 2011a).  The SF-36 PF10 has 
demonstrated convergent validity through a strong association with serious medical 
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conditions and discriminant validity with patients with solely mental health conditions (Brazier 
et al 1992; McHorney, Ware & Raczeck, 1993; Ware et al 1995). 
High internal consistency reliability of the SF-36 PF10, when used with people with gout, has 
been demonstrated by a Cronbach alpha score of 0.97 (ten Klooster et al 2011).  Acceptable 
test-retest reliability of SF-36 subscales has been reported by Becker et al (2009) in a gout 
specific population.  The SF-36 has been shown to have an acceptable internal consistency and 
test-retest reliability in a primary care based postal questionnaire survey in the UK (Brazier et 
al 1992).  
The median readability of items within the SF-36 has been determined to be at a reading level 
of around 6th grade (Calderon et al 2006; Paz et al 2009).  SF-36 has been endorsed as a patient 
reported outcome for the assessment of HRQOL by Outcome Measures in Rheumatology 
Meeting (OMERACT) in light of the acceptable validity, responsiveness to change and 
reliability (de Latour, Taylor & Dalbeth, 2015; Singh et al 2011a). 
HAQ-DI  
Self-reported activity limitation was assessed by the inclusion of the Health Assessment 
Questionnaire Disability Index (HAQ-DI) (Bruce & Fries, 2003).  The HAQ-DI is a generic 
measure of physical disability, which constitutes dimension one of the full Health Assessment 
Questionnaire and is widely used in rheumatology research (Bruce & Fries, 2003).  The HAQ-
DI consists of 20 items, arranged in eight categories of functioning relating to dressing & 
grooming, arising, eating, walking, hygiene, reach, grip and activities (Bruce & fries, 2003). 
Respondents are asked to report how much difficulty they have experienced in the past one 
week whilst undertaking these tasks via a four-point ordinal response scale (ranging from 
‘without any difficulty’ to ‘unable to do’) (Bruce & Fries, 2003).  Respondents are also asked 
to indicate whether they utilise any aids, devices or assistance (Bruce & Fries, 2003).  Each  
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scale is scored from 0-3 with higher scale scores indicating activity limitation.   A HAQ-DI score 
of zero suggests no disability in contrast to a score of three which suggests complete disability 
(Bruce & Fries, 2003). The MCID cited by Singh et al (2016) in HAQ-DI scores in people with 
gout was 0.22. See Table 3.3 for details relating to the recall period, calculation and 
interpretation of scores. 
The face validity of the HAQ-DI when used with people living with gout has been described 
(Alvarez-Hernandez et al 2008), however floor effects, where 20.5 to 42.2% of participants 
have a HAQ-DI score of zero, have also been reported (Alvarez-Hernandez et al 2008; Taylor 
et al 2008).  HAQ-DI scores have been shown to correlate well with task performance thus 
providing evidence of criterion validity (Bruce & Fries, 2003). The construct validity of the 
HAQ-DI when used with patients with gout, has been demonstrated by correlation with SF-36 
PF10 scores and visual analogue scales (VAS) pain scores (Alvarez-Hernandez et al 2008; Taylor 
et al 2008), along with the ability to discriminate between different levels of health and 
disease characteristics (Alvarez-Hernandez et al 2008; Van Groen et al 2010).  The HAQ-DI has 
been shown to be sensitive and responsive to change in a six-month prospective study of gout 
patients, with an effect size of 0.62 (Alvarez-Hernandez et al 2008).  
The test-retest validity of the HAQ-DI in subjects with gout has been shown to be acceptable, 
with intraclass correlation coefficients (ICC) of 0.76 to 0.84 (Alvarez-Hernandez et al 2008; 
Becker et al 2009). Internal consistency of the HAQ-DI, when used to measure function in 
subjects with gout, has been reported as excellent with Cronbach alphas of 0.91 to 0.97 
(Alvarez-Hernandez et al 2008; Taylor et al 2008; ten Klooster et al 2010).  
Due to the acceptable validity, responsiveness and reliability demonstrated in gout studies 
HAQ-DI has been endorsed by the 2010 Outcome Measures in Rheumatology Meeting 
(OMERACT 10) as a patient-reported outcome for measurement of activity limitation in 
chronic gout (Singh et al 2011a). 
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NRS Pain and Patient Global 
The VAS pain scale and patient global assessment VAS from dimension two of the full HAQ 
have been endorsed as patient-reported outcomes in OMERACT 10 (Singh et al 2011a) due to 
the acceptable validity and reliability of these measures in studies measuring outcomes of 
gout (Singh et al 2011a; Singh et al 2011b).  There was agreement at OMERACT 10 that the 
VAS used in the HAQ could be converted to numerical rating scales (NRS) when measuring 
patient-reported outcomes.  An 11-point NRS used to measure pain (where 0 indicates ‘no 
pain’ to 10 indicates ‘pain as bad as it can be') and a patient global assessment NRS (where 0 
indicates ‘very well’ and 10 indicates ‘very poor health’) were included within this 
questionnaire (see Table 3.3).   
Body pain 
Assessment of body pain in this survey was undertaken by asking participants whether they 
had experienced any pain, ache, discomfort or stiffness lasting longer than one day in any part 
of their body during the past 4 weeks.   
Comorbidities 
Participants were asked to indicate in the baseline study questionnaire whether they had ever 
been diagnosed with or treated for a range of different comorbidities (diabetes, hypertension 
(HT), hyperlipidaemia (HL), myocardial infarction (MI), angina, cerebrovascular accident (CVA), 
transient ischaemic attack (TIA), renal failure (RF), renal calculi).  Self-reporting of 
comorbidities has been shown to have acceptable test-retest reliability and correlation with 
documented medical record comorbidities (Sangha et al 2003; Simpson et al 2004).        
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3.6.4 Questions about depression and anxiety  
PHQ-9 
Depression in this study was assessed using the Patient Health Questionnaire-9 (PHQ-9). The 
PHQ-9 is a validated measure of depression severity which was adapted from the longer 
patient health questionnaire (Kroenke, Spitzer & Williams, 2001). The self-administered 
questionnaire consists of a checklist of nine items and responses via a four-point ordinal scale 
(Kroenke, Spitzer & Williams, 2001).  Respondents are asked to recall how often they have 
been bothered by these nine different issues in the last two weeks (Kroenke, Spitzer & 
Williams, 2001). Scores indicate the severity of depression and it is the recommended tool for 
the measurement of depressive symptoms by the Diagnostic and Statistical Manual of Mental 
Disorder; with scores of 0-4 indicating minimal depression and 20-27 severe depression 
(Kroenke, Spitzer & Williams, 2001; Moriarty et al 2015). See Table 3.3 for details relating to 
the recall period, calculation and interpretation of scores. 
 The PHQ-9 has displayed criterion and construct validity when used with in primary care and 
both the test-retest reliability and internal reliability have been found to be excellent 
(Kroenke, Spitzer & Williams, 2001).  
The association of gout severity with depression in this cohort study at baseline has been 
published previously (Prior et al 2016). 
GAD-7 
Anxiety was assessed using the Generalised Anxiety Disorder-7 (GAD-7).  The GAD-7 is a brief 
scale devised to identify probable cases of generalised anxiety disorder (Spitzer et al 2006).  
This self-reported tool was adapted from the 13 item GAD scale (Spitzer et al 2006).  
Respondents are asked to state, by the selection of one of 4 ordinal responses, how often in 
the last 2 weeks they have been bothered by the issues described in the 7 items (Spitzer et al 
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2006).  Scores specify the degree of general anxiety disorder with 5 to 9 indicating mild 
generalised anxiety and 15 to 21 indicating severe generalised anxiety (Spitzer et al 2006).  See 
Table 3.3 for details relating to the recall period, calculation and interpretation of scores. 
The GAD-7 has demonstrated construct validity when used within primary care (Spitzer et al 
2006). The internal consistency of the GAD-7 has been shown to be excellent and the test-
retest validity good (Spitzer et al 2006).   
3.6.5 Questions about socio-demographics, height, weight and alcohol consumption 
Participants were asked their date of birth, sex, and whether they had attended further 
education.  The selection of one response from six nominal category responses was used in 
the questionnaire to collect data relating to relationship status (married, widowed, co-
habiting, divorced, separated or single) and ethnic origin (White UK/European, Asian, Afro 
Caribbean, African, Chinese, or other) respectively. 
Participants were asked their weight and height in either metric or imperial units.  Self-
reported weight and height has been shown to be highly correlated with measured weight 
and height and is thus valid for detecting associations between weight and height with disease 
in epidemiological studies (Spencer et al 2002; McAdams, Van Dam & Hu, 2007). The self-
reported weight and height was used to calculate body mass index (BMI) calculated as weight 
(kg)/height (m2) (Keys et al 1972).  BMI calculated from self-reported weight and height has 
been shown to be highly correlated with measured BMI (Spencer et al 2002; McAdams, Van 
Dam & Hu, 2007).  BMI was classified into the categories of underweight, normal range, 
overweight and obese using classification criteria specified by the World Health Organisation 
(World Health Organisation, 2000).  
Self-reported alcohol consumption was recorded using a frequency and quantity approach, 
which has been described as a generally reliable and valid method to investigate alcohol intake 
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in surveys (Del Boca & Darkes 2003; Grant et al 1995). Participants were asked how often 
alcoholic drinks were consumed using six ordinal categories (never, special occasions, 1 to 3 
times a month, once or twice a week, 3 to 4 times a week, daily almost daily) and how many 
alcoholic drinks of a specific volume were consumed in an average week.                                                                                                                                                                                                                            
Participant postal codes were used to derive indices of multiple deprivation (IMD) 
(Department for communities and Local Government, 2011).  
3.7 Questionnaire Design and Administration; attempts to maximise response and 
minimise bias. 
Several aspects of this study’s method, regarding the administration of the questionnaire, 
have been advocated to optimise the response rates in postal questionnaire surveys.  The 
questionnaires were accompanied with a letter personalised with each participant’s name 
(Edwards et al 2009; Sinclair et al 2012; Sahlqvist et al 2011). This personalised letter was from 
a named doctor, displayed sponsorship from a local University and explained the importance 
of the questionnaire (Edwards et al 2009; Bowling, 2014).  Non-responders were sent 
reminders, which has been shown to be an economical and effective method to increase 
survey response rates (Edwards et al 2009; Sahlqvist et al 2011; Shih & Fan, 2008).  Non-
responders were posted a reminder card 14 days after the original posting of the 
questionnaire (Salhlqvist et al 2011). At 14 days after the postcard reminder non-responders 
were sent a further reminder with a second copy of the questionnaire included (Edwards et al 
2009). 
The questionnaire started with questions relating specifically to the medical condition of 
interest, gout, rather than general health questions thus increasing the saliency of the 
questionnaire to the respondent which has been shown to increase response time and 
response rate (Dunn, Jordan & Croft, 2003).  Specifically, the first question in the questionnaire 
related to gout flares, which have been identified by patients as an essential factor to consider 
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when measuring outcomes in chronic gout (Schumacher et al 2009).  The questionnaire ended 
with demographic questions, which if placed at the beginning of the questionnaire may deter 
respondents from continuing to complete the questionnaire (Boynton & Greenhalgh, 2004). 
Within this questionnaire the response scales used, and the direction in which responses were 
presented, changed at various different points in the questionnaire.  Such changes in the 
direction of questionnaire items and responses have been advocated as strategies to limit a 
response set from respondent and acquiescence bias (Bowling et al 2014).     
The use of self-administered methods, such as this postal survey, have been proposed to avoid 
overstated estimates of HRQOL and health status that may occur in more direct modes of 
enquiry such as face to face or telephone interviews (Bowling et al 1999; Lyons et al 1999).  
3.8 Conclusion 
In conclusion, this chapter describes the prospective cohort study in which this thesis is 
nested.  This chapter describes the study design, participants & setting, medical record review, 
ethical consideration, data management, questionnaire content, and attempts made to 
minimize bias.  The aim of the following chapter is to describe the cohort of participants in 
this study and to investigate attrition bias and missing data.    
 
 
 
 
 
 
 
63 
 
4 Chapter Four Description of cohort and assessment of bias  
4.1 Overview of chapter and aim 
The previous chapter described the prospective postal questionnaire cohort study in which 
this thesis is nested.  The aim of this chapter is to describe the cohort of participants in this 
study and to investigate attrition bias and missing data.  Thus, within this chapter the flow of 
participants through the cohort will be described, and the potential for attrition bias and 
extent of item non-response missing data investigated. 
4.2 Background 
Attrition from a survey can occur when participants who are originally recruited to the survey 
do not then respond at every potential time-point (Lacey, Jordan & Croft, 2013; Matthews et 
al 2004; Twiske & de vente, 2002; Twisk, 2003).  Participants may drop out of a survey by not 
responding to the later time-points in a survey (Twiske & de vente, 2002; Twisk, 2003) or 
attrition may be caused by participants responding intermittently to a survey (Cumming & 
Goldstein, 2016; Twiske & de vente, 2002; Twisk, 2003).  Attrition in a survey has the potential 
to lead to attrition bias if the responders to the survey are systematically different in relation 
to baseline characteristics, confounders, and outcomes of interest, in comparison with those 
who did not respond or those who refused to take part (Chatfield, Brayne & Matthews, 2005; 
Kristman, Manno & Côté, 2005).  
Item non-response is a form of missing data where information is not provided for certain 
items within a questionnaire (Fayers & Machin, 2016; Yan & Curtin, 2010). Missing data can 
also arise due to unit non-response; where a participant has not responded therefore a whole 
questionnaire has not been returned (Fayers & Machin, 2016; Yan & Curtin, 2010).  Missing 
data can be classified as; missing completely at random (MCAR) when the absence of the data 
is unrelated to observed and unobserved data, missing at random (MAR) when the absence 
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of the data is related to observed data but not the unobserved data, or missing not at random 
(MNAR) when the absence of the data is related to the unobserved data (Twisk et al 2013).  
Attrition and missing data may have several detrimental consequences including a reduction 
in sample size, loss of statistical power, and biased inferences (Biering, Hjollund & Frydenberg, 
2015; Deeg, 2002). 
4.3 Method and Analysis Plan 
4.3.1 Aim and Objectives  
Aim 
The aim of this chapter was to describe the flow of participants through this cohort study and 
investigate attrition bias and missing data.  
Objectives 
The objectives of this chapter were to: 
1. Describe the response and the flow of participants through this cohort study. 
2. Compare characteristics of responders and non-participants at the five questionnaire mail-
out time points (i.e. Baseline, 6, 12, 24, 36 months). 
3. Compare characteristics of participants who responded on a different number of occasions 
(i.e. only baseline, baseline plus one other time-point, baseline plus two other time-points, 
baseline plus three other time-points, all time-points).  
4. Determine the number and percentage of missing item responses of key variables within 
the questionnaire and medical record review data; indicating the type and volume of missing 
item response data. 
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4.3.2 Data source 
Data in this chapter were derived from the cohort study (Chandratre et al 2012) described in 
chapter three. The questionnaire was mailed to participants at baseline (October and 
November 2012), 6 months, 12 months, 24 months and 36 months.  The data sources used in 
this chapter include the cohort study’s mailing database, questionnaire responder database, 
and medical record review database.  
4.3.3 Analysis plan  
Flow through the cohort study was described by reporting in a flowchart the number of 
participants excluded before mailing, eligible for mailing, mailed, excluded during mailing and  
who refused or did not respond, at each time-point.  Response to the questionnaire mail-outs 
at each time-point was calculated as the number of returned questionnaires as a percentage 
of the number of questionnaires mailed out to eligible participants at that time-point, thus 
providing an adjusted response (Bruce, Pope & Stanistreet, 2008; Sahlqvist et al 2011).  
The data used to investigate attrition bias were taken from questionnaire responses at 
baseline and medical record review from the two years prior to baseline and included gout-
specific factors, medications, comorbidities, socio-demographic factors, BMI, alcohol 
consumption and HRQOL scores.  Characteristics at baseline are commonly used for 
comparison when investigating factors associated with attrition (Dumville, Torgerson & 
Hewitt, 2006; Fewtrell et al 2008; Lacey, Jordan & Croft, 2013; Matthews et al 2004). As 
attrition bias can arise when the distribution of potential confounders and outcomes are 
associated with whether participants remain in a study (Kristman, Manno & Côté, 2005), the 
variables included in this analysis of attrition bias were outcomes and potential covariates 
relevant to this thesis. The baseline characteristics of responders were compared with those 
of non-participants at each follow-up time-point.  The baseline characteristics of participants 
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who responded only at baseline, baseline plus one other time-point, baseline plus two other 
time-points, baseline plus three other time-points, and all time-points were also compared.   
Nominal and ordinal categorical baseline variables were analysed by undertaking frequency 
counts and calculating percentages. Continuous variables were analysed by calculating the 
mean and standard deviation.   
To assess item non-response missing data, the number and percentage of responders who did 
not respond to each item of the GIS subscales, SF-36 PF10 and HAQ-DI was calculated at each 
time-point separately. The total number and percentage of responders who responded to an 
insufficient number of items to permit calculation of a GIS subscales score, SF-36 PF10 score 
and HAQ-DI score was also calculated. The frequency and percentage of missing data for gout-
specific, comorbid, socio-demographic, BMI and alcohol missing data was calculated. 
The analysis within this chapter was undertaken using SPSS version 24. 
4.4 Results 
4.4.1  Cohort response flow-chart 
Figure 4.1 to Figure 4.5 display the number of participants at each stage of the study, the 
proportion excluded before mailing, eligible for mailing, mailed, excluded during mailing, 
refused or not responding, and reasons for exclusion or refusal at each time-point.  
1184 participants responded at baseline (adjusted response 65.9%), with 818 (79.7%), 721 
(73%), 696 (75.4%), and 605 (68.4%) participants responding at 6, 12, 24 and 36 months 
respectively.   1079 (91.1%) of participants responding at baseline consented to medical 
record review.  Reasons for refusal at baseline included reporting ‘no gout’ (n=43), health 
reasons (n=9), participant not wanting to take part (n=43) and a late response (n=1).  Reasons 
given for refusal after baseline related to health (n=12) or participants not wanting to take 
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part (n=126).  Reasons for exclusion during mailing included death (n=15), address/contact 
problems (n=16) and health reasons (n=2). 
 
 
 
Figure 4.1 Flow diagram of exclusions, refusal, and response at baseline 
CRN= Clinical Research Network 
 
The response at baseline and number of participants consenting to medical record review have been 
published previously (Chandratre et al 2018). 
 
68 
 
 
Figure 4.2 Flow diagram of exclusions, refusal and response at 6 months 
 
 
Figure 4.3 Flow diagram of exclusions, refusal and response at 12 months 
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Figure 4.4 Flow diagram of exclusions, refusal and response at 24 months 
 
 
Figure 4.5 Flow diagram of exclusions, refusal and response at 36 months 
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4.4.2 Assessment of attrition bias 
Comparison of the characteristics of responders with non-participants 
Table 4.1 to Table 4.6 display the baseline characteristics of responders and non-participants 
at each follow-up time-point. The characteristics of the full cohort at baseline are included in 
each table for comparison.  
Gout-specific characteristics 
The proportion of individuals who had experienced two or more gout flares was slightly higher 
in the non-participants (ranging from 43.2 to 45.4%) in comparison with responders at six 
months onwards (40.0 to 40.8%) (Table 4.1). The proportion of individuals experiencing a 
current flare at baseline was also slightly higher in the non-participants (ranging from 12.0 to 
13.6%) in comparison with responders (8.8 to 10.8%).  Non-participants also had a slightly 
shorter mean disease duration (ranging from 10.96 to 11.28 years) than responders (ranging 
from 12.31 to 12.79 years).   Non-participants at each time-point also had a lower proportion 
of individuals with a serum urate greater than 360 µmol/L (24.6 to 28.0%) when compared 
with responders (31.4% to 32.7%).  However, the proportion of individuals with a serum urate 
greater than 360 µmol/L, as a proportion of those who had a serum urate record in their notes, 
was similar between non-participants and responders at 6, 12 and 36 months.  The proportion 
of individuals missing a serum urate record in their medical records in the two years prior to 
baseline was higher in the non-participants (63.4 to 67.5%), compared with responders (57.8 
to 58.8%).  
Other characteristics presented in Table 4.1 did not appear to differ substantially between 
responders and non-participants.
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Table 4.1 Gout-specific characteristics at baseline of responders and non-participants at baseline, 6, 12, 24 and 36 months 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
0 gout flares 398(33.6) 284(34.7) 114(31.1) 251(34.8) 147(31.7) 248(35.6) 150(30.7) 222(36.2) 176(30.4) 
1 gout flare 231(19.5) 168(20.5) 63(17.2) 145(20.1) 86(18.6) 137(19.7) 94(19.3) 115(19.0) 116(20.0) 
2 gout flares 187 (15.8) 134(16.4) 53(14.5) 116(16.1) 71(15.3) 111(15.9) 76(15.6) 99(16.4) 88(15.2) 
3 gout flares 103(8.7) 69(8.4) 34(9.3) 64(8.9) 39(8.4) 58(8.3) 45(9.2) 57(9.4) 46(7.9) 
4 gout flares 67(5.7) 39(4.8) 28(7.7) 36(5.0) 31(6.7) 38(5.5) 29(5.9) 29(4.8) 38(6.6) 
 5 or more  gout flares 137(11.6) 86(10.5) 51(13.9) 78(10.8) 59(12.7) 72(10.3) 65(13.3) 57(9.4) 80(13.8) 
>2 gout flares 494(41.7) 328(40.1) 166(45.4) 294(40.8) 200(43.2) 279(40.1) 215(44.1) 242(40.0) 252(43.5) 
Disease duration years 
mean (SD) 
11.91 
(12.13) 
12.32 
(11.77) 
10.98 
(12.89) 
12.31 
(11.75) 
11.28 
(12.69) 
12.36 
(11.52) 
11.26 
(12.95) 
12.79 
(11.74) 
10.96 
(12.47) 
Occurrence of current 
flare 
132(11.1) 88(10.8) 44(12.0) 72(10.0) 60(13.0) 67(9.6) 65(13.3) 53(8.8) 79(13.6) 
History of oligo/ 
polyarticular flares 
436(36.8) 305(37.3) 131(35.8) 271(37.6) 165(35.6) 260(37.4) 176(36.1) 224(37.0) 212(36.6) 
Record of tophi  25(2.1) 18(2.2) 7(1.9) 17(2.4) 8(1.7) 13(1.9) 12(2.5) 12(2.0) 13(2.2) 
Maximum serum urate 
level mean (SD) 
µmol/L* 
441.36 
(115.51) 
438.63 
(110.80) 
449.23 
(128.25) 
439.20 
(111.38) 
445.55 
(123.38) 
437.41 
(110.25) 
448.06 
(123.96) 
437.45 
(111.27) 
445.96 
(120.40) 
Serum urate level >360 
µmol/L * 
352(29.7) 262(32.0) 90(24.6) 236(32.7) 116(25.1) 221(31.8) 131(26.8) 190(31.4) 162(28.0) 
Serum urate level >360 
µmol/L as % of those 
with serum urate 
record* 
 
352(76.4) 
 
262(76.6) 90(75.6) 236(77.6) 116(73.9) 221(76.2) 131(76.6) 190(76.3) 162(76.4) 
Missing serum urate 
record 
723(61.1) 476(58.2) 247(67.5) 417(57.8) 306(66.1) 406(58.3) 317(65.0) 356 (58.8) 367(63.4) 
Values are n(%) unless stated otherwise   in previous 12 months at baseline; In medical record in the two years prior to baseline; *highest serum urate recorded 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Medications  
The non-participant group at each time-point had lower proportions of individuals reporting 
taking allopurinol (45.9 to 48.7%) and 300mg of allopurinol (20.2 to 21.2%) at baseline 
compared with responders (allopurinol 56.5 to 57.5%; 300 mg 27.6% to 29.6% ) (Table 4.2).  
This observation remained when the number of people reporting to take allopurinol, as a 
proportion of those who responded to the allopurinol use item, was compared between non-
participants and responders. In addition, a lower proportion of individuals in the non-
participant group had a prescription of allopurinol in their medical record in the two years 
prior to baseline (41.0 to 47.5%) in contrast with all responders at baseline (54.6%) and 
responders from six months onwards (60.2 to 61.3 %).  A greater proportion of the non-
participants either did not report an allopurinol dose or reported not knowing the allopurinol 
dose (52.3 to 54.6%), compared with responders (43.9 to 44.5%).   
Fewer non-participants had a prescription for NSAIDs in the medical record in the two years 
prior to baseline (43.7 to 48.9%) in contrast with responders (57.8 to 58.5%).   
Other characteristics presented in Table 4.2 did not appear to differ substantially between 
responders and non-participants. 
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Table 4.2 Medication of responders and non-participants at baseline, 6, 12, 24 and 36 months 
 
 Baseline 
characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
Using 
allopurinol*  
630(53.2) 
 
462(56.5) 168(45.9) 411(57.0) 219(47.3) 399(57.3) 231(47.3) 348(57.5) 282(48.7) 
Using 
allopurinol*† 
630(56.3) 462(59.5) 168(49.0) 411(60.2) 219(50.1) 399(60.5) 23(50.2) 348(60.8) 282(51.5) 
Allopurinol 
dose* 
         
≤100 mg 228(19.2) 162(19.8) 66(18.0) 146(20.2) 82(17.7) 134(19.2) 94(19.3) 114(18.8) 114(19.7) 
150-200 mg 61(5.2) 43(5.3) 18(4.9) 33(4.6) 28(6.1) 36(5.2) 25(5.1) 32(5.3) 29(5.0) 
300mg 302(25.5) 226(27.6) 76(20.8) 207(28.7) 95(20.5) 203(29.2) 99(20.2) 179(29.6) 123(21.2) 
≥400 mg 29(2.5) 23(2.8) 6(1.6) 18(2.5) 11(2.4) 16(2.3) 13(2.7) 19(3.1) 10(1.7) 
Don’t know 
dose or 
missing  
564(47.6) 364(44.5) 200(54.6) 317(44.0) 247(53.3) 307(44.1) 257(52.7) 261(43.1) 303(52.3) 
Prescription 
Allopurinol 
646(54.6) 496(60.6) 150(41.0) 440(61.0) 206(44.5) 419(60.2) 227(46.5) 371(61.3) 275(47.5) 
Prescription 
Colchicine 
345(29.1) 246(30.1) 99(27.0) 222(30.8) 123(26.6) 203(29.2) 142(29.1) 176(29.1) 169(29.2) 
Prescription 
NSAIDs 
634(53.5) 474(57.9) 160(43.7) 417(57.8) 217(46.9) 407(58.5) 227(46.5) 351(58.0) 283(48.9) 
Prescription 
Diuretic 
286(24.2) 207(25.3) 79(21.6) 183(25.4) 103(22.2) 169(24.3) 117(24.0) 136(22.5) 150(25.9) 
Values are n(%) unless stated otherwise 
* Self-reported allopurinol use and dose is taken from questionnaire responses; † as a proportion of participants who answered item about self-reported allopurinol;   In medical 
record in the two years prior to baseline. 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Comorbidities 
In the non-participants the proportion of individuals self-reporting a diagnosis of diabetes 
(18.8 to 21.6%), myocardial infarction (MI) (10.6 to 12.1%), or angina (13.4 to 14.1%) was 
higher, and self-reporting hyperlipidaemia was lower (40.4 to 41.7%), compared with 
responders (diabetes 15.2 to 16.4%; MI  8.1 to 9.7%; angina 11.2 to 12 %; hyperlipidaemia 
43.7 to 45.3%) (Table 4.3).   
Non-participants also had slightly higher mean scores for PHQ-9 (3.99 to 4.19), GAD-7 (3.02 to 
3.30), pain NRS (2.62 to 2.70), and global health NRS (2.93 to 3.01), in comparison with 
responders  (PHQ-9 3.28 to 3.42; GAQ-7 2.55 to 2.61; pain NRS 2.03 to 2.15; global health NRS 
2.38 to 2.58) (Table 4.4).   
Other characteristics presented in Table 4.3 and Table 4.4 did not appear to differ substantially 
between responders and non-participants. 
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Table 4.3 Self-reported comorbidities, total comorbidities and  eGFR <60  mL/min/1.73m2 of responders and non-participants at baseline, 6, 12, 24 
and 36 months 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
Comorbidity*          
Diabetes  205(17.3) 126(15.4) 79(21.6) 118(16.4) 87(18.8) 106(15.2) 99(20.3) 94(15.5) 111(19.2) 
Cerebrovascular accident (CVA) 37(3.1) 24(2.9) 13(3.6) 24(3.3) 13(2.8) 19(2.7) 18(3.7) 14(2.3) 23(4.0) 
Hypertension (HT) 731(61.7) 501(61.2) 230(62.8) 440(61.0) 291(62.9) 421(60.5) 310(63.5) 364(60.2) 367(63.4) 
Transient ischaemic attack (TIA) 62(5.2) 38(4.6) 24(6.6) 33(4.6) 29(6.3) 36(5.2) 26(5.3) 30(5.0) 32(5.5) 
Hyperlipidaemia (HL) 508(42.9) 360(44.0) 148(40.4) 315(43.7) 193(41.7) 311(44.7) 197(40.4) 274(45.3) 234(40.4) 
Myocardial Infarction (MI)                 119(10.1) 78(9.5) 41(11.2) 70(9.7) 49(10.6) 65(9.3) 54(11.1) 49(8.1) 70(12.1) 
Renal failure (RF) 56(4.7) 42(5.1) 14(3.8) 36(5.0) 20(4.3) 33(4.7) 23(4.7) 21(3.5) 35(6.0) 
Renal calculi 81(6.8) 53(6.5) 28(7.7) 48(6.7) 33(7.1) 45(6.5) 36(7.4) 45(7.4) 36(6.2) 
Angina 147(12.4) 98(12.0) 49(13.4) 85(11.8) 62(13.4) 78(11.2) 69(14.1) 68(11.2) 79(13.6) 
Total comorbidities mean (SD)  1.6 (1.4) 1.6(1.3) 1.7(1.5) 1.6(1.4) 1.7(1.4) 1.6 (1.4) 1.7(1.4) 1.6(1.4) 1.7(1.4) 
eGFR <60  mL/min/1.73m2 318(26.9) 229(28.0) 89(24.3) 198(27.5) 120(25.9) 187(26.9) 131(26.8) 148(24.5) 170(29.4) 
Values are n(%) unless stated otherwise  *comorbidities self-reported in baseline questionnaire 
total number of comorbidities self-reported in baseline questionnaire (diabetes, hypertension, hyperlipidaemia, myocardial infarction, angina, cerebrovascular accident, 
transient ischaemic attack, renal failure, renal calculi) 
eGFR <60 mL/min/1.73m2 indicative of chronic kidney disease       In medical record in the two years prior to baseline 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
76 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.4 Depression scores, anxiety scores, pain and global health of responders and non-participants at baseline, 6, 12, 24 and 36 months 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
Depression (PHQ-9 category)           
Minimal 763(64.4) 547(66.9) 216(59.0) 490(68.0) 273(59.0) 475(68.2) 288(59.0) 430(71.1) 333(57.5) 
Mild 148(12.5) 108(13.2) 40(10.9) 83(11.5) 65(14.0) 85(12.2) 63(12.9) 71(11.7) 77(13.3) 
Moderate 65(5.5) 44(5.4) 21(5.7) 42(5.8) 23(5.0) 38(5.5) 27(5.5) 30(5.0) 35(6.0) 
Moderately severe 40(3.4) 22(2.7) 18(4.9) 19(2.6) 21(4.5) 17(2.4) 23(4.7) 15(2.5) 25(4.3) 
Severe 26(2.2) 15(1.8) 11(3.0) 16(2.2) 10(2.2) 14(2.0) 12(2.5) 14(2.3) 12(2.1) 
PHQ-9 score mean(SD) 3.64(5.22) 3.41(4.94) 4.19(5.83) 3.42(5.08) 3.99(5.44) 3.35(4.97) 4.07(5.57) 3.28(4.97) 4.06(5.48) 
Anxiety (GAD-7 category)          
Minimal 844(71.3) 607(74.2) 237(64.8) 533(73.9) 311(67.2) 518(74.4) 326(66.8) 454(75.0) 390(67.4) 
Mild 141(11.9) 99(12.1) 42(11.5) 90(12.5) 51(11.0) 91(13.1) 50(10.2) 75(12.4) 66(11.4) 
Moderate 64(5.4) 39(4.8) 25(6.8) 36(5.0) 28(6.0) 30(4.3) 34(7.0) 25(4.1) 39(6.7) 
Severe 45(3.8) 28(3.4) 17(4.6) 24(3.3) 21(4.5) 22(3.2) 23(4.7) 22(3.6) 23(4.0) 
GAD-7 score mean(SD) 2.79(4.49) 2.58(4.21) 3.30(5.07) 2.61(4.26) 3.08(4.84) 2.55(4.14) 3.15(4.96) 2.58(4.25) 3.02(4.74) 
Body pain 651(54.9) 465(56.8) 186(50.8) 415(57.6) 236(51.0) 383(55.0) 268(54.9) 339(56.0) 312(53.9) 
NRS pain in last week mean (SD) 2.32(2.85) 2.15(2.72) 2.70(3.11) 2.11(2.74) 2.65(2.99) 2.08(2.73) 2.67(2.99) 2.03(2.68) 2.62(3.00) 
NRS global health mean (SD) 2.68(2.77) 2.58(2.70) 2.93(2.92) 2.51(2.70) 2.97(2.87) 2.48(2.68) 2.98(2.88) 2.38(2.68) 3.01(2.84) 
Values are n(%) unless stated otherwise 
PHQ-9 score ranges from 0 to 27  Minimal depression 0-4, Mild 5-9, Moderate 10-14, Moderately Severe 15-19, Severe 20-27; GAD-7 score ranges from 0 to 21 Minimal anxiety 
0-4, Mild 5-9, Moderate 10-14, Severe 15-21; Body pain (including ache or discomfort or stiffness) for one day or longer in the 4 weeks prior to baseline; NRS pain in last week 
ranges from 0 (no pain ) to 10 (pain as bad as it can be);  NRS global health ranges from 0 (very well ) to 10 (very poor health). 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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HRQOL measures; GIS subscales, SF-36 PF10 and HAQ-DI 
The mean GIS unmet treatment need (UTN) score of non-participants was higher (ranging 
from 36.64 to 37.89) thus indicating slightly worse gout-specific HRQOL, in contrast with the 
mean GIS UTN scores of responders (30.57 to 31.60) (Table 4.5).  However, there did not 
appear to be substantial differences in the other GIS subscales scores between responders 
and non-participants. 
The mean SF-36 PF10 scores at each time-point were lower for non-participants (69.54 to 
70.31) thus indicating worse HRQOL, in comparison with responders (78.79 to 81.52).   
At each time-point, the mean HAQ-DI scores were higher for non-participants (0.63 to 0.64) 
thus indicating greater activity limitation in comparison with responders (0.39 to 0.46).       
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Table 4.5 GIS subscales, SF-36 PF10 and HAQ-DI scores of responders and non-participants at baseline, 6, 12, 24 and 36 months 
 
 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
GIS Concern overall (CO) 48.65(28.33) 47.68(28.10) 50.89(28.77) 47.65(27.93) 50.25(28.92) 47.96(28.40) 49.67(28.23) 47.52(28.14) 49.87(28.51) 
GIS Medication side effects (MSE) 40.45(26.33) 40.20(25.75) 41.05(27.67) 40.01(25.68) 41.17(27.36) 40.30(26.40) 40.68(26.24) 40.59(26.46) 40.31(26.20) 
GIS Unmet treatment need (UTN) 33.46(20.57) 31.60(20.11) 37.89(20.99) 31.35(20.09) 36.93(20.90) 30.72(19.65) 37.61(21.24) 30.57(19.26) 36.64(21.49) 
GIS Wellbeing during an attack 
(WBDA) 
45.19(26.41) 45.32(25.94) 44.88(27.49) 45.24(25.93) 45.12(27.19) 45.44(26.36) 44.83(26.51) 45.94(26.45) 44.38(26.37) 
GIS Concern during an attack (CDA) 40.13(24.35) 39.59(23.68) 41.38(25.83) 39.40(23.83) 41.32(25.15) 39.55(24.40) 40.99(24.27) 39.40(23.93) 40.92(24.79) 
          
SF-36 PF10 75.91(26.12) 78.79(24.12) 69.57(29.09) 79.45(24.00) 70.31(28.30) 80.25(23.89) 69.54(27.92) 81.53(22.78) 69.78(28.10) 
          
HAQ-DI  0.51(0.71) 0.46(0.67) 0.63(0.80) 0.43(0.64) 0.63(0.80) 0.41(0.63) 0.64(0.80) 0.39(0.62) 0.64(0.78) 
Values are mean (SD) 
Each GIS subscale scored from 0 to 100; higher scores on each scale indicating a greater impact of gout on HRQOL/ worse HRQOL. 
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities including the most vigorous without limitations due to health.   
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation. 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Socio-demographic characteristics 
As displayed in Table 4.6 responders were more likely to be male (86.2 to 89.4% male), 
attended further education (23.6 to 26.0%) and drink alcohol either daily or almost daily (24.4 
to 26.9%), compared with non-participants (male 77.5 to 78.1%; further education 15.3 to 
16.2%; alcohol daily 18.4 to 19.9%).  Fewer responders were over the age of 80 (8.6 to 10.5%) 
and classified as most deprived (27.1 to 29.0%), in comparison with non-participants (over 80 
16.8 to 18.2%; most deprived 35.4 to 36.5%).   
 
BMI and alcohol frequency 
 As displayed in Table 4.7 responders were more likely to be drink alcohol either daily or 
almost daily (24.4 to 26.9%), compared with non-participants (alcohol daily 18.4 to 19.9%).   
No marked differences were observed in the BMI of responders and non-participants. 
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Table 4.6 Socio-demographic characteristics of responders and non-participants at baseline, 6, 12, 24 and 36 months 
 
Baseline 
characteristic 
Baseline  
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
Male  990(83.6) 705(86.2) 285(77.9) 629(87.2) 361(78.0) 609(87.5) 381(78.1) 541(89.4) 449(77.5) 
Age mean (SD) 65.61(12.49) 65.43(11.96) 66.01(13.58) 65.35(11.68) 66.01(13.66) 65.09(11.48) 66.35(13.78) 64.58(11.48) 66.68(13.40) 
Age categories           
<40  26(2.2) 17(2.1) 9(2.5) 16(2.2) 10(2.2) 15(2.2) 11(2.3) 15(2.5) 11(1.9) 
40-49.9 116(9.8) 73(8.9) 43(11.7) 59(8.2) 57(12.3) 56(8.0) 60(12.3) 50(8.3) 66(11.4) 
50-59.9 210(17.7) 151(18.5) 59(16.1) 137(19.0) 73(15.8) 132(19.0) 78(16.0) 121(20.0) 89(15.4) 
60-69.9 343(29.0) 253(30.9) 90(24.6) 227(31.5) 116(25.1) 232(33.3) 111(22.7) 206(34.0) 137(23.7) 
70-79.9 339(28.6) 238(29.1) 101(27.6) 210(29.1) 129(27.9) 200(28.7) 139(28.5) 161(26.6) 178(30.7) 
>80 150(12.7) 86(10.5) 64(17.5) 72(10.0) 78(16.8) 61(8.8) 89(18.2) 52(8.6) 98(16.9) 
Neighbour 
deprivation status†  
         
Most deprived 369(31.2) 237(29.0) 132(36.1) 200(27.7) 169(36.5) 193(27.7) 176(36.1) 164(27.1) 205(35.4) 
Middle 405(34.2) 289(35.3) 116(31.7) 257(35.6) 148(32.0) 260(37.4) 145(29.7) 45(38.3) 173(29.9) 
Least deprived 410(34.6) 292(35.7) 118(32.2) 264(36.6) 146(31.5) 243(34.9) 167(34.2) 37(34.5) 201(34.7) 
Ethnic origin           
White UK/European 1126(95.1) 789(96.5) 337(92.1) 698(96.8) 428(92.4) 670(96.3) 456(93.4) 589(97.4) 537(92.7) 
Asian 16(1.4) 9(1.1) 7(1.9) 8(1.1) 8(1.7) 10(1.4) 6(1.2) 6(1) 10(1.7) 
Afro Caribbean  2(0.2) 2(0.2) 0(0) 1(0.1) 1(0.2) 1(0.1) 1(0.2) 1(0.2) 1(0.2) 
African 2(0.2) 1(0.1) 1(0.3) 0(0) 2(0.4) 0(0) 2(0.4) 3(0.5) 2(0.3) 
Chinese 1(0.1) 0(0) 1(0.3) 0(0) 1(0.2) 0(0) 1(0.2) 0(0) 1(0.2) 
 Other   7(0.6) 4(0.5) 3(0.8) 4(0.6) 3(0.6) 4(0.6) 3(0.6) 0(0) 4(0.7) 
Values are n(%) unless stated otherwise 
† calculated using tertiles of indices of multiple deprivation (IMD)     Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Table 4.6 cont. Socio-demographic characteristics of responders and non-participants at baseline, 6, 12, 24 and 36 months 
 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
Relationship status           
Married 809(68.4) 570(69.7) 239(65.3) 495(68.7) 314(67.8) 491(70.5) 318(65.2) 432(71.4) 377(65.1) 
Widowed 114(9.6) 74(9.0) 40(10.9) 67(9.3) 47(10.2) 55(7.9) 59(12.1) 45(7.4) 69(11.9) 
Cohabiting 73(6.2) 53(6.5) 20(5.5) 43(6.0) 30(6.5) 43(6.2) 30(6.1) 37(6.1) 36(6.2) 
Divorced 69(5.8) 44(5.4) 25(6.8) 45(6.2) 24(5.2) 38(5.5) 31(6.4) 34(5.6) 35(6.0) 
Separated 22(1.9) 13(1.6) 9(2.5) 14(1.9) 8(1.7) 12(1.7) 10(2.0) 9(1.5) 13(2.2) 
Single 78(6.6) 54(6.6) 24(6.6) 48(6.7) 30(6.5) 48(6.9) 30(6.1) 42(6.9) 36(6.2) 
Attendance at further education  249(21.0) 193(23.6) 56(15.3) 175(24.3) 74(16.0) 170(24.4) 79(16.2) 157(26.0) 92(15.9) 
Values are n(%) unless stated otherwise 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Table 4.7  BMI and alcohol frequency of responders and non-participants at baseline, 6, 12, 24 and 36 months
 
Baseline characteristic 
Baseline 
characteristics 
6 Month mail-out 
characteristics at baseline 
12 Month mail-out 
characteristics at baseline 
24 Month mail-out 
characteristics at baseline 
36 Month mail-out 
characteristics at baseline 
All responders 
at baseline 
(n=1184) 
Responders 
(n=818) 
Non-
participants 
(n=366) 
Responders 
(n=721) 
Non-
participants 
(n=463) 
Responders 
(n=696) 
Non-
participants 
(n=488) 
Responders 
(n=605) 
Non-
participants 
(n=579) 
BMI kg/m2   mean (SD) 29.13(5.11) 29.30(5.24) 28.73(4.78) 29.08(5.06) 29.21(5.20) 29.21(5.04) 29.01(5.21) 29.32(5.06) 28.92(5.15) 
BMI categories           
<18.5  kg/m2    1(0.1) 1(0.1) 0(0) 1(0.1) 0(0) 1(0.1) 0(0) 1(0.2) 0(0) 
18.5-24.9  kg/m2    219(18.5) 144(17.6) 75(20.5) 134(18.6) 85(18.4) 122(17.5) 97(19.9) 106(17.5) 113(19.5) 
25-29.9  kg/m2    511(43.2) 358(43.8) 153(41.8) 323(44.8) 188(40.6) 313(45.0) 198(40.6) 262(43.3) 249(43.0) 
30-34.9  kg/m2    260(22.0) 188(23.0) 72(19.7) 160(22.2) 100(21.6) 155(22.3) 105(21.5) 147(24.3) 113(19.5) 
35-39.9  kg/m2    90(7.6) 61(7.5) 29(7.9) 48(6.7) 42(9.1) 54(7.8) 36(7.4) 46(7.6) 44(7.6) 
≥40  kg/m2    37(3.1) 31(3.8) 6(1.6) 25(3.5) 12(2.6) 22(3.2) 15(3.1) 21(3.5) 16(2.8) 
Alcohol frequency           
Never 113(9.5) 73(8.9) 40(10.9) 57(7.9) 56(12.1) 57(8.2) 56(11.5) 46(7.6) 67(11.6) 
Special occasions 155(13.1) 98(12.0) 57(15.6) 86(11.9) 69(14.9) 81(11.6) 74(15.2) 62(10.2) 93(16.1) 
1 to 3 times per month 109(9.2) 77(9.4) 32(8.7) 71(9.8) 38(8.2) 67(9.6) 42(8.6) 60(9.9) 49(8.5) 
Once or twice per week 254(21.5) 180(22.0) 74(20.2) 156(21.6) 98(21.2) 148(21.3) 106(21.7) 132(21.8) 122(21.1) 
3 to 4 times per week 263(22.2) 183(22.4) 80(21.9) 163(22.6) 100(21.6) 153(22.0) 110(22.5) 139(23.0) 124(21.4) 
Daily or almost daily 273(23.1) 200(24.4) 73(19.9) 182(25.2) 91(19.7) 183(26.3) 90(18.4) 163(26.9) 110(19.0) 
Values are n(%) unless stated otherwise 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Comparison of the characteristics of participants responding on a different number of 
occasions 
Table 4.8 to Table 4.13 display the baseline characteristics of participants who responded on 
a different number of occasions (i.e. only baseline, baseline plus one other time-point, 
baseline plus two other time-points, baseline plus three other time-points, and all time 
points). 
Gout-specific characteristics 
Participants who responded only at baseline had a shorter disease duration (10.98 years) and 
fewer of these participants had a serum urate greater than 360 µmol/L (21.8%) compared with 
participants who responded more often (Table 4.8).  However, there was less difference in the 
proportion of individuals with a serum urate greater than 360 µmol/L, as a proportion of those 
who had a serum urate record in their notes.  The proportion of individuals missing a serum 
urate record in their medical records in the two years prior to baseline was higher in 
participants who responded only at baseline (70.7%), compared with participants who 
responded more often. 
Participants who responded at all five time-points had the longest disease duration (12.83 
years) and fewer of these participants reported experiencing two or more flares (37.4%) or a 
current flare whilst completing the baseline questionnaire (7.6%) compared with participants 
who responded less often. 
Other characteristics presented in Table 4.8 did not appear to differ substantially between the 
groups of participants who responded on a different number of occasions. 
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Table 4.8 Gout-specific characteristics of participants responding on different number of occasions 
Baseline characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders at 
baseline 
 and at least 
one other 
time-point 
(n= 904) 
Responders at 
baseline 
 and at least 
two other 
time-points 
(n=771) 
Responders at 
baseline 
 and at least 
three other 
time-points 
(n=655) 
Responders at 
baseline 
 and  
all time- 
points 
(n=510) 
0 gout flares 398(33.6) 91(32.5) 307(34.0) 267(34.6) 236(36.0) 195(38.2) 
1 gout flare 231(19.5) 51(18.2) 180(19.9) 152(19.7) 131(20.0) 102(20.0) 
2 gout flares 187 (15.8) 38(13.6) 149(16.5) 123(16.0) 106(16.2) 82(16.1) 
3 gout flares 103(8.7) 22(7.9) 81(9.0) 69(8.9) 55(8.4) 43(8.4) 
4 gout flares 67(5.7) 18(6.4) 49(5.4) 40(5.2) 31(4.7) 22(4.3) 
 5 or more gout flares 137(11.6) 40(14.3) 97(10.7) 85(11.0) 67(10.2) 44(8.6) 
≥2 gout flares 494(41.7) 118(42.1) 376(41.6) 317(41.1) 259(39.5) 191(37.4) 
Disease duration years mean 
(SD) 
11.91 
(12.13) 
10.98 
(13.25) 
12.19 
(11.77) 
12.34 
(11.71) 
12.54 
(11.55) 
12.83 
(11.76) 
Occurrence of current flare 132(11.1) 34(12.1) 98(10.8) 81(10.5) 62(9.5) 39(7.6) 
History of oligo/ polyarticular 
flares 
436(36.8) 97(34.6) 339(37.5) 291(37.7) 248(37.9) 182(35.7) 
Record of tophi  25(2.1) 5(1.8) 20(2.2) 18(2.3) 13(2.0) 9(1.8) 
Maximum serum urate level 
mean (SD) µmol/L* 
441.36 
(115.51) 
445.55 
(132.12) 
440.46 
(111.77) 
439.95 
(111.17) 
438.08 
(109.63) 
431.91 
(110.42) 
Serum urate level >360 
µmol/L * 
352(29.7) 61(21.8) 291(32.2) 248(32.2) 209(31.9) 161(31.6) 
Serum urate level >360 
µmol/L as % of those with 
serum urate record* 
352(76.4) 61(74.4) 291(76.8) 248(77.5) 209(76.8) 161(75.2) 
Missing serum urate record 723(61.1) 198(70.7) 525(58.1) 451(58.5) 383(58.5) 296(58.0) 
Values are n(%) unless stated otherwise 
 in previous 12 months at baseline; In medical record in the two years prior to baseline; *highest serum urate recorded 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Medication 
Fewer participants who responded only at baseline reported allopurinol use at baseline 
(46.1%) with fewer taking a dose of 300 mg (17.9%) compared to participants who responded 
at more time-points (Table 4.9).  The number of people reporting to take allopurinol, as a 
proportion of those who responded to the allopurinol use item, was also less in the 
participants who responded only at baseline (50.8%), compared with other participants.  Also, 
fewer participants who responded only at baseline had prescriptions for allopurinol (39.6%), 
colchicine (24.6%), NSAIDs (39.4%), and diuretics (21.1%) in their medical records compared 
with other participants.  Conversely the group of participants who responded at all five time-
points had more participants reporting to take allopurinol (59.0%) and with a prescription for 
allopurinol (62.5%).  
 
Other characteristics presented in Table 4.9 did not appear to differ greatly between the 
groups of participants who responded on a different number of occasions. 
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Table 4.9 Medications of participants responding on different number of occasions 
Baseline 
characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders at 
baseline 
 and at least  
one other 
time-point 
(n= 904) 
Responders at 
baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders at 
baseline 
 and at least  
three other 
time-points 
(n=655) 
Responders at 
baseline 
 and all time- 
points 
(n=510) 
Using allopurinol * 630(53.2) 129(46.1) 501(55.4) 440(57.1) 378(57.7) 301(59.0) 
Using allopurinol *† 630(56.3) 129(50.8) 501(58.4) 440(60.3) 378(61.0) 301(62.2) 
Reported 
allopurinol dose 
      
≤100mg 228(19.3) 59(21.0) 169(18.6) 153(19.8) 129(19.7) 105(20.5) 
150-200 mg 61(5.2) 14(5.0) 47(5.2) 39(5.1) 33(5.0) 25(4.9) 
300 mg 302(25.5) 50(17.9) 252(27.9) 220(28.5) 190(29.0) 153(30.0) 
>400mg 29(2.4) 5(1.8) 24(2.7) 22(2.9) 17(2.6) 13(2.6) 
Missing or don’t 
know dose 
564(47.6) 152(54.3) 412(45.6) 337(43.7) 286(43.7) 214(42.0) 
Prescription 
Allopurinol 
646(54.6) 111(39.6) 535(59.2) 470(61.1) 402(61.4) 319(62.5) 
Prescription 
Colchicine 
345(29.1) 69(24.6) 276(30.5) 236(30.6) 191(29.2) 144(28.2) 
Prescription 
 NSAIDs 
634(53.5) 111(39.4) 523(57.9) 448(58.7) 382(58.3) 296(58.0) 
Prescription 
Diuretic 
286(24.2) 59(21.1) 227(25.1) 191(24.8) 158(24.1) 119(23.3) 
Values are n(%) unless stated otherwise 
*Self-reported allopurinol use and dose is taken from questionnaire responses; † as a proportion of participants who answered 
item about self-reported allopurinol;   In medical record in the two years prior to baseline 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Comorbidities 
The group who responded only at baseline had a higher proportion of participants reporting 
diabetes (22.5%) (Table 4.10) and a higher PHQ-9 (3.90), GAD-7 (3.04), NRS pain (2.73) and 
NRS global health (2.91) score compared to participants who responded more often (Table 
4.11).  The group of participants who responded at all five time-points had the lowest mean 
PHQ-9 (2.96), GAD-7 (2.32), NRS pain (1.90) and NRS global health (2.31) scores. 
Other characteristics presented in Table 4.10 and Table 4.11 did not appear to differ 
substantially between the groups of participants who responded on a different number of 
occasions. 
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Table 4.10 Self-reported comorbidities, total comorbidities and eGFR <60  mL/min/1.73m2 of participants 
responding on different number of occasions 
Baseline characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
 and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and all 
time-points 
(n=510) 
Comorbidity*        
Diabetes  205(17.3) 63(22.5) 142(15.7) 119(15.4) 102(15.6) 81(15.9) 
Cerebrovascular accident (CVA) 37(3.1) 9(3.2) 28(3.1) 24(3.1) 18(2.7) 11(2.2) 
Hypertension (HT) 731(61.7) 177(63.2) 554(61.3) 467(60.6) 397(60.6) 308(60.4) 
Transient ischaemic attack (TIA) 62(5.2) 17(6.1) 45(5.0) 36(4.7) 31(4.7) 25(4.9) 
Hyperlipidaemia (HL) 508(42.9) 109(38.9) 399(44.1) 340(44.1) 287(43.8) 234(45.9) 
Myocardial Infarction (MI)                 119(10.1) 30(10.7) 89(9.8) 71(9.2) 58(8.9) 44(8.6) 
Renal failure (RF) 56(4.7) 11(3.9) 45(5.0) 37(4.8) 31(4.7) 19(3.7) 
Renal calculi 81(6.8) 24(8.6) 57(6.3) 51(6.6) 46(7.0) 37(7.3) 
Angina 147(12.4) 31(11.1) 116(12.8) 90(11.7) 69(10.5) 54(10.6) 
Total comorbidities mean (SD) 1.6(1.4) 1.7 (1.4) 1.6(1.4) 1.6(1.4) 1.6(1.3) 1.6(1.3) 
eGFR <60  mL/min/1.73m2 318(26.9) 71(25.4) 247(27.3) 206(26.7) 173(25.4) 136(26.7) 
Values are n(%) unless stated otherwise    *comorbidities self-reported in baseline questionnaire 
 total number of comorbidities self-reported in baseline questionnaire (diabetes, hypertension, hyperlipidaemia, myocardial 
infarction, angina, cerebrovascular accident, transient ischaemic attack, renal failure, renal calculi) 
eGFR <60 mL/min/1.73m2 indicative of chronic kidney disease         In medical record in the two years prior to baseline 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Table 4.11 Depression scores, anxiety scores, pain and global health  of participants responding on different 
number of occasions 
Baseline characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
 and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and all 
time-points 
(n=510) 
Depression (PHQ-9 category)        
Minimal 763(64.4) 169(60.4) 594(65.7) 525(68.1) 451(68.9) 372(72.9) 
Mild 148(12.5) 32(11.4) 116(12.8) 92(11.9) 79(12.1) 60(11.8) 
Moderate 65(5.5) 11(3.9) 54(6.0) 45(5.8) 35(5.3) 20(3.9) 
Moderately severe 40(3.4) 16(5.7) 24(2.7) 20(2.6) 18(2.7) 11(2.2) 
Severe 26(2.2) 6(2.1) 20(2.2) 17(2.2) 13(2.0) 9(1.8) 
PHQ-9 score mean(SD) 3.64(5.22) 3.90(5.59) 3.56(5.12) 3.44(5.07) 3.35(4.99) 2.96(4.61) 
Anxiety (GAD-7 category)       
Minimal 844(71.3) 182(65.0) 662(73.2) 570(73.9) 487(74.4) 393(77.1) 
Mild 141(11.9) 28(10.0) 113(12.5) 98(12.7) 84(12.8) 60(11.8) 
Moderate 64(5.4) 19(6.8) 45(5.0) 37(4.8) 30(4.6) 18(3.5) 
Severe 45(3.8) 11(3.9) 34(3.8) 26(3.4) 21(3.2) 15(2.9) 
GAD-7 score mean (SD) 2.79(4.49) 3.04(4.89) 2.72(4.37) 2.62(4.25) 2.55(4.13) 2.32(3.96) 
Body pain 651(54.9) 137(48.9) 514(56.9) 438(56.8) 369(56.4) 281(55.1) 
NRS pain in last week mean (SD) 2.32(2.85) 2.73(3.10) 2.19(2.76) 2.13(2.75) 2.08(2.74) 1.90(2.55) 
NRS global health mean (SD) 2.68(2.77) 2.91(2.90) 2.62(2.73) 2.50(2.69) 2.47(2.69) 2.31(2.62) 
Values are n(%) unless stated otherwise     
PHQ-9 score ranges from 0 to 27  Minimal depression 0-4, Mild 5-9, Moderate 10-14, Moderately Severe 15-19, Severe 20-27; 
GAD-7 score ranges from 0 to 21 Minimal anxiety 0-4, Mild 5-9, Moderate 10-14, Severe 15-21; body pain (including ache or 
discomfort or stiffness) for one day or longer in the 4 weeks prior to baseline;  NRS pain in last week ranges from 0 (no pain ) to 
10 (pain as bad as it can be);  NRS global health ranges from 0 (very well ) to 10 (very poor health). 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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HRQOL measures; GIS subscales, SF-36 PF10 and HAQ-DI 
The group of participants who responded only at baseline had a slightly higher mean GIS UTN 
score (38.27) indicating worse gout-specific HRQOL, along with a lower SF-36 PF10 score 
(67.98) indicating worse HRQOL, and a higher HAQ-DI score (0.65) indicating greater activity 
limitation in comparison with other participants (Table 4.12).   
The group which responded at all five time-points had slightly lower GIS subscale scores (30.05 
to 45.43) indicating slightly better gout-specific HRQOL, compared with scores for the whole 
cohort at baseline (GIS subscales ranging from 33.46 to 48.65), with the GIS CO and UTN 
displaying more difference compared with other GIS subscale scores.  The group which 
responded at all five time-points also had a higher score for SF-36 PF10 (81.36) indicating a 
better HRQOL, and a lower mean score for HAQ-DI (0.37) indicating less activity limitation, 
compared with scores for the whole cohort at baseline (HAQ-DI 0.51; SF-36 PF10 75.91).     
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                      Table 4.12 GIS subscales, SF-36 PF10 and HAQ-DI scores of participants responding on different number of occasions 
 
 
 
 
 
 
 
 
 
Baseline characteristic 
All 
responders at 
baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and at least   
all time- 
points 
(n=510) 
GIS Concern overall 48.65(28.33) 49.61(28.61) 48.37(28.26) 48.31(28.35) 47.86(28.25) 45.43(27.36) 
GIS Medication side effects 40.45(26.33) 39.37(27.07) 40.77(26.12) 40.77(26.39) 39.97(25.77) 38.98(25.71) 
GIS Unmet treatment need 33.46(20.57) 38.27(21.10) 32.07(20.22) 31.23(19.75) 30.42(19.61) 30.05(19.40) 
GIS Wellbeing during an attack 45.19(26.41) 43.05(27.18) 45.83(26.16) 45.76(26.18) 45.33(26.22) 44.53(25.99) 
GIS Concern during an attack 40.13(24.35) 39.7(25.14) 40.26(24.13) 39.85(23.99) 39.02(23.86) 38.23(23.64) 
       
SF-36 PF10 75.91(26.12) 67.98(29.41) 78.34(24.54) 79.97(23.71) 80.84(23.30) 81.36(22.93) 
       
HAQ-DI  0.51(0.71) 0.65(0.80) 0.46(0.68) 0.43(0.64) 0.41(0.625) 0.37(0.59) 
Values are mean (SD) 
Each GIS subscale scored from 0 to 100; higher scores on each scale indicating a greater impact of gout on HRQOL/worse HRQOL. 
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities including the most vigorous without 
limitations due to health.  
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation. 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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Socio-demographic characteristics 
Participants who responded only at baseline were less likely to be male, married or cohabiting, 
have attended further education, or consume alcohol daily and more likely to be older, or 
more deprived, in comparison with participants who responded at more time-points (Table 
4.13).   
 
BMI and alcohol frequency 
Participants who responded only at baseline were less likely to consume alcohol daily, in 
comparison with participants who responded at more time-points (Table 4.14). 
No marked differences were observed in the BMI of participants who responded on a different 
number of occasions. 
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Table 4.13 Socio-demographic characteristics of participants responding on different number of 
occasions 
Baseline characteristic 
All 
responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
 and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and all 
time- points 
(n=510) 
Sex n(%)        
Male 990(83.6) 213(76.1) 777(86.0) 672(87.2) 579(88.4) 456(89.4) 
Age mean (SD) 65.61(12.49) 67.41(13.07) 65.05(12.26) 65.08(11.70) 65.14(11.42) 65.41(10.90) 
Age categories n(%)       
<40  26(2.2) 4(1.4) 22(2.4) 17(2.2) 14(2.1) 10(2.0) 
40-49.9 116(9.8) 30(10.7) 86(9.5) 66(8.6) 52(7.9) 34(6.7) 
50-59.9 210(17.7) 43(15.4) 167(18.5) 149(19.3) 127(19.4) 98(19.2) 
60-69.9 343(29.0) 63(22.5) 280(31.0) 247(32.0) 214(32.7) 177(34.7) 
70-79.9 339(28.6) 85(30.4) 254(28.1) 219(28.4) 188(28.7) 148(29) 
>80 150(12.7) 55(19.6) 95(10.5) 73(9.5) 60(9.2) 43(8.4) 
Neighbour deprivation 
status† n(%) 
 
 
    
Most deprived 369(31.2) 113(40.4) 256(28.3) 217(28.1) 181(27.6) 140(27.5) 
Middle 405(34.2) 85(30.4) 320(35.4) 281(36.4) 244(37.3) 193(37.8) 
Least deprived 410(34.6) 82(29.3) 328(36.3) 273(35.4) 230(35.1) 177(34.7) 
Ethnic origin n(%)       
White UK/ European 1126(95.1) 258(92.1) 868(96.0) 746(96.8) 632(96.5) 500(98.0) 
Asian 16(1.4) 4(1.4) 12(1.3) 9(1.2) 8(1.2) 4(0.8) 
Afro Caribbean  2(0.2) 0(0) 2(0.2) 1(0.1) 1(0.2) 1(0.2) 
African 2(0.2) 1(0.4) 1(0.1) 0(0) 0(0) 0(0) 
Chinese 1(0.1) 1(0.4) 0(0) 0(0) 0(0) 0(0) 
Other   7(0.6) 1(0.4) 6(0.7) 4(0.5) 4(0.6) 1(0.2) 
† calculated using tertiles of indices of multiple deprivation  
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Table 4.13 cont. Socio-demographic characteristics of participants responding on different number of 
occasions 
Baseline characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
 and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and all 
time-points 
(n=510) 
Relationship status n(%)       
Married 809(68.4) 183(65.4) 626(69.2) 540(70.0) 462(70.5) 360(70.6) 
Widowed 114(9.6) 34(12.1) 80(8.8) 68(8.8) 54(8.2) 39(7.6) 
Cohabiting 73(6.2) 11(3.9) 62(6.9) 48(6.2) 37(5.6) 29(5.7) 
Divorced 69(5.8) 18(6.4) 51(5.6) 43(5.6) 37(5.6) 30(5.9) 
Separated 22(1.9) 4(1.4) 18(2.0) 12(1.6) 11(1.7) 7(1.4) 
Single 78(6.6) 21(7.5) 57(6.3) 51(6.7) 45(6.9) 39(7.6) 
Attendance at further education 
n(%) 
249(21.0) 42(15.0) 207(22.9) 186(24.1) 166(25.3) 136(26.7) 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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     Table 4.14 BMI and alcohol frequency of  participants responding on different number of occasions 
 
 
 
Baseline characteristic 
All responders 
at baseline 
(n=1184) 
 
Responded 
only at 
baseline 
(n=280) 
Responders 
at baseline 
 and at least   
one other 
time-point 
(n=904) 
Responders 
at baseline 
 and at least   
two other 
time-points 
(n=771) 
Responders 
at baseline 
 and at least   
three other 
time-points 
(n=655) 
Responders 
at baseline 
 and all 
time-points 
(n=510) 
BMI kg/m2   mean (SD) 29.13(5.11) 28.65(4.95) 29.27(5.15) 29.31(5.17) 29.17(5.12) 29.08(4.92) 
BMI categories n(%)       
<18.5  kg/m2    1(0.1) 0(0) 1(0.1) 1(0.1) 1(0.2) 1(0.2) 
18.5-24.9  kg/m2    219(18.5) 60(21.4) 159(17.6) 136(17.6) 120(18.2) 91(17.8) 
25-29.9  kg/m2    511(43.2) 111(39.6) 400(44.2) 340(44.1) 288(44.0) 228(44.7) 
30-34.9  kg/m2    260(22.0) 56(20.0) 204(22.6) 176(22.8) 147(22.5) 123(24.1) 
35-39.9  kg/m2    90(7.6) 21(7.5) 69(7.6) 59(7.7) 48(7.3) 33(6.5) 
>40  kg/m2    37(3.1) 5(1.8) 32(3.5) 29(3.8) 22(3.4) 16(3.1) 
Alcohol frequency n(%)       
Never 113(9.5) 32(11.4) 81(9.0) 62(8.0) 53(8.1) 37(7.3) 
Special occasions 155(13.1) 45(16.1) 110(12.2) 90(11.7) 73(11.1) 54(10.6) 
1 to 3 times per month 109(9.2) 22(7.9) 87(9.6) 73(9.5) 62(9.5) 53(10.4) 
Once or twice per week 254(21.5) 55(19.6) 199(22.0) 168(21.8) 140(21.4) 109(21.4) 
3 to 4 times per week 263(22.2) 68(24.3) 195(21.6) 176(22.8) 149(22.7) 118(23.1) 
Daily or almost daily 273(23.1) 49(17.5) 224(24.8) 196(25.4) 172(26.3) 136(26.7) 
Baseline data for cohort have been published previously (Chandratre et al 2018). 
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4.4.3 Assessment of Item non-response 
GIS subscale item non-response 
The percentage of item non-response (percentage of responders at each time-point who did 
not provide a response to an individual item) for the items of the GIS subscale was below 10% 
for all items except two items from the GIS WBDA relating to missing work because of gout 
symptoms (proportion missing at different time-points ranged from 10.9 to 13.6%) and have 
difficulty working because of gout symptoms (9.4 to 12.1%) (Table 4.15).   Other items with 
between 5 and 10% item non-response at any time-point included all of the items from the 
GIS MSE and GIS UTN subscale and selected items from the GIS WBDA subscale.  Neither the 
GIS CO nor GIS CDA subscales had more than 5% item non-response at any time-point.  With 
the exception of the GIS UTN subscale, less than 5% of responders had insufficient item 
responses to enable calculation of each GIS subscale total at each time-point (Table 4.18).  5% 
to 6.4% of responders had insufficient item responses to the GIS UTN subscale over the five 
time-points, to permit calculation of a GIS UTN score.  
SF-36 PF 10 item non-response 
The percentage of item non-response was below 5% for all items of the SF-36 PF10 except the 
item relating to vigorous activity at 12-month time-point where 5.4% was missing (Table 4.16).  
Over the five time-points, 18.9 to 21% of participants had insufficient item response to enable 
calculation of a SF-36 PF10 score (see Table 4.19). 
HAQ-DI item non-response 
The percentage of item non-response was below 5% for all items of the HAQ-DI except the 
item relating to taking a bath at baseline and 12 months which had 5.2% and 5.4% missing 
(Table 4.17).  Over all five time-points fewer than 5% of participants had insufficient item 
responses to enable the calculation of a HAQ-DI score (see Table 4.19).
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Table 4.15 Number and percentage of responders at each time-point who did not provide a response to each individual item of GIS 
questionnaire (item non-response to GIS subscale questionnaire items) 
 
GIS item 
 
 
Baseline 
n(%) 
missing  
6 months 
n(%) 
missing  
12 months 
n(%) 
missing  
24 months 
n(%) 
missing  
36 months 
n(%) 
missing  
Gout Concern overall (CO)      
1A I am worried that I will have a gout attack within the next year  48(4.1) 21(2.6) 17(2.4) 20(2.9) 18(3.0) 
1B I am afraid that my gout will get worse with time 41(3.5) 18(2.2) 20(2.8) 20(2.9) 19(3.1) 
1C I worry that I will not be able to continue my leisure activities as a result of my 
gout 
44(3.7) 23(2.8) 20(2.8) 23(3.3) 18(3.0) 
1D I feel anxious that my gout will interfere with my future activities 45(3.8) 22(2.7) 19(2.6) 23(3.3) 17(2.8) 
Gout Medication Side-effects (MSE)      
1E I am bothered by side-effects from my gout medications 63(5.3) 37(4.5) 33(4.6) 33(4.7) 34(5.6) 
1K I worry about the long-term side-effects of gout medications 68(5.7) 42(5.1) 35(4.9) 32(4.6) 31(5.1) 
Gout Unmet treatment need (UTN)      
1I My current medications are effective for treating a gout attack when I have one 79(6.7) 47(5.7) 39(5.4) 44(6.3) 33(5.5) 
1L My current medications do not work well to prevent attacks from happening 106(9.0) 63(7.7) 53(7.4) 61(8.8) 42(6.9) 
IM I have control over my gout  72(6.1) 32(3.9) 22(3.1) 28(4.0) 26(4.3) 
Wellbeing during attack (WBDA)      
2 During your last gout attack, how much of the time did you experience the 
following? 
     
A Miss work because of your gout symptoms 161(13.6) 107(13.1) 93(12.9) 93(13.4) 66(10.9) 
B Have difficulty working because of your gout symptoms 136(11.5) 99(12.1) 84(11.7) 82(11.8) 57(9.4) 
C Have difficulty with recreational or social activities because of your gout 
symptoms 
40(3.4) 31(3.8) 28(3.9) 35(5.0) 21(3.5) 
D Have difficulty with self-care activities, e.g. feeding, bathing or dressing, 
because of your gout symptoms 
33(2.8) 26(3.2) 25(3.5) 28(4.0) 19(3.1) 
3 During your last gout attack, how much did your symptoms interfere with the 
following things? 
     
A Your mood 43(3.6) 29(2.6) 36(5.0) 30(4.3) 22(3.6) 
B Your ability to move about 33(2.8) 21(2.6) 38(5.3) 28(4.0) 20(3.3) 
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C Your sleep 39(3.3) 30(3.7) 41(5.7) 31(4.5) 23(3.8) 
D Your normal work 67(5.7) 54(6.6) 52(7.2) 45(6.5) 26(4.3) 
E Your recreational activities 51(4.3) 31(3.8) 42(5.8) 35(5.0) 20(3.3) 
F Your enjoyment of life 37(3.1) 28(3.4) 38(5.3) 29(4.2) 20(3.3) 
G Your ability to do what you want to do 31(2.6) 25(3.1) 34(4.7) 28(4.0) 18(3.0) 
Gout Concern during attack (CDA)      
1F I am mad or angry when I experience a gout attack 56(4.7) 26(3.2) 27(3.7) 24(3.4) 18(3.0) 
1G It is difficult to plan ahead for events or activities because I may have a gout 
attack 
46(3.9) 23(2.8) 23(3.2) 20(2.9) 19(3.1) 
1H I feel depressed when I experience a gout attack  53(4.5) 22(2.7) 27(3.7) 23(3.3) 17(2.8) 
1J I miss planned or important activities when I have a gout attack 53(4.5) 28(3.4) 21(2.9) 30(4.3) 20(3.3) 
 
Table 4.16 Number and percentage of participants at each time-point who did not provide a response to each individual item of SF-36 PF10 questionnaire 
(item non-response to SF-36 PF10 questionnaire items) 
 
 
 
 
 
 
 
 
 
SF-36 PF10 item 
Baseline 
n(%) 
missing  
6 months 
n(%) 
missing  
12 months 
n(%) 
missing  
24 months 
n(%) 
missing  
36 months 
n(%) 
missing  
Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 
44(3.7) 24(2.9) 39(5.4) 26(3.7) 18(3.0) 
Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling or playing golf 
29(2.4) 17(2.1) 29(4.0) 17(2.4) 13(2.1) 
Lifting or carrying groceries 29(2.4) 17(2.1) 30(4.2) 17(2.4) 11(1.8) 
Climbing several flights of stairs 36(3.0) 28(3.4) 30(4.2) 13(1.9) 15(2.5) 
Climbing one flight of stairs 34(2.9) 18(2.2) 29(4.0) 14(2.0) 15(2.5) 
Bending, kneeling or stooping 29(2.4) 22(2.7) 35(4.9) 16(2.3) 13(2.1) 
Walking more than a mile 35(3.0) 21(2.6) 31(4.3) 18(2.6) 17(2.8) 
Walking half a mile 38(3.2) 23(2.8) 32(4.4) 21(3.0) 13(2.10 
Walking one hundred yards 31(2.6) 20(2.4) 28(3.9) 15(2.2) 16(2.6) 
Bathing and dressing yourself 26(2.2) 14(1.7) 28(3.9) 12(1.7) 11(1.8) 
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Table 4.17  Number and percentage of participants at each time-point who did not provide a response to each 
individual item of HAQ-DI questionnaire (item non-response to HAQ-DI questionnaire items) 
 
HAQ-DI item 
Baseline 
n(%) 
missing  
6 months 
n(%) 
missing  
12 months 
n(%) 
missing  
24 months 
n(%) 
missing  
36 months 
n(%) 
missing  
Dress      
A Dress yourself include tying shoe-laces and doing buttons 41(3.5) 15(1.8) 21(2.9) 9(1.3) 16(2.6) 
B Shampoo your hair 52(4.4) 14(1.7) 24(3.3) 12(1.7) 15(2.5) 
Arise      
C Stand from a chair 46(3.9) 17(2.1) 27(3.7) 10(1.4) 16(2.6) 
D Get in and out of bed 50(4.2) 11(1.3) 25(3.5) 8(1.1) 16(2.6) 
Eat      
E Cut your meat 49(4.1) 15(1.8) 24(3.3) 10(1.4) 15(2.5) 
F Open a milk carton 43(3.6) 15(1.8) 25(3.5) 8(1.1) 14(2.3) 
G Lift a full glass or cup to your mouth 42(3.5) 12(1.5) 24(3.3) 10(1.4) 14(2.3) 
Walk      
H Walk outdoors on flat ground 40(3.4) 15(1.8) 24(3.3) 9(1.3) 15(2.5) 
I Climb up 5 steps 41(3.5) 14(1.7) 24(3.3) 11(1.6) 14(2.3) 
Hygiene      
J Wash and dry your entire body 43(3.6) 14(1.7) 22(3.1) 8(1.1) 13(2.1) 
K Take a tub bath 61(5.2) 33(4.0) 39(5.4) 22(3.2) 27(4.5) 
L Get on and off the toilet 40(3.4) 13(1.6) 22(3.1) 9(1.3) 13(2.1) 
Reach      
M Reach and get a 5 lb object from above your head 40(3.4) 11(1.3) 23(3.2) 8(1.1) 14(2.3) 
P Bend down and pick up clothing from the floor 42(3.5) 15(1.8) 25(3.5) 8(1.1) 16(2.6) 
Grip      
N Open car doors 40(3.4) 15(1.8) 25(3.5) 11(1.6) 14(2.3) 
O Open jars that have been previously opened 42(3.5) 13(1.6) 24(3.3) 8(1.1) 14(2.3) 
Q Turn taps on and off 42(3.5) 15(1.8) 24(3.3) 10(1.4) 15(2.5) 
Daily      
R Run errand and shop 42(3.5) 20(2.4) 27(3.7) 13(1.9) 19(3.1) 
S Get in and out of a car 39(3.3) 17(2.1) 25(3.5) 12(1.7) 19(3.1) 
T Do vacuuming or yard work 37(3.1) 17(2.1) 30(4.2) 13(1.9) 15(2.5) 
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Table 4.18 Proportion of responders at each time-point with insufficient item responses to enable calculation of each GIS subscale total 
 
 
 
 
 
 
 Table 4.19 Proportion of responders with insufficient item responses to enable calculation of SF-36 PF10 and HAQ-DI 
 
 
 
 
GIS subscale 
 
 
Baseline 
n(%) 
missing scores 
6 months 
n(%) 
missing scores 
12 months 
n(%) 
missing scores 
24 months 
n(%) 
missing scores 
36 months 
n(%) 
missing scores 
GIS Concern overall (CO) 38(3.2) 17(2.1) 18(2.5) 19(2.7) 17(2.8) 
GIS Medication side-effects (MSE) 54(4.6) 29(3.5) 26(3.6) 23(3.3) 27(4.5) 
GIS Unmet treatment need (UTN) 76(6.4) 42(5.1) 36(5.0) 40(5.7) 32(5.3) 
GIS Wellbeing during attack (WBDA) 34(2.9) 26(3.2) 35(4.9) 29(4.2) 19(3.1) 
GIS Concern during attack (CDA) 45(3.8) 19(2.3) 22(3.1) 19(2.7) 17(2.8) 
 
Baseline 
n(%) 
missing scores 
6 months 
n(%) 
missing scores 
12 months 
n(%) 
missing scores 
24 months 
n(%) 
missing scores 
36 months 
n(%) 
missing scores 
SF-36 PF10 224(18.9) 152(18.6) 142(19.7) 146(21.0) 123(20.3) 
HAQ-DI 40(3.4) 11(1.3) 22(3.1) 8(1.1) 13(2.1) 
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Gout-specific variables, comorbidities, socio-demographic variables, BMI and alcohol 
missing data 
Variables with greater than 10% missing data included serum urate level at 61.1%, eGFR 
21.4%, body pain at 18.2%, and PHQ-9 score at 12% (Table 4.20).   Variables with between 5 
and 10% missing data included number of gout flares (but less than 5% missing after baseline), 
reported oligo/polyarticular flares (greater than 5% only at 36 months), disease duration, 
tophi, self-reported allopurinol use, prescription for allopurinol, prescription for NSAIDs, GAD-
7 score, BMI and attendance at further education.  The missing data for tophi and prescription 
for allopurinol were attributable to participants who did not consent to medical note review 
(n=105).  All other variables had less than 5% missing data.  
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Table 4.20 Missing data for gout-specific variables, comorbidities, socio-demographic 
variables, BMI and alcohol frequency 
 
Baseline 
n(%) 
missing  
6 months 
n(%) 
missing  
12 months 
n(%) 
missing  
24 months 
n(%) 
missing  
36 months 
n(%) 
missing  
Gout Specific      
Number of flares  61(5.2) 17(2.1) 20(2.8) 31(4.5) 25(4.1) 
Current flare 49(4.1) 12(1.5) 20(2.8) 30(4.3) 21(3.5) 
Oligo/polyarticular flares 53(4.5) 13(1.6) 21(2.9) 31(4.5) 31(5.1) 
Disease duration  89(7.5)     
Record of tophi 105(8.9)     
Serum urate Level 723(61.1)     
Allopurinol use* 64(5.4) 38(4.6) 29(4.0) 34(4.9) 31(5.1) 
Allopurinol prescription 105(8.9)     
Comorbidities       
Diabetes Mellitus 0(0)     
CVA 0(0)     
Hypertension 0(0)     
TIA 0(0)     
Hyperlipidaemia 0(0)     
MI 0(0)     
Angina 0(0)     
Renal Failure 0(0)     
Renal Calculi 0(0)     
Total number comorbidities 0(0)     
eGFR <60  253(21.4)     
NRS pain  63(5.3) 44(5.4) 29(4.0) 35(5.0) 27(4.5) 
Body pain 215(18.2)     
Depression (PHQ 9 score) 142(12.0)  41(5.7)  41(6.8) 
Anxiety (GAD 7 score) 90(7.6)  36(5.0)  23(3.8) 
Socio-demographic      
Sex 0(0)     
Age 0(0)     
Ethnicity 30(2.5)     
IMD 0(0)     
Marital status 19(1.6)     
Attendance at further 
education 
65(5.5)     
BMI & alcohol      
BMI 65(5.5) 16(2.0) 14(1.9) 23(3.3) 10(1.7) 
Alcohol 17(1.4)     
Grey shading = variable was not collected at this time-point 
 Number of gout flares in previous 12 months at baseline, 12 months and 36 months,  in  previous 6 months 
at 6 and 12 months; * Self-reported allopurinol use taken from questionnaire responses In medical record 
in the two years prior to baseline; total number of comorbidities self-reported in baseline questionnaire 
(diabetes, hypertension, hyperlipidaemia, myocardial infarction, angina, cerebrovascular accident, transient 
ischaemic attack, renal failure, renal calculi); eGFR <60 mL/min/1.73m2 indicative of chronic kidney disease;  
NRS pain in last week ranges from 0 (no pain ) to 10 (pain as bad as it can be); body pain (including ache or 
discomfort or stiffness) for one day or longer in the 4 weeks prior to baseline;  PHQ-9 score ranges from 0 
to 27  Minimal depression 0-4, Mild 5-9, Moderate 10-14, Moderately Severe 15-19, Severe 20-27; GAD-7 
score ranges from 0 to 21 Minimal anxiety 0-4, Mild 5-9, Moderate 10-14, Severe 15-21; IMD indices of 
multiple deprivation; BMI body mass index kg/m2 
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4.5 Discussion 
The aim of this chapter was to describe the cohort that will be analysed in chapters five, six, 
seven and eight and to investigate potential sources of bias within the cohort.  The flow of 
participants through the cohort was described and the potential for attrition bias and item 
non-response missing data was investigated. The detailed reporting of an observational 
cohort study undertaken in this chapter, including participant flow, assessment of potential 
sources of bias such as attrition bias, and the extent of missing data for each exposure of 
interest, has been advocated by the ‘strengthening the reporting of observational studies in 
epidemiology’ (STROBE) guidelines (Vandenbroucke et al 2007).   
4.5.1 Flow of participants through the cohort study  
The adjusted response to the questionnaire at baseline was 65.9% of eligible mailed 
participants, with subsequent adjusted responses of 79.1%, 72.8%, 75.4% and 68.4% at 6, 12, 
24 and 36 months respectively.   Whilst there is debate regarding what constitutes an 
acceptable response in epidemiological studies (Morton et al 2012), a response of 60% or 
more has been advocated as acceptable (Bowling, 2009; Fincham, 2008; Sim & Wright, 2000).  
Thus, an acceptable adjusted response was observed at every time-point.    However, it is 
important to acknowledge that attrition of participants was observed during follow-up, due 
to either exclusion from mailing and refusal or non-response.  Various reasons for attrition 
were identified including deaths, address or contact problems, health reasons, participants 
not wishing to take part, or returning a questionnaire too late.  Attrition is a common 
occurrence in prospective cohort studies (Bankhead, Aronson & Nunan, 2018; Lacey, Jordan 
& Croft, 2013), particularly in cohorts of older persons (Lacey, Jordan & Croft, 2013). Several 
strategies detailed in section 3.7, were deployed in this study to maximise response and 
minimise bias in this cohort. 
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Of the 1184 participants who responded at baseline, 605 (51%) responded to the 
questionnaire at 36 months.  The attrition observed is lower than that reported in prospective 
cohorts in people with gout by Becker et al (attrition 53% over one year) (2009) and Khanna 
et al (74% over two years) (2011a).  However, lower attrition rates were reported by Dalbeth 
et al (2013) where of the 291 participants who attended at baseline, 249 (85.6%) provided 
information at one year via a mailed survey.    The difference in the attrition observed in the 
cohort analysed in this chapter, in comparison with these published studies, could be 
attributable to this cohort being based in primary care, the sole use of a questionnaire survey 
(Dalbeth et al 2013 and Khanna et al 2011a utilised clinic visits in their studies), a longer follow-
up period, or the older age of this cohort.   Comparable attrition has been observed in a 
prospective cohort study postal questionnaire survey of back pain in primary care in the West 
Midlands; Lacey, Jordan & Croft (2013) reported that of 11,209 respondents at baseline, 5,121 
went on to respond at three years (46%) thus demonstrating a similar overall proportion of 
attrition to those described in this chapter.  
4.5.2 Assessment of attrition bias and comparison with existing studies 
Whilst the attrition of participants from a cohort study is common, attrition bias is not an 
inevitable consequence of attrition (Lacey, Jordan & Croft, 2013).   Thus, the potential for 
attrition bias, where attrition caused the characteristics of responders to be systematically 
different than those who did not participate (Chatfield, Brayne & Matthews, 2005; Kirstman, 
Manno & Cote, 2005), was assessed in this chapter.   
Responders in this cohort study tended to have a slightly longer disease duration and less 
frequent gout flares, compared with non-participants.  A higher proportion of responders had 
a serum urate greater than 360 µmol/L, although the responders were more likely to have a 
record of their serum urate in their medical records.  More of the responders also reported 
taking allopurinol or had a prescription for either allopurinol or NSAIDs in their medical record.  
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Responders were less likely to report a history of diabetes, MI or angina,  and had slightly 
lower PHQ-9, GAD-7, pain NRS, and global health scores, compared with non-participants.  
Responders also had lower GIS UTN scores, higher SF-36 PF10 scores, and lower HAQ-DI 
scores, indicating better HRQOL and less activity limitation respectively.  Responders were less 
likely to be over the age of 80 years, female or classified as most deprived, but more reported 
attending further education, or consuming alcohol daily or almost daily.  However, many of 
the differences observed in this chapter between responders and non-participants were small. 
A limited number of studies have compared the characteristics of responders and non-
participants in prospective cohort studies of gout patients.  In contrast to this cohort, Becker 
et al (2009) reported that participants who did not complete follow-up in a prospective cohort 
study in treatment failure gout had more swollen and tender joints at baseline compared with 
those who remained in the study.  There were no differences between completers and non-
completers in gout flare frequency, disease duration, or serum urate levels.  In addition, 
Stewart et al (2018) reported no difference in flare frequency, disease duration or activity 
limitation at baseline between participants in a prospective cohort study of gout patients at 
one year compared with those lost to follow-up.  However, these smaller studies included 
participants recruited from secondary care thus with different gout severity in comparison to 
this primary care cohort.     In addition, existing studies have failed to compare a wide range 
of characteristics when comparing attrition bias.  These findings in this chapter are consistent 
with the observations in the same cohort at baseline reported by Roddy et al (2015) who found 
that responders at baseline were more likely to be male and were less socioeconomically 
deprived.  However, responders at baseline tended to be older compared with non-
participants, whilst this investigation has shown that older participants were more likely to be 
lost to follow-up after baseline.  
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The findings of this prospective cohort are also consistent with other studies and multivariable 
systematic reviews investigating attrition bias.     A shorter disease duration, higher modified-
HAQ, and depression scores for participants who dropped out of a longitudinal study in 
Rheumatoid Arthritis has been described by Iannaccone et al (2013).  In an analysis of attrition 
in cohort studies in primary care Lacey, Jordan & Croft (2013) also reported a lower prevalence 
of depression in responders and reported that responders in prospective questionnaire 
surveys had a higher number of prescriptions for disease specific medications.  In cohorts of 
older participants, attrition has been shown to be more likely in participants with low levels 
of physical activity or poor functioning in multivariate analysis (Brilleman, Pachana & Dobson, 
2010; Chatfield, Brayne & Matthews, 2005).  Other studies have also reported that 
participants who self-reported poor health status are more likely to be lost to follow-up 
(Brilleman, Pachana & Dobson, 2010; Schmidt et al 2011).  
Chatfield, Brayne & Matthews (2005) described how older age was associated with attrition 
in a multivariable analysis.  Potential factors contributing to more attrition post baseline for 
older participants may have been cognitive impairment, frailty or death, which are more 
common in older persons and are factors acknowledged to be associated with a greater 
chance of attrition (Brilleman, Pachana & Dobson, 2010; Chatfield, Brayne & Matthews, 2005).     
Other reported risk factors for attrition include being female, living alone or being unmarried 
(Chatfield, Brayne & Matthews, 2005) and a lower educational attainment (Brilleman, 
Pachana & Dobson, 2010; Chatfield, Brayne & Matthews, 2005; Gustavson et al 2012).  
Conversely, Galea & Tracey (2007) stated that a higher socio-economic status has been 
associated with increased participation in studies.  
The analysis undertaken in this chapter has provided a greater understanding of the 
characteristics of participants who responded to this survey.  These findings are helpful when 
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considering the generalisability of the findings in this thesis to the wider population of people 
living with gout who may be encountered in clinical practice.     
The group of participants responding at all five time-points had a longer disease duration, 
more allopurinol use, less frequent gout flares, lower PHQ-9, GAD-7, pain NRS, global health, 
GIS UTN, HAQ-DI scores and higher SF-36 PF10 scores.  These finding suggest that the inclusion 
of only participants who responded at each time-point could potentially yield a cohort with 
less generalisable characteristics compared to all responders.  As these differences were in 
key dependent and independent outcomes this could have influenced results if only complete 
cases (participants who responded at all five time-points) had been used in the analyses in this 
thesis.  This justifies the inclusion where possible of all responders when analysing outcome 
measures in this thesis. 
4.5.3 Item non-response missing data 
Missing data is a common occurrence in quantitative research (Dong & Peng, 2013; Peyre, 
Leplege & Coste, 2011) and has the potential to lead to bias (Biering, Hjollund & Frydenberg, 
2015; Bland, 2015), a reduction in sample sizes and thus potentially misleading results 
(Biering, Hjollund & Frydenberg, 2015; Fayers & Machin, 2016; Peyre, Leplege & Coste, 2011).  
When evaluating missing data there is no universally accepted level of missing data which is 
considered acceptable (Dong & Peng, 2013).  It has been proposed that less than 5% missing 
data may lead to less biased inferences (Dong & Peng, 2013; Schafer, 1999) whilst an 
alternative level of less than 10% missing has been described as being less likely to yield biased 
results from statistical analysis (Bennett, 2001).   
The analysis in this chapter revealed that less than 5.2 % of self-reported gout flare data was 
missing at any time-point, this is a dependent variable in the analysis undertaken in the next 
two chapters (five and six) where further analysis and discussion of missing data for this 
variable can be found. 
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Most of the GIS subscales, SF-36 PF10, and HAQ-DI items had less than 5% missing responses, 
however there were some exceptions including items related to work on the GIS WBDA 
subscale, items related to medication on the GIS UTN & MSE subscales, the item related to 
vigorous activities on the SF-36 PF10, and the item related to taking a bath on the HAQ-DI. The 
questionnaires did not allow participants to indicate where items were not applicable.  In this 
older cohort, questions relating to employment may have been less relevant to some 
participants.  When one considers that not all participants had a prescription for Allopurinol 
within their medical record, and the widely reported suboptimal prescribing of medication to 
manage gout symptoms (Kuo et al 2015a), it is possible that many participants may have felt 
that questions about gout medication were less relevant to them and thus did not respond to 
these items.  Higher proportions of missing data for the vigorous activity item of the SF-36 
PF10 have been reported previously by older participants, where many participants reported 
they felt the question was irrelevant as they were unable to do any vigorous activity (Hayes et 
al 1995).  It is also possible that the proportion of missing data on the item of the HAQ-DI 
relating to taking a bath was higher because those participants without a bath felt the 
question was less relevant to them. 
Missing data from item non-response may be particularly problematic if the missing data 
means there are insufficient responses to permit calculation of a total score (Peyre, Leplege & 
Coste, 2011).   Except for the UTN subscale (which had 5 to 6.4% missing), all the GIS subscales 
had less than 5% of total scores for participants missing.  However, the SF-36 PF10 had more 
than 10% of total scores for participants missing, due to insufficient items to calculate the total 
score.  The HAQ-DI had less than 5% of total scores for participants missing.   These HRQOL 
measures are the dependent variables which were statistically modelled in chapter eight 
where further discussion of missing data for these outcomes can be found. 
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The percentage of missing data at each time-point was below 10% for all the gout-specific, 
comorbid, socio-demographic and other variables, apart from data relating to serum urate 
level, eGFR, body pain, and PHQ-9 score. The very high percentage of missing data relating to 
serum urate levels is perhaps not surprising when one considers that suboptimal monitoring 
of serum urate has been reported in other cohorts of gout patients (Wall et al 2010) and the 
acknowledged suboptimal management of gout in the wider population (Kuo et al 2015a).  
The percentage of participants with missing eGFR data in this cohort is very similar to the 
proportion of patients registered with GPs in the West Midlands missing a recent eGFR from 
their primary care records reported by Cottrell, Chambers & O’Connell (2012).   Over 10% 
missing data for the PHQ-9 has also been reported in other cohorts living with chronic disease 
(Wang et al 2016), and over 10% of pain data was found to be incomplete in a postal 
questionnaire investigating multiple body site pain and HRQOL in people living with 
osteoarthritis in primary care in the West Midlands (Lacey et al 2014).   
Variables with 5 to 10% of missing data at any time-point included a history of 
oligo/polyarticular flares, disease duration, tophi, allopurinol use, GAD-7, BMI, and 
attendance at further education.    Some missing data for variables obtained from medical 
record is attributable to not all participants consenting to medical record review.   
As some missing data was identified in the main outcome measures to be modelled in this 
thesis, gout flares (chapter five & six) and HRQOL measures GIS subscales, SF-36 PF10 and 
HAQ-DI (chapters seven & eight), these findings had implications for the type of statistical 
modelling techniques which can be used.   Consequently, statistical modelling techniques 
which can accommodate missing data in longitudinal dependent variables were used to 
analyse gout flares (latent class growth analysis) and GIS subscales, SF-36 PF10 and HAQ-DI 
(linear mixed models) (Berlin, Parra & Williams, 2014; Cheng et al 2010; Jung & Wickrama, 
2008; Locascio & Atri, 2011).   
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4.5.4 Strengths and limitations 
This chapter follows good practice recommended when reporting observational studies, by 
describing the participants in this prospective study, reasons for non-participation, the 
proportion of missing data, and the potential sources of bias (Vandenbroucke et al 2007).  
As attrition can arise because participants may respond intermittently to a survey (Cumming 
& Golstein, 2016; Twiske & de vente, 2002; Twisk, 2003) or because participants may drop out 
completely from a survey (Twiske & de vente, 2002; Twisk, 2003), the potential for attrition 
bias was assessed in this chapter using different approaches.  A wide range of characteristics 
were compared including gout-specific characteristics, comorbidities, socio-demographic 
characteristics and HRQOL scores. Some differences between responders versus non-
participants, and also between participants who responded only at baseline compared with 
participants who responded at multiple time-points, were identified.  A decision was made 
not to undertake any statistical analysis of the differences between the different groups as, 
due to the wide variety of characteristics compared, this would have involved multiple 
comparisons and multiple statistical tests.  Such multiple statistical testing has the potential 
to lead to type 1 error; suggesting there was a difference between groups when in fact there 
was not (Sedgwick, 2014). In addition, undertaking statistical testing on differences which 
were not an a priori hypothesis has been highlighted as poor practice when investigating the 
consequences of attrition (Dumville, Torgerson & Hewitt, 2006).     
The investigation of the proportion of missing data in independent and dependent variables 
was important due to the potential consequences for sample sizes, interpretation of results 
and the potential for bias (Biering, Hjollund & Frydenberg, 2015; Fayers & Machin, 2016). 
However, it is important to acknowledge that the mechanism of missing data can be as 
important as the proportion of missing data (Dong & Peng, 2013).  Additional analysis could 
have been undertaken to investigate the potential mechanism of missing data, whether the 
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missing data was missing completely at random (MCAR), missing at random (MAR) or missing 
not at random (MNAR).  Such tests could have included Little’s missing completely at random 
(MCAR) test, or statistical test comparing the difference between groups with complete and 
missing data, or undertaking logistic regression (Dong & Peng, 2013).  However, tests such as 
Little’s MCAR test cannot indicate whether the mechanism is MAR, but instead provides 
evidence for or against the mechanism being MCAR (Fielding, Fayers & Ramsay, 2010).  It is 
not possible to distinguish between whether data is MAR and MNAR based on observed data, 
as the values of unobserved data are not known (Fielding, Fayers & Ramsay, 2009; Kristman, 
Manno & Cote, 2005).     
Whilst various sources of potential bias were investigated with in this chapter, it is important 
to acknowledge that there is still the potential that other sources of bias may exist with in this 
cohort.  Further potential sources of bias are discussed in chapter nine.   However, in a 
prospective study of HRQOL measures of this nature, it is rarely possible to identify all 
potential sources of bias (Fayers and Machin, 2016).   
4.6  Conclusion 
In conclusion, this chapter described the flow of participants through this cohort study and 
investigated attrition bias and item non-response missing data.  Some small differences were 
observed between the characteristics of participants who responded at different time-points 
compared with non-participants.  The proportion of independent and dependent variable 
missing data was below 10% for the majority of variables.    The findings of this chapter were 
used to inform the analysis in future chapters by influencing how gout flares (chapter five and 
chapter six) and HRQOL measures (chapter eight) were statistically modelled.    The aim of the 
next chapter is to describe the frequency and pattern of self-reported gout flares in this 
prospective cohort of people living with gout in primary care. 
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5 Chapter Five Frequency and pattern of gout flares 
5.1  Overview of chapter and aim   
The previous chapter described the cohort of participants in this study and investigated 
potential sources of bias within the cohort. The aim of this chapter is to describe the frequency 
and pattern of self-reported gout flares in this prospective cohort of people living with gout in 
primary care.  
5.2 Background  
5.2.1 Latent trajectory modelling; a patient-centred approach  
The within-person pattern of a longitudinal outcome over time is referred to as a trajectory 
(Curran, Obeidat & Losardo, 2010; Nagin & Odgers, 2010). Individuals with outcomes which 
follow a similar within-person pattern over time can be grouped together, to create distinct 
groups of individual trajectories which were previously unobserved or latent (Nagin, 1999; 
Nagin & Land, 1993).  Research methods which are focused on detecting groups of individuals 
based on similarity in latent trajectories have been described as person-centred approaches; 
as the focus is on the relationship between individuals, rather than the relationship between 
variables (Muthen & Muthen, 2000).  Such methods include latent class growth analysis and 
growth mixture modelling (Muthen & Muthen, 2000) and have the potential to detect inter-
individual differences in intra-individual patterns of change over time (Curran, Obeidat & 
Losardo, 2010; Jung & Wickrama, 2008).  This is in contrast with a variable centred approach 
where the focus would be on the relationship solely among variables (Muthen & Muthen, 
2000).  
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5.2.2 Latent growth curve models 
An initial step in identifying latent trajectories in cohorts involves latent growth curve 
modelling (LGCM) (Berlin, Parra & Williams, 2014), which can also be referred to as growth 
modelling, latent growth modelling, latent curve analysis, growth curve analysis, latent 
variable growth curve modelling, latent trajectory modelling and latent trajectory analysis 
(Burant, 2016; Berrington, Smith & Sturgis, 2006; Curran & Hussong, 2003; Duncan & Duncan, 
2009).  During such modelling a growth curve is specified which best describes the intra-
individual change in observed longitudinal outcomes for a whole cohort (Stoel, van de 
Wittenoer & Hox, 2004; Wang & Bodner, 2007).  The shape of the growth curve describing the 
intra-individual change can assume any number of polynomial forms such as linear, quadratic 
or piecewise (Wickrama et al 2016).   
5.2.3 Assumptions and limitations of latent growth curve models 
LGCMs require data from a minimum of three, ideally more, time-points with the same 
measurement instrument used on each occasion (Curran & Hussong, 2003; Duncan & Duncan, 
2009).  An advantage of current approaches to undertaking latent growth curve modelling is 
that not all individuals are required to have repeated measures data recorded at all time-
points, thus permitting the inclusion of individuals with partially missing data (Curran, Obeidat 
& Losardo, 2010; Hox & Stoel, 2005). It has been proposed that inclusion of individuals with 
partially missing data is associated with less bias, compared with the inclusion of individuals 
with only complete data (Curran & Hussong, 2003). Current approaches to undertaking latent 
growth curve modelling also afford greater flexibility regarding the time points at which 
repeated measures are recorded and thus unequally spaced time points are permitted 
(Curran, Obeidt & Losardo, 2010).   A further advantage of current approaches to undertaking 
latent growth curve modelling is that methods of estimation exist which do not assume that 
residuals of repeated measures are normally distributed (Curran & Hussong, 2003).  
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Specifying a single LGCM to describe the change in longitudinal data, follows the assumption 
that all individuals come from a single population and that a single latent growth curve can 
adequately describe growth parameters for the entire population (Jung & Wickrama, 2008; 
Ram & Grimm, 2009).    This limitation is of particular relevance when modelling clinical 
outcomes in health research as change in symptoms is likely to vary amongst individuals within 
a cohort (Nagin & Odgers, 2010; Wickrama et al 2016).  Despite this limitation, it is important 
to specify a LGCM prior to progressing on to more complicated models, as determining the 
functional form of the latent growth curve will inform the type of models used in further 
analysis (Curran & Hussong, 2003; Curran, Obeidat & Losardo, 2010). Latent growth curve 
modelling was undertaken in this chapter, in order to inform the latent class growth analysis 
undertaken in the next chapter (chapter six). 
5.2.4 Latent class growth analysis  
Latent class growth analysis (LCGA) is a person-centred method which can be considered as a 
special type of latent variable modelling (Berlin, Parra & Williams, 2014; Jung & Wickrama, 
2008; Muthen & Muthen, 2000). LCGA models allocate individuals to different groups or 
classes based on the shape of their latent growth curve trajectory (Muthen & Muthen 2000).  
Thus, each class is summarised by latent growth curve with growth parameters. For example, 
in a quadratic model the growth parameters are a mean intercept, a mean linear slope and a 
mean quadratic slope. The class’s intercept and slopes are referred to as latent parameters as 
these parameters were unobserved prior to undertaking the analysis (Wickrama et al 2016).   
In LCGA, the variance and covariance within each latent class is eliminated by fixing the 
variance of the intercept and slope(s) to zero (Berlin, Parra & Williams, 2014; Jung & 
Wickrama, 2008; Muthen & Muthen, 2000; Wickrama et al 2016). Thus, due to the lack of 
within-class variance, LCGA models assume that all individual growth trajectories within a 
specific class are homogenous (Berlin, Parra & Williams, 2014; Jung & Wickrama, 
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2008;Wickrama et al 2016).  LCGA can thus be thought of as a fixed effect model (Peugh & 
Fan, 2012). For example, for a quadratic model all class members have the same intercept, 
linear slope and quadratic slope (Berlin, Parra & Williams, 2014; Wickrama et al 2016).   
Individuals are probabilistically assigned to the latent class which best reflects their latent 
trajectory; with individuals assigned to the class for which they have the highest posterior 
probability (Andruff et al 2009). The LCGA process sequentially increases the number of latent 
classes, until the optimal number of classes is determined (Wickrama et al 2016).   
A limitation of LCGA is that the lack of within-class variance may be unrealistic and it has the 
potential to generate more classes than a model which permits within class variance 
(Wickrama et al 2016). Widely acknowledged advantages to using LCGA include the reduced 
computational burden and faster model conversion (Wickrama et al 2016).  Thus, LCGA is 
advocated as a method to determine latent classes prior to progressing to growth mixture 
modelling (Berlin, Parra & Williams, 2014; Jung & Wickrama, 2008).   
5.2.5 Growth mixture modelling 
Growth mixture modelling (GMM) is also a longitudinal modelling technique which estimates 
a different latent growth curve for each latent class within a population (Muthen & Muthen, 
2000; Jung & Wickrama, 2008; Peugh & Fan, 2012). The LGCMs for each class have mean 
intercepts and slope(s) but also, unlike LCGA, (Berlin, Parra & Williams, 2014; Jung & 
Wickrama, 2008), GMM permits variance and covariance of the intercept and slope (Berlin, 
Parra & Williams, 2014; Jung & Wickrama, 2008; Wang & Bodner, 2007).  Thus, GMM can be 
considered a random effects model (Peugh & Fan, 2012). The mixture of distributions of 
observed variables which are permitted within this type of model is acknowledged by the 
inclusion of ‘mixture’ in the name growth mixture modelling (Peugh & Fan, 2012; Wickrama 
et al 2016). 
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Whilst the advantage of GMM is the ability to accommodate within class variability, this 
method also has limitations (Ram & Grimm, 2009; Wang & Bodner, 2007).  GMM requires the 
estimation of more latent parameters than LCGA, which requires an increased computational 
load and increases with the number of latent classes in the model (Wang & Bodner, 2007). 
This has the potential to lead to less stable models with convergence and computational 
problems (Wang & Bodner, 2007). 
5.3 Method and Analysis Plan 
5.3.1 Aim and Objectives 
Aim 
The aim of this chapter is to describe the frequency and pattern of self-reported gout flares in 
a prospective cohort of people living with gout in primary care. 
Objectives  
The objectives of this chapter are to: 
1. Use descriptive statistics and spaghetti plots to describe the frequency and pattern of 
self-reported gout flares.  
2. Use latent growth curve modelling (LGCM) to determine the shape of the growth curve 
which best describes the longitudinal gout flare data. 
 
Figure 5.1 on the following page is a flowchart summary of the stages of the latent growth 
curve modelling used in this chapter and the latent class growth analysis used in chapter 6 
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Figure 5.1 Flowchart summary of latent growth curve modelling and latent class growth analysis 
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5.3.2 Data source 
The data for this secondary analysis were derived from the study described in chapter three. 
The primary observed variable used for the analysis in this chapter was the number of gout 
flares reported by participants at each questionnaire time-point (baseline, 6, 12, 24 and 36 
months).  The number of gout flares in the previous 12 months was reported in the baseline, 
24, and 36-month questionnaires, whilst the number of flares reported in the previous 6 
months was reported in the 6, and 12-month questionnaires. 
5.3.3 Ordinal data considerations 
The gout flare data were considered to be ordinal data, as respondents were asked to report 
the number of gout flares they experienced in a specified time period by selecting one of the 
response options 0, 1, 2, 3, 4, ≥5.  
Ordinal data are frequently modelled as continuous data in research (Feldman, Masyn & 
Conger, 2009). If there are a large number of categories and the distribution of responses are 
symmetrical then modelling ordinal data as continuous may not distort estimates or model fit 
(Hox & Stoel, 2005). However, where there is a smaller number of categories, ordinal data 
should be modelled in a manner which takes the ordinal nature of the data in to account, as 
treating ordinal data as continuous data has the potential to lead to biased estimates and 
errors in fit statistics (Feldman, Masyn & Conger, 2009). Also ordinal data are often skewed, 
having a greater proportion of responses in the lowest category, which can make growth 
modelling with ordinal data a challenge, and require that the data are modelled appropriately 
(Feldman, Masyn & Conger, 2009). 
Thus, within this analysis the gout flare data were coded specifically as categorical ordinal 
data. Such ordinal data can be thought of as observed response variables in categories, which 
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are actually taken from a range of latent unobserved continuous response variables (Curran 
& Hussong, 2003; Hox & Stoel, 2005).   
5.3.4 Count data considerations 
The number of self-reported gout flares can also be considered to be count data.  
Consequently, in addition to undertaking the latent growth curve modelling which treated the 
gout flare data as ordinal data, the data were also modelled treating the data as count data.   
Poisson 
Count data, which follow a Poisson distribution, are particularly common in health research 
but are frequently modelled incorrectly (Shiyko, Yuelin & Rindskopf, 2012).  Where latent 
growth curve modelling and latent class growth analysis use count data following a Poisson 
distribution, the observed variable Y is not modelled directly instead the natural log of the 
Poisson parameter is used e.g. In(λit) (Shiyko, Yuelin & Rindskopf, 2012), where λi represents 
the mean and variance parameter of the Poisson distribution and the equivalence of the mean 
and the variance is a familiar characteristic of the Poisson distribution (Liu & Powers, 2007).   
Zero-inflated Poisson 
Not all count data follow a Poisson distribution (Bohning et al 1999; Lambert, 1992; Liu & 
Powers, 2007). Medical and health research frequently yield count data which contain many 
zeros and if the prevalence of zeros is not considered when modelling data there is the 
potential for biased results and inferences (Lee et al 2006; Yoon et al 2015).  Where count 
data include an excessive proportion of zeros an alternative distribution, the zero-inflated 
Poisson (ZIP) distribution, is recommended (Lambert, 1992).  Unlike the Poisson distribution, 
which is defined by just one parameter (λi) the ZIP distribution is defined by two parameters 
λi  and pi (which is the probability of being zero-inflated) (Liu & Powers, 2007).   
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 Negative binomial 
The Poisson distribution and Poisson models assume equidispersion; where the mean and the 
variance of count data are equal (Hilbe, 2007; Zhou & Carin, 2015).  However, count data are 
often overdispersed; where the variance of the count data is greater than the mean (Hilbe, 
2007; Zhou & Carin, 2015).  Such overdispersion has the potential to affect the reliability of 
assessments of model fit and the model parameter estimates (Hilbe, 2007). Where there is 
overdispersion in count data, the assumptions of Poisson models are not valid and negative 
binomial models are recommended for the latent variable modelling of over dispersed count 
data (Reincke & Sedding, 2011; Zhou & Carin, 2015).   
The potential for zero-inflation or overdispersion of the gout flare data modelled in this thesis 
was assessed via the methods described in section 5.3.5.       
5.3.5 Prior to modelling data  
Where possible, the use of prior theory or existing research has been recommended prior to 
undertaking latent variable modelling; to guide a hypothesis relating to the potential 
functional form of latent growth curves and also the number of anticipated classes that may 
be found (Belin, Parra & Williams, 2013; Ram & Grimm, 2009).  However, until this point there 
has not been any research undertaken relating specifically to latent variable modelling of gout 
flares.   
In the absence of prior research, a preliminary stage in LGCM was the inspection of raw data 
to inform the modelling of the data (Berlin, Parra & Williams, 2014; Berrington, Smith & 
Sturgis, 2006).  The proportion of participants reporting 0, 1, 2, 3, 4, or ≥ 5 or more flares at 
each time point was displayed in a stacked column chart.  This descriptive analysis of the gout 
flare count data revealed the proportion of participants reporting zero flares.  It is important 
to assess the proportion of zeros within this data, as the data could be considered to be count 
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data and a higher proportion of zeros would indicate that the data is likely to follow a zero-
inflated Poisson (ZIP) distribution, rather than a Poisson distribution (Lambert, 1992). At each 
time-point, the mean number of gout flares was compared to the variance of the gout flares, 
to test whether the mean was equal to variance; as would be the case with Poisson distributed 
data (Liu & Powers, 2007) but not the case with overdispersed data (Hilbe, 2007; Zhou & Carin, 
2015).   Any difference in distribution would need to be taken into consideration when 
modelling data (Bohning et al 1999; Lambert, 1992; Liu & Powers, 2007).  The median 
(interquartile range, IQR) number of gout flares at each time-point was also calculated.  The 
number of gout flares reported by each participant at each available time point was displayed 
in a spaghetti plot, where a single line linked repeated measures over time for each 
participant.  An interpolation line was also added to the spaghetti plot, to demonstrate which 
functional form displayed the overall change in gout flares. 
SPSS version 24 was used for the descriptive statistics and spaghetti plots. 
5.3.6 Latent growth curve modelling 
Specifying a single unconditional latent growth curve model 
The first stage in latent variable modelling of the longitudinal data was to specify a baseline 
single class unconditional (with no covariates included) LGCM (Jung & Wickrama, 2008; Ram 
& Grimm 2009; Wickrama et al 2016). All participants who self-reported how many gout flares 
they had experienced on at least one time-point were included in the modelling.  To determine 
the optimal LGCM for the data-set, a series of unconditional latent growth curves were fitted 
to the data (Ram & Grimm 2009), the types of latent growth curves models fitted can be found 
in Figure 5.2.   These included linear and quadratic ordinal models, linear and quadratic zero-
inflated Poisson (ZIP) models and linear and quadratic negative binomial (NB) models. Mplus 
version 8.1 was used for the latent growth curve modelling.   
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Figure 5.2 Stages of latent growth curve modelling undertaken in this chapter 
 
Assessment of model fit of unconditional latent growth curve models 
It was important to evaluate the fit of the different LGCMs generated in order to determine 
which type of LGCM would be used in the latent class growth analysis in the next chapter 
(Burant, 2016; Curran & Hussong, 2003; Currang, Obeidat & Losardo, 2010). Several factors 
need to be considered when evaluating the goodness of fit of LGCMs (Wickrama et al 2016).  
Consequently, a range of model fit indices were reviewed, the latent growth curve models 
were plotted, and the latent growth curve model results were inspected.   
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Review of model fit indices 
The use of a range of model fit indices, rather than sole reliance on one model fit indices, has 
been recommended as different indices reflect different aspects of a latent growth curve 
model fit (Hooper, Coughlan & Mullen, 2008; Wu, West & Taylor, 2009). 
Table 5.1 below displays the model fit indices that were considered in this chapter and how 
the results from the model input were interpreted.  
Table 5.1 Model fit indices and interpretation of fit for latent growth curve modelling 
 
 
 
 
 
 
 
 
 
 
*A description of each of these indices, along with the indices used in chapter six, can be found 
in appendix 10. 
 
 
 
Indices * 
 
Perfect fit Good fit Acceptable fit 
Chi-Squared 
Statistic  
(χ 2) 
- P value >0.05 
(Hooper, Coughlan & 
Mullen, 2008; 
Wickrama et al 2016) 
- 
Comparative 
Fit Index 
(CFI) 
(Bentler, 1990) 
1.0 
(Wickrama et al 2016) 
0.95 or more 
(Hu & Bentler, 1999) 
0.90 or more 
(Hu & Bentler, 1999) 
Tucker-Lewis 
Index (TLI) 
(Tucker & Lewis, 
1973) 
1.0 
(Wickrama et al 2016) 
0.95 or more 
(Hu & Bentler, 1999) 
0.90 or more 
(Hu & Bentler, 1999) 
Root mean 
square error of 
approximation 
(RMSEA)  
(Steiger & Lind, 1980) 
0.0 
(Wickrama et al 2016) 
0.06 or less 
(Hu & Bentler, 1999) 
0.08 or less 
(MacCallum, Browne 
& Sugawara, 1996) 
Weighted root-
mean-square 
residual 
(WRMR) 
- - Around 1.10 or 
less for latent 
growth model 
with 5 timepoints 
and n= >500 
(Yu, 2002)  
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Plotting latent growth curve models 
Each of the different latent growth curves were examined graphically by plotting the latent 
growth curve.  This permitted a visual comparison of the growth curve of the actual 
longitudinal data, with the growth curve estimated by the latent growth curve model. Where 
the data were modelled as ordinal data, the probability for specific categories was calculated 
(Lee, Wickrama & O’Neal, 2017).  For the ordinal data, the probability of reporting two or more 
gout flares at each time point was plotted. The probability of two or more gout flares was 
selected for the y axis of the plots, as when patients experience two or more flares in the last 
12 months it has been advocated that urate-lowering therapy should be advised (Hui et al 
2017), as highlighted in chapter one.   For the count data, the mean number of gout flares for 
the estimated model and the sample were plotted.     
5.3.7 Sensitivity analysis  
All latent growth curve models were initially modelled including participants who had 
reported the number of gout flares they had experienced on at least one time-point.   Latent 
growth curve models were also then specified using two other different data sets: i) those 
participants who had reported gout flares on at least three time-points and ii) those 
participants who had reported gout flares at every time-point. 
5.4 Results 
5.4.1 Gout flare data descriptive results 
1164 participants self-reported gout flares on at least one time-point and were included in the 
analysis in this chapter. Twenty participants were excluded from this analysis as they did not 
report the number of gout flares experienced at any time-point.  
At each time-point, the largest proportion of participants reported experiencing no gout 
flares; 35.4%, 56.8%, 57.8%, 51.6% and 54.7% at baseline, 6, 12, 24 and 36 months respectively 
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(Table 5.2 and Figure 5.3).  Of the participants who reported experiencing gout flares more 
people reported experiencing one flare (ranged from 13.8-20.6% at different time-points), 
followed by two flares (9.3-16.7%), three flares (5.6-9.2%) and five or more flares (5.8-12.2%). 
The smallest proportion (2.6-6%) reported experiencing four gout flares.  In the analysis 
sample, the number of participants with missing gout flare data due to no response to the 
gout flare frequency item in the questionnaire (item-non response) ranged from 1.5 to 3.5%, 
whilst the number of participants with missing gout flare data due to a questionnaire not being 
returned (unit-non response) ranged from 0 to 48.0%. 
The mean number of gout flares was 1.66 baseline and 1.18 at 36 months, whilst the median 
was 1 at baseline and 0 at 36 months.  The variance was 2.94 at baseline and 2.69 at 36 
months.  
Table 5.2 Self-reported gout flares at each time point for participants who reported at ≥1 time-
points (n=1164) 
 
Baseline 
(n=1123) 
6 Months 
(n=801) 
12 Months 
(n=701) 
24 Months 
(n=665) 
36 Months 
(n=580) 
0 flares 
n(%) 
398(35.4) 455(56.8) 405(57.8) 343(51.6) 317(54.7) 
1 flare 
n(%) 
231(20.6) 127(15.9) 121(17.3) 107(16.1) 80(13.8) 
2 flares 
n(%) 
187(16.7) 86(10.7) 67(9.6) 62(9.3) 74(12.8) 
3 flares 
n(%) 
103(9.2) 45(5.6) 47(6.7) 52(7.8) 34(5.9) 
4 flares 
n(%) 
67(6.0) 21(2.6) 20(2.9) 33(5.0) 22(3.8) 
≥5 flares 
n(%) 
137(12.2) 67(8.4) 41(5.8) 68(10.2) 53(9.1) 
Mean flares* 
(Standard 
Deviation) 
1.66 
(1.72) 
1.06 
(1.57) 
0.97 
(1.46) 
1.29 
(1.71) 
1.18 
(1.64) 
Median 
flares* (IQR) 
1.0 
(0,3) 
0.0 
(0,2) 
0.0 
(0,1.5) 
0.0 
(0, 2) 
0.0 
(0,2) 
Variance* 2.94 2.47 2.12 2.92 2.69 
≥2 gout flares 
n(%) 
494 (42.4) 219(27.3) 175(24.9) 215(32.3) 183(31.3) 
Item response 
missing  
41(3.5) 17(1.5) 20(1.7) 31(2.7) 25(2.3) 
Unit response 
missing 
0(0) 346(29.7) 443(38.1) 468(40.2) 559(48.0) 
*calculated treating category ≥5 as 5 flares   denominator n=1164  
Baseline gout flare data for cohort have been published previously (Chandratre et al 2018). 
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Figure 5.3 Proportion of participants reporting gout flares in each frequency category at each 
time-point 
Baseline gout flare data for cohort have been published previously (Chandratre et al 2018). 
 
 
5.4.2 Individual participant gout flare pattern of change 
The spaghetti plot shown in Figure 5.4 plots the reported gout flares for each participant as a 
line. The lines in the figure show the diverse range of different patterns of reported gout flares 
over time. An interpolation line is shown as the bold black line in the dataset, suggested a 
quadratic functional form.  
 
Figure 5.4 Spaghetti plot of self-reported gout flares for all participants self-reporting the 
frequency of gout flares at ≥1 time-points (n=1164) 
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5.4.3 Latent growth curve modelling 
Ordinal latent growth curve models 
The p-values for the chi-squared statistics were statistically significant for both the linear and 
the quadratic ordinal LGCM (Table 5.3).  The CFI and TLI for the quadratic ordinal LGCM were 
0.97 and 0.99 respectively, which were slightly higher than the CFI and TLI of 0.95 and 0.98 for 
the linear model.  The RMSEA (with confidence intervals) for the quadratic LGCM of 0.08 
(0.07,0.09) was lower than the RMSEA for the linear model which was 0.10 (0.09, 0.11). The 
WRMR result was also lower for the quadratic model, 1.71, than the result of 2.31 returned 
from the linear model. 
 
 Table 5.3 Latent growth curve model fit indices and results for linear and quadratic ordinal 
models 
 
 
 
 
In the plot of the quadratic LGCM (see Figure 5.5), the data points in the plots for the observed 
data and estimated model were closer together at all time-points (except at 24 months), 
compared to the observed data and estimated model plots for the linear model (Figure 5.6). 
Models χ 2 CFI TLI RMSEA (CI) WRMR 
Linear 
Ordinal 
LGCM 
278.06  
p<0.0001 
0.95 0.98 0.10 
(0.09, 0.11) 
2.31 
Quadratic 
Ordinal  
LGCM* 
174.63 
p<0.0001 
0.97 0.99 0.08 
(0.07, 0.09) 
1.71 
*fixing the quadratic slope to zero variance improved the running of the model 
128 
 
 
Figure 5.5 Quadratic ordinal latent growth curve model plot; the probability of ≥2 gout flares 
at each time-point 
 
 
Figure 5.6 Linear ordinal latent growth curve model plot; the probability of ≥2 gout flares at 
each time-point 
   
Zero-inflated Poisson and negative binomial latent growth curve models 
The ZIP LGCMs required a change to the Mplus coding to change the integration method, in 
order to successfully run.  Yet despite these amendments the linear and quadratic ZIP LGCM 
output still displayed warnings that the model was modified to avoid singularity, warnings that 
some of the standard errors of the model parameter estimates were not trustworthy and two 
separate warnings of the possible non-identification of the model. These warnings remained 
despite amending the code in several ways including changing the number of integration 
points.  
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Both the linear and quadratic negative binomial models had a longer computational time.  
Despite amending the code and allowing both models to run over several days the models 
failed to run successfully and output from the models was not obtained. 
The performance of the ZIP and negative binomial models did not improve when smaller data 
sets (those participants who had reported gout flares on at least three time-points (n=729) 
and those participants who had reported gout flares at every time-point (n=437)) were used. 
5.4.4 Sensitivity analysis for latent growth curve modelling 
In addition to undertaking the LGCM including participants who had reported the number of 
gout flares they had experienced on at least one time-point, latent growth curve models were 
also then specified using two other different data sets: i) those participants who had reported 
gout flares on at least three time-points (n=729) and ii) those participants who had reported 
gout flares at every time-point (n=437).   
For those participants who had reported gout flares for at least three time-points the chi-
squared statistics were statistically significant for both the linear and the quadratic ordinal 
LGCM (Table 5.4).  The CFI and TLI for the quadratic ordinal LGCM were 0.98 and 0.99 
respectively, which are slightly higher than the CFI and TLI of 0.96 and 0.98 for the linear 
model. The RMSEA for the quadratic LGCM of 0.09 (0.08, 0.11) was lower than the RMSEA for 
the linear model which was 0.11 (0.10, 0.13). The WRMR result was also lower for the 
quadratic model, 1.55, than the result returned from the linear model of 1.99. 
In the plot of the quadratic LGCM (Figure 5.7), the data points in the plots for the observed 
data and estimated model are closer together at all time-points (except at 24 months), 
compared to the observed data and estimated model plots for the linear model (Figure 5.8). 
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Table 5.4 Latent growth curve model fit indices (for model including those participants who 
reported gout flares at ≥3 time-points) 
 
 
 
 
 
Figure 5.7 Quadratic ordinal latent growth curve model plot; the probability of ≥2 gout flares 
at each time-point (including those participants who had reported gout flares at ≥3 time-
points)  
 
 
Figure 5.8 Linear ordinal latent growth curve model plot; the probability of ≥2 gout flares at 
each time-point (including those participants who had reported gout flares at ≥3 time-points) 
 
 
 
Models χ 2 CFI TLI RMSEA (CI) WRMR 
Linear 
Ordinal 
LGCM 
226.07 
p<0.0001 
0.96 0.98 0.11 
(0.10, 0.13) 
1.99 
Quadratic 
Ordinal  
LGCM* 
151.71 
p<0.0001 
0.98 0.99 0.09 
(0.08, 0.11) 
1.55 
*fixing the quadratic slope to zero variance improved the running of the model 
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For those participants who had reported gout flares at every time-point the chi-squared 
statistics were statistically significant for both the linear and the quadratic ordinal LGCM (see 
Table 5.5).  The CFI and TLI for the quadratic ordinal LGCM were 0.98 and 0.99 respectively, 
which were slightly higher than the CFI and TLI of 0.97 and 0.98 for the linear model.  The 
RMSEA for the quadratic LGCM of 0.08 (0.07, 0.10) was lower than the RMSEA for the linear 
model which was 0.10 (0.09, 0.12).  The WRMR result was also lower for the quadratic model, 
1.14, than the result returned from the linear model of 1.44. 
In the plot of the quadratic LGCM (Figure 5.9),  the data points in the plots for the observed 
data and estimated model were closer together at all time-points (except at 24 months), 
compared to the observed data and estimated model plots for the linear model (Figure 5.10). 
 
Table 5.5 Latent growth curve model fit indices (for model including those participants who 
reported gout flares at all five time-points) 
 
Models χ 2 CFI TLI RMSEA (CI) WRMR 
Linear 
Ordinal 
LGCM 
125.44 
p<0.0001  
0.97 0.98 0.10 
(0.08, 0.12) 
1.44 
Quadratic 
Ordinal  
LGCM* 
85.41 
p<0.0001 
0.98 0.99 0.08 
(0.07, 0.10) 
1.14 
*fixing the quadratic slope to zero variance improved the running of the model 
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Figure 5.9 Quadratic ordinal latent growth curve model plot; the probability of ≥2 gout flares 
at each time-point (including those participants who had reported gout flares at every time-
point) 
 
 
Figure 5.10 Linear ordinal latent growth curve model plot; the probability of ≥2 gout flares at 
each time-point (including those participants who had reported gout flares at every time-
point) 
  
 
5.5 Discussion  
5.5.1 Gout flares 
This chapter describes the frequency of gout flares self-reported by participants at five time-
points in a prospective cohort study.  At each time-point, the largest proportion of participants 
reported experiencing no gout flares in the reference period.  The median number of gout 
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flares was 1 at baseline and 0 at 36 months, whilst the mean was 1.66 at baseline and 1.18 at 
36 months.   
Previous studies where patients have self-reported gout flare frequency over a 12-month 
period have reported a higher mean number of gout flares of 3.1-3.9 (ten Klooster et al 2014; 
Spaetgens et al 2015) and a median number of gout flares of 1 (IQR 0,3) (Scire et al 2013). In 
a cross-sectional survey by Khanna et al (2012c), 23% of participants reported experiencing no 
gout flares over 12 months, which is lower than the proportion reporting no flares within 12 
months within this cohort.   The lower gout flare frequency observed in this cohort compared 
to other studies could reflect the primary care setting, whereas ten Klooster et al (2014), Scire 
et al (2013) and Spaetgens et al (2015) all recruited from secondary care Rheumatology clinics 
and Khanna et al (2012c) used online recruitment.  A lower mean number of flares of 0.51 was 
reported by Saseen et al (2012) in a subgroup of patients pre-defined by having ‘infrequent’ 
gout flares.  Conversely, a higher mean number of flares of 6.4-6.8 was reported by Strand et 
al (2012) but this was in a cohort of patients with refractory chronic gout thus these results 
are less likely to be generalizable to a primary care gout population.    
Despite the low mean and median gout flares, there was still a substantial proportion (24.9-
42.4%) of the cohort who reported two or more gout flares at each time-point. This finding is 
comparable with the 25% of participants, with self-reported physician diagnosed gout, who 
reported two or more gout flares in the population-based survey by Proudman et al (2019).  
Frequent gout flares, as reported by more than a quarter of this cohort at each time-point, is 
associated with poorer HRQOL (Hirsch et al 2008; Khanna et al 2012c; Scire et al 2013), 
functional disability (Lee et al 2009; Scire et al 2013), higher use of healthcare resources 
(Jackson et al 2015; Khanna et al 2012c; Saseen et al 2012), and lower productivity (Khanna et 
al 2012c).  Experiencing two or more gout flares in the previous 12 months has been 
highlighted as a situation where ULT should be particularly advised in order to optimally 
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manage gout symptoms (Hui et al 2017).  The identification of a substantial proportion of 
participants within this cohort reporting frequent gout flares is consistent with previous 
observations that gout is frequently poorly managed (Kuo et al 2015a).  
The spaghetti plot of gout flares self-reported at each time-point show participants reporting 
a diverse range of different patterns in gout flares over time.  The pattern of gout flares over-
time was investigated further through latent growth curve modelling as discussed in section 
5.5.2. 
5.5.2 Latent growth curve modelling 
Ordinal models 
The results of the latent growth curve modelling indicate a closer fit for the quadratic ordinal 
latent growth curve model, in comparison to other models trialled.  The CFI and TLI results 
returned for both the linear and quadratic ordinal LGCM suggest good fit for both models as 
the results were greater than the level of 0.95 suggested by Hu & Bentler (1999) to indicate 
good fit. However, the results returned by the quadratic model were higher than those results 
returned from the linear model, indicating a potentially better fit.  The RMSEA of 0.08 for the 
quadratic model indicates an acceptable fit as it was within the criteria, of 0.08 or less, 
suggested by MacCallum, Browne & Sugawara (1996).  The RMSEA for the linear model of 0.10 
(0.09, 0.11) suggested a less favourable fit for the model as the result, along with the 
confidence intervals, was above 0.08.  The chi-squared result for both the quadratic and linear 
model was statistically significant. However, the study sample size was 1164 and a statistically 
significant result is often returned for the chi-squared statistic where there is a large sample 
size in latent growth curve modelling (Bentler & Bonnet, 1980).  The WRMR result returned 
for the quadratic model (1.71) was lower than the result returned for the linear model (2.31) 
and a smaller WRMR had been proposed to suggest better fit (Wu, West & Taylor, 2009) and 
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the quadratic model returned a result which was closer to the value suggested by Yu (2012) 
as suggesting acceptable fit. 
In addition to the model fit indices results obtained, the spaghetti plots and LGCM plots 
suggest that the gout flare data appear to display more of a quadratic form rather than a linear 
form.   In the plot of the quadratic LGCM the data points in the plots for the observed data 
and estimated model are closer together at all time-points (except at 24 months), compared 
to the observed data and estimated model plots for the linear model; thus suggesting that the 
quadratic model displays a closer fit compared with the observed data. 
Sensitivity analysis 
The linear and quadratic ordinal LCGM were run using 3 different data sets; i) participants who 
self-reported gout flares on at least one time-point (n=1164), ii) those who had reported gout 
flares on at least three time-points (n=729) and iii) those who had reported gout flares at every 
time-point (n=437).  The model fit indices results displayed a similar pattern in each data set; 
with a slightly higher CFI and TLI but lower RMSEA and WRMR returned for the quadratic 
ordinal LGCM.   The same pattern in the plots of the linear and quadratic ordinal LGCM in the 
three different data sets were also observed.  Thus, the results from the sensitivity analysis 
showed that a quadratic model was favoured in all three data sets.   
Zero-inflated Poisson and negative binomial models. 
The descriptive analysis prior to latent growth curve modelling, displayed zero-inflation in the 
self-reported gout flares; as the majority of participants at every time point reported no gout 
flares.  This zero-inflation in the data and the fact that the gout flares data might be considered 
‘count data’ justified modelling a zero-inflated Poission latent growth curve model (Liu & 
Powers, 2007). 
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The variance of the gout flare data was greater than the mean number of gout flares at each 
time-point.  This finding indicated over dispersion in the data, thus providing justification for 
modelling a negative binomial latent growth curve model (Zhou & Carin, 2015).    
However, when the ZIP and negative binomial models were run several problems were 
encountered; including multiple warnings in the output of the ZIP and excessive 
computational time with the negative binomial model.  Such problems were not encountered 
when running the ordinal latent growth curve models. 
5.5.3 Strengths and limitations 
Gout flares 
 A strength of this study was the analysis of gout flare data from five time-points enabling the 
investigation of the dynamic nature of the change in gout flares overtime.  Flares have been 
identified as a key reported outcome measure by Outcome Measures in Rheumatology Clinical 
Trials (OMERACT) (Schumacher et al 2009).  However, a standardised definition of a gout flare 
outcome measure has yet to be endorsed as a clinical outcome measure by OMERACT (de 
Latour, Dalbeth & Taylor, 2015), as until recently there has been no widely agreed definition 
of gout flare used in the research literature and no consensus on how flares should be 
measured as an outcome (Gaffo et al 2012; de Latour, Dalbeth & Taylor, 2015; Taylor et al 
2009).   The recent definition of flares validated for use in clinical research (Gaffo et al 2018) 
was validated prior to the development of this study and requires data about clinical features 
not included in the questionnaire.  As a definition of a flare was not included in the 
questionnaire this could have led to the potential for misclassification bias.  Also, since the 
outcome measure used in this analysis was self-reported, and as participants were asked to 
recall the number of flares experienced in a reference period over 12- or 6- months, the 
potential for recall bias cannot be ruled out.   However, patient-reported gout flare frequency,  
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as used in this study, has been identified as a feasible method in clinical trials (de Latour, 
Dalbeth & Taylor, 2015).  Self-reported flares have also been compared to the criterion of an 
assessment by a rheumatologist and shown to have a sensitivity of 91% and negative 
predictive value of 96% (Gaffo et al 2012).  There are several advantages to this self-reported 
approach to assess flares.  Self-reports of flares can avoid the limitations of alternative 
methods of collecting gout flare data; such as using data derived from medical record review 
which often under-report the frequency of flares, as gout flares are often self-managed 
without seeking medical attention (Macfarlane et al 2016; Neogi et al 2006; Rothenbacher et 
al 2011; Sarawate et al 2006).   
The mean number and variation in flares were calculated in this chapter based on the 
frequency of flares reported in categories.  Thus, a limitation of these calculations is that the 
category ≥5 was taken to indicate five gout flares. Consequently, the mean number of flares, 
along with the variance, presented in this chapter is likely to be lower than if the flares were 
not reported within categories.  However, as flares were reported in categories this justifies 
the decision made to model the gout flares data as ordinal data. 
Latent growth curve modelling 
An acknowledged limitation of latent growth curve modelling is that it follows the assumption 
that all individuals come from a single population and that a single latent growth curve can 
adequately describe growth parameters for the entire population (Jung & Wickrama, 2008; 
Ram & Grimm, 2009).  The analysis undertaken in this chapter has identified a LGCM which 
describes the pattern of gout flares for 1164 participants, however the findings in this chapter 
(spaghetti plots, descriptive analysis of gout flares) also show that not all participants report 
similar patterns of flares over-time.     Despite the limitations of LGCM it was important to 
determine the functional form of the latent growth curve for the gout flare data, in order to 
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inform the type of models used in the latent class growth analysis in the next chapter (Curran 
& Hussong, 2003; Curran, Obeidat & Losardo, 2010).   
There are limitations to using multiple indices to assess model fit in latent growth curve 
modelling.  Multiple indices were used in this chapter as the reporting of a variety of indices 
has been advocated due to the lack of consensus on the optimal model fit indices (Hooper, 
Coughlan & Mullen, 2008).  A limitation of this approach is that there is no agreement about 
which of these multiple indices should carry more weight or be used in preference to other 
criteria.  Using a range of criteria may lead to researcher bias if model fit indices are selected 
to support a particular viewpoint (Hooper, Coughlan & Mullen, 2008). 
The latent growth curve modelling undertaken in this chapter took an exploratory approach 
to latent growth curve modelling; trialling various ways of modelling the data.  The exploratory 
approach taken in this chapter is justified as there has not been previous research involving 
latent variable modelling of flare data.  The findings from this chapter, relating to the quadratic 
ordinal model, informed the analysis in the next chapter of this thesis which aimed to identify 
classes (groups) of participants within this cohort who reported similar gout flare trajectories. 
5.6 Conclusion 
In conclusion, this chapter described self-reported gout flares over time within this 
prospective cohort.  The frequency of self-reported flares, along with the diverse range in 
individual patterns of change in flares over time (trajectories), are presented. At each time-
point, the largest proportion of participants reported experiencing no flares, however over a 
quarter of the cohort reported two or more flares.  Various approaches to modelling the 
longitudinal flare data for the whole cohort were undertaken and more favourable results 
were returned for the quadratic ordinal latent growth curve model. This quadratic ordinal 
latent growth curve model was used in this chapter to describe the whole cohort.  The findings 
of this chapter will be used to inform the analysis in the following chapter, where classes 
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(groups) of participants who reported similar flare trajectories will be identified within this 
cohort using latent class growth analysis.  
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6 Chapter Six Gout flare trajectory classes 
6.1 Overview of chapter and aim 
In the previous chapter the frequency of self-reported gout flares and the overall pattern of 
change (trajectory) of gout flares over three years for the whole cohort were presented.  The 
aim of this chapter is to identify and describe latent classes (groups) of distinct gout flare 
trajectories in this prospective cohort of people living with gout in primary care.  Thus, in the 
following chapter classes (groups) of people living with gout who have self-reported similar 
patterns of gout flares over time will be identified and the characteristics of class members 
described. 
6.2 Background 
The latent growth curve modelling undertaken in the previous chapter selected a quadratic 
ordinal model to describe the gout flare data for the whole cohort.  However, the previous 
chapter also demonstrated that there was variation in the gout flare trajectories of individual 
participants within this cohort.  Latent class growth analysis (LCGA) and growth mixture 
modelling (GMM) can enable classes (groups) of participants with similar trajectories to be 
identified (Muthen & Muthen, 2000).  Once classes have been identified profiles describing 
the characteristics of each class can be created (Nagin, 1999). 
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6.3 Method and Analysis Plan 
6.3.1 Aims and Objectives 
Aim 
The aim of this chapter is to identify and describe latent classes (groups) of distinct gout flare 
trajectories in a prospective cohort of people living with gout in primary care. 
Objectives  
The objectives of this chapter are to: 
1. Use latent class growth analysis (LCGA) and growth mixture modelling (GMM) to 
identify distinct latent classes of gout flare trajectories in people living with gout in 
primary care.  
2. Describe the characteristics of members of each gout flare trajectory class. 
A flowchart summary of the stages in the LCGA used in this chapter’s methods, and how this 
follows on from the latent growth curve modelling in the previous chapter, can be found in  
Figure 6.1 on the next page. 
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Figure 6.1 Flowchart summary of latent class growth analysis and latent growth curve modelling 
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6.3.2 Data source 
The data source for this analysis was derived from the cohort study described in chapter three. 
The primary observed variable used for the analysis in this chapter was the number of gout 
flares reported by participants at each questionnaire time-point (baseline, 6, 12, 24 and 36 
months).  Data related to gout-specific characteristics, medications, comorbidities, socio-
demographics, BMI and alcohol consumption were taken from the questionnaire responder 
database, and medical record review database. 
6.3.3 Sample size  
No widely accepted sample size has been recommended for use in latent class growth analysis 
(Berlin, Parra & Williams, 2014).  In simulation studies, the sample size requirements for latent 
growth curve modelling have been shown to be strongly influenced by the size of the 
regression coefficient, the degree of missing data and the inclusion of covariates (Muthen & 
Muthen, 2002).  A simple growth curve with no covariates or missing data requires a sample 
of only 40 to obtain a sufficient power, whilst a conditional growth curve (with covariates) 
with missing data and a regression coefficient of 0.2 requires a sample of 250 to achieve a 
power of 0.8 (Muthen & Muthen, 2002).  This variation in sample size requirement, dependent 
on the degree of missing data, has also been described by more recent simulation studies 
investigating optimal sample size in structural equation modelling (Wolf et al 2013).   
Previous studies have successfully used patient reported outcomes to identify three to five 
latent class trajectories through LCGA in clinical cohorts in primary care with sample sizes of 
approximately 500 participants (Nicholls et al 2014; Rzewuska et al 2015).  Thus, the analysis 
in this chapter, which is an unconditional analysis and has a sample size of 1164, is expected 
to be an adequate sample size to achieve appropriate power.  However, due to the exploratory 
nature of the LCGA and GMM, the size of the regression coefficient required to reject the null 
hypothesis that the regression coefficient is zero was not known.   
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6.3.4 Missing data and sensitivity analysis 
The extent of missing data in the gout flare data was presented in chapter four and chapter 
five.  The LCGA and GMM in this chapter was undertaken using the statistical programme 
Mplus. LCGA and GMM in Mplus handle missing data of the observed outcome variable by the 
use of full information maximum likelihood (FIML) estimation (Berlin, Parra & Williams, 2014; 
Jung & Wickrama, 2008; Muthen & Muthen, 2017; Ram & Grimm, 2009). FIML uses available 
observed outcome responses to supplement missing outcome responses to produce 
parameter estimates (Little et al 2014).   
The LCGA was undertaken in the first instance by including all participants who self-reported 
the number of gout flares they had experienced on at least one time-point (n=1164). After this 
first LCGA, a sensitivity analysis was undertaken to see if including participants who reported 
flares at more time points yielded different trajectory patterns or optimal class number.  Thus 
the LCGA was repeated with two other datasets: i) participants with observed outcome data 
(number of gout flares) at three or more time points (baseline plus two additional time points) 
(n=729) and ii) participants with complete data (an outcome reported at all five time points) 
(n=437).  The findings from the three analyses were compared.  After LCGA was undertaken, 
the extent of missing data within each class at each time point was described. 
6.3.5 Prior to latent class growth analysis 
The previous chapter (chapter five) details the descriptive analysis and latent growth curve 
modelling of gout flares which was undertaken in order to inform the analysis in this chapter. 
6.3.6 Latent class growth analysis 
In the absence of previously published latent variable modelling involving gout flares, LCGA 
was used in an exploratory manner in this chapter (Belin, Parra & Williams, 2014; Jung & 
Wickrama, 2008; Ram & Grimm, 2009).    The optimal latent growth curve model functional 
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form determined in the previous chapter, the ordinal quadratic latent growth curve model, 
was used for the LCGA in this chapter (Berlin, Parra & Williams, 2014; Jung & Wickrama, 2008; 
Ram & Grimm, 2009; Wickrama et al 2016).    
Specifying an unconditional latent class growth model with one-class only  
LCGA utilises a forward classifying approach which commences with specifying a LCGA model 
which yields one latent class (Twisk & Hoekstra, 2012). Consequently, the initial stage in this 
latent class growth analysis was to specify an unconditional LCGA model with one class only, 
where within class variances are fixed to zero (Jung & Wickrama, 2008; Muthen & Muthen, 
2000; Wickrama et al 2016) (see figure Figure 6.1).    
After running this one-class LCGA model the output from the model was recorded and 
considered in line with the criteria described in Table 6.1. 
Specifying unconditional latent class growth models with more latent classes  
After the specification of a one-class LCGA model, the model was amended to estimate a two-
class LCGA model. An iterative process then continued, sequentially increasing the number of 
classes within the LCGA model, until the optimal number of classes was achieved (see Table 
6.1 and Figure 6.1) (Wickrama et al 2016).  This continued estimation of as many classes as 
required until the optimal number of classes is achieved has been advocated as an exploratory 
approach in the investigation of LCGA (Berlin, Parra & Williams, 2014). 
The starts and iterations were increased to the maximum, in order to be able to replicate the 
log likelihood (Muthen & Muthen, 2017). 
After running each LCGA model, the output from the model was recorded and considered in 
line with the criteria described in the Table 6.1. 
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Determination of the optimal number of latent classes 
A combination of different criteria need to be considered when determining the optimal 
number of latent classes in a LCGA analysis, due to the absence of one commonly accepted 
criterion (Nylund, Asparouhov & Muthen, 2007).  The criteria considered whilst determining 
the optimal number of latent classes can be found in Table 6.1.   The criteria used were 
selected because they have been recommended for use with LCGA and GMM, where the 
objective is to identify the model with the optimal number of classes and where the models 
have the same functional form (Berlin, Para & Williams, 2014; Jung & Wickrama, 2008).  These 
criteria are different to the model fit criteria used in chapter five which were selected because 
they have been recommended in LGCM, where the objective is to evaluate the fit of models 
with different functional forms  in order to decide which model is used to describe the whole 
cohort  (Berlin, Para & Williams, 2014; Wu, West & Taylor, 2009). 
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Table 6.1 Guidance for the interpretation of criteria used to determine the optimal number of 
latent classes in LCGA  
Criteria Guidance  
Bayesian 
information 
criteria (BIC) 
A lower BIC indicated a better fitting model (Feldman, Masyn 
& Conger, 2009; Muthen & Muthen, 2000). The BIC has been 
advocated as the better performing information criteria when 
deciding the number of latent classes in LCGA in comparison 
to Akaike Information Criteria (AIC) (Nylund, Asparouhov & 
Muthen, 2007; Peugh & Fan, 2012). 
Akaike 
information 
criteria (AIC) 
A lower AIC result indicated a better fitting model (Nylund, 
Asparouhov & Muthen, 2007). 
The AIC has been found to be inconsistent and does not 
perform as well as the BIC when deciding the number of 
classes in LCGA (Nylund, Asparouhov & Muthen, 2007; Peugh 
& Fan 2012).  
Lo Mendell 
Rubin 
Likelihood ratio 
Test (LMR-LRT)  
Statistically significant result (p < 0.05) indicated an 
improvement in fit with the current model (K) versus a model 
with one less class (K-1) (Nylund, Asparouhov & Muthen, 
2007; Peugh & Fan, 2012; Wickrama et al 2016).   
Due to inconsistencies with LMR-LRT (Jeffries, 2003), the LMR-
LRT should not be used in isolation to decide the optimal 
number of latent classes (van de Schoot et al 2017). 
Bootstrap 
Likelihood ratio 
test (BLRT) 
Statistically significant result (p < 0.05) indicated an 
improvement in fit with the current model (K) versus a model 
with one less class (K-1) (Nylund, Asparouhov & Muthen, 
2007; Peugh & Fan, 2012; Wickrama et al 2016).  
The BLRT has been shown to outperform other tests such as 
the BIC and LMR-LRT when determining the optimal number 
of latent classes (Nylund, Asparouhov & Muthen, 2007).  The 
BLRT is associated with a significantly increased 
computational time and is more sensitive to non-normal 
distributions (Nylund, Asparouhov & Muthen, 2007; 
Wickrama et al 2016).  
Plotting log 
likelihood and 
BIC 
Reviewing plots of the log likelihood and BIC as the number 
of latent classes increased enables the point at which the log 
likelihood increases or BIC decreases to be identified on the 
graph (Muthen, 2001; van de Schoot et al 2017).   
Average 
posterior 
probabilities 
Average posterior probability results nearer 1.0 indicate that 
individuals are assigned to a latent class with a high probability 
(Jung & Wickrama, 2008). Results greater than 0.70 to 0.80 
indicate that the latent classes are grouping individuals with 
similar patterns of change, whilst separating individuals with 
different patterns of change (Andruff et al 2009). 
Entropy An entropy of 1.0 would indicate that each individual has a 
probability of membership of just one class (Feldman, Masyn 
& Conger, 2009).  Entropy result cut offs of 1.0 (perfect), 0.8 
(high), 0.60 (medium), 0.4 (low) have been proposed (Clark & 
Muthen, 2009).   
However, entropy was not originally intended to be used for 
model selection (Feldman, Masyn & Conger 2009) and high 
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levels of entropy do not necessarily indicate that a model is 
clearly identifying trajectory classes (Clark & Muthen, 2009; 
Feldman, Masyn & Conger, 2009).     
Number of 
members per 
class 
A minimum number of members per latent class of less than 
1% of the total cohort is insufficient and the number should 
ideally be >5% (Jung & Wickrama, 2008; Wickrama et al 2016). 
Parsimony Where there is uncertainty regarding the optimal number of 
latent classes based on the results from information criteria 
and likelihood ratio tests, then a model with less estimated 
parameters and less classes would be preferable (Feldman, 
Masyn & Conger, 2009).   
Plot latent class 
growth analysis 
models 
Plotting the growth trajectories of the classes in each model 
aided interpretability and identified very similar growth 
trajectories (Feldman, Masyn & Conger, 2009; Ram & Grimm, 
2009).   
Interpretation, 
practicality and 
theoretical 
justification of 
classes and 
trajectories. 
The results of the LCGA must be interpreted within the 
context of the specific research question (Bauer & Curran, 
2003; Feldman, Masyn & Conger 2009; Jung & Wickrama, 
2008).  The different potential latent growth trajectories were 
reviewed within the context of whether they can be practically 
interpreted as being realistic distinct gout flare trajectories.  
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Description of gout flare latent class growth analysis trajectories 
After deciding on the optimal number of latent classes of flare trajectories, the final gout flare 
latent class trajectories were presented in graphical form. As the data were ordinal, the 
probability of reporting two or more flares at each time point was plotted rather than the 
mean number of flares.  Each latent class trajectory was allocated a descriptive title which 
described the pattern in flares over time displayed by the latent class growth trajectory.  These 
descriptive names were derived following discussion with the supervisory team which 
included clinicians and statisticians.  The trajectory classes were also presented to and 
discussed with both a wider rheumatological and general practice audiences at regional 
meetings and national conferences. 
Consultation with patient and public involvement  
The proposed latent trajectories were presented and discussed with a patient and public 
involvement and engagement group who were lay members of the Keele University Research 
User Group (RUG) living with gout.  The group included both female and male members who 
had been living with gout for different periods of time. Individuals shared their views on the 
descriptive names assigned to the latent classes, along with the interpretability of the classes 
and class characteristics.   
Characteristics and profile of members of different trajectory classes 
After the identification of distinct latent class trajectories, descriptive statistics for each of the 
different latent classes, relating to baseline gout-specific variables, medications, 
comorbidities, socio-demographic variables, BMI and alcohol consumption, were derived.  
Nominal and ordinal categorical baseline variables were analysed by undertaking frequency 
counts and calculating percentages.  Continuous numerical variables were analysed by 
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calculating the mean and standard deviation.  These descriptive characteristics of trajectory 
class members (profiles) for different classes were then compared (Nagin, 1999).   
6.3.7 Growth mixture modelling 
A quadratic ordinal Growth Mixture Model (GMM) was explored. Unlike the LCGA model, in a 
GMM typically the latent intercept, linear slope and quadratic slope variances are not all fixed 
to zero and thus covariance is permitted (Berlin, Parra & Williams, 2014; Jung & Wickrama, 
2008; Wickrama et al 2016).  An iterative process of increasing the number of classes in the 
GMM, using the criteria in Table 6.1 to assess the optimal number of classes, was followed. 
6.4 Results 
6.4.1 Latent class growth analysis 
1164 participants had reported the number of gout flares they had experienced on at least 
one time point.  Table 6.2 displays the model fit indices for the different LCGA models with 
increasing number of classes.  The lowest BIC was returned for the six-class LCGA model, the 
lowest AIC was returned for the eight-class model. However, the four, seven, and eight-class 
models displayed warnings as indicated in Table 6.2.  A statistically significant BLRT result was 
returned for all LCGA models with one to eight classes.  Statistically significant LMR-LRT results 
were achieved for models of five classes or less.  The highest entropy score, 0.703, was 
returned for the two-class model with 0.649 and 0.648 returned for the three-class model and 
six-class models respectively.  In the plot of the change in log likelihood (Figure 6.2) and BIC 
(Figure 6.3) as the number of classes increased, the log likelihood continued to rise, whereas 
the lowest BIC was seen in the LCGA model with six classes. Figure 6.4 to Figure 6.11   display 
plots of the one, two, three, four, five, six, seven, and eight-class LCGA models respectively.   
The six-class model was selected as the optimal LCGA model.  This model returned the lowest 
BIC and a statistically significant BLRT.  When selecting the optimal number of latent classes 
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the BIC has been advocated as the better performing information criterion and the BLRT has 
been shown to out-perform other tests (Nylund, Asparouhov & Muthen, 2007).  The six-class 
model also returned medium to high entropy, which was higher than all models except the 
two and three-class models.  The six-class model yielded trajectory patterns which could 
reflect the range of potential gout flare trajectories in clinical practice.   Whilst the two and 
three class models returned higher posterior probabilities and entropy results, these models 
yielded gout flare trajectory patterns which displayed little change over time, therefore not 
fully reflecting the range of patterns of change in flares identified in the previous chapter.  The 
two and three-class models yielded less favourable BIC results. 
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Table 6.2 Model fit results for LCGA (participants who reported gout flares at ≥1 time-points) 
 
 
Number 
of 
classes 
AIC BIC BLRT LMR-LRT Entropy Average posterior probabilities 
 
Number per class (%)  
based on most likely class 
membership 
1 11200.304 11235.722 - - -  1164 
(100) 
2 10096.374 10152.029 P value  
 <0.001 
P value  
<0.001 
 0.703 0.884/0.933 
 
460/704 
(39.5/60.5) 
3 9900.376 9967.270 P value 
 <0.001 
P value 
 <0.01 
0.649 0.794/ 0.865/0.808 
 
369/603/192 
(31.7/51.8/16.5) 
4
a
 9843.368 9939.501 P value 
 <0.001 
P value 
 <0.01 
0.623 0.790/0.757/0.758/0.694 
 
360/299/409/96 
(30.9/25.7/35.1/8.3) 
5 9799.746 9916.117 P value  
<0.001 
P value  
<0.05 
0.616 0.744/0.761/0.724/0.769/0.665 
 
354/140/330/251/89 
(30.4/12.0/28.4/21.6/7.6) 
6 9765.561 9902.171 P value 
 <0.001 
P value 
 0.1110 
0.648 0.750/0.709/0.644/0.768/0.815/0.758 349/276/95/287/14/143 
(29.9/23.7/8.2/24.7/1.2/12.3) 
    7
a,b
 
 
9757.126 9913.974 P value 
<0.001 
b
 
P value 
 0.0967 
0.635 0.652/0.683/0.706/0.788/0.743/0.733/0.734 
 
95/37/280/12/125/350/265 
(8.2/3.1/24.1/1.0/10.7/30.1/22.8) 
      8
a,b,c
 9746.744 
 
9923.830 P value  
<0.001
b,c
 
P value 
0.1121 
0.602 0.698/0.663/0.713/0.726/0.581/0.687/0.752/ 
0.552 
37/118/344/125/226/223/13/78 
(3.2/10.1/29.6/10.7/19.4/19.1/1.1/6.7) 
AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo Mendell Rubin likelihood ratio test. 
The lowest BIC and statistically significant BLRT for the six-class solution indicated the optimal number of classes. 
a model fixed to avoid singularity, warning given that model may not be identified,  b Warning that not all of bootstraps converged,        C Warning that some draws had smaller LRT than observed LRT 
Table formatted as per Guidelines for Reporting on Latent Trajectory Studies (GRoLTs) (van de Schoot et al 2017) 
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Figure 6.2 Plot of change in log likelihood for LCGA models with different number of classes 
 
 
Figure 6.3 Plot of change in BIC for LCGA models with different number of classes 
 
Figure 6.4 to Figure 6.11 display the plots of the one, two, three, four, five, six, seven, and 
eight-class LCGA models respectively.   In each plot, the probability of two or more gout flares 
is plotted on the Y axis and the growth curve of classes for the estimated model is shown.   The 
plot of LCGA models with five and six classes both show class trajectory plots where the 
probability decreases steeply and the six class LCGA model also displays a trajectory class 
where the probability is shown to slowly increase over time. 
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Figure 6.4 One class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
Figure 6.5 Two class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
Figure 6.6 Three class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
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Figure 6.7 Four class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
 
Figure 6.8 Five class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
 
Figure 6.9 Six class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point  
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Figure 6.10 Seven class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
 
 
Figure 6.11 Eight class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point 
 
6.4.2 Descriptive names for latent trajectory classes 
Figure 6.12 displays a plot of the estimated model class trajectories for the six class LCGA and 
the descriptive name allocated to each class.  The classes were ‘Frequent and Persistent’ n=95, 
‘Gradually worsening’ n=276, ‘Frequent then improving’ n=14, ‘Moderately frequent’ n=287, 
‘Moderately frequent then improving’ n=143, and ‘Infrequent’ n=349.  Individual spaghetti 
plots were also created (see appendix 11) displaying the gout flares reported for each 
participant in each class and an interpolation line fitted, the pattern of these spaghetti plots 
were also considered when creating the descriptive names for the classes.
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Figure 6.12 Plot of six class ordinal quadratic LCGA model with descriptive names and class sizes 
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6.4.3 Missing data and sensitivity analysis 
Missing data due to unit and item non-response per class 
The percentage of missing gout flare data due to unit non-response (where the questionnaire 
was not returned) in all classes was 0% at baseline but ranged from 21.4% to 69.5% at 36 
months (see Table 6.3).  From six months onwards the ‘frequent then improving’ had the 
lowest proportion of missing data at all time-points compared to other classes, whereas the 
‘frequent and persistent’ had the highest proportion of missing data. 
Table 6.3 Missing data due to unit non-response per class for six-class LGCA model 
 
The percentage of missing gout flare data due to item non-response (where there was no 
response to the gout flare item in a returned questionnaire) in the different classes ranges 
from 0 to 7.1% at baseline and from 0 to 2.9% at 36 months (Table 6.4).  The proportion of 
missing data due to item non-response was far less than the proportion of missing data due 
to unit non-response (Table 6.3). 
 
 
Missing data 
 per class 
self-reported  
gout flares 
 ‘frequent 
 and 
 persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent  
then 
 improving’ 
n=14 
 ‘moderately  
frequent’ 
       n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
‘infrequent’ 
n=349 
Baseline 
n(%) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
0 
(0.0) 
6 months 
n(%) 
45 
(47.4) 
109 
(41.3) 
1 
(7.1) 
70 
(24.4) 
11 
(7.7) 
110 
(31.5) 
12 months 
n(%) 
53 
(55.8) 
124 
(44.9) 
1 
(7.1) 
85 
(29.6) 
37 
(25.9) 
143 
(41.0) 
24 months 
n(%) 
56 
(58.9) 
126 
(45.7) 
1 
(7.1) 
93 
(32.4) 
47 
(32.9) 
145 
(41.5) 
36 months 
n(%) 
66 
(69.5) 
144 
(52.2) 
3 
(21.4) 
120 
(41.8) 
62 
(43.1) 
164 
(47.0) 
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Table 6.4 Missing data due to item non-response per class for six-class LGCA model 
 
 
Sensitivity analysis 
For the different LCGA models using the dataset consisting of participants who self-reported 
gout flares at three or more time-points (n=729), the lowest BIC was returned for the six-class 
LCGA model, the lowest AIC was returned for the eight-class model (Table 6.5). A statistically 
significant BLRT result was returned for all LCGA models with one to eight classes.  Statistically 
significant LMR-LRT results were achieved for models of four classes or less and also the eight-
class model (although the eight-class model displayed a warning about the LRT result).   The 
highest entropy score, 0.850, was returned for the two-class model with 0.783 and 0.777 
returned for the three-class model and six-class models respectively.    
In the plot of the change in log likelihood and BIC in participants who self-reported gout flares 
at three or more time-points, as the number of classes increased the log likelihood continued 
to rise, whereas the lowest BIC was seen in the LCGA model with six classes. (Figure 6.13 and 
Figure 6.14 respectively). 
The plot of the six-class LCGA model in this dataset (Figure 6.15) displayed the same 
trajectories observed in the LCGA including all participants who self-reported gout flares on at 
Missing data 
 per class 
self-reported  
gout flares 
 ‘frequent 
 and 
 persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent  
then 
 improving’ 
n=14 
 ‘moderately  
frequent’ 
       n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
‘infrequent’ 
n=349 
Baseline 
n(%) 
3 
(3.2) 
10 
(3.6) 
1 
(7.1) 
11 
(3.8) 
0 
(0.0) 
16 
(4.6) 
6 months 
n(%) 
3 
(3.2) 
5 
(1.8) 
0 
(0.0) 
6 
(2.1) 
1 
(0.7) 
2 
(0.6) 
12 months 
n(%) 
1 
(1.1) 
4 
(1.4) 
0 
(0.0) 
5 
(1.7) 
4 
(2.8) 
6 
(1.7) 
24 months 
n(%) 
2 
(2.2) 
7 
(2.5) 
1 
(7.1) 
8 
(2.8) 
4 
(2.8) 
9 
(2.6) 
36 months 
n(%) 
0 
(0.0) 
8 
(2.9) 
0 
(0.0) 
7 
(2.4) 
3 
(2.1) 
7 
(2.0) 
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least one time-point.  The plots of all the LCGA models (one to eight classes) for this dataset 
can be found in appendix 12. 
The LCGA including participants who reported self-reported gout flares at three or more time-
points also identified the six-class model as the optimal LCGA model; as the six-class model 
yielded the lowest BIC, a statistically significant BLRT and clinically interpretable trajectory 
patterns.
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Table 6.5 Model fit results for LCGA (participants who reported gout flares at ≥3 time-points) 
 
 
 
Number 
of classes 
AIC BIC BLRT LMR-
LRT 
Entropy Average posterior probabilities 
 
Number per class (%)  
based on most likely class membership 
1 9202.198 9234.113  -  - - - 729 
(100) 
2 8155.788 8206.297 P value  
 <0.001 
P value 
<0.001 
0.850 0.969/0.942 
  
457/272 
(62.7/37.3) 
3 7971.349 8040.224 P value 
 <0.001 
P value 
<0.05 
0.783 0.859/0.894/0.931 
 
239/114/376 
(32.8/15.6/51.6) 
4
a
 7919.649 8006.891 P value 
 <0.001 
P value 
<0.05 
0.763 0.862/0.872/0.847/0.879 
 
46/174/255/254 
(6.3/23.8/35/34.9) 
5 7877.637 7983.245 P value  
 <0.001 
P value 
1 .000 
0.749 0.845/0.909/0.861/0.823/0.841 
 
112/32/164/215/206 
(15.4/4.4/22.5/29.5/28.2) 
6 7843.885 7967.860 P value 
 <0.001
 
 
P value  
0.0940 
0.777 0.877/0.829/0.895/0.844/0.862/0.853 
 
34/213/11/208/153/110 
(4.7/29.2/1.5/28.5/21/15.1) 
   7
b,c
 7834.252 7976.594 P value 
<0.001 
P value 
0.3076 
0.726 0.710/0.834/0.820/0.750/0.780/0.831/00.842 
 
115/32/105/80/178/206/13 
(15.8/4.4/14.4/10.9/24.4/28.3/1.8) 
   8
b,c
 7821.807 7982.516 P value 
<0.001 
P value 
0.0338 
0.737 0.738/0.817/0.831/0.777/0.829/0.760/0.83/ 
0.712 
22/105/3/168/205/59/14/125 
(3/14.4/4.3/23.1/28.1/8.1/1.9/17.1) 
AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo Mendell Rubin. 
The lowest BIC and statistically significant BLRT for the six-class solution indicated the optimal number of classes 
a model fixed to avoid singularity, warning given that model may not be identified, b Warning that not all of bootstraps converged, 
C Warning that some draws had smaller LRT than observed LRT 
Table formatted as per Guidelines for Reporting on Latent Trajectory Studies (GRoLTs) (van de Schoot et al 2017) 
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Figure 6.13 Plot of change in log likelihood for LCGA models with different number of classes 
(for participants who responded at ≥3 time-points) 
 
 
Figure 6.14 Plot of change in BIC for LCGA models with different number of classes (for 
participants who responded at ≥3 time-points) 
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Figure 6.15 Six class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point (for participants who responded at ≥3 time-points) 
 
For the LCGA models in the dataset consisting of participants who self-reported gout flares at 
five time-points (n=437), the lowest BIC was returned for the six-class LCGA model, the lowest 
AIC was returned for the eight-class model (Table 6.6). A statistically significant BLRT result 
was returned for all LCGA models with one to eight classes.  Statistically significant LMR-LRT 
results were achieved for the one-class, two-class and six-class LCGA model.   The highest 
entropy score, 0.876 was returned for the two-class model.  There were warnings for the 
seven and eight-class models that related to non-convergence of bootstraps and problems 
with the LRT results.  In the plots of the change in log likelihood and BIC for the LGCA models 
(Figure 6.16 and Figure 6.17 respectively) the log likelihood continued to rise as the number 
of classes increased, whereas the lowest BIC was seen in the LCGA model with six classes.  
The LCGA in participants who self-reported gout flares at five time-points also identified the 
six-class model as the optimal LCGA model; as the six-class model yielded the lowest BIC, a 
statistically significant BLRT and clinically interpretable trajectory patterns. 
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The plot of the six-class LCGA model in this dataset (Figure 6.18) displayed the same 
trajectories observed in the LCGA including all participants who self-reported gout flares on at 
least one time-point and also the dataset including all participants who self-reported gout 
flares on at least three time-points.  The plots of all the LCGA models (one to eight classes) for 
this dataset can be found in appendix 12. This sensitivity analysis revealed that each LCGA in 
the three datasets displayed the same gout flare trajectory patterns for the six-class model.
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Table 6.6 Model fit results for LCGA (participants who reported gout flares at all 5 time-points)  
 
 
Number 
of classes 
AIC BIC BLRT LMR-
LRT 
Entropy Average posterior probabilities 
 
Number per class (%)  
based on most likely class 
membership 
1 6017.515 6046.074 - - - - 437 
(100) 
2 5262.490 5307.369 P value 
 <0.001 
P value 
 <0.001 
0.876 0.967/0.962 
 
284/153 
(65/35) 
3 5140.591 5201.790 P value 
<0.001 
P value 
<0.01 
0.823 0.897/0.947/0.889 
 
61/238/138 
(14/54.5/31.5) 
4 5102.776 5180.295 P value 
<0.001 
P value 
0.0509 
0.872 0.901/0.955/0.908/0.892 
 
129/238/59/11 
(29.5/54.5/13.5/2.5) 
5
a
 5067.561 5161.399 P value 
<0.001 
P value 
0.2814  
0.821 0.907/0.931/0.894/0.857/0.892 
 
141/10/29/95/162 
(32.3/2.3/6.6/21.7/37.1) 
6 5036.774 5146.932 P value 
<0.001 
P value 
 <0.001 
0.799 0.853 /0.870/0.937/0.901/0.861/0.892 
 
139/113/10/24/84/67 
(31.8/25.9/2.3/5.5/19.2/15.3) 
   7
b,c
 5025.453 5151.931 P value 
<0.001 
P value 
 0.3300 
0.799 0.824/0.928/0.888/ 0.788/ 0.868/0.912/0.854 
 
74/10/67/21/111/15/139 
(16.9/2.3/15.3/4.8/25.4/3.4/31.8) 
    8
a,b,c
 5024.706 5167.503 P value 
<0.001 
P value 
0.1533 
0.776 0.849/0.926/0.779/0.826/0.864/0.776/0.821/ 
0.941 
105/10/26/21/52/74/135/14 
(24.0/2.3/6.0/4.8/11.9/16.9/30.9/3.2) 
AIC, Akaike Information Criteria; BIC, Bayesian Information Criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo Mendell Rubin. 
The lowest BIC and statistically significant BLRT for the six-class solution indicated the optimal number of classes 
a model fixed to avoid singularity, warning given that model may not be identified, b Warning that not all of bootstraps converged, 
C Warning that some draws had smaller LRT than observed LRT 
Table formatted as per Guidelines for Reporting on Latent Trajectory Studies (GRoLTs) (van de Schoot et al 2017) 
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Figure 6.16 Plot of change in log likelihood for LCGA models with different number of classes 
(for participants who responded at 5 time-points) 
 
 
Figure 6.17 Plot of change in BIC for LCGA models with different number of classes (for 
participants who responded at 5 time-points) 
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Figure 6.18 Six class quadratic ordinal LCGA model plot; probability of ≥2 gout flares at each 
time-point (for participants who responded at 5 time-points) 
 
6.4.4 Descriptive characteristics of trajectory class members 
Gout-specific characteristics 
In the ‘frequent and persistent’, ‘frequent then improving’ and ‘gradually worsening’ classes 
95.7%, 92.9% and 86.2% of class members respectively had experienced two or more gout 
flares in the 12 months prior to baseline, in contrast to 0% in the ‘infrequent’ class and 26.5% 
in the ‘moderately frequent’ class (Table 6.7). The ‘infrequent’ class had the longest mean (SD) 
disease duration of 15.6 (12.3) years, whilst the disease duration in the other classes ranged 
from 7.5 to 11.6 years.   A larger proportion of the ‘frequent and persistent’ and ‘frequent 
then improving‘ classes (68.4% and 78.6% respectively) had a history of self-reported 
oligo/polyarticular flares, compared with the ‘infrequent’, ‘moderately frequent’ and 
‘moderately frequent then improving’ classes (26.6%, 30.3%, and 30.8% respectively). In 
addition, 4.2% and 7.1% of class members in the ‘frequent and persistent’ and ‘frequent then 
improving’ had tophi recorded in their medical records in the two years prior to baseline, 
compared with only 1.4% and 1.1% in the ‘moderately frequent’ and ‘infrequent’ classes 
respectively.  The ‘gradually worsening’ class had the highest mean maximum serum urate 
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level (481 µmol/L) recorded in their medical records in the two years prior to baseline, 
followed by the ‘frequent and persistent’ class  (469 µmol/L), whilst the ‘infrequent’ class had 
the lowest mean maximum serum urate level (377 µmol/L).   The ‘frequent and persistent’ 
class had the highest proportion of class members (44.2%) with a maximum serum urate level 
greater than 360 µmol/L, in contrast with 15.2% in the ‘infrequent’ class.    
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Table 6.7 Gout specific characteristics of class members at baseline 
 
 
 
 
Baseline  
 
All in LCGA 
n=1164 
 ‘frequent 
and 
persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent 
then 
improving’ 
n=14 
 ‘moderately 
frequent’ 
n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
 ‘infrequent’ 
n=349 
0 gout flares 398(34.2) 0 (0.0) 7(2.5) 0 (0.0) 55(19.2) 3(2.1) 333(95.4) 
1 gout flare 231(19.8) 1(1.1) 21(7.6) 0 (0.0) 145(50.5) 64(44.8) 0 (0.0) 
2 gout flares 187(16.1) 1(1.1) 93(33.7) 0 (0.0) 49(17.1) 44(30.8) 0 (0.0) 
3 gout flares 103(8.8) 2 (2.1) 72(26.1) 0 (0.0) 13(4.5) 16(11.2) 0 (0.0) 
4 gout flares 67(5.8) 4 (4.2) 46(16.7) 0 (0.0) 10(3.5) 7(4.9) 0 (0.0) 
5 or more gout flares 137(11.8) 84 (88.4) 27(9.8) 13 (92.9) 4(1.4) 9(6.3) 0 (0.0) 
≥2 gout flares  494(42.4) 91(95.7) 238(86.2) 13 (92.9) 76(26.5) 76(53.1) 0(0.0) 
Missing gout flare  41(3.5) 3(3.2) 10(3.6) 1(7.1) 11(3.8) 0(0) 16(4.6) 
Disease duration mean 
(SD)  
11.9(12.0) 11.6(12.3) 11.0(11.6) 7.5(5.9) 9.6(11.2) 9.8(12.3) 15.6(12.3) 
Occurrence of current 
flare  
131(11.3) 48(50.5) 43(15.6) 8(57.1) 19(6.6) 10(7) 3(0.9) 
History of 
oligo/polyarticular flares  
432(37.1) 65(68.4) 132(47.8) 11(78.6) 87(30.3) 44(30.8) 93(26.6) 
Record of tophi  25(2.1) 4(4.2) 8(2.9) 1(7.1) 4(1.4) 4(2.8) 4(1.1) 
Serum urate level 
 >360 µmol/L * 
349(30.0) 42(44.2) 87(31.5) 6(42.9) 103(35.9) 58 (40.6) 53(15.2) 
Maximum serum urate 
µmol/L mean (SD) * 
440.98 
(115.2) 
469.08 
(116.6) 
480.51 
(113.3) 
461.43 
(185.5) 
450.71 
(102.8) 
434.48 
(105.7) 
377.15 
(107.7) 
Missing Serum urate 707(60.7) 44(46.3) 174(63.0) 7(50.0) 164(57.1) 68(47.6) 250(71.6) 
Values are n(%) unless stated otherwise 
 in previous 12 months at baseline; In medical record in the two years prior to baseline; *highest serum urate recorded 
 
170 
 
Medications  
In the ‘infrequent’ class, 73% of class members reported taking allopurinol at baseline, in 
contrast with 28.6% in the ‘frequent then improving’ class (Table 6.8),  whilst 48.4%, 46.7%, 
40.1% and 52.4% of class members in the ‘frequent and persistent’, ‘gradually worsening’, 
‘moderately frequent’ and ‘moderately frequent then improving’ respectively reported taking 
allopurinol. The ‘infrequent’ class also had the highest proportion of class members with a 
prescription for allopurinol in their medical records in the two years prior to baseline (73.4%).  
The ‘infrequent’ class had the lowest proportion of class members with a prescription for 
colchicine 11.7%, compared with the 46.3% and 50% in the ‘frequent and persistent’ and 
‘frequent then improving’ classes respectively.   The highest proportion of class members with 
a prescription for NSAIDs and a prescription for diuretics in the two years prior to baseline 
were seen in the ‘moderately frequent then improving’ (70.6%) and the ‘frequent then 
improving’ (42.9%) classes respectively.  
The ‘infrequent’ class had the highest proportion of class members reporting taking 
allopurinol at each time-point as a percentage of those who returned a questionnaire (Figure 
6.19).   The proportion of class members taking allopurinol in the ‘frequent then improving’ 
class increased over time, reaching 8 (73%) at 36 months.  
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Table 6.8 Class members self-reporting allopurinol use at baseline or with prescriptions for allopurinol, colchicine, NSAIDS and diuretics in medical 
records in the 2 years prior to baseline 
Baseline  
 
All in LCGA 
n=1164 
 ‘frequent and 
persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent then 
improving’ 
n=14 
 ‘moderately 
frequent’ 
n=287 
 ‘moderately 
frequent then 
improving’ 
n=143 
 ‘infrequent’ 
n=349 
Using allopurinol*  624(53.6) 46(48.4) 129(46.7) 4(28.6) 115(40.1) 75(52.4) 255(73.0) 
Allopurinol dose*        
<100 mg 224(19.2) 25(26.3) 46(16.6) 1(7.1) 47(16.4) 29(20.3) 76(21.8) 
200 mg 61(5.15) 4(4.2) 14(5.0) 0 (0.0) 10(3.5) 6(4.2) 27(7.7) 
300 mg  300(25.8) 16(16.8) 52(18.8) 3(21.4) 55(19.4) 32(22.4) 142(40.7) 
≥400 mg 30(2.6) 5(5.3) 14(5.1) 0 (0.0) 2(0.7) 3(2.1) 7(2.0) 
Allopurinol 
prescription 
635(54.6) 47(49.5) 133(48.2) 7(50.0) 118(41.1) 74(51.7) 256(73.4) 
Colchicine 
Prescription 
340(29.2) 44(46.3) 97(35.1) 7(50.0) 103(35.9) 48(33.6) 41(11.7) 
NSAIDs 
Prescription 
625(53.7) 59(62.1) 163(59.1) 9(64.3) 158(55.1) 101(70.6) 135(38.7) 
Diuretics 
Prescription  
280(24.1) 28(29.5) 74(26.8) 6(42.9) 67(23.3) 41(28.7) 64(18.3) 
Values are n(%) unless stated otherwise 
*Self-reported allopurinol use and dose is taken from baseline questionnaire responses;  In medical record in the two years prior to baseline 
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Figure 6.19 Plot of the participants per class who self-reported allopurinol use at each time-point as a percentage of those who returned a 
questionnaire at each time-point 
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Comorbidities 
The most common comorbidity reported by class members in all classes was hypertension, 
with 61.8% of all participants reporting this comorbidity (Table 6.9). The proportion of 
participants with hypertension was similar across classes except for the ‘frequent then 
improving’ class who had a higher proportion of class members (78.6%) with hypertension. 
The ‘frequent then improving’, ‘frequent and persistent’ and ‘gradually worsening’ classes had 
higher proportions of class members with an eGFR<60 mL/min/1.73m2 (42.9%, 30.5%, 30.1% 
respectively) compared with other classes. The ‘frequent then improving’ (14.3%), ‘frequent 
and persistent’ (9.5%) and ‘gradually worsening’ (8.3%) classes had higher proportions of class 
members with renal calculi compared with other classes.  The ‘frequent and persistent’ and 
‘gradually worsening’ classes had the highest proportion of class members reporting a history 
of myocardial infarction (MI) (11.6% and 11.6% respectively), compared with other classes. 
The ‘frequent and persistent’ class also had more class members reporting diabetes (23.2%) 
or a cerebrovascular accident (CVA) (6.3%) in contrast with the other five classes. The 
‘frequent and persistent’ class had the highest mean number of self-reported comorbidities 
per class of 1.9, with the ‘frequent then improving’, ‘gradually worsening’, ‘moderately 
frequent’, ‘moderately frequent then improving’ and ‘infrequent’ classes having a mean 
number of 1.4, 1.7, 1.5, 1.5 and 1.7 respectively.
174 
 
                                      Table 6.9 Comorbidities of class members at baseline 
 
 
 
 
 
 
 
 
 
 
 
Baseline 
 
All in LCGA 
n=1164 
 ‘frequent 
and 
persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent 
then 
improving’ 
n=14 
 ‘moderately 
frequent’ 
n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
 ‘infrequent’ 
n=349 
Self-reported 
comorbidity  
       
   Diabetes  202(17.4) 22(23.2) 41(14.9) 2(14.3) 48(16.7) 15(10.5) 74(21.2) 
   Hypertension (HT) 719(61.8) 62(65.3) 173(62.7) 11(78.6) 170(59.2) 86(60.1) 217(62.2) 
   Cerebrovascular         
   Accident (CVA) 
36(3.1) 6(6.3) 9(3.3) 0 (0.0) 8(2.8) 1(0.7) 12(3.4) 
   Transient ischaemic 
    attack (TIA) 
60(5.2) 6(6.3) 13(4.7) 0 (0.0) 12(4.2) 5(3.5) 24(6.9) 
   Hyperlipidaemia (HL) 499(42.9) 44(46.3) 123(44.6) 4(28.6) 116(40.4) 61(42.7) 151(43.3) 
   Myocardial Infarction          
   (MI)                
114(9.8) 11(11.6) 32(11.6) 1(7.1) 27(9.4) 14(9.8) 29(8.3) 
   Renal failure (RF) 54(4.6) 8(8.4) 19(6.9) 0 (0.0) 12(4.2) 5(3.5) 10(2.9) 
   Renal calculi 76(6.5) 9(9.5) 23(8.3) 2(14.3) 13(4.5) 6(4.2) 23(6.6) 
   Angina 142(12.2) 13(13.7) 40(14.5) 0 (0.0) 28(9.8) 19(13.3) 42(12.0) 
Total comorbidities 
mean (SD) 
1.6(1.4) 1.9(1.6) 1.7(1.5) 1.4(0.9) 1.5(1.4) 1.5(1.3) 1.7(1.3) 
eGFR <60 
mL/min/1.73m2 
311(26.7) 29(30.5) 83(30.1) 6(42.9) 71(24.7) 34(23.8) 88(25.2) 
Values are n(%) unless stated otherwise 
Total number of comorbidities self-reported in baseline questionnaire (diabetes, hypertension, hyperlipidaemia, myocardial 
infarction, angina, cerebrovascular accident, transient ischaemic attack, renal failure, renal calculi); eGFR <60 mL/min/1.73m2 indicative 
of chronic kidney disease;  In medical record in the two years prior to baseline 
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Socio-demographic characteristics 
The ‘frequent and persistent’ and ‘gradually worsening’ classes had the highest proportion of 
class members, 41.1 % and 40.6 % respectively, classified as ‘most deprived’ based on the IMD 
tertile (Table 6.10), whilst the ‘frequent then improving’ class had the lowest proportion 
(7.1%).  The ‘frequent and persistent’ (11.6%), ‘gradually worsening’ (15.2%) and ‘frequent 
then improving’ (7.1%) classes had the lowest proportions of class members, who reported 
attending further education.   
 
BMI and alcohol frequency 
The ‘frequent and persistent’ class had the highest mean BMI of 30.5 kg/m2 compared to a 
mean BMI ranging from 28.3 to 29.4 kg/m2 for the other classes (Table 6.11).  The ‘frequent 
and persistent’, ‘gradually worsening’ and ‘frequent then improving’ classes had the highest 
proportion of class members classified as obese (BMI ≥30 kg/m2) at 43.2%, 35.1% and 35.7% 
respectively.  The ‘frequent and persistent’ class had the highest proportion of class members, 
17.9%, who reported never consuming alcohol and the lowest proportion of class members, 
15.8%, who reported consuming alcohol daily or almost daily.
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Table 6.10 Socio-demographic characteristics of class members at baseline 
Baseline 
 
All in LCGA 
n=1164 
 ‘frequent 
and 
persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent 
then 
improving’ 
n=14 
 ‘moderately 
frequent’ 
n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
 ‘infrequent’ 
n=349 
Male n(%) 972(83.5) 79(83.2) 226(81.9) 11(78.6) 248(86.4) 115(80.4) 293(84.0) 
Age mean (SD) 65.6(12.5) 64.2(12.5) 64.5(13.1) 68.7(9.5) 65.3(12.7) 65.5(12.5) 67.0(11.7) 
Age categories n(%)        
<40  25(2.2) 2(2.2) 9(3.3) 0 (0.0) 7(2.4) 3(2.1) 4(1.1) 
40-49.9 114(9.8) 13(13.7) 29(10.5) 0 (0.0) 30(10.5) 17(11.9) 25(7.2) 
50-59.9 207(17.8) 15(15.8) 61(22.1) 2(14.3) 55(19.2) 20(14) 54(15.5) 
60-69.9 339(29.1) 32(33.7) 70(25.4) 6(42.9) 84(29.3) 45(31.5) 102(29.2) 
70-79.9 333(28.6) 25(26.3) 72(26.1) 5(35.7) 72(25.1) 43(30.1) 116(33.2) 
>80 146(12.5) 8(8.4) 35(12.7) 1(7.1) 39(13.6) 15(10.5) 48(13.8) 
Indices of Multiple 
deprivation tertile n(%) 
       
Most deprived 360(30.9) 39(41.1) 112(40.6) 1(7.1) 82(28.6) 44(30.8) 82(23.5) 
Middle Deprived 398(34.2) 29(30.5) 80(29.0) 7(50.0) 100(34.8) 51(35.7) 131(37.5) 
Least deprived 406(34.9) 27(28.4) 84(30.4) 6(42.9) 105(36.6) 48(33.6) 136(39.0) 
Ethnic origin n(%)         
White UK/European 1107(95.1) 93(97.9) 260(94.2) 14(100) 270(94.1) 138(96.5) 332(95.1) 
Asian 16(1.4) 1(1.1) 8(2.9) 0 (0.0) 4(1.4) 1(0.7) 2(0.6) 
Afro Caribbean  2(0.2) 0 (0.0) 0 (0.0) 0 (0.0) 1(.03) 0 (0.0) 1(0.3) 
African 2(0.2) 0 (0.0) 1(0.4) 0 (0.0) 0 (0.0) 1(0.7) 0 (0.0) 
Chinese 1(0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1(0.3) 
 Other   7(0.6) 0 (0.0) 3(1.1) 0 (0.0) 1(0.3) 1(0.7) 2(0.6) 
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Table 6.10 cont. Socio-demographic characteristics of class members at baseline 
Relationship status n(%)        
Married 793(68.1) 63(66.3) 192(69.6) 8(57.1) 188(65.5) 97(67.8) 245(70.2) 
Widowed 112(9.6) 10(10.5) 24(8.7) 2(14.3) 33(11.5) 11(7.7) 32(9.2) 
Cohabiting 73(6.3) 4(4.2) 13(4.7) 2(14.3) 24(8.4) 9(6.3) 23(6.6.) 
Divorced 69(5.9) 4(4.2) 22(8.0) 1(7.1) 10(3.5) 12(8.4) 19(5.4) 
Separated 22(1.9) 2(2.1) 6(2.2)  5(1.7) 3(2.1) 6(1.7) 
Single 76(6.5) 11(11.6) 17(6.2) 1(7.1) 21(7.3) 9(6.3) 17(4.9) 
Further education n(%) 245(21) 11(11.6) 42(15.2) 1(7.1) 78(27.2) 27(18.9) 86(24.6) 
178 
 
 
 
 
 Table 6.11 BMI and alcohol frequency of class members at baseline 
 
 Baseline 
 
All in LCGA 
n=1164 
 ‘frequent 
and 
persistent’ 
n=95 
 ‘gradually 
worsening’ 
n=276 
 ‘frequent 
then 
improving’ 
n=14 
 ‘moderately 
frequent’ 
n=287 
‘moderately 
frequent 
then 
improving’ 
n=143 
 ‘infrequent’ 
n=349 
BMI kg/m2   mean (SD) 29.1(5.1) 30.5(5.5) 29.4(5.0) 28.3(3.1) 28.8(4.8) 29.1(4.9) 28.8(5.3) 
BMI categories n(%)        
<18.5  kg/m2    1(0.1) 0 (0.0) 0 (0.0) 0 (0.0) 1(0.3) 0 (0.0) 0 (0.0) 
18.5-24.9  kg/m2    216(18.6) 12(12.6) 44(15.9) 1(7.1) 57(19.9) 29(20.3) 73(20.9) 
25-29.9 kg/m2    503(43.2) 36(37.9) 117(42.4) 8(57.1) 129(44.9) 60(42.0) 153(43.8) 
30-34.9  kg/m2    255(21.9) 23(24.1) 68(24.6) 5(35.7) 58(20.2) 31(21.7) 70(20.1) 
35-39.9  kg/m2    89(7.6) 12(12.6) 21(7.6) 0 (0.0) 20(7.0) 12(8.4) 23(6.6) 
≥40  kg/m2    36(3.1) 6(6.3) 8(2.9) 0 (0.0) 6(2.1) 4(2.8) 12(3.4) 
Classified as obese n(%) 380(32.6) 41(43.2) 97(35.1) 5(35.7) 85(29.6) 47(32.9) 105(30.1) 
Alcohol frequency n(%)        
Never 112(9.6) 17(17.9) 29(10.5) 1(7.1) 21(7.3) 11(7.7) 33(9.5) 
Special occasions 154(13.2) 14(14.7) 43(15.6) 3(21.4) 31(10.8) 20(14.0) 43(12.3) 
1 to 3 times per month 109(9.4) 7(7.4) 28(10.1) 1(7.1) 28(9.8) 11(7.7) 34(9.7) 
Once or twice per week 249(21.4) 21(22.1) 62(22.5) 4(28.6) 61(21.3) 30(21.0) 71(20.3) 
3 to 4 times per week 255(21.9) 19(20.0) 57(20.7) 2(14.3) 68(23.7) 26(18.2) 83(23.8) 
Daily or almost daily 269(23.1) 15(15.8) 55(19.9) 3(21.4) 73(25.4) 44(30.8) 79(22.6) 
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6.4.5 Feedback from healthcare professionals and PPIE group members 
The trajectory classes were presented and discussed with rheumatologists, general 
practitioners and other healthcare professionals who commented that the flare trajectories 
reflected the type of patients encountered in clinical practice (those experiencing worsening, 
improving and no change in symptoms) and the characteristics of class members was in 
keeping with the pattern of gout flares.  Several healthcare professionals commented that the 
smallest trajectory class displayed a very interesting pattern which, as it included participants 
with frequent then improving flares, was of clinical relevance.  Keele RUG PPIE group members 
were able to identify with trajectories from the different classes and PPIE group members 
identified classes which they felt they would be assigned to based on their own symptoms. 
6.4.6 Growth mixture modelling 
In addition to modelling the gout flare data using LCGA, GMM was also undertaken.  The 
growth mixture models took over two days to run and the quadratic slope had to be fixed to 
zero in order for the model to run. Consequently, only the intercept parameter was permitted 
to vary in this model.   In addition, the smaller dataset, consisting of participants who self-
reported gout flare data at five time-points, needed to be used to enable the model to run.   
GMMs beyond two classes displayed warnings including a warning that the bootstraps for the 
BLRT did not converge. The lowest BIC was achieved for the two-class model; which consisted 
of a class with an improving trajectory and a worsening trajectory.  Thus, the GMM model 
indicated that an improving and worsening trajectory existed within this cohort. However, the 
limitations described above prevented GMM being used as the primary model for selecting 
the optimal number of classes.  The model fit indices for the GMM and the plots for the GMM 
can be found in appendix 13. 
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6.5 Discussion 
6.5.1 Gout flare trajectory classes  
Using LCGA, six distinct gout flare trajectory classes were identified in this primary care cohort.  
The selection of a six trajectories solution was based on a combination of the statistical indices 
and the clinical interpretation of the trajectories. This is the first-time gout flare trajectories 
have been described thus providing a unique insight into the occurrence of gout flares over 
time. 
The six-class model returned both the lowest BIC in comparison to other classes and also 
returned a statistically significant BLRT thus indicating a better fitting model (Nylund, 
Asparouhov & Muthen, 2007; Peugh & Fan, 2012).  The BIC and the BLRT have been identified 
as performing better in comparison to other indices when selecting the optimal number of 
latent classes (Nylund, Asparouhov & Muthen, 2007).  The sensitivity analysis undertaken 
provided additional justification for the selection of the six-class model.  In all three analyses 
(varying according to the number of time-points flare data were reported), the six-class model 
returned the lowest BIC and a statistically significant result for the BLRT. Furthermore, the 
trajectory plots for the six-class models in each dataset followed very similar patterns, 
indicating that these trajectory patterns existed in databases with varying degrees of missing 
gout flare data. 
The six classes were allocated descriptive names to describe the classes’ trajectory of gout 
flares; ‘frequent and persistent’,  ’gradually worsening’, ‘frequent then improving’, 
‘moderately frequent’ ‘moderately frequent then improving’ and ‘infrequent’.  Thus, this six-
class model displayed a range of distinct gout flare trajectories experienced by participants.  
In the absence of previous latent trajectory modelling of gout flares this was an exploratory 
analysis, however the range of gout flare trajectories identified share features wit h                  
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 trajectories of disease activity in spondyloarthritis (Molto et al 2017) and joint pain (Nicholls 
et al 2014; Verklei et al 2012) as they described classes displaying persistent, worsening, 
improving, moderate, and infrequent patterns.  These gout flare trajectories have been 
presented and discussed with patients, health care professionals, and researchers, 
demonstrating face and content validity of the six-class model.  
6.5.2 Gout flare trajectory class characteristics 
The class members of the gout flare trajectory classes identified in this chapter displayed 
distinct gout-specific, comorbid, socio-demographic and other characteristics.  
Most members in the frequent or worsening trajectory classes had experienced two or more 
gout flares in the 12 months prior to baseline.  These classes also had higher prevalence of 
tophi, elevated serum urate levels and flares involving more than one joint.  These findings 
are consistent with previous studies where tophi and  having a serum urate level above 360 
µmol/L were associated with a higher number of gout flares in the last year (Annemans et al 
2008; Halpern et al 2009; Khanna et al 2012c; Jackson et al 2015; Rashid et al 2015; Sarawate 
et al 2006; Wu et al 2009).    
The ‘infrequent’ class, where no members had experienced two or more gout flares in the 
previous 12 months, had more members reporting allopurinol use, the lowest mean serum 
urate level, and the lowest proportion of class members with oligo/polyarticular flares or 
tophi.  The lowest proportion of participants reporting taking allopurinol at baseline was seen 
in the ‘frequent then improving’ class.  This class was the only class which reported an increase 
in allopurinol use at subsequent time points. The lower frequency of gout flares, when the 
proportion of participants using ULT increases, has been described by other authors (Rees, 
Jenkins & Doherty, 2013).   This class also had the highest proportion of class members with a 
prescription for diuretics in their medical records in the two years prior to baseline (42.9%) 
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consistent with the findings of Hunter et al (2006) that recent use of diuretics is a risk factor 
for gout flares (Hunter et al 2006). 
The ‘frequent and persistent’, ‘gradually worsening’ and ‘frequent then improving’ classes had 
higher proportions of class members with an eGFR<60 mL/min/1.73m2.  The ‘frequent and 
persistent’ and ‘gradually worsening’ classes also had more participants with a self-reported 
history of myocardial infarction. The ‘frequent and persistent’ class had the highest mean BMI 
and the highest proportion of class members classified as obese at baseline.  The ‘frequent 
then improving’ and the ‘gradually worsening’ classes also had a higher proportion of class 
members classified as obese at baseline compared to other classes. These findings are 
consistent with a study in the UK THIN database, which found that renal disease, ischaemic 
heart disease, or obesity were independent risk factors for first post-diagnosis gout flare 
(Rothenbacher et al 2011). The ‘frequent and persistent’ class also had the highest mean 
number of comorbidities of 1.9.  An increased risk of gout flares in the presence of three or 
more comorbidities has been reported in other cohorts (Rashid et al 2015).  
More members in the ‘frequent and persistent’ and ‘gradually worsening’ classes were 
classified as ‘most deprived’ and less had attended higher education, compared with other 
classes.   The level of education attainment, combined with a measure of deprivation, has 
been advocated as a measure of socio-economic status (Grundy & Holt, 2001).  Thus, these 
trajectory findings are consistent with previous studies which have highlighted an association 
between poorer health outcomes and social vulnerability & low socio-economic status (Baker, 
Mead & Campbell, 2002; Jaffe et al 2005).   A cross-sectional analysis using baseline data from 
this cohort has previously shown that both deprivation and non-attendance at further 
education are associated with more frequent flares (Bowen-Davies et al 2018).   Lower levels 
of educational attainment, such as no further education, have also been associated with 
having limited (low or marginal) health literacy (Protheroe et al 2017) and limited health 
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literacy has been associated with poor concordance with medication and poor overall health 
status (Berkman et al 2011).  
6.5.3 Strengths and limitations 
This LCGA was undertaken in a large cohort of 1164 participants using robust statistical 
methodology and optimal number of trajectory classes was determined based on the results 
of tests which are considered the better performing statistical tests for latent class model 
selection.  The clinical interpretation of the trajectories, along with the characteristics of class 
members, provide validity to the selected model.   
A range of statistical indices were considered when deciding the optimal number of latent 
classes, due to the absence of one commonly accepted criterion (Nylund, Asparouhov & 
Muthen, 2007).  The result of one of the statistical indices, the LMR-LRT, returned a non-
significant result for the six latent class model. However, this statistical index has been 
identified as being inconsistent when deciding the optimal number of classes (Jeffries, 2003; 
van de Schoot et al 2017) and the better performing index, the BLRT, did return a statistically 
significant result for the six-class model.  The average posterior probability of one of the six 
classes in the latent class growth analysis model, the ‘frequent and persistent’ class, was 0.644 
which is just below the level of >0.7 recommended when deciding the optimal number of 
latent classes (Andruff et al 2009). However, Mplus uses observed data to supplement missing 
outcome responses via FIML when producing estimates (Little et al 2014) and the posterior 
probability result of 0.644 was returned for the class with the highest proportion of missing 
data and more missing outcome responses supplemented.  All other classes in this six-class 
model returned posterior probabilities above 0.7 in the analysis in the data set of participants 
who responded on at least one time-point. Average posterior probabilities of >0.8 were 
returned for all six classes in the six-class LCGA undertaken in the two sensitivity analyses in 
datasets which had less or no missing data.  
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As this chapter reported a range of different model selection criteria, it is important to 
acknowledge that there is no consensus regarding which of these multiple indices should be 
prioritised when deciding the optimal number of latent classes in LCGA.  Future research could 
investigate what weight should be assigned to each criterion when selecting the ideal number 
of classes and the application of a weighting system would help to provide uniformity in latent 
trajectory reporting. The current use of multiple indices without weighting can lead to 
challenges where indices are not in agreement and also the potential for the ‘cherry picking’ 
of indices by researchers when selecting models (van de Schoot et al 2017). 
Only 14 individuals were assigned to the ‘frequent then improving’ class.  This class size is 
below the level of 5%, which has been advocated by some as the ideal size of classes (Jung & 
Wickrama, 2008; Wickrama et al 2016). However, this class size comprised 1.2% of all 
participants included in LCGA and is thus above the absolute minimum class size of 1% 
advocated (Jung & Wickrama, 2008; Wickrama et al 2016).  This class also displayed a very 
distinctive and clinically relevant ‘improving’ gout flare trajectory.  Due to the exploratory 
nature of this analysis, such a distinct and clinically relevant trajectory could not be 
disregarded.  However, due to the smaller class size, caution is prudent when considering the 
results of the subgroup analysis of the class’ characteristics. 
The fact that 30% of the cohort had serum urate levels above 360 µmol/L is consistent with 
well-documented sub optimal management of gout (Kuo et al 2015a; Roddy et al 2007b). This 
proportion could potentially be higher as 60% of cohort participants did not have a serum 
urate level within the medical record review two years prior to baseline.  Suboptimal serum 
urate monitoring has been demonstrated in other cohorts (Wall et al 2010). The ‘infrequent’ 
class had the highest amount of missing serum urate data, which could be in part attributable 
to the long disease duration and the fact that serum urate may have been checked less often 
in these patients as their symptoms were not frequent. 
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6.5.4 Implications for clinical practice and further research 
This identification of gout flare latent classes increases our understanding of how flares occur 
over time.  A range of flare trajectories with distinct class characteristics were identified.    This 
finding is of particular relevance to clinical practice as the cohort was based in primary care 
where the majority of patients with gout are managed. 
The analysis in this chapter identified an ‘infrequent’ class with more class members taking 
allopurinol and a ‘frequent then improving’ class where there was an increase over time in 
members taking allopurinol.  A reduction in flare frequency, where there is greater allopurinol 
use and achievement of serum urate levels, was demonstrated in a recent nurse-led 
intervention treat to target RCT (Doherty et al 2018).  
Whilst this analysis was undertaken in an observational cohort and causal interpretations 
should not be surmised, the findings are compatible with existing clinical guidelines (Hui et al 
2017) which advocate that urate-lowering therapy should be advised, in order to optimally 
manage gout symptoms, in patients who have experienced two or more gout flares in the 
previous 12 months. 
The characteristics of members of the classes with persistently frequent or worsening gout 
flare trajectories may provide an opportunity to target interventions according to gout, 
comorbid, socio-demographic or other characteristics and subsequently improve patient care.  
For example, the observation that the ‘frequent & persistent’ and ‘gradually worsening’ 
classes all had a lower proportion of people who attended further education and a greater 
proportion classified as ‘most deprived’ could have implications for more tailored patient 
education and prioritisation of resources.   
It is important to consider that the latent class growth analysis undertaken was intentionally 
exploratory in nature and the investigation of the characteristics of class members was 
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descriptive.  As this is the first investigation of latent gout flare trajectories, it would be 
prudent to explore whether similar trajectories can be identified in other cohorts of people 
living with gout and undertake further analysis to identify potential predictors of gout flare 
trajectory membership.  Due to the exploratory nature of this analysis a model to predict 
trajectory membership was not fitted.    
6.6 Conclusion 
In conclusion, this chapter presents the LCGA of self-reported gout flares in a prospective 
cohort in primary care.  Six distinct gout flare trajectory classes were identified; revealing a 
variety of gout flare patterns over time.  The classes were assigned descriptive names based 
on the probability of class members experiencing two or more gout flares at each time-point; 
‘frequent and persistent’, ‘gradually worsening’, ‘frequent then improving’, ‘moderately 
frequent’, ‘moderately frequent then improving’ and ‘infrequent’. The key characteristics of 
gout flare trajectories have been presented; revealing distinct characteristics specific to gout 
flare trajectory classes.  The selection of six gout flare trajectory classes was justified by the 
results of statistical indices and clinical relevance.  The potential clinical relevance of these 
gout flare trajectory classes is discussed.  
In view of the range of trajectories identified, and the previously established association 
between gout flare frequency and health-related quality of life (HRQOL) in cross-sectional 
studies,  the next two chapters will explore change in HRQOL over a three-year period HRQOL 
in people living with gout in primary care in this cohort and the factors associated with change 
in HRQOL. 
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7 Chapter Seven Change in Health-Related Quality of Life  
7.1 Overview of chapter and aim 
The previous chapter identified and described distinct latent classes of gout flare trajectories 
over a three-year period in people living with gout in primary care.  Since previous studies 
have suggested that frequent flares are associated with poor HRQOL (see chapter one, section 
1.9.4), the focus of the remainder of this thesis will be on how HRQOL changes in gout over 
time and which factors are associated with change in HRQOL.  The aim of this chapter is to 
describe change in health-related quality of life (HRQOL) over a three-year period in people 
living with gout in primary care.  
7.2 Method  
7.2.1 Aim and Objectives 
Aim 
To describe how gout-specific and generic HRQOL in people living with gout changes over a 
three-year period 
Objectives 
1. Describe change in GIS subscales (CO, MSE, UTN, WBDA, CDA), SF-36 PF10 and HAQ-
DI scores over a three-year period.  
2. Describe the correlation, and distribution of the GIS subscales (CO, MSE, UTN, WBDA, 
CDA), SF-36 PF10 and HAQ-DI scores over a three-year period. 
3. Describe the GIS subscale, SF-36 PF10 and HAQ-DI scores over three years for 
participants in each distinct latent gout flare trajectory class identified in chapter 6. 
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7.2.2 Data source 
This secondary analysis used data from the study described in chapter three, including 
questionnaire data from baseline, 6, 12, 24 and 36-month follow-up.  
7.2.3 Analysis plan 
A range of descriptive analyses were used to analyse change in HRQOL scores, these have 
been advocated in order to investigate the wide range of potential change which can occur in 
longitudinal data (Leffondre et al 2004; Long, 2012; van Belle et al 2004). Longitudinal data 
allow both individual change and the overall mean change in an outcome to be investigated 
(Fayers & Machin, 2016; Van Belle et al 2004). However, as repeated measurements on the 
same individual are likely to be correlated (Diggle, Liang & Zeger, 1994; Long, 2012; Van Belle 
et al 2004) longitudinal data may not be independent (Fayers & Machin, 2016).   The 
investigation of the extent of correlation in longitudinal data has been advocated as it can 
indicate the strength of the dependency in the outcome measures over time (Van Belle et al 
2004; Long, 2012)  and influences the way longitudinal data are statistically modelled (Fayers 
& Machin, 2016).    
The following analysis was undertaken for the scores of the GIS subscales, SF36 PF10, and 
HAQ-DI, using SPSS version 24. The interpretation of GIS subscales, SF36 PF10, and HAQ-DI 
scores are described in chapter three, section 3.6.2 and section 3.6.3. 
Measures of central tendency and spread at five time-points 
A mean score (with SD) and median score (with IQR) for the GIS subscales, SF-36 PF10 and 
HAQ-DI were calculated for each time-point (baseline, 6, 12, 24 and 36 months). 
Measures of change between time-points 
The mean change (with SD) between each GIS subscale, SF-36 PF10 and HAQ-DI score at 
baseline and 36 months was calculated.   
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The standardised response mean (SRM) between baseline and 36 months was calculated by 
dividing the result of the mean change, by the standard deviation of change scores (Fayers & 
Machin, 2016; Morris, 2000; Morris & DeShon, 2002; Wolff Smith & Beretvas, 2009).   This 
method has been recommended as a measurement of effect size in repeated measures data 
(Fayers & Machin, 2016; Morris, 2000; Morris & DeShon, 2002; Wolff Smith & Beretvas, 2009).   
The effect size between baseline and 36 months was also calculated for the HRQOL measures 
by dividing the result of the mean change, by the standard deviation of baseline scores (Fayers 
& Machin, 2016; Middel & Van Sonderen, 2002; Sim & Wright, 2000).   
Mean change (SD), SRM and effect size were also calculated between baseline and 12 months 
to allow comparison with existing studies.  
Graphing longitudinal data 
Graphing longitudinal data has been advocated to provide information about mean change 
but also to indicate the degree of variability and change at an individual level (Locascio & Atri, 
2011; Long, 2012).    The median GIS subscale, SF-36 PF10 and HAQ-DI with IQR were plotted 
at each time point as box plots to visualise change in each HRQOL score over time.    Spaghetti 
plots were created showing plots of the pattern of change in the HRQOL outcome measure 
for each individual and the individual variability within the cohort (Locascio & Atri, 2011; Long, 
2012; van Belle et al 2004), thus demonstrating within-subject change and between-subject 
differences in change (Locascio & Atri, 2011). An interpolation line was fitted to the spaghetti 
plots to indicate the overall pattern of change.     
Correlation and distribution of outcome measures  
To investigate the correlation between outcome measures at different time-points, and hence 
the level of dependency, scatterplots were created plotting the HRQOL outcome at one time-
point with another time-point, thus creating a matrix of scatter plots with related correlation 
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coefficients.  Histograms and quantile-quantile plots (Q-Q plots) of the GIS subscales, PF10 
and HAQ-DI were undertaken in order to determine whether the scores were normally 
distributed (Bland, 2015; Ghasemi & Zahediasl, 2012)  with the Q-Q plots used to compare the 
quantiles of the observed frequency distribution against the corresponding quantiles of the 
theoretical normal distribution..  
The investigation of the linear form, correlation, and distribution of these HRQOL scores was 
undertaken to inform how they should be statistically modelled later in the thesis.  
HRQOL over three years in each latent gout flare trajectory class 
Mean (SD) GIS subscale, SF-36 PF10 and HAQ-DI scores were calculated at each time-point 
(baseline, 6, 12, 24 and 36 months) for participants in each distinct latent gout flare trajectory 
class identified in the previous chapter. 
7.3 Results 
7.3.1 Measures of central tendency and spread of HRQOL scores over five time-points 
The mean (SD) GIS subscale scores at baseline ranged from 33.46 (20.57) for the GIS UTN to 
48.65 (28.33) for the GIS CO (Table 7.1). The mean (SD) GIS subscale scores at 36 months 
ranged from 28.74 (19.19) for the GIS UTN to 42.57 (27.85) for the GIS CO (Table 7.1).   The 
median (IQR) GIS subscale scores at baseline ranged from 33.33 (16.67, 41.67) for the GIS UTN 
to 50 (25.00, 67.75) for the GIS CO (Figure 7.1). The median (IQR) GIS subscale scores at 36 
months ranged from 25 (16.67, 41.67) for the GIS UTN to 37.50 (25.00, 62.50) for the GIS MSE 
(Figure 7.1).    The median (IQR) GIS MSE and CDA subscale scores did not change over the 
three years (Figure 7.1).  Lower mean and median GIS scores at 36 months for the GIS CO, UTN 
and WBDA indicate better HRQOL at a group level. 
Mean (SD) SF-36 PF10 score was 75.91 (26.12) at baseline and 80.63 (24.49) at 36 months, 
median (IQR) scores were 90 (53.33, 96.67) at baseline and 90 (66.67, 100) at 36 months (Table 
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7.1 and Figure 7.2 respectively).  Mean (SD) HAQ-DI score was 0.51 (0.71) at baseline and 0.47 
(0.67) at 36 months, median (IQR) scores were 0.13 (0.00, 0.88) at baseline and 0.13 (0.00, 
0.75) at 36 months (Table 7.1 and Figure 7.2 respectively). The median (IQR) scores for the SF-
36 PF10 and HAQ-DI did not change over 36 months (Figure 7.2). 
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Table 7.1 Mean (SD) GIS subscales, SF-36 PF10 and HAQ-DI score at each time-point (baseline, 6, 12, 24, 36 months) 
 
Time-
point 
(months) 
 
 
 
GIS CO GIS MSE GIS UTN GIS WBDA GIS CDA 
 
SF-36 PF10 
 
 
HAQ-DI 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
Sample 
Mean 
(SD) 
 
0 
 
1146 
48.65 
(28.33) 
1130 
40.45 
(26.33) 
1108 
33.46 
(20.57) 
 1150 
45.19 
(26.41) 
1139 
40.13 
(24.35) 
960 
75.91 
(26.12) 
1144 
0.51 
(0.71) 
 
6  
 
801 
48.68 
(27.80) 
789 
40.91 
(26.35) 
776 
31.77 
(20.16) 
792 
43.20 
(25.31) 
779 
40.26 
(23.82) 
666 
78.28 
(25.56) 
807 
0.49 
(0.70) 
 
12  
 
703 
46.37 
(27.27) 
695 
39.10 
(25.57) 
685 
30.72 
(20.13) 
686 
40.47 
(25.88) 
699 
39.72 
(23.91) 
579 
77.36 
(27.29) 
699 
0.46 
(0.68) 
 
24  
 
677 
44.77 
(27.52) 
673 
38.86 
(27.32) 
656 
30.56 
(19.49) 
667 
41.19 
(26.65) 
677 
39.17 
(24.07) 
550 
80.25 
(24.77) 
688 
0.45 
(0.68) 
 
36  
 
588 
42.57 
(27.85) 
578 
38.02 
(26.20) 
573 
28.74 
(19.19) 
586 
39.64 
(25.49) 
588 
38.94 
(24.03) 
482 
80.63 
(24.49) 
592 
0.47 
(0.67) 
GIS subscales scored from 0 to 100; higher scores on each scale indicating a greater impact of gout on HRQOL/worse HRQOL. 
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities including the most vigorous without limitations due to health. 
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation.  
Baseline HRQOL scores for cohort has been published previously (Chandratre et al 2018). 
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Figure 7.1 Box and whisker plot displaying the median, IQR, and outliers for the GIS subscale scores at each time-point (baseline, 6, 12, 24, 36 
months) 
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Figure 7.2 Box and whisker plot displaying the median, IQR, and outliers for the SF-36 PF10 and HAQ-DI scores at each time-point (baseline, 6, 
12, 24, 36 months) 
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7.3.2 Mean change, standardised response mean and effect size of HRQOL scores 
Baseline to 36 months 
The mean change (SD) in scores from baseline to 36 months for the GIS subscales ranged from 
-0.46 (20.03) for the GIS CDA to -6.36 (20.31) for the GIS WBDA (Table 7.2).  The SRM between 
baseline and 36 months ranged from -0.02 for the GIS CDA to -0.31 for the GIS WBDA and the 
effect sizes ranged from -0.02 for the GIS CDA to -0.24 for the GIS WBDA (Table 7.2).  The SRM 
for the GIS WBDA and GIS CO were consistent with small effect sizes (-0.31, -0.21 respectively) 
(Cohen, 1992).  The change in GIS WBDA score was consistent with a small effect size (-0.24) 
(Cohen, 1992).   
The mean change (SD) between scores at baseline and 36 months for the SF-36 PF10 was -
0.34 (18.87) (Table 7.2).   The change in SF-36 PF10 score was consistent with a negligible 
effect size (0.02) (Cohen, 1992).   
The mean change (SD) between scores at baseline and 36 months for the HAQ-DI was 0.08 
(0.39) (Table 7.2).  The SRM for HAQ-DI is consistent with a small effect size (0.21) (Cohen, 
1992).  The effect size of the HAQ-DI score was consistent with a negligible effect size (0.13) 
(Cohen, 1992).   
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Table 7.2 The mean scores (SD) at baseline and 36 months, mean change (SD) from baseline 
to 36 months, standardised response mean (SRM) and effect size (ES) for the GIS subscales, 
PF10 and HAQ-DI. 
HRQOL 
measure 
 
Change in scores Baseline to 36 Months 
 
Sample 
Mean at 
baseline 
(SD) 
Mean at 
36 months 
(SD) 
Mean 
change 
 [CI] 
(SD) 
SRM 
Effect 
size 
GIS CO 576 
47.77 
(28.21) 
42.64 
(27.92) 
-5.13 
[-7.18,-3.08] 
(25.06) 
-0.21 -0.18 
GIS MSE 567 
40.65 
(26.25) 
38.12 
(26.31) 
-2.54 
[-4.63,-0.05] 
(25.19) 
-0.10 -0.10 
GIS UTN 556 
30.48 
(19.25) 
28.68 
(18.95) 
-1.80 
[-3.57,-0.03] 
(21.27) 
-0.09 -0.09 
GIS WBDA 579 
45.97 
(26.22) 
39.61 
(25.41) 
-6.36 
[-8.1,-4.70] 
(20.31) 
-0.31 -0.24 
GIS CDA 575 
39.59 
(23.83) 
39.13 
(23.80) 
-0.46 
[-2.10,1.18] 
(20.03) 
-0.02 -0.02 
SF-36 PF10 420 
82.68 
(23.05) 
82.34 
(23.54) 
-0.34 
[-2.15,1.47] 
(18.87) 
-0.02 -0.02 
HAQ-DI 577 
0.38 
(0.62) 
0.46 
(0.67) 
0.08 
[0.05,0.11] 
(0.39) 
0.21 0.13 
Standardised response mean (SRM) calculated as mean change/SD of change scores Effect size 
calculated as mean change/SD of scores at baseline.  
 
GIS subscales scored from 0 to 100; higher scores on each scale indicating a greater impact of gout 
on HRQOL/worse HRQOL. 
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities 
including the most vigorous without limitations due to health. 
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation. 
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Baseline to 12 months 
Change between baseline and 12 months was analysed to allow comparison with previous 
published studies. 
The mean change (SD) in scores from baseline to 12 months for the GIS subscales ranged from 
0.20 (19.21) for the GIS CDA to -5.45 (19.11) for the GIS WBDA (Table 7.3).    The SRM for the 
change in GIS subscales between baseline and 12 months ranged from 0.01 for the GIS CDA 
to -0.29 for the GIS WBDA and the effect size ranged from 0.01 for the GIS CDA to -0.21 for 
the GIS WBDA (Table 7.3).  The change in GIS WBDA was consistent with a small effect size 
(0.21) (Cohen, 1992).  
The mean change (SD) between SF-36 PF10 scores at baseline and 12 months was -1.46 (22.30) 
(Table 7.3).  The change in SF-36 PF10 was consistent with a negligible effect size (0.06) 
(Cohen, 1992).  
The mean change (SD) between scores at baseline and 12 months for the HAQ-DI was 0.03 
(0.37) (see Table 7.3). The change in HAQ-DI was consistent with a negligible effect size (0.05) 
(Cohen, 1992).  
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Table 7.3 The mean scores (SD) at baseline and 12 months, mean change (SD) from baseline 
to 12 months, standardised response mean (SRM) and effect size (ES) for the GIS subscales, 
SF-36 PF10 and HAQ-DI 
HRQOL 
measure 
 
Change in scores Baseline to 12 Months 
 
Sample  Mean at 
baseline 
(SD) 
Mean at 
12 
months 
(SD) 
Mean 
change 
[CI] 
(SD) 
SRM 
Effect 
size 
GIS CO 687 
47.71 
(27.99) 
46.37 
(27.26) 
-1.34 
[-3.01,0.33] 
(22.26)  
-0.06 -0.05 
GIS MSE 678 
40.17 
(25.75) 
39.14 
(25.52) 
-1.03  
[-2.65,0.58] 
(21.42)  
-0.05 -0.04 
GIS UTN 663 
30.90 
(19.92) 
30.50 
(19.90) 
-0.40  
[-2.01,1.2] 
(21.02) 
-0.02 -0.02 
GIS WBDA 674 
45.45 
(25.68) 
40.00 
(25.68) 
-5.45  
[-6.89,-4.00] 
(19.11) 
-0.29 -0.21 
GIS CDA 683 
39.48 
(23.84) 
39.68 
(23.85) 
0.20 
[-1.23,1.65] 
(19.21)  
0.01 0.01 
SF-36 PF10 496 
80.92 
(24.0) 
79.46 
(26.57) 
-1.46  
[-3.43,0.51] 
(22.30)  
-0.06 -0.06 
HAQ-DI 681 
0.43 
(0.64) 
0.46 
(0.67) 
0.03 
[-3.43,0.51] 
(0.37) 
0.08 0.05 
Standardised response mean (SRM) calculated as mean change/SD of change scores Effect size 
calculated as mean change/SD of scores at baseline. 
 
GIS subscales scored from 0 to 100; higher scores on each scale indicating a greater impact of gout 
on HRQOL/worse HRQOL. 
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities 
including the most vigorous without limitations due to health. 
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation. 
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7.3.3 Spaghetti plots of individual change in HRQOL scores over five time-points 
The spaghetti plots of GIS subscales show the diverse range of different GIS scores at baseline 
and also patterns of change in GIS scores over 36 months (Figure 7.3).   
The spaghetti plot for the GIS WBDA subscale scores (Figure 7.3) shows a greater variation in 
individual GIS scores at baseline and individual patterns of GIS scores over time, compared to 
other GIS subscales.  Although all subscale scores show a wide variation in individual scores at 
baseline and over time. 
The spaghetti plot of SF-36 PF10 and HAQ-DI scores over 36 months (Figure 7.4) show the 
wide range of SF-36 PF10 and HAQ-DI scores at baseline and the patterns of longitudinal 
change in the scores.  The plots display the greater proportion of higher SF-36 PF10 scores and 
lower HAQ-DI scores over time. 
The interpolation lines fitted to all the HRQOL scores in Figure 7.3 and Figure 7.4 indicate a 
linear pattern to the scores over the 36-month period. 
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Figure 7.3 Spaghetti plots of individual participants’ GIS scores over 36 months with interpolation line 
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Figure 7.4 Spaghetti plot of individual participants’ SF-36 PF10 and HAQ-DI scores over 36 months with interpolation line 
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7.3.4 Correlation and distribution of outcome measures 
All the GIS score scatterplots (Figure 7.5) display a positive linear relationship between GIS 
scores at different time-points.  The correlation coefficients, r, ranged from 0.38 (between GIS 
UTN scores at baseline and 36 months) displaying moderate correlation, to 0.80 (between GIS 
WBDA at 24 and 36 months) displaying very high correlation (Figure 7.5). The histograms of 
GIS subscales (Figure 7.5) display some symmetry suggestive of a normal distribution, however 
the number of lower scores were higher than would be expected for a perfect normal 
distribution.  The Q-Q plots in appendix 14 confirm that the distribution of GIS scales is close 
to a normal distribution. 
All scatterplots of SF-36 PF10 and HAQ-DI scores (Figure 7.6) display a positive correlation 
between scores at different time-points.  The correlation coefficients for SF-36 PF10 scores 
ranged from 0.62 (between baseline and 12 months) and 0.77 (between 24 and 36 months) 
displaying a high correlation (Figure 7.6).  The SF-36 PF10 scatter plots and histograms showed 
two sub-groups (Figure 7.6).   The histograms also show a left skew; with a greater frequency 
of higher SF-36 PF10 scores.  The histograms also show a second much smaller peak in lower 
scores.   The correlation coefficients for HAQ-DI scores ranged from 0.82 (between baseline 
and 24 months, baseline and 36 months) and 0.86 (between 6 and 12 months, 12 and 24 
months), indicating a very high correlation between HAQ-DI at different time-points over all 
(Figure 7.6).  The histograms of HAQ-DI at each time-point display a right skew; with a greater 
frequency of lower scores.  The Q-Q plots for SF-36 PF10 scores and HAQ-DI scores at each 
time-point in appendix 14 confirm the left and right skew in these outcomes respectively. 
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Figure 7.5 Matrices of GIS score scatterplots at different time-points with the line of best fit and correlation 
coefficient on each scatter plot, with histograms of GIS scores at each time-point displayed on the diagonal of 
the matrix 
                      
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
r = 0.72 
r = 0.68 r = 0.74 
r = 0.64 r = 0.68 r = 0.69 
r = 0.60 r = 0.69 r = 0.68 r = 0.70 
r = 0.64 
r = 0.65 r = 0.70 
r = 0.59 r = 0.67 r = 0.64 
r = 0.54 r = 0.64 r = 0.64 r = 0.71 
r = 0.56 
r = 0.44 r = 0.49 
r = 0.39 r = 0.51 r = 0.48 
r = 0.38 r = 0.41 r = 0.41 r = 0.49 
r = 0.77 
r = 0.72 r = 0.79 
r = 0.71 r = 0.79 r = 0.76 
r = 0.69 r = 0.76 r = 0.76 r = 0.80 
r = 0.69 
r = 0.68 r = 0.72 
r = 0.64 r = 0.70 r = 0.71 
r = 0.65 r = 0.68 r = 0.70 r = 0.69 
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Figure 7.6 Matrices of SF-36 PF10 and HAQ-DI score scatterplots at different time-points with the line of best fit and correlation 
coefficient on each scatter plot, with histograms of SF-36 PF10 and HAQ-DI scores at each time-point displayed on the diagonal 
of each matrix 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
r = 0.73 
r = 0.62 r = 0.70 
r = 0.72 r = 0.71 r = 0.65 
r = 0.67 r = 0.73 r = 0.65 r = 0.77 
r = 0.85 
r = 0.84 r = 0.86 
r = 0.82 r = 0.83 r = 0.86 
r = 0.82 r = 0.84 r = 0.83 r = 0.85 
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7.3.5 HRQOL over three years in each latent gout flares trajectory class 
Table 7.4 to 7.10 display the mean (SD) GIS subscale, SF-36 PF10 and HAQ-DI scores at each 
questionnaire time-point per gout flare trajectory class.  
At baseline the ‘infrequent’ class had the lowest score on each of the five GIS subscales, 
indicating better disease-specific HRQOL, compared with other classes.   At each time-point 
the ‘frequent and persistent’ and ‘gradually worsening’ classes had higher mean scores on 
each of the GIS subscale scores, indicating worse disease-specific HRQOL, in comparison with 
other classes (Table 7.4 to Table 7.8).  The greatest decrease in all GIS subscale scores from 
baseline to 36 months was observed in the ‘frequent then improving’ and ‘moderately 
frequent then improving’ classes.  
At each time-point the ‘frequent and persistent’ and ‘gradually worsening’ classes had lower 
mean scores on the SF-36 PF10 and higher mean scores on the HAQ-DI, indicating worse 
generic HRQOL and greater activity limitation respectively, in comparison with other classes 
(Table 7.9 to Table 7.10).  In the ‘frequent and persistent’ class the mean HAQ-DI score was 
over 1.0, indicating moderate functional disability, at all time-points except 24 months.  The 
mean HAQ-DI score in the ‘frequent and persistent’ class at 36 months (1.22) was higher than 
at any previous time-point. 
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Table 7.4 Mean (SD) GIS CO scores per gout flare trajectory class 
 
 
 
 
 
 
 
 
Table 7.5 Mean (SD) GIS MSE scores per gout flare trajectory class 
 
 
 
 
 
 
 
 
 
 
 
 GIS CO 
Baseline 
GIS CO 
6 months 
GIS CO 
12 months 
GIS CO 
24 months 
GIS CO 
36 months 
Frequent & 
persistent 
78.46 
(20.67) 
77.67 
(21.54) 
75.15 
(22.02) 
75.17 
(21.42) 
68.32 
(30.16) 
Gradually worsening 
61.15 
(22.29) 
64.41 
(23.38) 
62.20 
(23.17 ) 
61.64 
(24.03) 
59.39 
(24.72) 
Frequent then 
improving 
61.61             
(22.45) 
60.10 
(21.88) 
56.73 
(27.77) 
39.42 
(23.16) 
45.00 
(28.38) 
Moderately frequent  
47.15            
(25.98) 
49.77 
(24.16) 
47.15 
(23.18) 
44.98 
(25.20) 
44.33 
(25.10) 
Moderately frequent 
then improving 
46.33 
(26.18) 
41.02 
(24.64) 
35.98 
(24.51) 
36.44 
(25.46 
29.61 
(24.07) 
Infrequent 
32.19            
(25.88) 
33.97 
(26.02) 
32.43 
(24.99) 
30.88 
(23.10) 
30.52 
(23.99) 
All in LCGA 
48.55   
(28.31)   
48.68  
 (27.80)   
46.37   
(27.27) 
44.77   
(27.52)    
42.57 
(27.85) 
 GIS MSE 
Baseline 
GIS MSE 
6 months 
GIS MSE 
12 months 
GIS MSE 
24 months 
GIS MSE 
36 months 
Frequent & 
persistent 
58.10 
(25.50) 
60.37 
(24.22) 
60.94 
(26.88) 
62.16 
(25.60) 
56.48 
(25.33) 
Gradually worsening 49.33 
(25.06) 
50.62 
(24.60) 
49.25 
(21.66) 
50.51 
(26.08) 
49.22 
(25.13) 
Frequent then 
improving 
45.54 
28.0 
50.96 
(23.64) 
45.19 
( 30.15 ) 
37.50 
(21.97) 
40.00 
(23.42) 
Moderately frequent  36.37 
(25.01) 
39.73 
(24.17) 
37.76 
(23.24) 
36.62 
(24.31) 
35.78 
(22.72) 
Moderately frequent 
then improving 
37.41 
(23.90) 
35.64 
(24.61) 
31.37 
(23.71) 
29.17 
(25.76) 
29.38 
(26.39) 
Infrequent 32.60 
(25.39) 
33.64 
(26.97) 
31.94 
(26.49) 
32.60 
(26.70) 
32.92 
(26.32) 
All in LCGA 40.22  
( 26.34)   
40.91 
 (26.35)    
39.10  
(25.57)    
38.86   
(27.32)   
38.02 
(26.20) 
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Table 7.6 Mean (SD) GIS UTN scores per gout flare trajectory class  
 
 
 
Table 7.7 Mean (SD) GIS WDA scores per gout flare trajectory class 
 
 
 
 
 
 GIS UTN 
Baseline 
GIS UTN 
6 months 
GIS UTN 
12 months 
GIS UTN 
24 months 
GIS UTN 
36 months 
Frequent & 
persistent 
48.63  
 (22.01)   
47.96  
(21.21)       
51.25   
(26.80)   
44.52  
 (20.80)   
45.06 
(20.58) 
Gradually worsening 38.15   
(19.34)   
39.97 
(17.72) 
37.33 
(18.14)     
39.31   
(18.61)   
38.64 
(18.0) 
Frequent then 
improving 
  50.00  
 (26.55)    
39.74 
(28.09)   
36.54 
(20.84)    
22.92  
(12.37)         
25.00 
(13.94) 
Moderately frequent  34.75   
 19.27   
33.41 
(18.26)   
33.00   
 (18.27)   
30.68   
(18.37)   
28.70 
(17.91) 
Moderately frequent 
then improving 
33.64  
 (18.68)   
30.42   
(19.70)   
26.66   
 (18.09)   
25.05  
(18.37)   
23.54 
(19.31) 
Infrequent 23.91 
(18.23) 
21.60 
(17.73) 
21.09 
(17.0) 
24.13 
(17.90) 
21.65 
(16.63) 
All in LCGA 33.46   
(20.59)   
31.77 
(20.16)    
30.72 
 (20.13)    
30.56   
(19.49) 
28.74 
(19.19) 
 GIS WBDA 
Baseline 
GIS WBDA 
6 months 
GIS WBDA 
12 months 
GIS WBDA 
24 months 
GIS WBDA 
36 months 
Frequent & 
persistent 
58.50 
(25.37) 
58.32 
(24.64) 
60.25 
(26.8) 
55.09 
(29.41) 
55.40 
(26.78) 
Gradually worsening 48.29 
(23.57) 
46.39 
(22.88) 
44.39 
(25.31) 
46.64 
(26.05) 
44.47 
(24.04) 
Frequent then 
improving 
41.33  
( 21.86)   
42.90   
(16.56)   
40.28   
(24.50)   
33.59   
(23.23)   
28.77 
(14.75) 
Moderately frequent  42.93   
 (27.02)   
38.86   
(23.38)    
34.51  
 (22.77)   
35.50 
 (24.92)    
34.67 
(24.06) 
Moderately frequent 
then improving 
45.01  
(26.72)   
42.68  
 (27.34)   
38.64  
 (26.48) 
39.90   
(26.91)    
36.22 
(26.08) 
Infrequent 40.89 
(27.13) 
42.02 
(26.76) 
40.41 
(26.64) 
40.95 
(26.72) 
40.3 
(26.27) 
All in LCGA 45.08   
(26.45)   
43.20 
(25.31)   
40.47   
(25.88)   
41.19 
(26.65)     
39.64 
(25.49) 
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Table 7.8 Mean (SD) GIS CDA scores per gout flare trajectory class 
 
 
 
 
 
Table 7.9 Mean (SD) SF-36 PF10 scores per gout flare trajectory class 
 
 
 GIS CDA 
Baseline 
GIS CDA 
6 months 
GIS CDA 
12 months 
GIS CDA 
24 months 
GIS CDA 
36 months 
Frequent & 
persistent 
55.60   
(28.42)   
58.50   
(26.27)   
57.44  
 (31.61)    
56.08 
 (31.57)   
51.94 
(29.51)     
Gradually worsening 46.59  
 (21.73)   
50.01 
 (22.65)     
49.59   
(22.24)   
49.06   
(24.39)   
47.35 
(22.87) 
Frequent then 
improving 
46.88 
(18.79)   
45.67  
(19.83)    
47.12   
(27.08)   
38.94   
(21.82)       
42.50 
(12.77)   
Moderately frequent  37.5  
 (23.15)   
37.56   
(20.19) 
37.90   
(20.13)   
35.85   
(20.69)   
36.95 
(22.33) 
Moderately frequent 
then improving 
40.18 
(24.85)   
38.28   
(24.09)   
31.98   
(23.67)   
35.78 
(23.19)   
31.33 
(24.17)   
Infrequent 32.20   
(22.67)    
32.79   
(23.11)   
33.99  
 (22.47)   
33.51 
 (22.45)    
35.76 
(23.57) 
All in LCGA 39.94  
(24.32)  
40.26 
(23.82) 
39.72  
 (23.91)   
39.17  
(24.07)    
38.94 
(24.03) 
 SF-36 PF10 
Baseline 
SF-36 PF10 
6 months 
SF-36 PF10 
12 months 
SF-36 PF10 
24 months 
SF-36 PF10 
36 months 
Frequent & 
persistent 
57.69  
(25.27)   
56.09 
(25.24)   
49.52   
(23.67)   
61.23  
 (24.56)   
59.85 
(25.31) 
Gradually worsening 68.95  
 (27.42)   
73.20   
(25.32) 
71.43   
(26.61)     
72.08 
(25.45) 
76.32 
(24.12) 
Frequent then 
improving 
78.25  
(23.78)   
82.25  
(18.94)     
83.03   
(18.59)   
74.14   
(32.85)   
75.67 
(34.75) 
Moderately frequent  81.20  
 (23.65)  
81.90  
 (23.77)   
81.42  
 (24.42)   
84.28 
  (21.69)   
82.86 
(23.58) 
Moderately frequent 
then improving 
79.88   
(23.00)   
80.23  
(27.19)    
79.18   
(28.53)   
79.36   
(26.00)   
85.38 
(20.51) 
Infrequent 80.31   
(25.07)   
81.56 
 (24.15)   
81.38   
(27.30)   
85.69   
(23.05) 
82.70 
(24.77) 
All in LCGA 76.14   
(25.98)  
78.28   
(25.56)   
77.36  
 (27.29)   
80.25   
(24.77)   
80.63 
(24.49) 
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Table 7.10 Mean (SD) HAQ-DI scores per gout flare trajectory class 
 
 
 
 
 
 
 
 
 
 
 
 
 
 HAQ-DI 
Baseline 
HAQ-DI 
6 months 
HAQ-DI 
12 months 
HAQ-DI 
24 months 
HAQ-DI 
36 months 
Frequent & persistent 1.01  
(0.89)   
1.09 
(0.81)      
1.10   
(0.77)   
0.90  
 (0.85)   
1.22 
(0.95)   
Gradually worsening 0.60  
(0.73)  
0.64 
(0.76)   
0.61   
(0.70)   
0.66 
 (0.76)    
0.59 
(0.68) 
Frequent then 
improving 
0.56  
(0.86)   
0.45  
(0.65)    
0.51   
(0.74)     
0.51  
 (0.76)    
0.54 
(0.65) 
Moderately frequent  0.44   
(0 .66)    
0.42 
(0.66)     
0.41   
(0.65)   
0.35   
(0.60)    
0.38 
(0.61) 
Moderately frequent 
then improving 
0.42   
(0.65)  
0.44   
(0.66)   
0.41 
 (0.67)    
0.45 
  (0.69)   
0.41 
(0.60) 
Infrequent 0.39  
(0.64)    
0.33 
(0.60)   
0.29 
(0.55)   
0.31    
(0.56) 
0.35 
(0.60) 
All in LCGA 0.50  
 (0.71)   
0.49  
 (0.70)    
0.46  
 (0.68)   
0.45  
 (0.68)   
0.47 
(0.67) 
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7.4 Discussion 
This chapter describes longitudinal change in gout-specific and generic HRQOL over three 
years in people living with gout.    The variance, correlation, distribution and functional form 
of HRQOL scores over three years was described.  The baseline GIS subscales, SF-36 PF10 and 
HAQ-DI scores in this cohort have been published previously (Chandratre et al 2018), thus the 
focus in this chapter was longitudinal change. 
7.4.1 HRQOL group level change and comparison with previous studies 
The measures of central tendency revealed a reduction in the GIS CO, UTN and WBDA subscale 
scores over the three-year period, thus indicating improving HRQOL at a group level.   
However, the GIS MSE and CDA scores changed negligibly over the three-year period.  
The mean change (SD) in all GIS subscales between baseline to 36 months displayed better 
HRQOL at 36 months, however there was negligible change in the GIS CDA.  Only the SRM and 
effect size for the WBDA and the SRM for the GIS CO was above 0.20, consistent with a small 
effect size.   This is the first study to collect GIS subscales scores over a three-year period, 
hence comparison of the change in GIS subscales observed over three years with other 
published results was not possible.  Consequently, change in HRQOL between baseline and 12 
months was also analysed to allow comparison to existing literature.  In comparison to mean 
change observed between baseline to 36 months, less change in the GIS subscales was 
detected between baseline and 12 months.  Of all of the GIS subscales only the GIS WBDA had 
an SRM and effect size over 0.20 over 12 months, consistent with a small effect. 
Change in GIS subscales have been reported from baseline to one year in an US longitudinal 
cohort by Wallace et al (2016).  The change in GIS subscales scores, SRMs and effect sizes from 
this study also displayed a reduction in GIS subscale scores over time, indicating an 
improvement in HRQOL.  However, smaller mean changes, SRMs and effect sizes were 
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observed for the GIS subscales in this cohort compared with this previous prospective study.  
There were also differences in the subscales displaying the most and least change in this 
cohort compared to previous studies.  For example, in contrast with this cohort the GIS CO 
had the greatest mean change and the GIS MSE had the smallest mean change in the study by 
Wallace et al (2016).  Improvement in GIS CO, UTN, WBDA and CDA scores were observed 
from week four to week eight in an US medication RCT by Khanna et al (2011b) in groups of 
participants who were deemed to have ‘minimally improved’ gout based on anchor questions.  
Mean change and effect sizes reported by Khanna et al (2011b) were larger than the effect 
sizes (range) observed in this cohort.  Change in GIS CO and UTN scores over two years in 
participants living with gout was reported by Doherty et al (2018) in a treat to target RCT.  
Improvements in GIS CO and UTN scores were reported over the two years for both the ‘nurse 
led’ and ‘usual care’ groups, with a greater improvement in HRQOL observed in the nurse led 
group.   
The measures of central tendency revealed little change in SF-36 PF10 scores overtime and 
the SRM and effect sizes for the change in SF-36 PF10 scores from baseline to 36 months and 
baseline to 12 months were all below 0.20, thus indicating a negligible change (Cohen, 1992).  
The measures of central tendency also displayed negligible change for the HAQ-DI over time.  
However, the mean change between baseline and 36 months displayed a very small increase 
in HAQ-DI scores indicating worse activity limitation HRQOL, and the SRM for the change in 
HAQ-DI scores from baseline to 36 months was 0.21, thus indicating a small change. This is the 
first study in gout to collect SF-36 PF10 and HAQ-DI scores over a follow-up period of longer 
than two years.  In observational studies, effect sizes for the SF-36 PF10 were reported over 
12 months in people with gout in a Spanish single centre cohort (Khanna et al 2011a) and for 
the HAQ-DI over 6 months in people with gout in a Mexican multicentre cohort study (Alvarez-
Hernandez et al 2008).  The effect sizes reported by these studies were larger than the effect 
sizes (range) observed in this cohort. 
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The differences between the magnitude of change in GIS subscales, SF-36 PF10, and HAQ-DI 
in these different cohorts could be attributable to differences in the study designs and 
participants.   Wallace et al (2016) recruited participants from US secondary care and primary 
care, Khanna et al (2011b) recruited participants who had experienced two or more gout flares 
in the previous year in a US clinical trial assessing rilonacept vs placebo, whilst both Khanna et 
al (2011a) and Alvarez-Hernandez et al (2008) included participants from specialist 
rheumatology clinics.  The secondary care setting and inclusion criteria of these existing 
studies meant that people with more severe gout were recruited compared with this primary 
care cohort. 
7.4.2 Changes observed in disease-specific and generic HRQOL at a group level 
The mean changes observed in both disease-specific and generic HRQOL scores at a group 
level were either small or negligible. This finding is perhaps not surprising considering that this 
is a study of prevalent cases in primary care, rather than an inception cohort or intervention 
study.   
Since gout flares are the major factor associated with HRQOL (Chandratre et al 2013), the 
finding that only small or negligible changes were observed in GIS scores at a group level is in 
keeping with the findings of the previous chapter that the trajectory of gout flares for the 
majority of participants did not change over time (most participants were allocated to either 
the infrequent, moderately frequent or frequent and persistent classes).  
The small improvement observed at a group level for some HRQOL scores could also be due 
to change in participants’ perceptions of their circumstances due to adaption or adjustment 
over time (Bowling, 2009; Blome & Augustin, 2015; Fayers & Machin, 2016).  HRQOL scores 
may also change over time because the internal scale that participants use to rate themselves 
when responding to items has changed (Blome & Augustin, 2015; Fayers & Machin, 2016). 
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There was negligible change in the SF-36 PF10 scores over time.  This is perhaps surprising as 
lower SF-36 PF10 scores, worse HRQOL, have been associated with older age in the general 
population (Bowling et al 1999; Brazier et al 1992).   However, this is change at a group level 
and there was more variation in change displayed in the spaghetti plots of SF-36 PF10 scores.  
It is possible that three years was insufficient time to demonstrate change in physical function 
in an already older cohort of participants.  The findings are consistent with the lack of change 
demonstrated in the SF-36 physical component scores over two years in participants living 
with gout receiving ‘usual care’ in an RCT by Doherty et al (2018).    
Worse activity limitation HRQOL was highlighted by HAQ-DI mean change.  In this older cohort 
it is perhaps understandable that HAQ-DI scores would increase for those participants who 
reported their HAQ-DI scores at both time-points, as HAQ-DI scores have been shown to 
increase exponentially with age in the general population (Krishnan et al 2004).   Worsening 
disability in older age can be due to a range of factors including the increased burden of 
comorbidities over time (Manini, 2012).   
This chapter compared the mean HRQOL outcomes in the different latent trajectory classes 
identified in the previous chapter via LCGA.  This comparison revealed worse disease-specific 
and generic HRQOL in the ‘frequent and persistent’ and ‘gradually worsening’ classes, in 
comparison to classes with less frequent flares. This finding is consistent with the findings of 
previous studies which have reported worse HRQOL with more frequent flares (Becker et al 
2009; Chandratre et al 2018; Hirsch et al 2008; Khanna et al 2011a; Khanna et al 2012c; 
Proudman et al 2019; Scire et al 2013; Stewart et al 2018) and also adds validity to the distinct 
latent gout flare trajectory classes. 
Whilst this chapter has described the change in HRQOL scores over a three-year period, 
investigation of the various factors potentially associated with change in HRQOL will be 
addressed in chapter eight. 
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7.4.3 Individual level change in HRQOL scores 
The spaghetti plots displayed change at an individual level and revealed both a wide range of 
HRQOL scores at baseline and a range of different patterns of change in HRQOL scores over 
three years. The plotting of intra-individual pattern of change revealed that the GIS WBDA 
subscale displayed the greatest amount of participants with different scores, in contrast with 
the MSE subscale which displayed the least amount of different GIS subscale scores.  This 
difference may be, at least in part, attributable to the greater number of items in the GIS 
WBDA subscale compared to other GIS subscales; thus, permitting a greater number of 
different scores.  Conversely, the GIS MSE has only two items in its scale. 
The interpolation lines fitted to the spaghetti plots confirmed the group level pattern of 
change discussed earlier in this discussion.  The interpolation line fitted to the spaghetti plots 
in this chapter also indicated a linear form for each of the HRQOL scores over time, this finding 
provides justification for linear modelling of the HRQOL scores.   
7.4.4 Correlation and distribution of HRQOL scores  
Each of the HRQOL scores were analysed individually to investigate the degree of correlation 
and dependency between scores at different time-points.  The correlation of GIS subscales 
scores between different time-points was moderate to very high, whilst the SF-36 PF10 and 
HAQ-DI scores displayed high and very high correlations respectively.  This correlation, 
referred to as auto-correlation or serial correlation, is commonly observed where HRQOL 
scores are collected on the same participants over time (Fayers & Machin, 2016).  It was 
important to identify this serial correlation within the HRQOL scores in this cohort, as the serial 
correlation in outcome measures requires special consideration during statistical modelling 
(Cheng et al 2010; West, Welch & Galecki, 2015) and this investigation confirmed the need to 
model the HRQOL scores taking the serial correlation in to account in the next chapter.    
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The investigation of the distribution of the HRQOL scores in this chapter was important in 
order to inform how they are statistically modelled.  Failure to consider non-normally 
distributed data during modelling can lead to biased parameter estimates and invalid 
inferences (Dagne & Huang, 2012; Spriensma et al, 2018).   The skewed distribution of the SF-
36 PF10 and HAQ-DI scores was confirmed by histograms and Q-Q plots, skewed distributions 
in these outcomes have been reported previously in gout populations (Alvarez-Hernandez et 
al 2008; Taylor et al 2008).    The distribution of GIS subscale scores was closer to a normal 
 distribution compared to the SF-36 PF10 and HAQ-DI scores.  Some departure of the outcome 
from a normal distribution is  deemed acceptable in the linear mixed modelling used in the 
following chapter, as long as the residuals of the model are normally distributed (Cheng et al 
2010; West, Welch & Galecki, 2015), thus the distribution of the residuals of linear mixed 
models  used in the next chapter was investigated. 
7.4.5 Implications for longitudinal modelling  
The results of the exploratory analysis in this chapter influenced the modelling of the GIS 
subscales, SF-36 PF10 and HAQ-DI scores in the following chapter.   The use of linear mixed 
modelling to investigate factors associated with change in individual GIS subscale scores 
appeared to be justified based on the identification of a linear form to the GIS scores over 
time, the correlation between scores from the same GIS subscale, and the lack of skew in the 
distribution of GIS scores.  This investigation also provided justification for modelling each GIS 
subscale separately, as the analysis displays differences in the magnitude of individual and 
group level change, correlation, and distribution between different subscales.  This 
justification for modelling the GIS subscales separately is in addition to the fact that the 
subscales address different conceptual domains relating to the impact of gout. 
The linear form and correlation of SF-36 PF10, and HAQ-DI scores also justified the use of 
linear mixed models to model these outcomes.  However, the presence of a skewed 
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distribution in the SF-36 PF10, and HAQ-DI scores indicated the need to adjust the linear mixed 
models to take this skewed distribution into account (Cheong, Fotiu & Radenbush, 2001; Maas 
& Hox, 2004).     
7.4.6 Clinical importance of change in HRQOL 
The analysis undertaken in this chapter increases our understanding of how HRQOL, in people 
living with gout, changes over time.  Undertaking this investigation in a primary care cohort is 
of particular relevance to clinical practice as the majority of patients with gout are managed 
within primary care.   
A ‘minimal clinically important difference’ (MCID) has been defined by Jaeschke, Singer & 
Guyatt (1989) as the smallest difference in a score on a quality of life domain of interest which 
patients perceive as beneficial.      MCID in people living with gout have been described for the 
GIS subscales (Khanna et al 2011b), SF-36 PF10 (Khanna et al 2011a) and the HAQ-DI (Singh et 
al 2016). The MCID in GIS subscale scores ranged from 5 to 8 points (CO, 7.2; UTN, 6.9; WBDA, 
5.2; CDA, 7.6) (Khanna et al 2011b).  Thus, based on these cut offs only the WBDA GIS subscale 
changed by a MCID over three years.  However, it is important to appreciate that the MCID 
refers to change at an individual level.  Also, Khanna et al (2011b) cautioned against 
interpreting changes for GIS subscales below the MCID cut offs as not being clinically 
important, as there is uncertainty relating to the MCID cut offs and the cut offs were derived 
from RCT data.  The MCID cited by Khanna et al (2011a) in SF-36 PF10 scores in people with 
gout was 5.  The SF-36 PF10 scores in this cohort study displayed a mean change which was 
below the cut off indicating a MCID.     The MCID cited by Singh et al (2016) in HAQ-DI scores 
in people with gout was 0.22.  The HAQ-DI scores in this cohort study displayed a mean change 
which was below the cut off indicating a MCID change in activity limitation.  However, these 
cut offs for MCID in SF-36 PF10 and HAQ-DI scores in people with gout were originally derived 
in patients with rheumatoid arthritis and scleroderma (Khanna et al 2011a; Singh et al 2016).  
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In addition, Khanna et al (2011b) determined these MCIDs in a cohort of fewer than 100 
people with gout, the majority of whom were prescribed urate-lowering therapy.   
Whilst the magnitude of change in HRQOL scores identified in this cohort at a group level may 
be judged negligible or small, this chapter has shown a wide variation in change in HRQOL 
scores over time at an individual level.   Thus, the levels of change in HRQOL scores seen in 
this cohort should not be considered clinically irrelevant, simply because the magnitude of 
change at a group level is negligible or small, or because some HRQOL scores display change 
at a group level below the levels advocated as a clinically important difference. 
7.4.7 Strengths and limitations 
This chapter provides a unique insight into change in HRQOL scores in a large cohort of people 
living with gout in primary care over a three-year period.    This analysis of longitudinal HRQOL 
scores, as opposed to solely cross-sectional analysis, enables the dynamic nature of HRQOL to 
be captured (Fayers & Machin, 2016; Hahn et al 2007) and addresses the paucity of research 
investigating change in HRQOL in people living with gout in primary care.  The investigation of 
change in this chapter addressed change in both disease-specific and generic HRQOL 
measures, thus seeking to capture information relating to a range of HRQOL domains (Hickey 
et al 2005; Testa & Simonson, 1996).  A further strength is that change at both group and 
individual levels was investigated, using a range of different descriptive analyses.  Use of 
different descriptive analysis techniques, including graphing individual and group level 
change, has been advocated in order to appreciate the extent of change which can potentially 
occur in longitudinal data (Leffondre et al 2004; Long, 2012).   
It is important to acknowledge that there are limitations in the preliminary exploratory 
analyses of the longitudinal HRQOL outcomes undertaken. 
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Some of the analysis methods do not associate participants with their repeated measures.  
The calculation of measures of central tendency and the creation of box plots, are treating 
scores at each time-point as being independent.    The mean change was calculated by 
including only participants with scores at two time-points (Locasico & Atri, 2011).  Thus, it is 
important to interpret mean changes with this in mind, as participants who responded at both 
time-points are likely to be different to the whole cohort overall.   
A strength of the analysis undertaken is that SRM and effect sizes were calculated. The 
calculation of SRM and effect size was justified as they provide information about the 
magnitude of change in each HRQOL, whilst taking variability in to account and can act as a 
‘scale free’ measure of change thus facilitating comparison of change in scores (Cohen, 1992; 
Fayers & Machin, 2016; Seidel, Miller & Chow, 2014).   The SRM is a specific effect size for use 
with repeated measures and is widely used for analysis of health outcome questionnaires 
(Fayers & Machin, 2016; Middel & Van Sonderen, 2002; Morris, 2000; Morris & DeShon, 2002; 
Wolff Smith & Beretvas, 2009).  A challenge when comparing research findings to published 
effects sizes is that the calculation of effect sizes can be undertaken using a range of different 
methods, which have the potential to yield different interpretations of change (Middel & Van 
Sonderen, 2002; Morris & Deshon, 2002; Seidel, Miller & Chow, 2014).   When interpreting 
SRM and effect sizes it is also important to acknowledge that the cut offs proposed by Cohen 
to interpret effect sizes were derived subjectively and originally intended for use with 
independent measures (Seidel, Miller & Chow, 2014).   
Despite some acknowledged limitations of the analysis in this chapter, it was important to 
undertake this preliminary analysis, in order to begin to understand the behaviour of HRQOL 
scores over time.  Investigation of the change, functional form, variance, correlation and 
distribution of the HRQOL scores was important before moving on to analyse the HRQOL 
scores using more advanced statistical modelling in the following chapter.   
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7.5 Conclusion 
In conclusion, this chapter describes the change in gout-specific HRQOL (GIS subscales) and 
generic HRQOL (SF-36 PF10, HAQ-DI) scores over a three-year period in a prospective cohort 
study of people living with gout in primary care.  Change in HRQOL scores at a group and 
individual level was described. At a group level, the magnitude of change in HRQOL scores was 
small and for some HRQOL scores negligible, however a wide variation in change in HRQOL 
scores at an individual level was identified.  The variation, correlation, and distribution of each 
HRQOL score over the three-year period was also described.   The findings of this chapter have 
been used to inform the analysis described in the next chapter, where factors associated with 
change in HRQOL scores will be identified within this cohort using linear mixed models.   
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8 Chapter Eight Factors associated with change in HRQOL 
8.1  Overview of chapter and aim 
In the previous chapter, change in gout-specific (GIS subscales) and generic HRQOL (SF-36 
PF10, HAQ-DI) scores over a three-year period was described.  The aim of the following 
chapter is to describe the gout-specific, comorbid, socio-demographic and other factors 
associated with change in disease-specific and generic HRQOL over a three-year period in 
people living with gout in primary care.  
8.2 Background 
8.2.1 Factors associated with HRQOL in existing studies 
A range of factors have been reported to be associated with disease-specific and/or generic 
HRQOL in people with gout in previous studies, as described in more detail in section 1.9.4 
and summarised in appendix 2.  Gout-specific factors associated with HRQOL in previous 
studies include frequency of flares, experiencing a current or recent flare, the number of joints 
affected by gout, disease duration, tophi, serum urate, and allopurinol, although studies 
investigating the relationship between HRQOL and tophi, serum urate levels, and medication 
to treat gout, have revealed conflicting findings.   Other factors associated with HRQOL in 
people living with gout include the number or type of comorbidities, anxiety, depression, pain, 
age, sex, level of deprivation, educational attainment, marital status, BMI and alcohol 
consumption.  Gout flares are the major factor associated with impaired disease-specific and 
generic HRQOL in people living with gout (Becker et al 2009; Chandratre et al 2018; Hirsch et 
al 2008; Khanna et al 2011a; Khanna et al 2012c; Proudman et al 2019; Scire et al 2013; Stewart 
et al 2018).  The majority of studies are cross-sectional, with a paucity of prospective studies 
investigating the factors associated with HRQOL particularly in primary care.  The previous 
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studies which have investigated factors associated with change in HRQOL in people with gout 
have done so over periods no longer than 12 months. 
8.3 Method and analysis plan 
8.3.1 Aim and Objective   
Aim 
To describe the factors associated with change in gout-specific and generic HRQOL in people 
living with gout in primary care over a three-year period. 
Objective 
1. Use linear mixed modelling to describe the variables associated with change in GIS 
subscales (CO, MSE, UTN, WBDA, CDA), SF-36 PF10, and HAQ-DI scores over a three-year 
period. 
8.3.2 Data source 
The data sources for the analysis presented in this thesis chapter are from the responder and 
medical record review databases of the prospective cohort study described in chapter three.  
8.3.3 Missing data 
The investigation of the proportion of missing data in the GIS subscales, SF-36 PF10 and HAQ-
DI and also covariates was undertaken in chapter four.  LMMs tolerate a degree of missing 
data, as they allow participants to have an unequal number of measurements and the 
measurements to have been collected at unevenly spaced time-points (Cnaan, Laird & Slasor, 
1997; Long, 2012; West, Welsh & Galecki, 2015). Thus, participants were included within the 
LMM analysis if they had an outcome response on a minimum of one time-point (Long, 2012).   
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8.3.4 Selection of potential covariates 
Covariates were selected based on whether they have been associated with HRQOL in people 
with gout in previous studies (including this cohort’s baseline analysis paper) and were 
introduced in chapter one.  This consideration of existing research when selecting predictors 
in linear mixed modelling has been advocated as good practice (Cheng et al 2010).   Table 8.1 
lists the range of variables which were included as covariates.  These covariates included gout-
specific, comorbid, socio-demographic and other factors.   
Continuous variables were added to the LMM as covariates in their continuous form, aiming 
to maximise the predictive information provided by that variable (Royston et al 2009). 
For non-time varying covariates, an interaction between each covariate and time was added 
to the model.  This addition of an interaction between time and covariates was used to test 
whether the impact of any of the covariates on the outcomes changed over time (Berrington, 
Smith & Sturgis, 2006).   
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Table 8.1 Selection of covariates in linear mixed models for GIS subscales, SF-36 PF10 and 
HAQ-DI 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Time-
varying 
covariate? 
Variable format Interpretation of 
reference group  
 
 
Gout-specific    
Number of gout flares  Categorical No gout flares 
Current flare  Dichotomous No current flare 
Oligo/polyarticular flares  Dichotomous No history of 
oligo/polyarticular 
flares 
Disease duration  Continuous - 
Allopurinol use (self- 
reported) 
 Dichotomous No allopurinol use 
Comorbidities    
Number of self-reported 
comorbidities 
 Continuous - 
eGFR <60 mL/min/1.73m2   Dichotomous eGFR ≥ 60 
0-10 NRS pain over previous 
week 
 Continuous - 
Presence of body pain  Dichotomous No body pain 
PHQ-9 score  Continuous - 
GAQ-7 score  Continuous - 
Socio-demographic    
Age   Continuous - 
Sex  Dichotomous Male 
Ethnicity  Dichotomous Caucasian 
    
Indices of multiple 
deprivation (IMD) decile 
 Continuous - 
Married or cohabiting  Dichotomous Not married or 
cohabiting 
Attendance at further 
education 
 Dichotomous No attendance at 
further education 
BMI and alcohol    
BMI  Continuous - 
Alcohol consumption  Categorical Alcohol consumption- 
Never 
Time-varying covariate in questionnaire at baseline, 6, 12, 24 and 36 months   
 Number of gout flares in previous 12 months at baseline, 12 months and 36 months, and in 
previous 6 months at 6 and 12 months    From medical records in the two years prior to baseline 
Total number of self-reported comorbidities are number of comorbidities, from pre-specified list, 
self-reported in baseline questionnaire  
eGFR <60 mL/min/1.73m2 indicative of chronic kidney disease stage ≥ 3 
NRS pain in last week ranges from 0 (no pain) to 10 (pain as bad as it can be) 
Body pain (including ache or discomfort or stiffness) for one day or longer in the 4 weeks prior to 
baseline 
PHQ-9 score ranges from 0 to 27 higher score indicates more severe depression  
GAD-7 score ranges from 0 to 21 higher score indicates more severe anxiety  
BMI body mass index kg/m2  
IMD Indices of multiple deprivation highest score indicates least deprived area 
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8.3.5 Linear Mixed Modelling 
A linear mixed model (LMM) is a linear statistical model which can be applied to parametric 
clustered, repeated measures, and longitudinal data (West, Welch & Galecki, 2015). Such 
models are extensions of traditional regression models (Long, 2012) and aim to quantify the 
relationship between a continuous outcome variable and covariates (West, Welch & Galecki, 
2015).  The models are referred to as ‘mixed’ as they include a mixture of both fixed and 
random effects (Locascio & Atri, 2011; West, Welch & Galecki, 2015).  The LMMs used in this 
chapter can also be referred to as multi-level or hierarchical models as the outcome measures 
are clustered within participants (Twisk, 2006).  Mixed models specifically take this hierarchy 
and dependency of observations into account when analysing longitudinal data (Twisk, 2006).    
Alternative names for linear mixed models used in the literature include multilevel models, 
random effects models, hierarchical models, mixed effects models (Kirkwood & Sterne, 2003; 
Twisk, 2006), linear mixed effects regression (Long, 2012), linear mixed effects models (Muth 
et al 2016), and multivariate/multivariable mixed effects regression (Singh et al 2016; Wallace 
et al 2016).  
The decision to analyse the GIS subscales, SF-36 PF10 and HAQ-DI scores using LMM was 
informed by the analysis in previous chapters.  LMM was used in this analysis because it allows 
missing data (Cheng et al 2010; Long, 2012; West, Welch & Galecki, 2015), auto-correlation/ 
serial correlation (Cheng et al 2010; West, Welch & Galecki, 2015), different covariance 
structures (Cheng et al 2010; Muth et al 2016), the inclusion of time-varying covariates (Long, 
2012; West, Welch  & Galecki, 2015), and data which are collected at irregularly spaced 
intervals (Cheng et al 2010; Locascio & Atri, 2011; Long, 2012).   
Fixed effects 
The fixed effects components in LMMs are called regression coefficients (represented by the 
symbol β) and are similar to regression coefficients in traditional regression (Cheng et al 2010; 
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West, Welch & Galecki, 2015). These fixed effects regression coefficients provide estimates of 
the average response in the outcome variable for the whole group, and consequently are 
population specific estimates (Cheng et al 2010; Long, 2012; West, Welch & Galecki, 2015). 
Thus, the fixed effects component of a LMM describes the relationship of a covariate to the 
whole population (West, Welch & Galecki, 2015).  As fixed effects describe the mean response 
for the whole population, they are often the primary interest of clinical and epidemiological 
research (Cheng et al 2010). 
Random effects 
In a LMM with random effects, conceptually each participant will have their own intercept and 
slope describing the relationship of interest, however in practice the regression coefficients 
for the intercept and the slope for each participant are not individually estimated; because 
this would be inefficient, as it would generate a large number of parameters (Ghisletta et al 
2015; Twisk, 2006).  Instead, in a LMM with random effects (a random intercept and slope), 
the variance of intercepts, the variance of the slopes and the covariance of these parameters 
are estimated (Ghisletta et al 2015; Twisk, 2006).   
Residual random error   
Random error in the model represents the error in the measurement of the outcome at an 
individual level (Long, 2012; West, Welch & Galecki, 2015).    Thus, the error variance 
estimated for all subjects reflects the within-subject error variance (Long, 2012). 
Stages of linear mixed modelling used in this chapter 
The stages of linear mixed modelling undertaken in this chapter can be found in Figure 8.1. 
The GIS CO, GIS MSE, GIS UTN, GIS WBDA, GIS CDA, SF-36 PF10 and HAQ-DI were each 
analysed in separate linear mixed models. 
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The linear mixed modelling was undertaken using STATA version 14.  Table 8.2 describes the 
range of criteria which were considered during the linear mixed modelling process, due to the 
absence of one widely accepted model fit criterion (Gurka, 2006; Wang & Schaalje, 2009).   
Estimation method and robust standard errors 
Residual maximum likelihood estimation (REML) is a method which is often used when 
estimating parameters in LMM, due to its ability to produce unbiased estimates of the 
covariance parameters (Gurka, 2006; West, Welsh & Galecki, 2015).     Thus, REML was used 
when modelling GIS outcomes.  However, the analysis in chapter six revealed that the SF-36 
PF10 and HAQ-DI scores displayed a left and right skew respectively.  If data are not normally 
distributed, estimates and tests will not be robust to the violation of distribution assumptions 
(Cheong, Fotiu & Radenbush, 2001).    Thus, the LMMs for the SF-36 PF10 and HAQ-DI scores 
were amended to use robust standard errors, in order to deal with the non-normal 
distribution of these outcomes (Cheong, Fotiu & Radenbush, 2001; Maas & Hox, 2004) and 
maximum likelihood estimation (MLE), rather than REML, was used to enable robust standard 
errors to be used. Whilst REML and MLE have different strengths and weaknesses as 
estimation methods, they are likely to yield similar results in large samples (Rabe-Hesketh & 
Skrondal, 2008; Twisk, 2006). 
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Figure 8.1 Stages of linear mixed modelling undertaken in this chapter 
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Table 8.2 Justification for criteria used in linear mixed modelling and guidance for 
interpretation of results 
Criteria  Justification and guidance  
Intraclass 
correlation 
coefficient 
(ICC) 
A significant ICC suggested that there were differences in the dependent variable 
between individuals (Garson, 2013), providing justification for a random intercept, 
whereas an ICC closer to zero suggested a lack of difference between individuals 
(Garson, 2013).   
Likelihood 
Ratio Test 
(LRT) 
A statistically significant LRT result (p < 0.05) indicated an improvement in model fit 
with the inclusion of a random slope compared to a nested model with just a 
random intercept (West, Welch & Galecki, 2015).   However, caution should be 
taken when interpreting LRT in linear mixed modelling as LRT results can be 
conservative with a tendency of P values to be large, thus leading to the selection 
of a model with less random effects (Long, 2012; West, Welch & Galecki, 2015).    
Fixed effects 
regression 
coefficients  
The fixed effects regression coefficients (95% CI) were reviewed to note any change 
when i) comparing models with and without random slopes, and ii) when comparing 
models with different covariance structures.    
Variance of 
intercept, 
slope and 
covariance 
The variance of the intercept, variance of slope and covariance of intercept with 
slope (along with 95 % CI) were reviewed to note any change (Twisk, 2006) when i) 
comparing models with and without random slopes, and ii) when comparing models 
with different covariance structures.  
Variance of 
residuals 
The variance of the residuals of each model were reviewed to see how changing the 
model changed the magnitude of the variance of the residuals (Twisk, 2006).  
Information 
criteria i.e. 
AIC 
Information criteria, Akaike Information Criteria (AIC) (Akaike, 1987), was used to 
select the covariance structure used in the models (Garson, 2013; Wang & Schaalje, 
2009).  Thus, the AIC results for models with different covariance structures for 
random effects and residuals were compared; with a smaller AIC result indicating a 
better fitting model (Garson, 2013; Gurka, 2006).   
AIC (Akaike, 1987) was also used to identify covariate interactions which could be 
removed from the model via backward deletion. The AIC for models with and 
without particular interactions were compared, with a smaller result indicating a 
better fitting model (Garson, 2013; Gurka, 2006).   
Wald χ 2 test Wald χ 2 test can be used when the full model has been fitted to identify fixed effects 
which could be removed from the linear mixed model (West, Welch & Galecki, 
2015). Thus, the Wald test, along with AIC, was used to select interactions which 
could be removed from the model. A statistically significant result (p < 0.05) 
indicated that a fixed effect (interaction) could be retained in the model (West, 
Welch & Galecki, 2015). As REML was used in the LMM the Wald χ 2 test was used 
as an alternative to LRT (StataCorp, 2013). 
Standardised 
residuals  
Standardised residuals were assessed to check the assumptions of the final LMMs 
(Cheng et al 2010; West, Welch & Galecki, 2015).  Histograms and Q-Q plots of 
standardised residuals were created and scrutinised to investigate whether the 
residuals were normally distributed (Cheng et al 2010).    A scatterplot of residuals 
verses fitted outcome values were created and scrutinised to investigate whether 
the residuals had constant variance.  
Best linear 
unbiased 
predictors 
(BLUPs) 
BLUPs, the predicted values of the random effects given the observed data, were 
plotted in histograms and Q-Q plots to investigate normality of the random effects 
(West, Welch & Galecki, 2015).    
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8.4 Results 
8.4.1 Specifying the linear mixed models 
Random intercept linear mixed models 
The LMM with random intercepts for each GIS subscale (Table 8.3), the SF-36 PF10 and HAQ-
DI (Table 8.5) demonstrated variance at an intercept level across all participants.   The ICC 
results ranged from 0.48 to 0.75 for the GIS subscales (Table 8.3) and were 0.73 for the SF-36 
PF10 and 0.86 for the HAQ-DI (Table 8.5), suggesting there were differences in the HRQOL 
scores between individuals. These findings justified the retention of a random intercept in the 
LMMs. 
Random intercept and slope linear mixed models 
The LRTs comparing the LMM models with both a random intercept and random slope, to a 
model with only a random intercept were statistically significant for each of the GIS subscales 
(GIS CO, MSE, WBDA p <0.001; GIS UTN p 0.03; GIS CDA p 0.003) (Table 8.3),  the HAQ-DI (p 
<0.001) but not the SF-36 PF10 (Table 8.5).  The statistically significant LRT results for the GIS 
subscales and the HAQ-DI indicated an improvement in model fit with the inclusion of more 
random effects (i.e. random slope in addition to random intercept) compared to a nested 
model with less random effects (i.e. random intercept only model). The LMM with both a 
random intercept and random slope for each GIS subscale demonstrated variance at both an 
intercept and slope level (Table 8.3).  The addition of a random slope reduced the residual 
error in each GIS subscale LMM (Table 8.3) in comparison with the residual error in the GIS 
LMM with a random intercept only (Table 8.3).   Although the variance at a slope level for the 
HAQ-DI LMM was small, the confidence interval did not cross zero (Table 8.5). The HAQ-DI 
model with both a random intercept and random slope also returned a slightly lower AIC, than 
the random intercept only model, indicating a better fitting model (Table 8.5).   
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Table 8.3 Comparison of results from GIS subscales LMMs with random intercept only, and random intercept with random slope independent 
covariance 
 GIS CO 
n=1167 
GIS MSE 
n=1156 
GIS UTN 
n=1143 
GIS WBDA 
n=1166 
GIS CDA 
n=1161 
Random intercept independent covariance 
Intercept 
β (95% CI) 
49.13 
(47.61, 50.65) 
40.68 
(39.26, 42.10) 
33.47 
(32.41, 34.53) 
44.39 
42.95, 45.83 
40.31 
(39.00, 41.63) 
Slope  
β (95% CI) 
-0.17 
( -0.21, -0.12) 
-0.07 
(-0.12, -0.03) 
-0.07 
(-0.12, -0.03) 
-0.16 
(-0.20, -0.13) 
-0.03 
(-0.07, 0.01) 
Variance intercept 
(95% CI) 
544.31 
(494.42, 599.24) 
446.83 
(404.26, 493.89) 
194.52 
(172.82, 218.94) 
518.16 
(472.29, 568.49) 
406.42 
(368.97, 447.67) 
Variance residuals 
(95% CI) 
241.11 
(228.70, 254.19) 
251.11 
(238.11, 264.81) 
212.62 
(201.49, 224.35) 
169.09 
(160.33, 178.33) 
181.72 
(172.34, 191.60) 
Intraclass correlation coefficient 
(ICC) (95% CI) 
0.69 
(0.67, 0.72) 
0.64 
(0.61, 0.67) 
0.48 
(0.44, 0.51) 
0.75 
(0.73, 0.77) 
0.69 
(0.67, 0.72) 
Akaike Information Criteria (AIC) 34957.76 34445.34 32647.10 33592.94 33727.52 
Random intercept and slope independent covariance 
Intercept  
β(95% CI) 
49.13 
(47.62, 50.63) 
40.67 
(39.27, 42.08) 
33.47 
(32.42, 34.52) 
44.39 
(42.96, 45.82) 
40.32 
(39.01,41.63) 
Slope  
β(95% CI) 
-0.17 
(-0.21, -0.12) 
-0.07 
(-0.12, -0.03) 
-0.07 
(-0.12, -0.03) 
-0.16 
(-0.20, -0.12) 
-0.03 
(-0.07, 0.01) 
Variance intercept 
(95% CI) 
545.78 
(495.29, 601.42) 
444.71 
(401.67, 492.36) 
194.31 
(172.35, 219.07) 
518.62 
(472.39, 569.34) 
405.14 
(367.51, 446.61) 
Variance slope 
(95% CI) 
0.10 
(0.06, 0.15) 
0.11 
(0.07, 0.16) 
0.03 
(0.01, 0.08) 
0.07 
(0.04, 0.105) 
0.04 
(0.02, 0.08) 
Variance residuals 
(95% CI) 
221.17 
(208.05, 235.10) 
230.09 
(216.39, 244.65) 
206.06 
(193.87, 219.01) 
155.81 
(146.46, 165.76) 
173.65 
(163.42, 184.52) 
Likelihood ratio test (LRT) p <0.001 p<0.001 p 0.03 p<0.001 p0.003 
Akaike Information Criteria (AIC) 34936.01 34421.93 32645.97 33576.04 33725.87 
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Table 8.4 GIS subscales LMMs with random intercept and random slope unstructured covariance results 
 GIS CO 
n=1167 
GIS MSE 
n=1156 
GIS UTN 
n=1143 
GIS WBDA 
n=1166 
GIS CDA 
n=1161 
Random intercept and slope unstructured covariance 
Intercept  
β (95% CI) 
49.13 
(47.59, 50.67) 
40.68 
(39.24, 42.12) 
33.54 
(32.44, 34.64) 
44.39 
42.94, 45.85 
40.33 
(39.00, 41.66) 
Slope 
β (95% CI) 
-0.17 
(-0.21, -0.12) 
-0.07 
(-0.12, -0.03) 
-0.08 
(-0.12, -0.04) 
-0.16 
(-0.20, -0.12) 
-0.03 
(-0.07, 0.01) 
Variance intercept 
(95% CI) 
581.03 
(524.64, 643.48 
474.01 
(425.09, 528.56) 
233.52  
(204.72, 266.38) 
538.43 
(488.41, 593.58) 
421.05 
(379.16, 467.56) 
Variance Slope 
(95% CI) 
0.13 
(0.09, 0.19) 
0.14 
(0.10, 0.20) 
0.09 
(0.06, 0.15) 
0.08 
(0.05, 0.12) 
0.06 
(0.03, 0.10) 
Covariance Slope, 
Intercept (95%CI) 
-2.14 
(-3.48, -0.79) 
-1.73 
(-3.03, -0.44) 
-2.08 
(-3.03, -1.12) 
-1.19 
(-2.23, -0.15) 
-0.85 
(-1.81, 0.11) 
Variance residuals 
(95% CI) 
216.09 
(203.20, 229.79) 
224.75 
(211.13, 239.25) 
195.26 
(183.36, 207.94) 
153.47 
(144.19, 163.35) 
171.18 
(160.89, 182.14) 
Akaike Information 
Criteria (AIC) 
34927.48 34416.44 32626.44 33572.74 33724.72 
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Table 8.5 Comparison of results for both SF-36 PF10 and HAQ-DI LMMs with random intercept 
only and random intercept with random slope 
 
 
 
 
 SF-36 PF10 
n=1097 
HAQ-DI 
n=1168 
HAQ-DI 
n=1168 
Random intercept independent covariance  
Intercept 
β (95% CI) 
74.73 
(73.22, 76.24) 
0.51 
(0.47, 0.55) 
- 
Slope 
β (95% CI) 
0.01 
( -0.03, 0.05) 
0.00 
(0.00, 0.00) 
- 
Variance intercept 
(95% CI) 
516.21 
(471.37, 565.32) 
0.45 
(0 .40, 0.50) 
- 
Variance residuals 
(95% CI) 
192.73 
(159.04, 233.55) 
0.07 
(0.06, 0.09) 
- 
Intraclass correlation 
coefficient (ICC) (95% CI) 
(calculated in model without 
robust standard errors) 
 0.73 
(0.70, 0.752) 
0.86 
(0.85, 0.87) 
- 
AIC  28481.42 4324.949 - 
Random intercept & 
random slope   
independent covariance 
 
unstructured 
covariance 
Intercept 
β (95% CI) 
74.73 
(73.22, 76.24) 
0.51 
(0 .47, 0.55) 
0.51 
(0.47, 0.55) 
Slope 
β (95% CI) 
0.01 
( -0.03, 0.05) 
0.00 
(0 .00, 0.00) 
0.00 
(0 .00, 0.00) 
Variance intercept 
(95% CI) 
516.21 
(471.37, 565.31) 
0.45 
(0 .40, 0.50) 
0.45 
(0.40, 0.50) 
Variance slope 
(95% CI) 
0.00 
(0.00, 1.63) 
0.00 
(0.00, 0.00) 
0.00 
(0.00, 0.00) 
Covariance slope, intercept 
(95%CI) 
- - 
0.00 
( -0.00, 0.00) 
Variance residuals 
(95% CI) 
192.73 
(159.04, 233.55) 
0.07 
(0.06, 0.08) 
0.07 
(0.06, 0.08) 
Likelihood ratio test (LRT) P=1.00 P<0.001 - 
AIC  28483.42 4312.898 4314.24 
Unstructured covariance was not explored for the SF-36 PF10 as the best fitting model for the SF-36 PF10 
was the intercept only model. 
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The residual error for the HAQ-DI LLM model was the same after the addition of a random 
slope, however the confidence interval did narrow slightly (Table 8.5).  There was no change 
in the residual error in the SF-36 PF10 LMM with the addition of a random slope (Table 8.5). 
There was little difference in the AIC for the SF-36 PF10 models with and without a random 
slope but the AIC for the random intercept only model was 1.68 lower indicating a better 
fitting model (Table 8.5). These findings justified the retention of a random slope, in addition 
to a random intercept, in the LMMs for the GIS subscales and the HAQ-DI but justified the use 
of a random intercept only LMM for SF-36 PF10 scores. 
Covariance structure 
The AIC results for each of the GIS LMMs with an unstructured covariance were lower (Table 
8.4) indicating a better fitting model, than the AIC results for the GIS LMMs with independent 
covariance structures (Table 8.3).    The variance of the residuals for all GIS LMMs reduced by 
small amounts, after the addition of the unstructured covariance (Table 8.4).  The findings 
justified the retention of an unstructured covariance for the random effects. A negative 
covariance was identified for GIS CO, GIS MSE, GIS UTN, and GIS WBDA LMMs (Table 8.4) 
indicating that the higher a person’s intercept the smaller the rate of change (Twisk, 2006).   
The addition of an unstructured covariance did not change the residual error in the HAQ-DI 
LMM.  The confidence intervals for the covariance estimated in the HAQ-DI LMM with an 
unstructured covariance also crossed zero.   The AIC for the HAQ-DI LMM with an independent 
covariance structure was slightly lower than the AIC for the HAQ-DI LMM with an unstructured 
covariance.  These results suggested that an unstructured covariance may not be necessary, 
however the HAQ-DI LMM model with an independent covariance plus the addition of 
covariates and all interactions failed to run/ converge (repeatedly displaying the warning ‘back 
up’). Therefore, the unstructured covariance was used to reduce the model and the 
covariance structure was then reassessed after reducing the model.   
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For both the GIS subscale and HAQ-DI models the other covariance structures (exchangeable, 
identity) trialled for the random effects (slope and intercept covariance) returned higher AIC 
results and greater residual variance.  Also covariance structures for the residuals trialled were 
not retained in the model as either the AIC or variance of the residual did not improve 
(autoregressive covariance) or the model did not run (exchangeable, unstructured, identity, 
Toeplitz).  
Reducing the model 
The interactions for the following time-invariant covariates and time were retained in the GIS 
LMM models due to a Wald test result of <p 0.05; sex x time (GIS CO model), alcohol x time 
(GIS UTN), non-Caucasian x time (GIS CDA), GAD-7 score x time (GIS CDA) and indices of 
multiple deprivation x time (both SF-36 PF10 and HAQ-DI models).   
Checking the covariance structure of the full model 
After reducing the models, the unstructured covariance was retained for the GIS subscale and 
HAQ-DI LMMs, as this covariance yielded lower residual error variance in comparison to an 
independent covariance structure.  Also, a lower AIC was observed for the GIS CO, GIS UTN 
and GIS WBDA when an unstructured covariance structure was used compared to an 
independent structure and there was little difference in the AIC observed for the GIS MSE and 
GIS CDA models with an independent or unstructured covariance structure.  There was also 
little difference in the AIC observed for the HAQ-DI LMM with an independent covariance 
structure (just 0.8 lower), compared to the unstructured covariance. 
Other covariance structures trialled either returned a greater AIC or variance of the residuals 
or the LMM did not run. 
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8.4.2 Factors associated with change in disease-specific HRQOL 
GIS Concern overall 
The following gout-specific factors were associated with a deterioration in HRQOL over three 
years, measured using the GIS Concern overall (GIS CO) subscale: frequency of gout flares (this 
was dose-dependent with stronger associations observed with more flares), experiencing a 
current flare, and a history of oligo/polyarticular flares (Table 8.6).  Longer disease duration at 
baseline was associated with an improvement in HRQOL. No association was observed 
between allopurinol use and change in HRQOL. 
Greater pain, the presence of body pain, and worse anxiety were associated with a 
deterioration in HRQOL, measured via the GIS CO, over three years (Table 8.6).   However, no 
associations with the number of comorbidities, eGFR <60, or depression severity, and change 
in HRQOL were observed.  
As shown in Table 8.6 older age was associated with an improvement in HRQOL, measured via 
GIS CO, over three years.  There was an association between the interaction between sex with 
time and HRQOL indicating that the relationship between sex and HRQOL changed over time.  
Change in GIS CO over three years was not associated with being non-Caucasian, BMI, IMD, 
married or cohabiting, attendance at further education, and alcohol consumption.  
When adjusted for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency, time was associated with an improvement in HRQOL measured via GIS CO (see 
Table 8.6). 
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Table 8.6 Factors associated with change in disease-specific HRQOL; results from GIS subscale LMMs with random intercept and random slopes 
with unstructured covariance 
 GIS CO 
n=595 
(β (95% CI)) 
GIS MSE 
n=595 
(β (95% CI)) 
GIS UTN 
n=591 
(β (95% CI)) 
GIS WBDA 
n=593 
(β (95% CI)) 
GIS CDA 
n=595 
(β (95% CI)) 
Intercept  68.14(53.82, 82.47) 43.23(27.84, 58.64) 32.13(21.48, 42.78) 65.27(50.45, 80.09) 38.81(25.35, 52.28) 
Time -0.14(-0.20, -0.08) -0.06(-0.12, 0.00) 0.10(-0.10, 0.30) -0.17(-0.23, -0.12) 0.03(-0.03, 0.09) 
Gout-specific      
0 gout flares reference reference Reference reference reference 
1 gout flare 6.29(4.04, 8.54) 3.36(0.98, 5.74) 4.42(2.33, 6.52) -1.69(-3.71, 0.33) 2.60(0.56, 4.64) 
2 gout flares 11.69(8.94, 14.43) 4.94(2.01, 7.86) 7.94(5.43, 10.46) -1.36(-3.84, 1.11) 4.81(2.32, 7.31) 
3 gout flares 12.09(8.67, 15.50) 7.26(3.68, 10.84) 8.52(5.39, 11.66) 0.59(-2.50, 3.68) 3.27(0.17, 6.37) 
4 gout flares 16.30(12.01, 20.59) 7.85(3.36, 12.34) 11.80(7.87, 15.72) 1.46(-2.39, 5.30) 4.67(0.78, 8.55) 
≥5 gout flares 19.31 (15.65, 22.97) 10.14(6.29, 14.00) 12.17(8.88, 15.45) 1.28(-2.07, 4.64) 7.87(4.54, 11.20) 
Current flare 4.24(1.12, 7.35) -0.34(-3.64, 2.95) 7.01(4.08, 9.94) -3.30(-6.06, -0.54) -0.45(-3.27, 2.36) 
Oligo/polyarticular 
flares 
4.88(2.77, 6.99)  2.86(0.62, 5.09) -0.22(-2.06, 1.61) 3.46(1.52, 5.41) 3.34(1.42, 5.26) 
Allopurinol use -0.84(-3.52, 1.85) 1.34(-1.52, 4.20) -7.13( -9.28, -4.99) 2.63(0.03, 5.24) 2.35(-0.13, 4.83) 
Disease duration -0.27(-0.41, -0.13) -0.17(-0.32, -0.01) -0.12(-0.22, -0.02) -0.11( -0.26, 0.04) -0.16( -0.29, -0.02) 
Comorbidities      
Total number of 
Comorbidities 
-0.08(-1.33, 1.17) -0.11(-1.45, 1.24) 0.59(-0.30, 1.47) -0.09(-1.41, 1.23) 0.45(-0.73, 1.63) 
eGFR <60mL/min/1.73m2   1.34(-2.62,5.31) 0.52(-3.77, 4.80) -2.02(-4.77, 0.73) 1.47(-2.74, 5.70) 2.16(-1.59, 5.90) 
Pain NRS score 1.24(0.82, 1.66) 0.43( -0.02, 0.87) 0.64(0.26, 1.01) 1.61(1.22, 1.99) 0.54(0.16, 0.92) 
Body pain 5.23(1.74, 8.73) 7.69(3.91, 11.47) 1.92(-0.50, 4.35) 2.59(-1.11, 6.29) 1.97(-1.33, 5.27) 
PHQ-9 score 0.50(-0.02,1.01) 0.61(0.06, 1.17) 0.32(-0.04, 0.68) 1.10(0.55, 1.64) 0.82(0.34, 1.31) 
GAD-7 score 0.61(0.03, 1.19) 0.72(0.10, 1.35) -0.04(-0.44, 0.36) 0.40(-0.21, 1.01) 1.22(0.66, 1.77) 
GAD-7 X Time  - - - - -0.01(-0.03, -0.00) 
β linear mixed model coefficient     in previous 12 months at baseline, 12 months and 36 months,  in previous 6 months at 6 and 12 months  Time-varying covariate in questionnaire at 
baseline, 6, 12, 24 and 36 months.  Number of comorbidities total number of self-reported comorbidities in questionnaire;  eGFR <60 mL/min/1.73m2 indicative of chronic kidney disease;   
NRS pain in last week ranges from 0 (no pain) to 10 (pain as bad as it can be); Body pain (including ache or discomfort or stiffness) for one day or longer in the 4 weeks prior to baseline;  
PHQ-9 depression score ranges from 0 (minimal) to 27 (severe); GAD-7 anxiety score ranges from 0 (minimal) to 21 (severe).  
Each GIS subscale scored from 0 to 100; higher scores on each scale indicating a greater impact of gout on HRQOL/worse HRQOL, positive β coefficient = deterioration, and negative β 
coefficient = improvement. 
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Table 8.6 cont. Factors associated with change in disease-specific HRQOL; results from GIS subscale LMMs with random intercept and 
random slopes with unstructured covariance 
 GIS CO 
 n=595 
(β (95% CI)) 
GIS MSE 
 n=595 
(β (95% CI)) 
GIS UTN 
n=591 
(β (95% CI)) 
GIS WBDA 
n=593 
(β (95% CI)) 
GIS CDA 
 n=595 
(β (95% CI)) 
Socio-demographic      
Age -0.53(-0.69, -0.37) -0.27(-0.45, -0.10) -0.03(-0.15, 0.08) -0.44(-0.61, -0.27) -0.26(-0.41, -0.10) 
Female 0.73(-4.66, 6.13) -1.03(-6.46, 4.40) 2.54(-1.00, 6.07) 1.10(-4.24, 6.44) 2.03(-2.72, 6.77) 
Female x Time 0.19(0.00, 0.37) - - - - 
Non-Caucasian 1.39(-10.37, 13.16) 4.37(-8.23, 16.97) 5.02(-3.31, 13.35) 1.00(-11.35, 13.36) 1.09(-10.58, 12.75) 
Non-Caucasian X Time - - - - 0.75(0.27, 1.22) 
IMD 0.25(-0.31, 0.81) 0.37(-0.23, 0.98) 0.28(-0.11, 0.67) 0.36(-0.24, 0.95) 0.19 -0.34, 0.72) 
Married or cohabiting 2.47(-1.41,6.35)   0.01(-4.20, 4.18) 1.04(-1.67, 3.75) -0.11(-4.22, 4.01) -1.52(-5.18, 2.14) 
Further education -1.15(-4.80, 2.51) -1.56(-5.53, 2.40) -2.58(-5.10, -0.06) -3.87(-7.76, 0.03) -3.42(-6.88, 0.04) 
BMI & alcohol      
BMI -0.03(-0.25, 0.20) -0.02(-0.26, 0.21) -0.12(-0.30, 0.06) 0.03(-0.18, 0.24) 0.20(-0.01, 0.40) 
Alcohol - Never reference reference Reference reference reference 
Special occasions -5.18( -12.45, 2.08) -3.85(-11.43, 3.74) 2.67(-3.18, 8.52) -6.89(-14.30, 0.52) -5.27(-11.89, 1.35) 
1-3 times/month -5.18( -12.43, 2.08) 1.32(-6.52, 9.17) 2.33(-3.66, 8.32) -7.32(-15.02, 0.39) -6.10(-12.95, 0.75) 
1-2 times/week -1.03( -7.64, 5.58) 0.57( -6.57, 7.71) -0.28(-5.40, 5.15) -2.30(-9.29, 4.69) -2.33( -8.56, 3.91) 
3-4 times/week -1.25(-7.82, 5.32) 1.96( -5.15, 9.07) -2.10(-7.48, 3.27) -5.97(-12.91, 0.98) -3.31(-9.51, 2.89) 
Daily or almost daily -4.73(-11.13, 1.66) -3.30(-10.22, 3.62) -0.02(-5.48, 5.04) -7.53(-14.30, -0.75) -4.8(-10.92, 1.16) 
Alcohol - Never reference reference Reference reference reference 
Special occasions x Time - - -0.15(-0.41, 0.11) - - 
1-3 times/month x Time - - -0.20(-0.45, 0.06) - - 
1-2 times/week x Time - - -0.10(-0.33, 0.14) - - 
3-4 times/week x Time - - -0.13(-0.35, 0.09) - - 
Daily x Time - - -0.23(-0.46, -0.01) - - 
β linear mixed model coefficient       Time-varying covariate in questionnaire at baseline, 6, 12, 24 and 36 months.  
BMI body mass index kg/m2; IMD Indices of multiple deprivation, highest score indicates least deprived.  
Each GIS subscale scored from 0 to 100; higher scores on each scale indicating a greater impact of gout on HRQOL/ worse HRQOL, positive β coefficient = deterioration, and negative β 
coefficient = improvement. 
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GIS Medication side effects 
Over three years a deterioration in HRQOL, measured via GIS Medication side effects (GIS 
MSE) subscale, was associated with the frequency of gout flares (this was dose-dependent 
with stronger associations observed with more flares), and a history of oligo/polyarticular 
flares (Table 8.6).  However, no association was observed between change in HRQOL and 
experiencing a current flare, or using allopurinol. Longer disease duration at baseline was 
associated with an improvement in HRQOL.   
The presence of body pain, worse depression, and worse anxiety were associated with a 
deterioration in HRQOL, measured via the GIS MSE (Table 8.6).  Change in GIS MSE over three 
years was not associated with the number of comorbidities, eGFR <60, or greater pain. 
Older age was associated with an improvement in HRQOL over three years (Table 8.6).  No 
association between change in HRQOL and sex, being non-Caucasian, BMI, IMD, married or 
cohabiting, attendance at further education, and alcohol consumption was observed. 
After adjustment for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency, time was not associated with an improvement in HRQOL measured by GIS MSE 
(Table 8.6). 
GIS Unmet treatment need 
A deterioration in HRQOL, measured via the GIS Unmet treatment need (GIS UTN) subscale, 
over three years in this cohort was associated with the frequency of gout flares (this was dose-
dependent with stronger associations observed with more flares), and also experiencing a 
current flare (Table 8.6).  Longer disease duration at baseline, and allopurinol use were 
associated with an improvement in HRQOL.  No association was observed between a history 
of oligo/polyarticular flares and change in HRQOL. 
No association in change in HRQOL, measured via GIS UTN, and the number of comorbidities,  
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eGFR <60, the presence of body pain, depression severity or anxiety severity were observed 
(Table 8.6).  However, greater pain was associated with a deterioration in GIS UTN in this 
cohort.   
No association with change in HRQOL, measured via GIS UTN, was seen between either age, 
sex, being non-Caucasian, BMI, IMD, or married or cohabiting (Table 8.6).  However, 
attendance at further education was associated with an improvement in HRQOL in this cohort. 
There was also an association between the interaction between the alcohol category ‘daily or 
almost daily’ with time and HRQOL.   This association indicated that the relationship of alcohol 
consumption and HRQOL, measured via UTN, changed over time. However, no association 
between time and the other alcohol consumption categories were observed.  
Time was not associated with an improvement in HRQOL measured by GIS UTN after 
adjustment for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency (Table 8.6). 
GIS Wellbeing during an attack 
A history of oligo/polyarticular flares, and allopurinol use were associated with a deterioration 
in HRQOL, measured using the GIS Wellbeing during an attack (GIS WBDA) subscale, over three 
years in this cohort (Table 8.6).  An improvement in GIS WBDA was associated with 
experiencing a current flare.  The frequency of gout flares or disease duration were not 
associated with change in GIS WBDA.  
Greater pain and worse depression were associated with a deterioration in HRQOL (Table 8.6).  
No associations between change in HRQOL, measured via GIS WBDA, and the number of 
comorbidities, eGFR <60, the presence of body pain, or anxiety severity were observed. 
An improvement in HRQOL, measured via GIS WBDA, was associated with older age in this 
cohort (Table 8.6).  Reporting daily or almost daily alcohol consumption, was also associated 
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with an improvement in HRQOL, however no associations were observed with the other 
alcohol categories.  No associations with change in HRQOL and sex, being non-Caucasian, BMI, 
IMD, married or cohabiting, or further education were observed.  
When adjusted for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency time was associated with an improvement in HRQOL measured by GIS WBDA (Table 
8.6). 
GIS Concern during an attack 
Over three years the frequency of gout flares, and a history of oligo/polyarticular flares were 
associated with a deterioration in HRQOL, measured via the GIS Concern during an attack (GIS 
CDA) subscale (Table 8.6).  Longer disease duration was associated with an improvement in 
HRQOL.  Change in GIS CDA was not associated with either experiencing a current flare or 
using allopurinol in this cohort.  
A deterioration in HRQOL over three years, measured via GIS CDA, was associated with greater 
pain, worse depression, and worse anxiety (Table 8.6).  There was also an association with the 
interaction between GAD-7 score at baseline with time and HRQOL. This association indicated 
that the relationship between anxiety and HRQOL may change over time. No associations 
between change in HRQOL and the number of comorbidities, eGFR <60, or the presence of 
body pain were observed. 
Older age was associated with an improvement in HRQOL, measured via GIS CDA, over three 
years (Table 8.6).  The interaction between being non-Caucasian and time was associated with 
a deterioration in HRQOL.  This association indicated that the relationship between being non-
Caucasian and HRQOL may change over time.  Sex, BMI, IMD, being married or cohabiting, 
further education or alcohol consumption were not associated with change in HRQOL 
measured via GIS CDA. 
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After adjustment for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency, time was not associated with an improvement in HRQOL measured by GIS CDA 
(Table 8.6). 
8.4.3 Factors associated with change in generic HRQOL 
SF-36 PF10 
The following gout-specific factors were associated with a deterioration over three years in 
generic HRQOL, measured via the SF-36 PF10: experiencing two flares, four flares, or five or 
more flares, and allopurinol use (Table 8.7).  No associations were observed between change 
in HRQOL and experiencing a current flare, a history of oligo/polyarticular flares, or disease 
duration (Table 8.7).  
A higher total number of comorbidities, eGFR <60, greater pain, the presence of body pain, 
and worse depression were associated with a deterioration in HRQOL, measured via SF-36 
PF10, over three years (Table 8.7). No association between anxiety and change in SF-36 PF10 
was observed in this cohort.  
Older age and being female were associated with a deterioration in HRQOL, measured via SF-
36 PF10, over three years (Table 8.7).  Living in a less socioeconomically deprived area (IMD) 
and consuming alcohol (daily or almost daily, 3-4 times/week, 1-2 times/week and special 
occasions) were associated with an improvement in generic HRQOL (Table 8.7).  There was an 
association between the interaction between IMD and HRQOL (Table 8.7).  This association 
indicated that the relationship between IMD and HRQOL changed over time.  No associations 
between change in HRQOL and being non-Caucasian, BMI, married or cohabiting, or 
attendance at further education were observed.  
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When adjusted for gout-specific, comorbid, socio-demographic factors, BMI and alcohol 
frequency time was not associated with an improvement in generic HRQOL measured by the 
SF-36 PF10 (see Table 8.7).  
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Table 8.7 Factors associated with generic HRQOL; results from SF-36 PF10 LMM with random 
intercept, and results from HAQ-DI LMM with random intercept and random slope with 
unstructured covariance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 SF-36 PF10 
n=554 
 (β (95% CI)) 
HAQ-DI 
n= 594 
(β (95% CI)) 
Intercept  123.97(112.16, 135.77) -0.89(-1.25, -0.53) 
Time 0.10(-0.00, 0.20) -0.00(-0.00, 0.00) 
Gout-specific   
0 gout flares reference reference 
1 gout flare -0.33(-2.19, 1.53) -0.00(-0.04, 0.03) 
2 gout flares -2.44(-4.58, -0.30)  0.02(-0.03, 0.07) 
3 gout flares -0.14( -2.45, 2.18) 0.03(-0.05, 0.11) 
4 gout flares -3.76( -6.83,  -0.69) 0.02(-0.07, 0.11) 
≥5 gout flares -6.07(-9.49, -2.65) 0.02(-0.06, 0.10) 
Current flare 1.40(-1.30, 4.10) 0.01(-0.06, 0.07) 
Oligo/polyarticular flares -1.46(-2.99, 0.08) 0.04(0.01, 0.08) 
Allopurinol use -2.34(-4.33, -0.35) 0.04(-0.01, 0.09) 
Disease duration 0.07(-0.03, 0.17) -0.00(-0.01, 0.00) 
Comorbidities   
Number of Comorbidities -1.15(-2.11, -0.19) 0.03(-0.01, 0.06) 
eGFR <60mL/min/1.73m2   -3.39(-6.34, -0.46) 0.10(0.01, 0.19) 
Pain NRS score -1.44(-1.89, -1.00) 0.05(0.04, 0.06) 
Body pain -3.17(-5.73, -0.61) 0.09(0.02, 0.17) 
PHQ-9 score -1.56(-2.00, -1.11) 0.05(0.03, 0.06) 
GAD-7 score -0.10(-0.57, 0.37) 0.01(-0.01, 0.02) 
Socio-demographic   
Age -0.57(-0.69, -0.45) 0.02(0.01, 0.02) 
Female -8.74(-12.74, -4.74) 0.17(0.03, 0.30) 
Non-Caucasian -5.45(-14.99, 4.09)   0.02(-0.33, 0.38) 
IMD 0.72(0.23, 1.22) -0.02(-0.03, -0.00) 
IMD x Time -0.02(-0.04, -0.00) 0.00(0.00, 0.00) 
Married or cohabiting 0.46(-2.42,3.34) 0.00(-0.90, 0.10) 
Further education 1.41(-1.10, 3.92) -0.05(-0.12, 0.03) 
BMI & alcohol   
BMI -0.09(-0.31, 0.12) 0.01(0.00, 0.01) 
Alcohol consumption- Never reference reference 
Special occasions 6.14(0.09, 12.18) -0.14(-0.34, 0.07) 
1-3 times/month 5.37(-0.61, 11.34) -0.25( -0.44, -0.05) 
1-2 times/week 6.68(1.30, 12.05) -0.29( -0.47, -0.11) 
3-4 times/week 8.45(3.05, 13.84) -0.31(-0.49, -0.13) 
Daily or almost daily 8.54(3.15, 13.93) -0.30(-0.49, -0.12) 
β linear mixed model coefficient     in previous 12 months at baseline, 12 months and 36 
months,  in  previous 6 months at 6 and 12 months   Time-varying covariate in questionnaire 
at baseline, 6, 12, 24 and 36 months  
Number of comorbidities total number of self-reported comorbidities in questionnaire; eGFR 
<60 mL/min/1.73m2 indicative of chronic kidney disease;   NRS pain in last week ranges from 
0 (no pain) to 10 (pain as bad as it can be); Body pain (including ache or discomfort or stiffness) 
for one day or longer in the 4 weeks prior to baseline;  PHQ-9 depression score ranges from 0 
(minimal) to 27 (severe); GAD-7 anxiety score ranges from 0 (minimal) to 21 (severe); BMI 
body mass index kg/m2; IMD Indices of multiple deprivation highest score indicates least 
deprived.  
SF-36 PF10 scored from 0 to 100; higher score indicating performs all types of physical activities 
including the most vigorous without limitations due to health, positive β coefficient = 
improvement, and negative β coefficient = deterioration. 
HAQ-DI scored from 0 to 3; higher score indicating greater activity limitation, positive β 
coefficient = deterioration, and negative β coefficient = improvement. 
244 
 
HAQ-DI 
A history of oligo/polyarticular gout flares was associated with worse activity limitation, 
measured via the HAQ-DI, over three years (Table 8.7).  The following gout-specific factors 
were not associated with change in activity limitation:  gout flare frequency, experiencing a 
current flare, allopurinol use, or a longer disease duration (Table 8.7).   
Worse activity limitation, measured using the HAQ-DI, was associated with eGFR <60, greater 
pain, the presence of body pain, and worse depression (Table 8.7).   No association between 
the number of comorbidities or anxiety, and change in activity limitation were observed (Table 
8.7).  
As shown in Table 8.7 older age, female sex, and a higher BMI were associated with worse 
activity limitation, measured via HAQ-DI, over three years.  However, an improvement in 
activity limitation was associated with living in a less socioeconomically deprived area (based 
on IMD) and alcohol consumption (1-3/month, 1-2/week, 3-4/week and daily or almost daily) 
(Table 8.7).  No associations between change in activity limitation and the following socio-
demographic factors were observed:  being non-Caucasian, married or cohabiting, and 
attendance at further education. 
Time was not associated with a change in activity limitation measured by the HAQ-DI when 
adjusted for gout-specific, comorbid, socio-demographic factors, BMI and alcohol frequency 
(see Table 8.7).   
8.4.4 Checking the assumptions of linear mixed models 
Analysis of residuals and BLUPs  
Figure 8.2 to Figure 8.15 display the Q-Q plots, histograms, scatter plots of GIS subscales, SF-
36 PF10 and HAQ-DI LMM residuals and BLUPs.  The Q-Q plots and histograms of the 
standardised residuals for each of the HRQOL do not display an obvious left or right skew. In  
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the scatterplots of the residuals for each HRQOL model plotted against fitted values the 
variance of the residuals is not increasing or displaying a ‘fanning out’ pattern, which would 
have suggested heteroskedasticity i.e. a lack of uniformity in the variance (Bland, 2015).  The 
Q-Q plots and histograms of the BLUPs for each of the HRQOL outcome do not display an 
obvious left or right skew. 
As the raw SF-36 PF10 and HAQ-DI scores demonstrated a left and right skew respectively, a 
sensitivity analysis was undertaken to transform the raw SF-36 PF10 and HAQ-DI scores.    Log, 
cubic, squared, and square root transformations were undertaken for the SF-36 PF10 and 
HAQ-DI scores, however these transformations did not improve the distribution plots of the 
LMM residuals or BLUPs.
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Results from the analysis of GIS CO LMM residuals and BLUPs 
Residuals 
     
Figure 8.2 Q-Q plot, histogram and scatter plot of GIS CO residuals 
Random Slope BLUPs            Random Intercept BLUPs 
       
Figure 8.3 Q-Q plots and histograms of GIS CO BLUPs 
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Results from the analysis of GIS MSE LMM residuals and BLUPs 
Residuals 
  
Figure 8.4 Q-Q plot, histogram, and scatter plot of GIS MSE residuals 
Random slope BLUPs          Random intercept BLUPs 
 
Figure 8.5 Q-Q plots and histograms of GIS MSE BLUPs 
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Results from the analysis of GIS UTN LMM residuals and BLUPs 
Residuals 
     
Figure 8.6 Q-Q plot, histogram, and scatter plot of GIS UTN residuals 
Random Slope BLUPs         Random intercept BLUPs 
       
Figure 8.7 Q-Q plots and histograms of GIS UTN BLUPs 
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Results from the analysis of GIS WBDA LMM residuals and BLUPs 
Residuals 
     
Figure 8.8 Q-Q plot, histogram, and scatter plot of GIS WBDA residuals 
Random Slope BLUPs       Random intercept BLUPs 
       
Figure 8.9 Q-Q plots and histograms of GIS WBDA BLUPs 
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Results from the analysis of GIS CDA LMM residuals and BLUPs 
Residuals 
     
Figure 8.10 Q-Q plot, histogram, and scatter plot of GIS CDA residuals 
Random slope BLUPs         Random intercept BLUPs 
 
Figure 8.11 Q-Q plots and histograms of GIS CDA BLUPs 
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Results from the analysis of SF-36 PF10 LMM residuals and BLUPs 
Residuals 
     
Figure 8.12 Q-Q plot, histogram, and scatter plot of SF-36 PF10 residuals 
Random intercept BLUPs  
 
Figure 8.13 Q-Q plots and histograms of SF-36 PF10 BLUPs 
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Results from the analysis of HAQ-DI LMM residuals and BLUPs 
Residuals 
     
Figure 8.14 Q-Q plot, histogram, and scatter plot of HAQ-DI residuals 
Random slope BLUPs       Random intercept BLUPs 
 
Figure 8.15 Q-Q plots and histograms of HAQ-DI BLUPs 
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8.5 Discussion 
This chapter described the gout-specific, comorbid, socio-demographic and other factors 
associated with change in disease-specific HRQOL (measured via GIS subscales) and generic 
HRQOL (measured by SF-36 PF10 and HAQ-DI) over three years, in people living with gout in 
primary care. 
8.5.1 Gout-specific factors associated with change in HRQOL  
Gout flares were associated with a deterioration in disease-specific HRQOL over three years, 
with a dose-response relationship observed; the magnitude of deterioration in GIS CO, GIS 
MSE, and GIS UTN increased with the number of gout flares reported.  This association 
between gout flare frequency and GIS subscale scores is consistent with the findings of 
previous cross-sectional studies (Chandratre et al 2018; Hirsch et al 2008) but was not 
investigated in previous prospective cohort studies.  However, an association between change 
in total GIS score (the mean of all five GIS scales) over one year and physician rated gout 
severity score was identified by Wallace et al (2016) in a prospective US Veteran’s medical 
centres cohort. 
Gout flares were also associated with a deterioration in generic HRQOL, measured via the SF-
36 PF10, which is in keeping with the association between the number of gout flares 
experienced and worse baseline SF-36 PF10 scores reported in cross-sectional studies 
previously (Becker et al 2009; Chandratre et al 2018).  The lack of association between gout 
flares and activity limitation, measured via the HAQ-DI was also reported by Becker et al 
(2009).    
Experiencing gout flares in more than one joint was associated with a deterioration in HRQOL 
in all of the GIS subscales (except GIS UTN) and in activity limitation (HAQ-DI).  Previous cross- 
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sectional analyses have reported associations between worse disease-specific HRQOL, 
measured by the GIS subscales, and the number of joints involved in a gout flare (Hirsch et al 
2010; Wallace et al 2016).  Wallace et al (2016) found that baseline HAQ-DI scores were highly 
correlated with the number of joints affected by gout, and both Becker et al (2009) and 
Alvarez-Hernadez et al (2008) reported associations between baseline HAQ-DI scores and the 
number of tender, swollen, or painful joints.  
Experiencing a current gout flare was associated with an improvement over three years in 
HRQOL measured by GIS WBDA.   It might be expected that experiencing a current flare would 
be associated with worse HRQOL, rather than an improvement in HRQOL.  A potential 
explanation for this finding relates to the time frame, ‘during your last attack’, used for 
questions in the GIS WBDA subscale.  Some participants may be experiencing a current flare 
when completing the questionnaire but perhaps providing responses relating to their 
wellbeing during a previous flare.  In contrast, experiencing a current flare was associated with 
a deterioration in the GIS CO and GIS UTN over the three years, indicating greater gout concern 
and unmet treatment need, which is consistent with the findings in previous cross-sectional 
studies (Chandratre et al 2018; Khanna et al 2015).  
Allopurinol use was found to be associated with an improvement in HRQOL, measured by GIS 
UTN, indicating less unmet treatment need.  Better HRQOL, measured by both GIS CO and 
UTN, over two years has also been reported in participants with greater ULT adherence in an 
RCT by Doherty et al (2018).  The findings of this quantitative analysis are congruent with the 
experiences of people living with gout described in qualitative studies, as the perceived 
benefits of using allopurinol on HRQOL have been described in focus groups including 
participants from this cohort study (Chandratre et al 2016).  Allopurinol was included as a 
time-varying covariate in the analysis in this chapter and was associated with a deterioration 
in HRQOL (GIS WBDA, SF-36 PF10) and activity limitation (HAQ-DI).  However, a lack of 
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association with both generic HRQOL or disability, and allopurinol use has been reported by 
several cross-sectional analyses (Alvarez-Negegyei et al 2005; Chandratre et al 2018; Roddy, 
Zhang & Doherty, 2007c; Scire et al 2013).  The association between allopurinol use and worse 
HRQOL observed in this cohort may be because participants with worse physical function, 
more severe comorbidities or gout symptoms impacting on wellbeing, were more likely to 
either be prescribed or take allopurinol. Consequently, this may indicate confounding by 
severity or indication (Szklo & Javier, 2014).  Participants in both focus groups and phone 
interviews have cited frequent flares, or the fear of recurrent flares or unpredictable flares, 
as reasons for starting allopurinol (Chandratre et al 2016; Harrold et al 2010). These comments 
from qualitative studies fit with the notion that people with worse gout may be more likely to 
take allopurinol.  In addition, as allopurinol can induce flares through a reduction in urate 
levels, due to initiation of allopurinol or an increase in allopurinol dose (Seth et al 2014), it is 
perhaps understandable that participants who reported to taking allopurinol would 
experience a deterioration in feelings of wellbeing during an attack  over time. 
Longer disease duration at baseline was associated with an improvement in disease-specific 
HRQOL in all GIS subscales with the exception of WBDA GIS subscale.   This could in part be 
attributable to the process of adaption.  Adapting to an illness over time and learning to cope 
are acknowledged aspects of living with a chronic illness which can influence how a person 
reflects on their HRQOL (Fayers & Machin, 2016).  The lack of association between disease 
duration and GIS WBDA, SF-36 PF10 or HAQ-DI suggests that living with gout for a longer 
period of time does not improve participants’ wellbeing during a flare or their generic HRQOL 
over time. 
8.5.2 Comorbidities associated with change in HRQOL  
A higher number of self-reported comorbidities at baseline was associated with a                      
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deterioration in generic HRQOL, measured via SF-36 PF10.      This result is consistent with the 
cross-sectional findings of Becker et al (2009) who reported worse SF-36 PF10 scores in 
participants with one or more comorbidities, compared to no comorbidities, and Scire et al 
(2013) who reported an association between the number of self-reported comorbidities and 
worse SF-36 PCS scores. However, no association between disease-specific HRQOL, measured 
via GIS, was identified.  Wallace et al (2016) reported a lack of association between the 
Charlson comorbidity index and change in total GIS over one year.   
Poorer generic HRQOL compared to controls has been reported in a general cohort of 
individuals with chronic kidney disease (CKD) at all stages of CKD (Pagels et al 2012), this is 
consistent with having an eGFR less than 60 mL/min/1.73m2 being associated with a 
deterioration in generic HRQOL and a worse activity limitation in people with gout in this 
cohort.  Worse generic HRQOL and activity limitation was also associated with self-reported 
renal failure in this cohort at baseline (Chandratre et al 2018) and a correlation between the 
PCS of the SF-36 and renal failure was reported in a cross-sectional analysis in people with 
gout by Lee et al (2009).    
Both the severity and presence of pain were associated with a deterioration in disease-specific 
and generic HRQOL over three years in this cohort.    Worse pain VAS scores have been shown 
to associate with the GIS subscale and SF-36 PF10 scores cross-sectionally (Becker et al 2009; 
Hirsch et al 2010) and both severity and presence of pain with activity limitation in prospective 
studies (Alvarez-Hernadez et al 2008; Stewart et al 2018). The association between worse 
HRQOL and pain is in keeping with qualitative studies as pain intensity has been highlighted in 
semi-structured interviews as something which people with gout find particularly worrying 
(Liddle et al 2015).   
A greater depression severity score (PHQ-9) at baseline was associated with a deterioration in  
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disease-specific HRQOL (GIS MSE, WBDA and CDA), generic HRQOL (SF-36 PF10) and activity 
limitation (HAQ-DI).  Cross-sectional associations between depression and worse GIS, SF-36 
PF10 and HAQ-DI scores have been reported previously (Chandratre et al 2018).   In a review 
of systematic reviews, Sivertsen et al (2015) also described associations between severity of 
depression and poorer generic HRQOL in older persons (without gout) in both cross-sectional 
and longitudinal studies. It has been postulated that this may partly be due to poorer coping 
strategies in individuals with depressive disorders (Sivertsen et al 2015), whilst other authors 
have highlighted that depression is associated with an increased risk of non-adherence to 
treatment in people living with chronic diseases (Grenard et al 2011).    
A more severe generalised anxiety score (GAD-7) at baseline was associated with a 
deterioration in disease-specific HRQOL but not generic HRQOL in this cohort.  This finding is 
understandable as the association with anxiety scores was with subscales which relate to 
‘concern’ (GIS CO or GIS CDA) or have items which explicitly refer to ‘worry’ (GIS MSE).  
Conversely no association between GAD-7 and either SF-36 PF10 or HAQ-DI scores over three 
years was identified in this cohort. Alvarez-Hernadez et al (2009) also reported no correlation 
between anxiety and HAQ-DI scores in their cohort study.  However, an association between 
anxiety and lower SF-36 PF10 scores have been reported in this cohort at baseline (Chandratre 
et al 2018) and also in a general primary care cohort in the US (Brenes, 2007).  However, these 
were cross-sectional analyses of the relationship between anxiety and generic HRQOL, 
whereas this analysis investigated change over time.  
8.5.3 Socio-demographic factors associated with change in HRQOL 
Older age at baseline was associated with an improvement in disease-specific HRQOL in all of 
the GIS subscales, except UTN, which is in keeping with Wallace et al (2016) who described an 
improvement in total GIS scores over one year for older participants.  The association between  
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age and better disease-specific HRQOL could be attributable to several factors.  Older 
participants are less likely to be working therefore may have responded more favourably to 
items relating to the impact of gout on work.  Also, as social interaction can often decline as 
adults age (Cudjoe et al 2020), the impact of gout on social activities may be perceived as less 
important for older members of the cohort.  Older participants may have also responded with 
a different internal rating scale, due to differing levels of stoicism, in comparison to younger 
participants (Moore et al 2013; Sivertsen et al 2015).  
Conversely, older age at baseline was associated with both a deterioration in generic HRQOL 
and worse activity limitation. Several cross-sectional studies have reported an association 
between age and worse HRQOL in the physical domain (Chandratre et al 2018; Lee et al 2009; 
Roddy, Zhang & Doherty, 2007c).  Deterioration in generic HRQOL in this older cohort could 
have perhaps been expected considering that the likelihood of experiencing complex health 
conditions, or being disabled, increases with age (Office for National Statistics, 2018).  A 
decline in HRQOL with increasing age has been identified in another longitudinal analysis of 
an older primary care cohort (Eisele et al 2015).   
Being female was associated with both a deterioration in generic HRQOL and worse activity 
limitation.  Although these findings are consistent with the association identified at baseline 
between being female and both worse SF-36 PF10 and HAQ-DI scores (Chandratre et al 2018), 
other authors have reported no association between sex and either activity limitation 
(Alvarez-Hernadez et al 2008) or HRQOL in the physical domain (Roddy, Zhang & Doherty, 
2007c).  However, the association observed in this prospective cohort study is in keeping with, 
a review of longitudinal (non-gout) population data for the SF-36 which showed that females 
experience greater declines in HRQOL in comparison to men (Obidoa, Reisine & Cherniack, 
2010).  
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Living in a less socioeconomically deprived area, indicated by IMD score, was associated with 
an improvement in generic HRQOL and less activity limitation. These findings are consistent 
with the association identified at baseline between worse deprivation and both worse SF-36 
PF10 and HAQ-DI scores (Chandratre et al 2018) and the association between measures of 
deprivation and change in physical health identified in longitudinal cohorts of older people 
(without gout) (Myck, Najsztub & Oczkowska, 2019).    Attendance at further education was 
associated with an improvement in disease-specific HRQOL GIS UTN.  This improvement in 
HRQOL on the unmet treatment domain may be attributable to a range of factors.  Individuals 
with higher levels of educational attainment may have developed better problems solving 
skills and be more able to adapt to the challenges of a change in health status (Edgerton, 
Roberts & von Below, 2012).  Also, higher educational attainment has been associated with 
greater concordance to medication (Mathes, Jaschinski & Pieper, 2014).  
8.5.4 Strengths and limitations 
For the first time the factors associated with change in disease-specific and generic HRQOL in 
people living with gout in primary care over three years have been described.   
Previous research, clinical knowledge, and findings from earlier chapters in this thesis were 
used to select the covariates included in the global model. This use of background knowledge 
to generate covariates for inclusion in the model has been advocated as good practice (Cheng 
et al 2010; Harrison et al 2018; Heinze, Wallsich & Dunkler, 2018; Long, 2012). It is important 
to acknowledge that not all covariates included in this analysis were time-varying covariates.  
Thus, interactions between time-invariant covariates and time were included in the LMMs 
initially to test whether the effect of these covariates on change in HRQOL altered with time 
(Berrington, Smith & Sturgis, 2006; Long, 2012).  The use of backward selection has been 
advocated in preference to forward deletion in the selection of covariates in a model (Cheng  
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et al 2010; Heinze, Wallsich & Dunkler, 2018), thus this method was used to identify 
interactions in the LMMs which could be removed.  Several interactions were retained in the 
model for this exploratory analysis, as they suggested that the effects of these covariates on 
specific HRQOL outcomes changed over time.   Previous authors investigating the factors 
associated with change in HRQOL in people with gout have reduced models further to remove 
covariates which did not yield a statistically significant association with GIS scores (Wallace et 
al 2016).  However, covariates should not be removed from a model if theory suggests they 
may be relevant to the outcome, or they may be a potential confounder in the relationship 
between another covariate and the outcome (Cheng et al 2010; Heinze, Wallsich & Dunkler, 
2018).  Consequently, further backward deletion to remove covariates was not undertaken. 
The potential for unmeasured confounding in this model should be acknowledged, however 
the optimal method to account for unmeasured confounding specifically in longitudinal data 
and time-varying covariates has yet to be determined (Streeter et al 2017).  The inclusion of a 
range of covariates relevant to disease-specific and generic HRQOL in the LMMs aimed to 
reduce the potential for unmeasured confounding in these models.   However, tophi and 
serum urate were not included as covariates in the LMMs due to the low prevalence of tophi 
(2.1%) and the high proportion of missing serum urate levels (missing 61.1%).  The presence 
of tophi has been associated with worse HRQOL measured via HAQ-DI and SF-36 in cross-
sectional analyses in people living with gout (Alvarez-Negegyei et al 2005).  Minimal 
correlations have been reported between the presence of tophi and GIS CO and GIS UTN and 
between serum urate and GIS CO in a cross-sectional study by Hirsch et al (2010).  However, 
no correlation between serum urate level and the GIS subscales was reported in a prospective 
study by Wallace et al (2016).   
To improve the accuracy of the results of this analysis, the statistical methods deployed  
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specifically dealt with the serial correlation, variance, and covariance in the longitudinal 
HRQOL outcomes (Long, 2012; West, Welsh & Galecki, 2015).  As the variance component and 
standard errors of multilevel models can be biased when the outcome is skewed (Maas & Hox, 
2004), the SF-36 PF10 and HAQ-DI were modelled in this chapter using robust standard errors.  
In simulation studies involving data with a skewed distribution, this use of robust standard 
errors with multilevel models has been shown to lead to less bias in standard errors compared 
with when standard multilevel models are used (Zhu & Gongalez, 2017).  The analysis of the 
residuals for each of the LMMs in this chapter, to investigate the assumptions of normality 
and constant variance, revealed acceptable results.  
As discussed in chapter four the outcomes and covariates included in the analyses in this 
chapter included a degree of missing data.  Missing data in outcome measures are permitted 
in LMM (Cnaan, Laird & Slasor, 1997; Long, 2012; West, Welsh & Galecki, 2015).  Imputation 
of missing data prior to linear mixed modelling has been deemed unnecessary and has been 
shown to not improve the precision of estimates (Peters et al 2012; Twisk et al 2013).   
As described in the cohort study’s protocol paper (Chandratre et al 2012) the a priori sample 
size for this analysis was 882.  This was based on detecting a smallest meaningful difference 
in HRQOL of 0.2 standard deviation units detected between two groups (less than 2 gout flares 
per year and two or more gout flares per year) at a significance of 0.05, power of 90% and 
autocorrelation of 0.8. This sample size calculation was based on an expected response rate 
of 70% at baseline and drop out over the three-year follow up of 30%.  However, as described 
in chapter four the response rate at baseline was below this expected level and the proportion 
of participants dropping out over three-years was higher than the 30% anticipated.  The 
samples sizes used in this thesis are discussed in the following discussion chapter. 
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8.5.5 Implications for clinical practice 
Measurement of HRQOL has the potential to facilitate decision making concerning clinical 
management, service development and health policy (Green, Brazier & Deverill, 2000; Hahn 
et al 2007; Hennessy et al 1994; Fayers & Machin, 2016) through an understanding of the 
wider impact of disease on patients and identifying patient characteristics associated with 
poorer outcomes (Calvert & Freemantle, 2003; Fitzpatrick et al 1992).  The identification of 
the factors associated with change in HRQOL in people living with gout in primary care is of 
particular relevance to clinical practice as the majority of patients are managed within primary 
care.    
This research demonstrates the impact of experiencing gout flares on disease-specific HRQOL, 
with the deterioration in HRQOL increasing with the number of gout flares experienced.   
When one considers that even one flare was associated with a deterioration in disease-specific 
HRQOL in this cohort, this provides additional justification for the recommendation that ULT, 
should be discussed with all patients living with gout (Hui et al 2017).  The deterioration of 
both disease-specific and generic HRQOL over time in participants with worse pain, the 
presence of body pain, and more severe depression could have implications for targeting 
interventions in clinical practice.   In addition, the improvement over time in disease-specific 
HRQOL in participants who attended further education and the improvement in generic 
HRQOL in participants living in less deprived areas, highlights the disparity in change in HRQOL 
for those with different levels of educational attainment and deprivation.  These findings could 
have implications for patient information and education, along with prioritisation of 
resources.   
The implications of the findings in this chapter for clinical practice and people living with gout 
are discussed further in section 9.4. 
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8.6 Conclusion 
In conclusion, this chapter describes the factors associated with change in gout-specific 
HRQOL and generic HRQOL scores over a three-year period in a prospective cohort study of 
people living with gout in primary care using linear mixed models.  Prospective analysis of 
HRQOL, with the inclusion of time-varying covariates, enabled the change in HRQOOL in 
people living with gout to be captured.  Factors associated with deterioration in both disease-
specific and generic HRQOL included more frequent gout flares, a history of oligo/polyarticular 
flares, allopurinol use, the presence of body pain, worse pain severity, and worse depression 
score.  Factors associated with improvement in disease-specific HRQOL included allopurinol 
use, a longer disease duration, older age, and attendance at further education, whilst factors 
associated with improvement in generic HRQOL included living in a less socioeconomically 
deprived area and consuming alcohol more frequently.  
In the next chapter key findings of the whole thesis are summarised, strengths and limitations 
are discussed, and the implications of the whole thesis for both clinical practice and future 
research are considered.  
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9 Chapter Nine Discussion and conclusion 
9.1 Overview of chapter and aim 
In the previous chapter, the factors associated with change in HRQOL over a three-year period 
in a prospective cohort study of people living with gout in primary care were described. 
The aims of the following chapter are to discuss the key findings of the whole thesis, 
considering the strengths, limitations, implications for clinical practice, implications for future 
research, and to draw conclusions. 
9.2 Key findings of the thesis 
The key findings in this chapter are derived from the analysis of outcomes from a three-year 
prospective cohort study in people living with gout in primary care.   
Frequency and pattern of gout flares over three years 
Chapter five described self-reported gout flares over time.  At each time-point, the largest 
proportion of participants reported experiencing no gout flares, however over a quarter of 
the cohort reported two or more gout flares indicating frequent flares. Diverse individual 
patterns of change in gout flares over time were identified. Various approaches to modelling 
longitudinal gout flare data for the whole cohort were trialled using latent growth curve 
modelling (e.g. trialling ordinal, zero-inflated Poisson and negative binomial models with 
different functional forms) and more favourable results were returned for a quadratic ordinal 
latent growth curve model. 
Gout flare trajectory classes 
In chapter six, latent class growth analysis was used to identify and describe distinct gout flare 
trajectory classes over a three-year period.  Six distinct trajectory classes were identified which 
displayed a range of patterns in gout flares over time: ‘frequent and persistent’, ‘gradually 
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worsening’, ‘frequent then improving’, ‘moderately frequent’, ‘moderately frequent then 
improving’ and ‘infrequent’.  The selection of a six-class solution was justified by the statistical 
fit and the clinical relevance of the trajectories.  Frequent flare classes had more participants 
who were socioeconomically deprived, obese, had chronic kidney disease, and a history of 
oligo/polyarticular flares.  Less frequent flare classes were associated with allopurinol use, and 
a lower serum urate level.   
Change in HRQOL over three years and factors associated with change 
Chapters seven and eight investigated the change in gout-specific HRQOL (GIS subscales) and 
generic HRQOL (SF-36 PF10 and HAQ-DI) over time and factors associated with change.  At a 
group level, the magnitude of change in HRQOL scores was small and for some HRQOL scores 
negligible, however wide variation in change in HRQOL scores at an individual level was 
identified.  HRQOL measures (GIS subscales, SF-36 PF10 and HAQ-DI) displayed a linear form 
and were correlated over time.  The SF-36 PF10 and HAQ-DI demonstrated a left and right 
skew respectively.  
Factors associated with deterioration in HRQOL over three years were gout flares (GIS CO, 
MSE, UTN, CDA, SF-36 PF10), current flare (GIS CO, UTN), history of oligo/polyarticular flares 
(GIS CO, MSE, WBDA, CDA, HAQ-DI), using allopurinol (GIS WBDA, SF-36 PF10), number of 
comorbidities (SF-36 PF10), eGFR <60mL/min/1.73m2  (SF-36 PF10, HAQ-DI), worse pain 
severity (GIS CO, UTN, WBDA, CDA, SF-36 PF10 and HAQ-DI), the presence of body pain (GIS 
CO, MSE, SF-36 PF10 and HAQ-DI), worse depression score (GIS MSE, WBDA, CDA, SF-36 PF10 
and HAQ-DI), worse anxiety score (GIS CO, MSE, CDA), older age (SF-36 PF10, HAQ-DI), being 
female (SF-36 PF10, HAQ-DI), and higher BMI (HAQ-DI). Factors associated with an 
improvement in HRQOL over three years were experiencing a current flare (GIS WBDA), using 
allopurinol (GIS UTN), longer disease duration (GIS CO, MSE, UTN, CDA), older age (GIS CO, 
MSE, WBDA, CDA), living in a less deprived area (SF-36 PF10, HAQ-DI), attendance at further 
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education (GIS UTN), and consuming alcohol more frequently (GIS WBDA, SF-36 PF10, HAQ-
DI).   
9.3 Strengths and Limitations 
New knowledge 
The analysis presented in this thesis is unique as it was undertaken in a large prospective 
cohort of over 1000 people living with gout in primary care and followed up for three years.  
This analysis of longitudinal outcome measures, as opposed to solely cross-sectional analysis, 
enabled the dynamic nature of these outcomes to be captured (Fayers & Machin, 2016; Hahn 
et al 2007). 
This thesis uniquely identified groups of people reporting similar patterns of change in gout 
flares over time.   Although trajectories of pain and disease activity have been studied 
previously in other rheumatological conditions, this is the first time that trajectories of gout 
flares and associated participant characteristics have been investigated. 
There was a paucity of previous research into longitudinal change in both disease-specific and 
generic HRQOL in people living with gout specifically in primary care.  This is the longest 
prospective study to investigate the factors associated with change in both disease-specific 
and generic HRQOL in people living with gout in primary care, whilst adjusting for a range of 
gout-specific, comorbid, socio-demographic and other factors.  
Combining statistical analysis and clinical interpretation 
The results of statistical analysis were not considered in isolation and the clinical 
interpretation of findings were considered throughout this thesis. For example, both the 
clinical interpretation of the pattern of gout flares over time and the characteristics of 
participants in the gout flares trajectory classes supported the selection of a model with six  
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gout flare trajectory classes.  The findings have also been presented to and discussed with 
Rheumatologists, GPs and lay members of the PPIE Keele University Research User Group 
(RUG).   Clinicians commented that the flare trajectories reflected patients encountered in 
clinical practice (experiencing worsening, improving and no change in symptoms), and the 
factors associated with change in HRQOL were plausible.  PPIE group members were able to 
identify with the trajectory classes and were able to say which trajectory class they feel they 
would be assigned to based on their symptoms.  PPIE group members were also able to relate 
to the factors associated with change in HRQOL identified in this study.  
Planning statistical analysis 
Decisions regarding the statistical analysis undertaken and criteria used to interpret results 
were informed by the literature in the field and specified a priori for each analysis.  Time was 
dedicated to understanding the behaviour of the outcome measures over time, prior to 
undertaking the main analyses, due to the paucity of previous studies undertaking longitudinal 
modelling on these outcomes.  This investigation then informed how these outcome measures 
should be statistically modelled.   Consideration of the behaviour of outcomes prior to analysis 
is frequently omitted and can have detrimental consequences for interpretation (Feldman, 
Masyn & Conger, 2009).   This led to the use of quadratic ordinal models for the LCGA of gout 
flares and the addition of robust standard errors to LMMs for the skewed HRQOL outcomes.      
Attrition bias  
The investigation in chapter four revealed that responders were more likely to be male and 
appeared to be younger, better educated and less deprived compared with non-
participants.  Responders also had less severe (or better treated) gout, were less unwell and 
had better quality of life.    Thus, these findings provided evidence for attrition bias within this 
cohort.   It was important to investigate attrition bias to better understand this cohort as this  
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thesis was the first time that prospective data from this cohort had been analysed.  As 
participants in this study seemed to have less severe gout and better HRQOL it is important to 
consider that the findings of this thesis, such as the strength of the associations observed, may 
have been different if no attrition bias had been identified.  
Missing data 
The proportion of independent and dependent variable missing data on the questionnaires 
was below 10% for most variables, however missing data was identified in some dependent 
variables and covariates.  The statistical modelling techniques used to analyse these 
outcomes, LCGA and LMM, were selected due to their ability to deal with missing data in 
outcome measures (Berlin, Parra & Williams, 2014; Cheng et al 2010; Jung & Wickrama, 2008; 
Locascio & Atri, 2011).  In LMM multiple imputation of outcome measures has been shown to 
not improve the precision of estimates (Peters et al 2012), thus imputation was not 
undertaken prior to using LMMs.    In the LCGA in this thesis the sensitivity analysis undertaken 
showed that a six-class gout flare trajectory model was selected (based on statistical indices 
and similar trajectories) regardless of the degree of missing data.    
Case ascertainment 
Participants were identified by a Read code for gout or a prescription for allopurinol or 
colchicine within the medical records in the two years prior to baseline.  Thus, the diagnosis 
was made in primary care where the gold standard for gout diagnosis, the detection of MSU 
crystals in joints or tissues, is not routinely undertaken (Richette et al 2020).  Whilst there is 
potential for misclassification bias, Read codes for gout have displayed a reported sensitivity 
of 93.7% and a positive predictive value of 97.6% (Hassey, Gerret & Wilson, 2001).   
 
 
269 
 
Outcome measures 
Although a definition of gout flares has recently been validated for research participants with 
gout (Gaffo et al 2018), at the initiation of the cohort study there was a lack of a widely 
accepted valid definition for flares (Gaffo et al 2012).  The validated flare definition by Gaffo 
et al (2018) requires information about clinical features (pain severity, warmth, swelling) of 
each flare but these clinical parameters were not collected within the questionnaire.  Whilst 
flares self-reported in this cohort study may be liable to misclassification bias, they have been 
shown to have a sensitivity of 91% and negative predictive value of 96% when compared to 
the criterion of an assessment by a rheumatologist (Gaffo et al 2012).  Alternative methods 
used to identify gout flares such as consultation or prescription data are likely to 
underestimate gout flare frequency, as flares are often self-managed by patients without 
seeking medical attention (Chandratre et al 2016; Macfarlane et al 2016; Neogi et al 2006; 
Rothenbacher et al 2011; Sarawate et al 2006).  
Whilst the SF-36 has been endorsed by OMERACT as a measure of HRQOL in people living with 
gout (Singh et al 2011a), only the SF-36 PF10 was included in the questionnaires and available 
for analysis in this study.  The inclusion of the SF-36 PF10 only was justified by existing 
evidence at that time that impairment of HRQOL was predominantly on the physical domain 
for people living with gout (Chandratre et al 2013) and reduced questionnaire length and 
therefore the burden to participants.  The disease-specific HRQOL measures analysed, the GIS 
subscales, have yet to be endorsed by OMERACT as an outcome measure for people living 
with gout.  When the GIS was considered by OMERACT in 2011 (Singh et al 2011a), it was not 
endorsed due to the panel’s lack of familiarity with the scale and a lack of information 
regarding the feasibility of its use.  The GIS remains the only disease-specific HRQOL measure 
for people living with gout (Janssens et al 2019) and it has been used to measure HRQOL in 
subsequent prospective cohort studies (Singh et al 2016; van Leeuwen 2018; Wallace et al 
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2016) and a RCT (Doherty et al 2018).  This study uniquely undertook longitudinal analysis of 
all five subscales of the GIS, which address different aspects of disease-specific HRQOL.  This 
use of the GIS prospectively adds to the limited knowledge regarding the behaviour of the GIS 
subscales over time. The responsiveness of the GIS scale, in relation to the effect sizes and 
standardised response means, have been reported previously over shorter periods of time, 8 
weeks in a RCT (Khanna et al 2011b) and a prospective cohort over 12 months in secondary 
care (Wallace et al 2016). The report of effect sizes and SRMs over three years in a primary 
care cohort is therefore unique, thus provided additional insight into the responsiveness of 
this outcome measure.   
Recall bias and measurement error 
It is important to acknowledge the potential for recall bias, where participants have selective 
memories when recalling past events (Bowling, 2009), in relation to the reporting of both 
outcome measures and covariates in this study.  Gout flares in this study were self-reported 
and hence at risk of recall bias however, flares are salient and memorable owing to their 
dramatic nature (Harrold et al 2010; Roddy, Mallen & Doherty, 2013; Taylor et al 2015; Teng, 
Nair & Saag, 2006).  Using more frequent questionnaires or symptom diaries may have 
reduced recall bias but would have increased participant burden (Bowling, 2009; McColl, 
2004). 
Unmeasured covariates  
Several gout-specific, comorbid, socio-demographic and other characteristics of participants 
were considered when investigating change in gout flares and HRQOL.  However, some factors 
were not available for inclusion, for example dietary factors. 
The inclusion of time-varying covariates enabled the dynamic relationship between covariates 
and HRQOL to be investigated. However, some covariates were only included in the HRQOL 
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models at baseline as they were not included in the questionnaire at every time point, for 
example comorbidities, body pain, depression and anxiety.   
Response shift 
A change in someone’s assessment of their HRQOL when in fact there has been no objective 
change in their circumstances is an example of ‘response shift’, which may be due to several 
factors including changes in the internal scale participants use to rate themselves when 
responding to items (Blome & Augustin, 2015; Fayers & Machin, 2016) and change in 
participants’ perceptions of their circumstances due to adaption or adjustment over time 
(Bowling, 2009; Blome & Augustin, 2015; Fayers & Machin, 2016).  Response shift may be 
considered a form of measurement bias (Blome & Augustin, 2015; Fayers & Machin, 2016) 
and has been identified in prospective studies investigating HRQOL and in other clinical 
conditions (Barclay-Goddard et al 2011; Zhang et al 2012c).  Whilst methods have been 
proposed to test for response shift e.g. ‘thentest’, they can be influenced by recall bias 
(Bloome & Augustine, 2015). Whether response shift is a form of bias or simply reflective of a 
person’s ability to cope and adjust to their circumstances has been debated (Blome & 
Augustin, 2015).     
Regression to the mean 
It is prudent to consider the potential for regression to the mean; where extreme 
measurements at the upper or lower end of the measurement scale are likely to be followed 
by less extreme results (Bowling, 2009; Barnett, van der Pols & Dobson, 2005).   The fact that 
this is a cohort study of prevalent cases rather than an inception or intervention study means 
that it is less likely participants were recruited at a time when their symptoms were more 
severe.  However, prevalent cases may have been more likely to take part if their symptoms 
were worse at the time of invitation.   The results from the LMMs without covariates do not  
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suggest that participants with poor HRQOL scores at baseline experienced better scores at 
later time-points.  In fact, the negative covariance between intercept and slopes for some of 
the HRQOL scores (eg. GIS CO, GIS MSE, GIS UTN, and WBDA) indicated that the higher the GIS 
subscale score at baseline (intercept) the smaller the rate of change (Twisk, 2006).  
Hawthorne effect 
It is important to acknowledge the potential for a ‘Hawthorne effect’ amongst participants in 
this observational cohort, where the fact that participants are being observed could influence 
the outcomes reported (Bowling, 2009). The fact that participants were followed up over time 
may have partly led to the short-term reduction in gout flares reported by some participants, 
perhaps because participation in the study influenced their behaviour by increasing their 
awareness of the topic or simply because they felt someone was taking an interest in them 
(Bowling, 2009).   
Sample size and power calculations 
A sample size calculation was not undertaken prior to investigating gout flare trajectories as 
there are no set rules for sample size calculations for LCGA.  However, previous studies 
analysing latent trajectories in clinical outcomes have successfully identified three to five 
latent class trajectories through latent class growth analysis in clinical cohorts in primary care 
with sample sizes of approximately 500 participants (Nicholls et al 2014; Rzewuska et al 2015) 
and over one thousand participants were included in the LCGA in this study.   
As acknowledged in the previous chapter, an a priori sample size of 882 was calculated in the 
protocol for the prospective cohort study using data at all five time-points to detect a smallest 
meaningful difference in HRQOL of 0.2 standard deviation units detected between two groups 
(fewer than two gout flares per year and two or more gout flares per year) at a significance of 
0.05, power of 90% and autocorrelation of 0.8 (Chandratre et al 2012).  As participants with 
273 
 
missing covariate data were omitted from the LMM analysis, the sample size included in each 
LMM is below the 882 specified a priori. 
The limitations of using sample size calculations in multilevel modelling has been highlighted 
due to its reliance on statistical significance and caution has been advised regarding using 
sample size calculations in multilevel modelling (Twisk, 2006).  A particular challenge with 
calculating sample size and power in multilevel modelling is selecting the fixed-effect which is 
to be tested (Grace-Martin, 2019) and where associations between several covariates and the 
outcome are tested this could involve multiple power calculations to determine the chance of  
detecting a real effect as statistically significant (rejecting the null hypothesis when it is false) 
(Petrie & Sabin, 2009).  The use of post-hoc power analysis has been specifically discouraged 
in the literature (Hoenig & Heisey, 2001; Zhang et al 2019).  As sample size and power 
calculations are closely related to statistical significance (Twisk, 2006), the interpretation of 
the width of confidence intervals can indicate how confident we are regarding the relation of 
the result to the null hypothesis, so it has been proposed that post-hoc power calculations 
provide no additional insight (Hoenig & Heisey, 2001).  
SF-36 PF10 missing data 
After the thesis was submitted an error in the original Stata do-file used to calculate the SF-36 
PF10 scores was found.  This error led to a greater proportion of missing data in the SF-36 
PF10 scores used in this thesis.  The original analysis has been retained in the thesis but an 
amended do-file will be used to generate SF-36 PF10 data for reanalysis prior to submission 
for publication. 
9.4 Implications for clinical practice and people living with gout 
The findings of this thesis are relevant to clinical practice as the thesis focuses on people living 
with gout in primary care, where the majority of people living with gout are managed.  The 
274 
 
implications of the findings for both clinical practice and people living with gout were 
discussed with both clinicians and members of the Keele RUG during a PPIE group meeting 
convened to specifically discuss the results of this study.  
When considering the implications of the findings to clinical practice, it is important to reflect 
on the generalisability of the cohort to the wider population encountered in clinical practice.  
This was an older cohort who were predominantly male, which is typical of patients seen in 
primary care (Kuo et al 2015a).  Responders in this cohort reported slightly less severe (better 
treated) gout and slightly better HRQOL compared to non-participants, thus it is important to 
appreciate that patients in clinical practice may experience more frequent gout flares and 
worse HRQOL in comparison to the study cohort.  Responders to this study are also likely to 
be less deprived and better educated compared to the wider population.   
The plotting of intra-individual gout flare frequency and HRQOL scores over time in this thesis, 
demonstrates the diverse experiences of people living with gout in primary care.  This is an 
important consideration for management in clinical practice and supports the role of 
individualised care.   
Relevance to clinical guidelines   
More members of the infrequent gout flare trajectory class reported using allopurinol and had 
a supressed urate level, whilst classes with more frequent flares were associated with elevated 
urate levels.  In addition, allopurinol use was associated with an improvement in HRQOL, 
specifically disease-specific unmet treatment need, however allopurinol use was also 
associated with lower wellbeing during an attack. More frequent flares were associated with 
worse disease-specific and generic HRQOL, however HRQOL was also impaired in those 
experiencing only one flare per year.  
 It is important to appreciate that these findings are derived from an observational cohort and 
thus causal interpretations cannot be made.  However, these findings are consistent with 
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existing recommendations in gout management guidelines for people living with gout to 
strongly consider ULT in those individuals with two or more flares per year, but also to discuss 
ULT early in the course of the disease and to support patients receiving ULT as reducing urate 
levels can trigger gout flares (Hui et al 2017). 
Both Rheumatologists and GPs have suggested that flare trajectory diagrams could be used as 
a visual aid to facilitate conversations with patients about management of gout and future 
outcomes.   
Suboptimal gout management 
Less than a third of the participants reported taking an allopurinol dose of  300mg or more per 
day and over 60% of the cohort were missing a serum urate record in their medical records.  
Such suboptimal management of gout in primary care is consistent with findings in previous 
studies.   Most patients receiving ULT do not receive a dose adjustment to optimise urate 
levels (Cottrell et al 2013) or are non-adherent to ULT (Scheepers et al 2018).  Inadequate 
serum urate monitoring has also been demonstrated in other cohorts (Wall et al 2010).  Due 
to suboptimal dosing of allopurinol and suboptimal serum urate recording it was not possible 
to investigate the full potential of the effects of allopurinol or serum urate levels on HRQOL in 
this cohort.  It is possible that the influence may have been greater, if allopurinol use was 
optimised. 
Thus, changes in HRQOL and gout flares were seen in people with suboptimal management 
within primary care.  Consequently, it is perhaps unsurprising that the trajectory of gout flares 
for the majority of participants did not display any change over time (the majority of 
participants were allocated to either the infrequent, moderately frequent or frequent and 
persistent classes) and group-level change in HRQOL scores were small or negligible.      
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When these results were discussed with the Keele RUG PPIE group they felt the key 
implications related to the associations between allopurinol use and both flare frequency and 
HRQOL. PPIE group members also felt that optimising best practice for management of gout 
was the key implication for clinical practice. 
Targeting interventions and resources 
The characteristics of participants in the frequent or worsening gout flare trajectories and the 
characteristics associated with change in HRQOL over three years could have implications for 
targeting interventions and healthcare resources to people living with gout.   
The fact that an improvement in generic HRQOL was associated with living in a less deprived 
area and more participants in frequent or worsening flare trajectories were classified as most 
deprived, suggests that outcomes in gout are linked to health inequality.  It is thus important 
that interventions, education, and resources which are targeted at people living with gout are 
likely to work well in areas of deprivation.  Consideration of deprivation when planning 
healthcare provision would be in line with recommendations in the National Health Service 
(NHS) long term plan to reduce healthcare inequality in the NHS (National Health Service, 
2019).  
Attendance at further education was associated with an improvement in disease-specific 
HRQOL over three years and fewer participants in the frequent and worsening gout flare 
trajectories had attended further education. Low educational attainment is associated with 
limited (low or marginal) health literacy (Protheroe et al 2017) suggesting that patient 
information resources for people with gout should use a range of health information materials 
which are clear, concise and use plain English (Public Health England, 2015).  
Whilst gout is more prevalent in males it is important for clinicians to appreciate the 
experiences of women living with gout.  In this cohort being female was associated with a 
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deterioration in SF36 PF10 and HAQ-DI over three years.  Existing studies have also reported 
the unique impact of a gout diagnosis on females (Richardson et al 2015) and how being 
female is a risk factor for non-adherence to ULT (Scheepers et al 2018).   
Since deterioration in HRQOL was associated with the presence of frequent flares, 
oligo/polyarticular flares, body pain, worse pain, more severe depression, and anxiety, and a 
higher BMI, obtaining information about these factors could help to identify people who 
should be offered ULT.   
Impact of findings for people with gout and the general public 
The Keele PPIE RUG members felt that dissemination of these findings could have an 
important role in increasing awareness of gout in the general population.  The group 
suggested that highlighting that gout can be associated with frequent painful inflammatory 
flares which lead to impairment of HRQOL might help to increase recognition and awareness 
that gout is as significant chronic inflammatory arthritis, rather than a humorous self-inflicted 
condition.  
9.5 Implications for future research 
Replication in other cohorts 
As this is the first time that gout flare trajectories have been identified, it would be prudent 
to investigate gout flare trajectories in other settings and populations.  Future analysis of flare 
trajectories could be undertaken in inception cohorts to gain a picture of the natural history 
of gout flares from disease onset.  A range of different covariates and outcomes were included 
thus it is possible that some of the associations observed may only exist in this cohort or may 
have arisen due to chance.  Whilst there is consistency with the factors associated with change 
in HRQOL and the factors associated with HRQOL in people living with gout in previous cross-
sectional studies, these should be explored in other cohorts.  In addition, as three years may 
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not be long enough to capture the full extent of change in a chronic illness such as gout, it may 
also be beneficial to investigate change in HRQOL over a longer period.  
Alternative methods of analysis of change over time 
SF-36 PF10 scores displayed negligible change at a group level over time and the amount of 
variation over time in SF-36 PF10 scores did not warrant a random slope at a group level.   Little 
change was also observed in SF-36 PF10 scores at a group level after adjustment for gout-
specific, comorbid, socio-demographic and other factors in the LMM.  However, plots of intra-
individual change in SF36 PF10 did show some variation in change in HRQOL scores over time 
for some individuals.  Thus, an alternative method of statistical modelling, such as latent class 
growth analysis, could be used in the future to identify individuals with different trajectories 
of generic HRQOL scores over time and describe the characteristics of participants with 
different trajectories. 
Studies to address modifiable factors 
Several modifiable factors, including depression, obesity and pain, were associated with 
deterioration in disease-specific and/or generic HRQOL over three years.  Primary care trials 
of intervention for obesity, depression, and/ or pain could investigate whether deterioration 
in HRQOL in people living with gout could be attenuated through identification and 
intervention.  A previous RCT which provided an intervention of depression care management 
to older persons living with arthritis reported less interference with daily activities and lower 
pain intensity (Lin et al 2003).   A RCT of optimised anti-depressant therapy followed by a pain 
management programme as the intervention, reported lower depression severity scores, a 
reduction in pain severity and disability, in a US study of primary care patients with 
musculoskeletal conditions (Kroenke et al 2009).  A systematic review by Nielsen et al (2017) 
identified 10 longitudinal weight loss studies in people living with gout and reported an effect 
of weight loss to reduce gout flares.   However, the lack of measurement of other outcomes 
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such as HRQOL and pain in these studies was noted.  Importantly studies included were low 
quality, particularly regarding bias due to confounding and departures from intended 
interventions, and rigorous RCTs are needed (Nielsen et al 2017).   
Prognosis research 
Due to the paucity of existing research the statistical analyses undertaken were intentionally 
exploratory in nature.  Future prospective research relating to gout flares and HRQOL in 
people living with gout could follow a prognosis research approach, where the relationship 
between future outcomes and baseline factors are investigated (Hemingway et al 2013).  This 
could include prognostic factor research, where a factor’s prognostic ability would be 
examined across multiple studies thus replicating and confirming the factor’s prognostic 
ability (Riley et al 2013).  Prognostic research might then be extended further to develop  
prognostic models which combine multiple predictors to calculate the risk of the outcome for 
individual patients (Steyerberg et al 2013).  Whilst such prognostic models can assist clinicians 
with their prediction of a patient’s future outcome and enhance informed decision making, 
they require careful development, validation and evaluation in clinical practice (Steyerberg et 
al 2013). 
9.6 Conclusion 
Until now little has been known about change in gout flares and HRQOL over time in people 
living with gout, and the factors associated with worse outcomes.  This thesis investigated the 
change in gout flares, disease-specific HRQOL (GIS subscales) and generic HRQOL (SF-36 PF10 
and HAQ-DI) over three years in a prospective cohort study of people living with gout in 
primary care.  Six distinct gout flare trajectory classes were identified.  The infrequent flare 
class had the lowest mean serum urate level and the highest proportion of patients taking 
allopurinol, whilst frequent flare classes had more patients who were socioeconomically 
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deprived, obese, had chronic kidney disease, and a history of oligo/polyarticular flares.  
Factors associated with deterioration in both disease-specific and generic HRQOL included 
more frequent gout flares, a history of oligo/polyarticular flares, allopurinol use, the presence 
of body pain, worse pain severity, and worse depression score.  Factors associated with 
improvement in disease-specific HRQOL included allopurinol use, a longer disease duration, 
older age, and attendance at further education.  Factors associated with improvement in 
generic HRQOL included living in a less socioeconomically deprived area and consuming 
alcohol more frequently.  
These thesis findings are relevant to clinical practice as they investigate the outcomes of 
people living with gout in primary care, where the majority of people are managed.  Gout is a 
common inflammatory arthritis with a well understood pathophysiology and readily available  
effective treatment, yet a significant number of patients continue to experience poor 
outcomes.  These observational findings are consistent with existing clinical guidelines that 
advise that the option of ULT should be discussed with all people living with gout but 
particularly people experiencing two or more flares and oligo/polyarticular flares (Hui et al 
2017).  The identification of people at risk of worse outcomes, for example worse pain, 
depression or obesity, could help to target interventions and healthcare resources for people 
living with gout.  Interventions, education and resources targeted at people living with gout 
need to be able to work well in areas of deprivation and in individuals with lower educational 
attainment.  
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Appendix 1: Studies which investigated HRQOL in people with gout reported in the systematic review by Chandratre  
et al (2013) and identified in this thesis in a subsequent review of the literature  
 
Author Publication 
year 
Study  
period 
Study design Country Setting / data source Sample 
size 
HRQOL 
outcome 
measure 
Alvarez-Nemegyei 
et al  
 
2005 1999 Cross-
sectional 
Mexico Rheumatology 
Service and Primary care 
medical units 
90 HAQ-DI 
Colwell et al  2006 Not reported 
(NR) 
Prospective United 
States 
Phase II program of Febuxostat 126 GAQ 1.0 
 
Roddy, Zhang & 
Doherty 
2007c NR  Cross-
sectional 
United 
Kingdom 
Two GP practices  13684 
 
WHO-QOL 
Alvarez-Hernandez 
et al 
2008 NR  Prospective 
 
Mexico Eight rheumatology 
departments 
206 HAQ-DI 
 
Hirsch et al  2008 NR  Cross-
sectional 
United 
States 
Family practice, 
internal medicine, and 
rheumatology clinics  
308 GIS 
Khanna et al  2008 NR Cross-
sectional 
United 
States 
General medicine and 
rheumatology clinics; Veterans 
Affairs Medical Centre, and a 
private rheumatology practice 
80 SF-36 
HAQ-DI 
EQ-5D 
 
Singh & Strand 
 
2008 1996-1998 Cross-
sectional 
United  
States 
Veterans seen in Veterans 
Integrated Service Network 
70334 SF-36 
 Taylor et al 2008 NR Cross-
sectional 
New Zealand Rheumatology outpatients  73 HAQ-DI 
334 
 
Alvarez-Hernandez 
et al 
2009 NR Prospective Mexico NR 49 HAQ-DI 
AIMS 
MOS-20 
 
Becker et al  2009 NR Prospective United 
States 
Academic and private 
rheumatology practices 
110 SF-36  
HAQ-DI 
 
Lee et al  2009 NR Cross-
sectional 
United 
States 
Arthritis and primary care 
clinics Veteran Affairs health 
care systems and surrounding 
communities  
371 SF-36 
Hirsch et al  2010 NR Cross-
sectional 
United 
States 
 
Family practice, 
internal medicine, and 
rheumatology 
308 GIS 
Sarkin et al 2010 NR Cross-
sectional 
United 
states 
Family practice, internal 
medicine, and rheumatology 
260 GIS 
Van Groen et al  2010 2005-2008 Cross-
sectional 
Netherlands Hospital rheumatology 
outpatient clinic 
102 SF-36 
HAQ-DI 
 
Dalbeth et al  2011 NR Prospective New Zealand Primary and secondary care 
settings 
 
142 HAQ-II 
Khanna et al  2011a NR Prospective Spain Academic centre-based gout 
clinic  
99 SF-36 
Khanna et al  2011b NR Prospective United 
States 
RCT assessing riloacept vs 
placebo 
73 GIS 
ten klooster et al  2011 2005-2008 Cross-
sectional 
Netherlands Outpatient rheumatology clinic 102 HAQ-DI 
HAQ-II 
SF-36 PF10 
335 
 
Khanna et al  2012c 2010 Cross-
sectional 
France, 
Germany, 
United 
Kingdom 
US and EU National Health and 
Wellness Surveys  
1936 SF-12v2 
Strand et al  2012 NR Prospective United 
States 
RCT of pegloticase in refractory 
gout 
212 SF-36 
HAQ-DI 
 
Dalbeth et al  2013 NR Prospective  
 
New Zealand Primary and secondary care 
clinics   
291 SF-36 
HAQ-II 
Scire et al  2013 June 2011-
Jan 2012 
Cross-
sectional  
 
Italy Rheumatology clinics  446 SF-36  
HAQ-DI 
ten Klooster et al 2014 July - Dec 
2012 
Cross-
sectional 
 
Netherlands Outpatient rheumatology clinics 34 
 
HAQ-DI 
Khanna et al  2015 April 2012-
July 2012  
 
Cross- 
sectional 
United 
States 
Health plan in the US 
Patients on healthcare plan 
were mailed survey 
257 
 
GIS 
SF-12 
Spaetgens et al 2015 NR Cross-
sectional 
Netherlands University Hospital outpatient 
rheumatology clinic  
122 GIS 
SF-36 
HAQ-DI 
Singh et al 2016 NR Prospective 
cohort 
United 
States 
Primary care, rheumatology 
and other specialist clinics 
Veterans Affairs institutions 
186 GIS 
SF-36 
HAQ-DI 
Wallace et al  2016 NR Prospective United 
States 
Rheumatology or primary care  147 GIS 
SF-36 
HAQ-DI 
Wood et al  2016 NR Cross-
sectional 
France, 
Germany, 
UK, United 
States 
Rheumatology 
and primary care  
 
1204 HAQ 
EQ-5D 
 
Fu et al  2017 Nov 2015- 
Jan 2017 
Cross-
sectional 
China University hospital outpatients 
and inpatients 
 
226  SF-36 
HAQ-DI 
 
336 
 
Lopez Lopez et al  2017 2010-2014 Cross-
sectional 
Mexico Secondary care  248 HAQ-DI 
Chandratre et al 2018 2012 Cross-
sectional 
United 
Kingdom 
Primary care  1184 GIS 
SF-36 PF10 
HAQ-DI 
 
La-Crette et al  2018 2015 Cross-
sectional  
United 
Kingdom 
Academic rheumatology clinic 102 GIS 
Stewart et al  2018 NR Prospective New Zealand Primary and 
secondary care clinics  
295 HAQ-II 
Chincilla, Doherty & 
Aberhishek 
2019 NR Prospective  United  
Kingdom 
RCT recruited from primary 
care 
517 GIS 
Edwards et al  2019  June 2006-
Oct 2007 
Cross-
sectional 
United 
States, 
Canada, 
Mexico 
 RCT of Pegloticase 212 SF-36 
HAQ-DI 
 
Lee et al  2019 NR Cross-
sectional 
Singapore Tertiary academic medical 
centre  
267 GIS 
Proudman et al  2019 2017  Cross-
sectional 
Australia Population survey 2778 SF-12 v1 
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Appendix 2: Factors associated with disease-specific and generic HRQOL in people living with gout in published studies 
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Alvarez-Nemegyei 
et al  
2005 HAQ-DI 
 
                       
Roddy, Zhang & 
Doherty  
2007 WHO-QOL 
                       
Alvarez-
Hernandez et al  
2008 HAQ-DI 
                       
Hirsch et al  2008 GIS                        
Alvarez-
Hernandez et al 
2009 HAQ-DI 
                       
Becker et al  2009 SF-36                        
  HAQ-DI                        
Lee et al  2009 SF-36                        
Hirsch et al  2010 GIS                        
Sarkin et al  2010 GIS                        
Dalbeth et al  2011 HAQ-II                        
Khanna et al  2011 SF-36                        
Khanna et al  2012 SF-12                         
Dalbeth et al  2013 SF-36                        
  HAQ-DI                        
Scire et al  2013 SF-36                        
  HAQ-DI                        
Khanna et al  2015 GIS                        
  SF-12                        
Spaetgens et al  2015 GIS                        
  SF-36                        
  HAQ-DI                         
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Singh et al  2016 GIS                         
  SF-36                        
  HAQ-DI                         
Wallace et al  2016 GIS                        
  SF-36                        
  HAQ-DI                        
Fu et al  2017 SF-36 PCS                        
  SF-36 MCS                        
  HAQ-DI                        
Lopez Lopez et al  2017 HAQ-DI                        
Chandratre et al  2018 GIS                        
  SF-36 PF10                        
  HAQ-DI                        
La-Crette et al  2018 GIS                        
Stewart et al  2018 HAQ-II                        
Chincilla,Doherty  
& Abhishek,  
2019 GIS 
                       
Edwards et al  2019 SF-36                         
  HAQ-DI                        
Lee et al  2019 GIS                        
Proudman et al  2019 SF-12                        
 
  Association reported in the literature (however association may not be with all subscales of this HRQOL measure) 
  A lack of association explicitly reported in the study 
 Association with ‘gout severity’ or ‘gout activity’    
* Association with ‘recent flares’ or flare(s) in the previous three months 
Association with oligo/polyarticular gout, polyarticular gout, or the number of tender/swollen/painful joints    
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Appendix 3: Cover letter sent with baseline questionnaire 
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Appendix 4: Participant information sheet (PIS) for prospective cohort study 
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Appendix 5:  Baseline questionnaire and consent forms 
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Appendix 6: Two week non-response reminder postcard sent after baseline questionnaire 
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Appendix 7:  Four week non-response reminder cover letter sent with repeat 
questionnaire 
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Appendix 8:  Ethical approval letter for prospective cohort study 
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Appendix 9: Summary table of questionnaire content (concept, operationalisation of 
concept, items and time-points) 
 
Adapted from Chandratre et al (2012)  
(Use permitted. Publisher Springer Nature, work is licensed under the Creative Commons 
Attribution 4.0 International License  http://creativecommons.org/licenses/by/4.0/) 
 
Gout 
 
How gout affects life 
 
 
 
Concept Operationalisation of concept Empirical measure Time-point  
Frequency of gout 
flares 
Number of flares in previous 
12 months at baseline, 24 and 
36 months, in previous 6 
months at 6 and 12 months 
5-point ordinal scale (0 to ≥5) All 
Age at gout diagnosis Age in years Numerical free text box Baseline 
Occurrence of 
current gout flare 
Acute gout flare at time of 
completion of questionnaire 
Yes/No All 
History of oligo/ 
polyarticular flares 
Reported experience of gout 
in more than one joint 
Yes/No All 
Use of allopurinol Reported use of allopurinol Yes/No All 
Reported dose of allopurinol 10 categories  
(9 dose categories, 1 option if 
dose unknown). 
Free text box for dose. 
All 
Concept Operationalisation of concept Empirical 
measure 
Time- 
point 
Disease-specific HRQOL 
 
 
 
 
 
Gout concern overall,  
Gout medication side effects, 
Unmet gout treatment needs, 
Wellbeing during an attack, 
Concern during an attack 
 
Gout Impact Scale (GIS) 
(Hirsch et al 2008)  
 
 
GIS subscales: 
 
GIS Concern overall (GIS CO),  
GIS Medication side effects (GIS MSE),   
GIS Unmet treatment needs (GIS UTN),  
GIS Wellbeing during an attack (GIS WBDA),  
GIS Concern during an attack (GIS CDA) 
24 items   
Response via 
5-point 
ordinal scale    
All  
Illness perception Questions from Revised Illness Perception 
Questionnaire (IPQ-R)  
(Moss-Morris et al 2002) 
4 items 
Response via 
5- point 
Likert scale 
All 
374 
 
General health 
 
  
 How participants feel 
 
 
 
Concept Operationalisation of concept Empirical measure Time- 
point 
Physical function 
 
36-Item Short-Form Health Survey 
Physical Function Subscale  
(SF-36 PF 10) 
(Ware & Sherbourne, 1992) 
10 items 
Response via 3-point ordinal 
scale 
 
All 
Activity 
limitation/disability 
Health Assessment Disability Index 
(HAQ-DI) 
(Bruce & Fries, 2003) 
20 items 
Response via 4-point ordinal 
scale 
 
Additional question regarding 
the use of aids, devices or 
assistance 
All 
Pain severity Numerical rating scale (NRS) Pain 
(Bruce & Fries, 2003) 
11-point NRS All 
Global assessment of 
health 
Numerical rating scale (NRS) 
Patient Global 
(Bruce & Fries, 2003) 
11-point NRS All 
Comorbidities Diabetes, Hypertension (HT), 
Hyperlipidaemia (HL), Myocardial 
infarction (MI), Angina, 
Cerebrovascular accident (CVA), 
Transient Ischaemic attack (TIA), 
Renal failure (RF), Renal calculi  
Yes/No Baseline 
only 
Concept Operationalisation of 
concept 
Empirical measure Time point 
Depression Patient Health 
Questionnaire-9 
(PHQ-9) 
(Kroenke, Spitzer & 
Williams, 2001) 
9 items 
Response via 4-point 
ordinal scale 
 
Additional question if 
subject check any of 9 
items above. 
Response via 4-point 
ordinal scale 
Baseline 
12 months 
36 months 
Anxiety Generalised Anxiety 
Disorder-7 
(GAD-7) 
(Spitzer et al 2006) 
7 items 
Response via 4-point 
ordinal scale 
Baseline 
12 months 
36 months 
375 
 
 Foot and other joint problems 
 
How gout affects work 
Concept Operationalisation of 
concept 
Empirical measure Time-point 
Occupational 
characteristics 
Current employment 
status 
11 nominal categories Baseline 
12 months 
36 months 
 Taken time off work due 
to gout in last 6 months 
Yes/No Baseline 
12 months 
36 months 
 
 Current abilities to 
undertaken usual 
employment 
 
5 nominal categories Baseline 
12 months 
36 months 
 Is inability to undertake 
normal employment 
attributed to joint 
problems 
Yes/No Baseline 
12 months 
36 months 
 
Concept Operationalisation of 
concept 
Empirical measure Time point 
Hallux Valgus Line drawings of left and 
right feet.  
(Roddy, Zhang & 
Doherty, 2007d) 
5 line drawings of left 
and right feet displaying 
increase in severity of 
HV 
Baseline  
12 months 
36 months 
Foot pain, aching & 
stiffness 
Frequency of foot pain 
or aching or stiffness.  
(Dufour et al 2009) 
1 item 
Response via 5-point 
ordinal scale 
Baseline  
12 months 
36 months 
Foot pain location Location of foot pain on 
manikin illustration 
(Garrow, Silman & 
Macfarlane, 2004) 
Foot manikin 
illustrations 
 
Baseline  
12 months 
36 months 
Foot function Manchester Foot Pain 
and Disability Index 
(Garrow et al 2000) 
17 Items 
Response via 3-point 
Likert scale 
Baseline  
12 months 
36 months 
Health care 
consultations regarding 
feet 
Consultant with GP 
relating to feet 
 
NHS or Private 
consultation with 
Physiotherapist, 
Podiatry & Chiropody 
relating to feet 
1 Item 
Yes/No 
 
6 nominal response 
categories 
Baseline  
12 months 
36 months 
Pain Pain, ache, discomfort or 
stiffness lasting longer 
than one day in any part 
of their body during the 
past 4 weeks 
 
Location of pain on a 
body manikin 
(Hunt et al 1999; Lacey 
et al 2005) 
1 Item 
Yes/No 
 
 
 
 
Body manikin  
Baseline  
12 months 
36 months 
 
 
 
 
Baseline  
12 months 
36 months 
376 
 
Demographics and socioeconomics, BMI and alcohol  
Concept Operationalisation of 
concept 
Empirical measure Time-point 
Date of birth Date of birth Date of birth Baseline 
Sex Sex Male/ Female Baseline 
Relationship status Relationship status 6 nominal categories Baseline 
Education Attendance at Higher 
Education 
Yes/No Baseline 
Ethnic origin Ethnic origin 6 nominal categories Baseline 
Anthropometry Height Metres/Feet & Inches All 
 Weight Kilograms/Stones & 
pounds 
All 
Alcohol consumption Frequency of alcohol 
consumption 
7 ordinal categories Baseline 
 Quantity of alcohol of 
specified type and 
volume consumed  
Free text Baseline 
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Appendix 10:   Descriptions of model fit indices included in thesis 
Chapter 5 Latent growth curve modelling 
 
Indices  
 
Description/comments 
Chi-Squared 
Statistic  
(χ 2) 
The Chi-Squared Statistic assesses the magnitude of discrepancy between the 
covariance matrices of the observed sample and fitted model (Hu & Bentler, 
1999). 
The chi-squared statistic is sensitive to sample size (Hooper, Coughlan & Mullen, 
2008; Wickrama et al 2016) and where the sample size is large a model will nearly 
always be rejected (Bentler & Bonnett, 1980). 
Comparative 
Fit Index 
(CFI) 
(Bentler, 1990) 
The Comparative Fit Index is an incremental fit index which evaluates the fit of 
the model compared to reduced nested null model which assumes that all the 
latent variables are uncorrelated (Hooper, Coughlan & Mullen, 2008; Hu & 
Bentler, 1998).  The CFI takes account of sample size and is thus less effected by 
sample size than χ2 (Hooper, Coughlan & Mullen, 2008). 
Tucker-Lewis 
Index (TLI) 
(Tucker & Lewis, 
1973) 
The Tucker-Lewis index is an incremental fit index which also evaluates the fit of 
the model compared to a nested model which assumes that all the latent 
variables are uncorrelated (Hooper, Coughlan & Mullen, 2008; Wickrama et al 
2016).  The TLI also considers the complexity of the model by consideration of 
the number of degrees of freedom (Kenny, 2015; Wickrama et al 2016). 
Root mean 
square error of 
approximation 
(RMSEA)  
(Steiger & Lind, 
1980) 
The Root mean square error of approximation is an absolute fit indices which 
evaluates how well the model fits the sample data whilst taking account of model 
complexity (Hooper, Coughlan & Mullen, 2008; Wickrama et al 2016).  As a model 
fit index the RMSEA is fairly insensitive to sample size (Wickrama et al 2016).  The 
result obtained from the RMSEA is accompanied with a confidence interval which 
can aid interpretation regarding the adequacy of model fit (Hooper, Coughlan & 
Mullen, 2008). 
Weighted root-
mean-square 
residual 
(WRMR) 
The Weighted root-mean-square residual measures the weighted average 
differences between the variances and covariances of the sample and the fitted 
model (Yu, 2002).  The appropriate cut off for the WRMR is increased for more 
time-points and increased sample size (Yu, 2002). 
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Chapter 6 Latent class growth analysis 
 
Criterion Description/comments 
BIC Bayesian information criteria (BIC) is based on the log likelihood for a model but 
then penalises for the number of free (estimated) parameters in the model and 
also the sample size (Feldman, Masyn & Conger, 2009; Nylund, Asparouhov & 
Muthen, 2007). BIC is the most commonly used information criterion when 
determining the optimal number of latent classes (Feldman, Masyn & Conger 
2009; Twisk & Hoekstra, 2012).  
AIC The Akaike information criteria (AIC) (Akaike, 1987) is an information criterion 
which based on the log likelihood for the model but then penalises for the number 
of free (estimated) parameters in the model (Nylund, Asparouhov & Muthen, 
2007).  
LMR-LRT  Likelihood ratio tests (LRTs) compare a current model (k-class) with a model which 
has one less class than the current model (k-1) (Feldman, Masyn & Conger, 2009; 
Jung & Wickrama, 2007; Nylund, Asparouhov & Muthen, 2007; Wickrama et al 
2016). The Lo-Mendell –Rubin Likelihood Ratio Test (LMR-LRT) was developed by 
Lo, Mendell & Rubin (2001) and uses an approximate sampling distribution for the 
likelihood ratio test (Peugh & Fan, 2012). The LMR-LRT compares the fit of adjacent 
class models, i.e. models which have K-1 and K classes, and generates a p value 
which indicates whether there is a statistically significant improvement in model 
fit of the K class model versus the previous K-1 class mode as displayed in table 
(Nylund, Asparouhov & Muthen, 2007; Wickrama et al 2016). 
BLRT The Bootstrapped Likelihood Ratio Test (BLRT) was developed by McLachlan & 
Peel (2000) to estimate the distribution of the log likelihood ratio test utilising 
bootstrap samples.  
BLRT compares the fit of adjacent class models, i.e. models which have K-1 and K 
classes, and generates a p value which indicates whether there is a statistically 
significant improvement in model fit of the K class model versus the previous K-1 
class model (Nylund, Asparouhov & Muthen, 2007; Wickrama et al 2016). 
Average 
posterior 
probabilities 
Posterior probability is calculated from the observed variable using maximum 
likelihood estimation and it is the probability of an individual belonging to any of 
the (latent) classes (Wickrama et al 2016). As part of the LCGA individuals are 
assigned to the latent class which is associated with the highest posterior 
probability (Berlin, Parra & Williams, 2104; Wickrama et al 2016).   The average 
posterior probability of each latent class is calculated in LCGA (Muthen & Muthen, 
2000; Wickrama et al 2016).  
Entropy Entropy is a standardised index of the classification accuracy of a model, with 
values for entropy ranging from 0 to 1 (Peugh & Fan 2012; Wickrama et al 2016).  
Calculation of entropy involves information about the posterior probabilities of 
individuals within classes and provides an overall entropy result for the latent 
class model (Clark & Muthen, 2009; Feldman, Masyn & Conger, 2009). 
 
 
 
 
 
379 
 
Chapter 8 Linear mixed modelling 
 
Indices  
 
Description/comments 
Intraclass 
correlation 
coefficient 
(ICC) 
The intraclass correlation coefficient is the ratio of the between subject variance to 
the total variance (which is a combination of the between and within subject 
variance).  An ICC is equal to 1 when all the variance is explained by the differences 
between individuals (Kirwood & Sterne, 2003; West, Welch & Galecki, 2015).  
Likelihood 
Ratio Test 
(LRT) 
The likelihood ratio test compares the log likelihood from one model with the log 
likelihood from another model e.g. comparing a nested and reference model 
(Kirwood & Sterne, 2003; West, Welch & Galecki, 2015). 
Wald χ 2 test The Wald χ 2 test statistic is equal to the estimated regression coefficient divided by 
its standard error, and its square approximates the Chi-squared distribution (Petrie 
& Sabin, 2009).  The Wald χ 2 test statistic is used to test the null hypothesis that a 
regression coefficient is zero (Petrie & Sabin, 2009; West, Welch & Galecki, 2015). 
Akaike 
Information 
Criteria (AIC) 
The Akaike Information Criteria (AIC) (Akaike, 1987) is an information criterion 
which is based on the log likelihood for the model but then penalises for the number 
of free (estimated) parameters in the model (Nylund, Asparouhov & Muthen, 2007). 
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Appendix 11:  Spaghetti plots displaying the individual gout flares reported for each participant in each latent class with an 
interpolation line fitted 
   
 
 
 
 
      NB. 5 = >5 flares
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Appendix 12:  Sensitivity analyses for quadratic ordinal LCGA models plots probability of ≥ 2 
gout flares at each time-point  
 
For participants who responded at >3 time-points) 
 
One class solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Two class solution 
 
Three class solution 
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Four class solution 
 
Five class solution 
 
Six class solution 
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Seven class solution 
 
Eight class solution 
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Appendix 12 cont.  Quadratic ordinal LCGA model plots; probability of >2 gout flares at each 
time-point  
 
For participants who responded at 5 time-points 
 
One class solution 
 
 
Two class solution 
 
Three class solution 
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Four class solution 
 
Five class solution 
 
Six class solution 
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Seven class solution 
 
Eight class solution 
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Appendix 13: Model fit indices for GMM and the plots for the GMM dataset consisting of participants who self-reported gout flare at five 
time-points 
 
Number 
of classes 
AIC BIC BLRT LMR-LRT Entropy Average posterior probabilities 
 
Number per class (%)  
based on most likely 
class membership 
1 5127.225 
 
5159.864 
 
- - - - 437 
(100) 
2 5021.396 
 
5070.356 
 
P value 
<0.001 
P value 
<0.001 
0.610 
 
0.846/0.873 
 
80/357 
(18.3/81.7) 
3b 5017.517 
 
5082.796 
 
P value 
0.0515b 
P value 
0.1889 
0.741 
 
0.676/0.979/0.830 
 
178/248/11 
(40.7/56.8/2.5) 
  4
 b,c
 5013.749 
 
5095.348 
 
P value 
0.0538b 
P value 
0.1223 
0.526 
 
0.889/0.761/0,735/0.589 
 
10/120/131/176 
(2.3/27.5/30/40.2) 
5b 5012.178 
 
5110.097 
 
P value 
1.000b 
P value 
0.1550 
0.581 
 
0.640/0.872/0.691/0.766/707 
 
175/11/16/133/102 
(40.1/2.5/3.7/30.4/23.3) 
6 - - - - - - - 
7 
 
- - - - - - - 
 8 - - - - - - - 
AIC, Akaike Information Criteria; BIC, Bayesian information criteria; BLRT, Bootstrap likelihood ratio test; LMR-LRT, Lo Mendell Rubin likelihood ratio test. 
a model fixed to avoid singularity, warning given that model may not be identified, b Warning that not all of bootstraps converged, C Warning that some draws had smaller LRT than observed 
LRT Table formatted as per Guidelines for Reporting on Latent Trajectory Studies (GRoLTs) (van de Schoot et al 2017) 
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One class solution GMM 
 
Two class solution GMM 
 
Three class solution GMM 
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Four class solution GMM 
 
Five class solution GMM 
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Appendix 14: Q-Q plots of all five HRQOL outcomes at all five time-points 
 
GIS CO Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months)  
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GIS MSE Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months)  
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GIS UTN Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months)  
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GIS WBDA Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months) 
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GIS CDA Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months) 
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SF-36 PF10 Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months) 
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HAQ-DI Q-Q plots at each time-point (baseline, 6, 12, 24 and 36 months) 
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Appendix 15: Covariance structures trialled during linear mixed modelling 
 
Structure  Description 
independent One unique variance parameter per random effect, all covariance 
0; the default unless notation is used 
exchangeable Equal variances for random effects, and one common pairwise 
covariance 
identity Equal variances for random effects, all covariance 0 
unstructured All variances and covariances to be distinctly estimated 
Toeplitz 1 Assumes that within-group errors have a Toeplitz structure for 
which correlations are constant with respect to time lags less than 
or equal to 1 and are 0 for lags greater than 1. 
autoregressive 1 Assumes that within-group errors have an autoregressive 
structure of order 1. 
 
p. 287 & 289 
(StataCorp, 2013) 
 
 
